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Retroelements are some of the most successful parasites studied because of their ability 
to reverse transcribe and permanently integrate into the host genome.  Host cells have, 
therefore, evolved multiple control mechanisms, such as cellular restriction factors, to 
protect their genomes from the pathogenic and mutagenic effects of retroelements.  
Identification of the full complement of these proteins is vital to comprehend the 
capacity of the host to regulate these genetic parasites.  Human MOV10 is a putative 
RNA helicase with inhibitory or stimulatory roles in the replication of several RNA 
viruses, and the homologs of which play vital roles in the restriction of viruses and 
endogenous retroelements.  Furthermore, MOV10 interacts with antiviral APOBEC3 
proteins and core post-transcriptional RNA silencing machinery, all of which co-
localise in cytoplasmic mRNA processing bodies and stress granules.  Considering 
MOV10 cellular associations and homolog functions, the capacity of MOV10 to 
regulate the replication of a diverse panel of genetically distinct retroelements was 
investigated here. 
 
Ectopically overexpressed MOV10 potently restricts the replication of retroviruses as 
well as the propagation of LTR and non-LTR endogenous retroelements.  Significantly, 
RNAi-mediated silencing of endogenous MOV10 enhances the replication of 
endogenous retroelements, but not exogenous retroviruses demonstrating that natural 
levels of MOV10 suppress retrotransposition.  MOV10 overexpression decreases the 
level of HIV-1 genomic RNA packaged into nascent virions and also impacts the 
accumulation of reverse transcription products in target cells.  The molecular 
mechanism/s by which MOV10 inhibits retroelements remains unclear, however, the 
anti-retroelement activities of MOV10 and APOBEC3 proteins are independent.  
Moreover, MOV10 is not essential for miRNA-mediated translation repression or slicer 
activity in cultured cells.  In sum, ectopically overexpressed human MOV10 inhibits 
divergent exogenous and endogenous retroelements and, more significantly, the 
capacity of endogenous MOV10 to specifically suppress retrotransposition highlights it 
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1.1 Retroviruses  
The Retroviridae, or retrovirus family consists of a large group of divergent RNA 
viruses.  Retroviruses replicate by reverse transcribing their single-stranded RNA 
genomes into copies of double-stranded DNA that are permanently integrated into the 
host chromosomal DNA.  The integrated provirus serves as a template for transcription 
of the viral RNA, which is incorporated into virions or forms the mRNA for translation 
of viral proteins, allowing the virus to maintain a persistent infection.  Unique steps 
such as reverse transcription and integration define, and also distinguish, retroviruses 
from all other virus families.       
 
1.1.1 Taxonomic classification 
Originally, retroviruses were classified according to the morphology of the virion core, 
for example, its shape and position, as visualised by electron microscopy.  The genera 
have since been expanded and in addition to core morphology are also based on the 
organisation of the viral genome and site of virus assembly.  Such criteria have allowed 
grouping of the genera into simple and complex retroviruses (Table 1.1).  Both simple 
and complex retroviruses encode genes for the group specific antigen (Gag), protease 
(Pro), polymerase (Pol) and envelope (Env) proteins, however, the latter harbour 
additional genes for accessory and regulatory proteins that play important roles in viral 
replication (Goff, 2001).  This thesis will focus predominantly on the human 
immunodeficiency virus type-1 (HIV-1); however, particular studies also extend to 
incorporate human immunodeficiency virus type-2 (HIV-2), rhesus macaque derived 
simian immunodeficiency virus (SIVmac), murine leukemia virus (MLV) and Mason-
Pfizer monkey virus (M-PMV) and, therefore, these will also be briefly discussed in this 







Table 1.1.  Taxonomic classification of the Retroviridae family. 







































Deltaretrovirus Human T-cell 
































1.2 Retroviral pathogenesis  
Retroviral infections can cause diseases that are directly tumourigenic or more 
cytopathic resulting in cell death and the development of immunodeficiencies as well as 
neuropathologies. 
 
1.2.1 Oncogenic retroviruses 
Acute transforming retroviruses are efficient and rapid inducers of tumours.  These 
viruses express oncogenes (v-onc) acquired following a recombination event between 
viral and proto-oncogenic host sequences (c-onc) that are subsequently transferred onto 
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the viral genome.  Inappropriate expression of the cellular oncogene during infection 
results in the formation of aggressive tumours.  These viruses are normally replication-
defective due to the loss of a viral gene required for replication during the acquisition of 
a host gene and, therefore, rely on a helper replication-competent virus for transmission 
(Goff, 2001).  The Rous sarcoma virus carries the c-src gene and was the first 
oncogenic virus to be identified, although this virus is replication competent and, 
therefore, an exception to the rule.  
 
Unlike acute transforming viruses, slow leukemia viruses are less efficient and slower at 
inducing tumours.  These viruses are replication-competent and do not express any 
oncogenes; instead they form tumours by a mechanism called proviral insertional 
mutagenesis that involves the integration of a provirus, at random, within or in close 
proximity to a cellular proto-oncogene causing it to be activated (Goff, 2001).  Several 
MLVs are slow leukemia viruses that induce the formation of thymic lymphomas. 
 
1.2.2 Cytopathic retroviruses 
Several retroviruses are the etiological agents for immunosuppressive diseases.  Primate 
lentiviruses are the prototype associated with a chronic progressive disease and 
immunodeficiency in both human and non-human primates. 
 
1.2.2.1 Origin of HIV 
HIV-1 and HIV-2 are distantly related human lentiviruses that were identified as the 
causative agents of acquired immunodeficiency syndrome (AIDS) (Barre-Sinoussi et 
al., 1983; Gallo et al., 1984; Clavel et al., 1986).  HIV-1 consists of four subtypes: 
groups M (major), N (non-M, non-O), O (outlier) and P (pending the identification of 
further human cases).  The group M subtype has infected people worldwide and is the 
cause of the HIV-1 pandemic.  The remaining subtypes are extremely rare and restricted 
to parts of West and Central Africa.  Similarly, HIV-2 is mainly restricted to West 
Africa and is normally associated with lower viral loads and transmission rates in 
comparison with HIV-1.  Although the clinical symptoms of HIV-2 infections are 
similar to HIV-1, in most cases, HIV-2 infected individuals do not progress to AIDS 




The simian immunodeficiency viruses (SIVs) are lentiviruses that infect African non-
human primates.  HIV-1 and HIV-2 are a result of zoonotic transfers of chimpanzee 
derived SIV (SIVcpz) and sooty mangabey monkey derived SIV (SIVsmm), 
respectively, into humans (Gao et al., 1992; Gao et al., 1999)[reviewed in (Hahn et al., 
2000)].  Likewise, SIVmac was identified not to be a natural pathogen of macaques, but 
a result of cross-species transmission of SIVsmm from mangabey monkeys in primate 
centres (Apetrei et al., 2005).  
 
1.2.2.2 HIV and SIV pathogenesis 
Both HIVs and SIVs infect target cells using CD4 as the primary cell surface receptor.  
In addition to T lymphocytes, CD4 is expressed on a range of cell types such as 
monocytes, macrophages and dendritic cells (DCs).  Broadly, HIV and pathogenic SIV 
infections result in the profound depletion of CD4+ T cells and, therefore, impairment 
of their function resulting in the onset of immunodeficiencies, opportunistic infections 
and ultimately AIDS.  Importantly, with the possible exception of SIVcpz, the majority 
of SIVs fail to cause disease in their natural African hosts (Keele et al., 2009).  
 
Transmitted HIV-1 requires CD4 and the CCR5 co-receptor for infection (R5-tropic 
virus), consistent with the knowledge that mucosal CD4+ T cells are the initial targets 
for infection.  CD4+ memory T cell subsets express high levels of CCR5 and are, 
therefore, the predominant cell type infected in both HIV and SIV infection (Douek et 
al., 2002).  The virus and virus-infected cells at the site of exposure spread to proximal 
lymph nodes to expand from a localised infection to systemic infection.  Furthermore, 
DCs can exacerbate infection by capturing and transmitting virus to T cells, although 
they are not productively infected (Lackner et al., 2011; Swanstrom and Coffin, 2011). 
 
Acute infection is characterised by the availability of a large number of activated CD4+ 
T cells and high levels of viremia.  This is ultimately controlled by the onset of early 
immune responses and, principally, a CD8+ cytotoxic T lymphocyte (CTL) response 
against infected cells (Swanstrom and Coffin, 2011).  The massive population of CD4+ 
memory T cells in the gut-associated lymphoid tissue (GALT) is depleted more rapidly 
than those in other lymphoid tissues or the blood, and associated damage to the GALT 
and intestinal lining moves bacterial products into the blood activating a more 
generalised immune response. Interestingly, the activation of such a proinflammatory 
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immune response distinguishes pathogenic and non-pathogenic models of SIV infection 
[reviewed in (Brenchley and Douek, 2008)].  
 
The onset of early immunodeficiency allows the virus to evolve and alter its tropism by 
using the CXCR4 co-receptor (X4-tropic virus), which correlates with rapid progression 
towards a disease state (Doranz et al., 1996; Koot et al., 1999).  Naïve T cells express 
high levels of the CXCR4 co-receptor allowing X4-tropic viruses to infect these cells, 
and continually infect memory T cell subsets due to the expression of high levels of 
CXCR4 on these as well.  Furthermore, late-evolving macrophage-tropic viruses can 
infect macrophages that express low levels of CD4 (Swanstrom and Coffin, 2011). 
 
Immune activation increases the turnover of CD4+ memory T cells, therefore, 
moderately replenishing the ‘stock’ of available target cells.  As HIV-1 replicates in 
activated CD4+ cells, chronic infection is characterised by a constant increase in the 
levels of viremia and, consequently, a gradual decrease in CD4+ T cell numbers.  
Ultimately the drop in CD4+ T cells reaches levels at which immune function is 
compromised causing opportunistic infections and the AIDS phase (Swanstrom and 
Coffin, 2011).  The mechanism of CD4+ T cell death is not fully understood; however, 
it is clear that over the course of infection cell death is a result of multiple factors 
involving the direct killing of infected cells, indirect killing of uninfected bystander 
cells and chronic immune activation (Li et al., 2005; Doitsh et al., 2010; Lackner et al., 
2011; Swanstrom and Coffin, 2011).   
 
1.2.2.3 HIV-1 therapy 
Currently, there is no cure for HIV-1 infection; however, to date, more than twenty 
Food and Drug Administration (FDA)-approved antiretroviral agents (ARVs) exist for 
the treatment of HIV-1.  With the advent of combined therapy, which is also known as 
highly active antiretroviral therapy (HAART), viral loads can be reduced to below the 
limit of detection.  The principle of HAART therapy is the use of three antiretroviral 
drugs that can target at least two separate molecular events in the viral life cycle 
preventing the evolution of drug resistant viral strains, which are common due to the 
highly error-prone reverse transcription process.  The stages of the HIV-1 life cycle 
targeted by inhibitors so far are entry, reverse transcription, integration and protease 
processing.  However, this list is by no means exhaustive and inhibitors of any stage of 
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the viral life cycle that are distinct from cellular functions may be potential targets.  
Furthermore, targeting of host cell restriction factors and cofactors may also provide a 
novel approach for treatment of HIV-1 infection (Arts and Hazuda, 2011).    
 
During acute infection a latent reservoir of HIV-1 infected resting CD4+ memory T 
cells is established.  A shortcoming of ARV therapy is its inability to clear latent 
infection, as these proviral integrations are not transcriptionally active and, therefore, do 
not produce viral proteins.  Furthermore, the development of severe drug toxicities, drug 
resistant mutant strains and general failure of treatment due to factors such as poor 
tolerability and low CD4+ T cells counts when treatment is started illustrate that novel 
therapies are still required.  
 
The development of a protective vaccine is an active area of research, the major 
obstacle of which is the heterogeneity between virus strains worldwide.  A successful 
vaccine would require the induction of broadly acting and cross-reactive neutralising 
antibodies against the Env glycoprotein, and recent HIV and SIV vaccine trials have 
provided clues that will likely advance this field of vaccine development in the right 
direction (Rerks-Ngarm et al., 2009; Barouch et al., 2012).  Vaccine research has also 
focused on the development of T-cell based vaccines that prevent the progression of 
disease, and primarily vaccines that can stimulate CD8+ CTL responses (Buchbinder et 
al., 2008). 
 
1.2.2.4 M-PMV pathogenesis 
M-PMV, also known as simian retrovirus type 3 (SRV-3) is a simian retrovirus that can 
lead to the development of a disease analogous to AIDS caused by pathogenic SIVs.  
Infection results in peripheral blood cytopenias causing immunodeficiency, ultimately 
resulting in the development of a range of pathological disorders attributed to 
opportunistic pathogen infections.  The molecular mechanisms of pathogenesis, 








1.3 Organisation of the retroviral genome 
Retroviruses are 7 to 13kb single-stranded, positive sense RNA viruses that package 
two identical copies of their genome into nascent virions.  The viral genome exists as a 
homodimer formed by interactions between the dimer linkage structures (DLS) found at 
the 5’ ends of each RNA.  As viral RNA is transcribed by the host transcriptional 
machinery it is capped and polyadenylated similar to cellular mRNAs.  Several 
important cis-acting elements exist in the retroviral RNA (Figure 1.1A); the repeated 
(R) region is present at both termini, which is followed by the unique 5’ sequence (U5) 
at the 5’ end and preceded by the unique 3’ sequence (U3) at the 3’ end.  The primer-
binding site (PBS) is located immediately downstream of the U5 region and is required 
for the initiation of reverse transcription (section 1.5.3).  The PBS is followed by the 
viral RNA packaging signal (Psi).  The polypurine tract (PPT), which also plays an 
important role in later stages of reverse transcription, is located immediately upstream 
of the U3 region (Goff, 2001).  Many cis-acting elements are unique to lentiviruses, 
such as HIV-1 (Figure 1.1A, illustrated in red).  In addition to the PPT at the 3’end of 
the viral RNA these also include a central polypurine tract (cPPT) (Charneau et al., 
1992).  Additionally, these viral RNAs contain two complex structures: the 
transactivation response (TAR) element and the Rev-response element (RRE) that are 
involved in transcription of the viral RNA and nuclear export, respectively (Malim et 
al., 1989; Dingwall et al., 1990) (sections 1.5.6 and 1.5.7). 
 
Following reverse transcription and integration of the retroviral cDNA, the viral RNA is 
transcribed and translation of the viral proteins ensues.  The sequences between the Psi 
and PPT are mainly coding regions for viral proteins, which for most simple 
retroviruses encode gag, pro, pol and env, and for the complex retroviruses, such as 
HIV-1 and HIV-2, encode additional genes for accessory and regulatory proteins 
(Figure 1.1B).  All primate lentiviruses encode the regulatory proteins transactivator of 
transcription (Tat) and regulator of virion expression (Rev), and the accessory proteins 
virion infectivity factor (Vif), viral protein R (Vpr) and negative factor (Nef).  
Additionally HIV-1/SIVcpz also encode viral protein U (Vpu), whereas HIV-






                  
 
Figure 1.1.  Organisation of the retroviral genome.   
 
(A) Retroviral RNA cis-acting elements.  All retroviral RNAs are capped at the 5’ end, polyadenylated 
at the 3’ end and contain a primer-binding site (PBS), packaging signal (Psi) and polypurine tract (PPT) 
(Illustrated in black).  The repeated (R) regions, unique 5’ (U5) and unique 3’ (U3) sequences are also 
depicted.  Lentiviruses contain additional cis-acting elements such as the transactivation response (TAR) 
element, central polypurine tract (cPPT) and Rev-response element (RRE) (Illustrated in red).  Adapted 
from (Goff, 2001) and (Freed and Martin, 2001).  (B) Simple and complex retrovirus protein coding 
regions.  Both simple retroviruses (MLV and M-PMV) and complex retroviruses (HIV-1 and HIV-2) 
encode gag, pro, pol and env, and additionally HIV-1 and HIV-2 also encode tat, rev, vif, vpr, vpu (HIV-1 









1.4 Mature retroviral virion 
Virions are released from infected cells as immature particles containing partially 
processed Gag and Gag-Pro-Pol proteins.  These are eventually fully processed into 
mature infectious particles that are roughly 100nm in diameter, although this can vary.  
Processing of Gag and Gag-Pro-Pol precursors results in the production of the Gag 
proteins nucleocapsid (NC), capsid (CA), matrix (MA) and other Gag products specific 
to the virus (Figure 1.2A).  Pro is processed into the enzyme protease (PR), and Pol is 
cleaved to produce the reverse transcriptase (RT) and integrase (IN) enzymes.  The viral 
genomic RNA is associated with NC in the virion, which is enclosed within a core made 
up of the CA protein.  The shape of the virion core can vary depending on the virus 
(section 1.1.1).  The MA protein loosely forms a shell around the virion core, and all the 
virion components are enclosed within a lipid bilayer containing the Env glycoprotein 
(Goff, 2001) (Figure 1.2B).  Cellular enzymes process the Env precursor into gp41 
(transmembrane subunit) and gp120 (surface unit subunit), the latter of which is an 
extravirion component observed as protrusions from the virion membrane.  Cellular 
proteins are also packaged into virions, some of which will be discussed in more detail 















             
 
Figure 1.2.  Mature retroviral virion. 
  
(A) Processed Gag domains.  Precursor retroviral Gag proteins are processed into matrix (MA), capsid 
(CA), nucleocapsid (NC) and additional domains dependent on the virus, for example, the spacer peptides 
p2, p1 and the p6 domain in the case of HIV-1.  (B) Organisation and components of the mature 
retroviral virion.  The mature virion consists of a dimeric RNA genome, the structural Gag proteins NC, 
CA and MA, the viral enzymes reverse transcriptase (RT), integrase (IN) and protease (PR), encompassed 
in a lipid bilayer containing trimeric complexes of the Env protein gp41 and gp120 domains.  Adapted 











1.5 Retroviral life cycle 
The retroviral life cycle is initiated with an RNA genome that traverses through a DNA 
intermediate and returns again to RNA form for packaging into virions.  These basic 
requirements of viral replication are accomplished via a number of specific and intricate 
viral processes (Figure 1.3).  The early phase of the retroviral life cycle is initiated with 
entry of the virus particle into a target cell by interacting with a specific cell surface 
receptor through the Env protein.  Receptor binding induces fusion of the viral and 
cellular membranes and subsequent internalisation of the viral core into the cell 
cytoplasm (section 1.5.1).  Uncoating of the viral capsid may occur prior to or during 
and following reverse transcription depending on the virus (section 1.5.2).  The process 
of reverse transcription is mediated by the RT enzyme, which catalyses the conversion 
of the viral RNA genome into a DNA copy that is imported into the nucleus and 
integrated into the host chromosomal DNA by the IN enzyme (sections 1.5.3 to 1.5.5).  
The late phase of the viral life cycle commences with transcription of the viral RNA 
coupled to elaborate splicing events and nuclear export of both unspliced and spliced 
viral transcripts into the cytoplasm (sections 1.5.6 and 1.5.7).  Viral proteins are 
translated and traffick either to specific sites in the cytoplasm or the plasma membrane 
for assembly and packaging of the viral RNA (sections 1.5.8 and 1.5.9), following 
which immature virus particles bud through the plasma membrane (section 1.5.10).  The 
PR enzyme cleaves and processes the viral structural and enzymatic proteins generating 
a mature virion that is able to infect a new target cell and repeat the cycle (sections 1.4 
and 1.5.11).  Due to the limited size of the retroviral genome an array of host proteins, 
or cofactors, are also hijacked by the virus to perform important functions in the viral 












Figure 1.3.  Retroviral life cycle. 
 
Mature retroviral particles bind to a specific cellular surface receptor via the Env glycoprotein (1) 
allowing fusion and entry of the viral core into the cell cytoplasm (2).  Following uncoating of the viral 
capsid and reverse transcription of the single-stranded RNA genome (3) the double-stranded DNA 
product enters the nucleus of the cell (4) and is integrated into the host chromosomal DNA (5).  
Transcription (6) and processing of the viral transcripts (7) ensues, following which viral mRNAs are 
exported into the cytoplasm of the cell (8) for translation of the viral proteins (9) and assembly of nascent 
virions (10).  Immature virions bud through the cell plasma membrane (11) and are processed into mature 


















1.5.1 Entry   
Retroviral entry is a complex, multi-step process initiated by binding of the viral Env 
glycoprotein to a specific cell surface receptor.   A diverse range of receptors are 
utilised for entry and these determine the cell type specificity of the virus, or viral 
tropism (Table 1.2) (Goff, 2001).  Subsequently, the viral Env protein undergoes radical 
conformational changes to expose the fusion peptide allowing fusion of the viral and 
cellular lipid bilayers.  Fusion is pH-independent for the majority of retroviruses, 
including HIV-1, suggesting that changes in the conformation of Env are not dependent 
on an endosomal acidification step and likely occur at the plasma membrane (Stein et 
al., 1987), although alternative theories have been proposed (Miyauchi et al., 2009).  
The viral core is internalised and delivered to the cytoplasm following the membrane 
fusion event.    
 
Table 1.2.  Retroviral receptors. 
Genus Example Receptor Function 
Betaretrovirus M-PMV RDR Neutral amino acid 
transporter 
 







































M-PMV (Tailor et al., 1999), E-MLV (Kim et al., 1991), A-MLV (Kavanaugh et al., 1994), X-MLV & P-






CD4 was the first retroviral entry receptor identified and is used by the majority of 
primate as well as feline lentiviruses (Maddon et al., 1986; McDougal et al., 1986).  
This receptor is a member of the immunoglobulin superfamily that functions in immune 
recognition and T cell receptor (TCR) signalling.  CD4 usage explains the narrow 
tropism of viruses such as HIV-1, which is mainly restricted to T lymphocytes and 
macrophages (section 1.2.2.2).  Interestingly, studies illustrated that CD4 expression 
alone was not sufficient for HIV-1 fusion (Maddon et al., 1986), which led to the 
identification of the chemokine receptors CCR5 and CXCR4 that serve as virus 
coreceptors (Choe et al., 1996; Deng et al., 1996; Dragic et al., 1996; Feng et al., 1996).  
Individuals that are homozygous for the CCR5∆32 allele are largely resistant to HIV-1 
infection, providing evidence for the importance of this coreceptor (Liu et al., 1996; 
Samson et al., 1996). 
 
For HIV and SIV entry, gp120 binds to CD4 causing rearrangements in gp120 that 
allow engagement with the CCR5 or CXCR4 coreceptors.  Viruses that utilise the 
CCR5 coreceptor are termed R5-tropic and those that use the CXCR4 coreceptor are 
called X4-tropic viruses (section 1.2.2.2).  R5X4-tropic viruses also exist that can utilise 
both coreceptors.  Evidence suggests that following receptor binding, viruses utilise host 
cell machinery, such as the actin cytoskeleton, to arrive at sites for membrane fusion by 
a mechanism termed ‘surfing’ (Lehmann et al., 2005).  Coreceptor binding exposes the 
gp41 fusion peptide, which is inserted into the host plasma membrane resulting in the 
formation of a six-helix bundle that brings the viral and cellular membranes in close 
proximity.  Formation of a fusion pore allows delivery of the viral core into the cell 
cytoplasm (Wilen et al., 2011). 
 
1.5.2 Uncoating  
Uncoating refers to disassembly of the viral core.  Retroviruses such as the primate 
lentiviruses can replicate in terminally differentiated, non-dividing cells as they actively 
import their viral genome through nuclear pores into the nucleus (Lewis et al., 1992).  
Alternatively, gammaretroviruses such as MLV can only replicate in dividing cells as 
they access the nuclear chromatin following breakdown of the nuclear membrane during 
mitosis (Roe et al., 1993).  The viral uncoating process may be at least partially 
responsible for these differences in mechanism of nuclear import and ability to infect 
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dividing and non-dividing cells.  The diameter of the retroviral core exceeds that of the 
nuclear pore; therefore, early uncoating may be necessary for active nuclear import 
[reviewed in (Fassati, 2006)].  Evidence suggests that HIV-1 uncoating occurs early in 
infection based on the detection of very small amounts of viral CA associated with 
intracellular reverse transcription and pre-integration complexes (RTC and PIC) (Farnet 
and Haseltine, 1991; Fassati and Goff, 2001).  On the other hand, the analysis of RTCs 
from MLV infection indicates that uncoating is a more gradual process occurring during 
reverse transcription and nuclear entry (Fassati and Goff, 1999).  However, the timing 
of HIV-1 uncoating is somewhat controversial, whereby a particular model suggests 
that viral core disassembly takes place at the nuclear pore upon completion of reverse 
transcription (Iordanskiy et al., 2006). 
 
The mechanism of uncoating is not very well understood, however, a mature virion is 
necessary for efficient uncoating of the viral capsid.  Furthermore, the host cell factor 
cyclophilin A (CypA), which has been shown to be necessary for efficient HIV-1 
infection, may function by facilitating uncoating (Braaten et al., 1996; Ylinen et al., 
2009).  More recently, the HIV-1 IN enzyme has also been implicated in the process of 
uncoating (Briones et al., 2010).  On the contrary, host cell restriction factors tripartite 
motif-containing protein 5α (TRIM5α), TRIMCyp and Fv1 inhibit retroviral infection 
by affecting the uncoating step and, therefore, downstream processes such as reverse 
transcription or nuclear entry (sections 1.8.2.2 and 1.8.2.3). 
 
1.5.3 Reverse transcription 
Reverse transcription is one of the defining hallmarks of the retrovirus life cycle, which 
involves copying of the single-stranded RNA genome to double-stranded DNA for 
integration into the host genome.  Although uncoating of the viral capsid is not fully 
understood, it is thought that exposure of the viral RNA to high levels of 
deoxyribonucleotide triphosphates (dNTPs) in the cytoplasm is sufficient for the 
initiation of reverse transcription.  The majority of this process takes place in target 
cells, however, very low amounts of early DNA products can be detected in virion 
preparations (Trono, 1992).  Exceptions to this rule are spumaviruses, which reverse 
transcribe predominantly during virus assembly so that the main form of genome in the 
virion is DNA (Goff, 2001). 
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The RT enzyme mediates reverse transcription and contains both DNA polymerase 
activity, incorporating dNTPs on a template, and RNase H activity, degrading RNA in a 
duplex (Baltimore, 1970; Mizutani et al., 1970; Molling et al., 1971).  Different 
retroviral PR enzymes cleave Pol to produce RT enzymes with varying subunit 
structures dependent on the retrovirus.  For example, the MLV RT enzyme is a 
monomer in solution, whereas the HIV-1 RT enzyme is a heterodimer consisting of a 
larger subunit with both DNA polymerase and RNase H activity (p66) and a smaller 
domain with only DNA polymerase activity (p51) (Goff, 2001).  Reverse transcription 
occurs as part of a RTC containing multiple host and viral proteins.  For HIV-1, the 
presence of CA in the RTC is controversial, however, other viral proteins such as MA, 
NC, IN and Vpr have been detected (Fassati and Goff, 2001; Nermut and Fassati, 2003; 
Iordanskiy et al., 2006).   
  
The process of reverse transcription involves a series of detailed steps (Figure 1.4), 
initiated with synthesis of the minus strand strong stop DNA; the 3’ end of a specific 
cellular transfer RNA (tRNA) primer, which is dependent on the virus, anneals to the 
complementary PBS in the plus strand RNA genome.  HIV-1 uses the tRNALys3.  The 
RT enzyme synthesises this early DNA product towards the 5’ end of the viral RNA 
using it as a template, producing the U5 and R sequences.  The RNA component of the 
RNA: DNA hybrid formed during this step is degraded by the RT enzyme RNase H 
activity.  This degradation allows transfer of the minus strand strong stop DNA from the 
5’end of the viral genome to the 3’end, where it anneals to the complementary R region.  
This process is termed minus strand transfer.  Using the minus strand strong stop DNA 
as a primer, minus strand DNA synthesis extends towards the 5’ end of the viral 
genome till the PBS.  Again, formation of an RNA: DNA hybrid results in degradation 
of viral RNA by RNase H activity, although the PPT is particularly resistant to 
degradation and remains annealed to the minus strand DNA.  The short PPT RNA 
sequence serves as a primer for the initiation of plus strand strong stop DNA synthesis 
and elongates towards the 5’ end of the minus strand DNA template generating the U3, 
R and U5 sequences as well as some of the complementary tRNA primer sequence.  
The PPT RNA sequence is degraded following this step and the tRNA primer at the 
5’end of the minus strand DNA is also degraded by RNase H activity.  Exposure of the 
3’ end of the plus strand strong stop DNA results in a second translocation step termed 
plus strand transfer, during which the plus strand strong stop DNA jumps to the 3’end 
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of the minus strand DNA and anneals with the PBS.  The process of reverse 
transcription is completed with elongation of the 3’ ends of both the minus strand DNA 
and plus strand DNA, ultimately resulting in the formation of a linear double-stranded 
DNA product that is the substrate for integration into the host genome.  The U3-R-U5 
blocks at either end of the DNA, referred to as the long-terminal repeats (LTRs), have 
important roles in the integration process (Goff, 2001; Hu and Hughes, 2011).   
 
In addition to the PPT at the 3’ end, lentiviruses such as HIV-1 have an additional cPPT 
located near the middle of the viral genome (section 1.3).  This results in the initiation 
of a second plus strand synthesis event and the presence of a discontinuity in the DNA 
owing to termination of elongation from upstream primers.  In the case of HIV-1, this 
creates a DNA overlap or flap that is thought to play an important role in replication 
(Charneau et al., 1992; Charneau et al., 1994).  
 
HIV-1 sequences vary considerably within the same individual due to the introduction 
of mutations into the viral genome during replication.  The error-prone RT enzyme that 
lacks a proofreading function contributes significantly to this mutation rate.  Matters are 
complicated further by the recombination rate of retroviruses, which is highest for HIV-
1, whereby viral templates are switched during reverse transcription generating a 
chimeric DNA that contains sequences from both viral RNA copies; this process results 
in the generation of a recombinant virus only in the instance that both viral template 
sequences are not identical.  Viral divergence allows the virus to evade the host immune 







          
 
Figure 1.4.  Reverse transcription. 
 
A specific cellular tRNA primer anneals to the viral RNA PBS initiating the process of reverse 
transcription.  The minus strand strong stop DNA is synthesised and the viral RNA component of the 
resultant RNA: DNA hybrid is degraded by RNase H activity.  The minus strand strong stop DNA is 
transferred to the 3’ end of the viral RNA and the minus strand DNA is synthesised.  The viral RNA in 
the RNA: DNA hybrid is degraded by RNase H activity, leaving only the PPT RNA sequence intact.  The 
remnant PPT sequence primes synthesis of the plus strand strong stop DNA.  Both the PPT sequence and 
tRNA primer in the resultant RNA: DNA hybrid are degraded by RNase H activity.  The plus strand 
strong stop DNA is transferred to the 3’ end of the minus strand DNA template.  Both the minus strand 
and plus strand DNA products are fully extended generating the final long-terminal repeat (LTR) 
containing viral cDNA product.  DNA is depicted with a red border and RNA degradation by RNase H 




1.5.4 Nuclear entry 
The viral cDNA must enter the nucleus for integration into the host chromosomal DNA, 
a process that is not well understood.  It is thought that the RTC converts to the PIC as 
reverse transcription progresses and, therefore, many of the cellular and viral proteins 
found in the RTC also remain in the PIC.  As discussed, the difference in ability of 
gammaretroviruses and lentiviruses to replicate in dividing and non-dividing cells is 
down to the mechanism of nuclear import, and viral core uncoating may influence the 
pathway adopted (section 1.5.2).  Furthermore, viral and host proteins have also been 
implicated in actively importing the PIC into the nucleus. 
 
The amino-terminal (N-terminal) region of the HIV-1 MA protein has been proposed to 
contain a nuclear localisation signal (NLS), the mutation of which was reported to block 
the ability of the virus to replicate in terminally differentiated cells (Bukrinsky et al., 
1993); however, subsequent studies have not been able to confirm these findings 
(Fouchier et al., 1997).  The HIV-1 accessory protein Vpr also contains at least two 
NLS domains and can bind directly to nucleoporins (Di Marzio et al., 1995; Fouchier et 
al., 1998), however, HIV-1 vector systems that lack Vpr are still able to infect non-
dividing cells (Zufferey et al., 1997).  The HIV-1 IN enzyme is karyophilic and putative 
NLS domains as well as an ability of IN to bind importins has been proposed (Gallay et 
al., 1997), although, the exact mechanism by which IN enters the nucleus is still a 
matter of debate (Devroe et al., 2003).  Interestingly, HIV-1 viruses in which IN has 
been replaced with the MLV IN enzyme can still replicate in non-dividing cells 
(Yamashita and Emerman, 2005).  Another HIV-1 element suggested to be required for 
nuclear import is the cPPT, however, spreading replication assays with wild-type virus 
containing a mutated cPPT only provide a modest inhibition of HIV-1 infection with no 
obvious defect in nuclear import (Limon et al., 2002). 
 
A number of cellular factors have also been implicated in HIV-1 nuclear entry, such as 
importin7 and also tRNAs (Fassati et al., 2003; Zaitseva et al., 2006).  Furthermore, 
genome-wide studies to identify cellular factors required for HIV-1 replication have 
identified a number of nuclear pore proteins to be required for nuclear entry (Lee et al., 
2010; Zhang et al., 2010; Matreyek and Engelman, 2011; Schaller et al., 2011).  
Although transportin 3 was originally thought to be necessary for nuclear entry a post-
nuclear entry role for transportin 3 has more recently been proposed (Christ et al., 2008; 
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Zhou et al., 2011).  Further studies are required to identify the full range of factors and 
exact mechanisms involved in facilitating this viral process.    
 
1.5.5 Integration 
The second distinguishing step of the retroviral life cycle is integration.  Following 
nuclear entry the viral cDNA is permanently integrated into the host genome, a step that 
is responsible for viral persistence, the tumourigenic properties of oncogenic viruses as 
well as vertical transmission of certain viruses into the germline.  In the nucleus, the 
viral DNA can exist in linear double-stranded DNA form or as closed circles containing 
one copy of the LTR formed by homologous recombination between the LTRs, or two 
copies of the LTRs formed by blunt-end ligation.  Non-functional closed circles are also 
formed by autointegration of DNA ends into internal sites within the viral DNA 
resulting in deletions and mutations.  It is clear that the linear DNA form is the substrate 
for integration and that closed circles are dead-end products (Ellis and Bernstein, 1989; 
Lobel et al., 1989).  
 
The IN enzyme, which is also processed from Pol by the PR enzyme, performs the 
integration step (Schwartzberg et al., 1984).  The N-terminal region of IN contains a 
zinc-finger motif, the central region contains the catalytic activity and the carboxy-
terminal (C-terminal) region is a less well-conserved DNA-binding domain (Engelman 
and Craigie, 1992).  Similar to the RT enzyme, IN exists within the PIC in infected cells 
and does not function alone.  Integration of the viral DNA takes place in two steps 
termed 3’ end processing and strand transfer, and the att sites in the LTRs of the linear 
viral DNA, which are recognised by IN, are important for both of these processes 
(Figure 1.5).  The first of these steps involves removal of two terminal nucleotides from 
the 3’ ends of the linear DNA substrate by the IN enzyme.  Cleavage occurs at a highly 
conserved ca sequence and in the case of most retroviruses releases a tt dinucleotide.  
During strand transfer, the generated free 3’ OH ends of the viral DNA attack the 
phosphodiester bonds of the target chromosomal DNA forming a new phosphodiester 
bond between the viral DNA and the host DNA (Fujiwara and Mizuuchi, 1988).  This 
process results in the formation of staggered ends at the site of attack that are repaired 
by the cellular machinery, possibly assisted by RT or IN, generating target site 
duplications at either end of the provirus.  The end product is a clean insertion of the 
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viral DNA, consisting of the 5’ LTR and 3’ LTR flanking viral sequences, into the host 
chromosomal DNA (Goff, 2001; Craigie and Bushman, 2011). 
 
Proviral integrations are generally random and can technically mutate any gene; 
however, studies have shown that retroviruses do have preferential aspects for target 
sites.  For example, HIV-1 insertions predominate in highly active or transcribed 
regions, whereas, MLV inserts itself upstream of transcriptional start sites (Schroder et 
al., 2002; Wu et al., 2003).  These differences in preference may be owed to the half-life 
of infected cells, or alternatively, the pathway of nuclear import.  HIV-1 and MLV IN 
swap experiments resulted in the integration of chimeric HIV-1 near transcription start 
sites, analogous to MLV, implicating the IN enzyme in determining the target site for 
insertion amongst other factors (Lewinski et al., 2006).  Interestingly, the cellular 
protein lens epithelium-derived growth factor (LEDGF/p75) is an essential cofactor for 
HIV-1 integration and target site selection (Llano et al., 2006; Shun et al., 2007).  
LEDGF/p75 interacts with IN and tethers it to the chromatin, and disruption of this 






















               
 
Figure 1.5.  Integration. 
 
The linear viral cDNA is integrated into the host chromosomal DNA through two processes termed 3’ end 
processing and strand transfer.  The IN enzyme recognises and processes att sites located at the 3’ ends of 
the viral cDNA releasing two terminal nucleotides (generally a tt dinucleotide). The resultant 3’ OH ends 
generate staggered breaks in the host DNA, following which new phosphodiester bonds form between the 









1.5.6 Transcription  
Post-integration steps of the retroviral life cycle are often referred to as the late phase of 
viral replication, and in contrast to the early phase are regulated mainly by cellular 
proteins performing functions such as transcription and translation.  Transcription of the 
viral RNA is mediated by the cellular DNA-dependent RNA polymerase II (RNA pol 
II).  The viral promoter, consisting of core promoter elements as well as enhancer 
elements, is located in U3 and transcription is initiated at the U3-R border.  The 5’end 
of the viral RNA is capped akin to cellular mRNAs by host capping machinery.  
Transcription continues through the 3’ LTR and into the downstream flanking host 
DNA, following which the RNA is cleaved and polyadenylated at the R-U5 border due 
to the presence of a polyadenylation signal at the end of R.  This long primary transcript 
is exported into the cytoplasm and either incorporated into assembling virions as the 
viral genome or forms the mRNA for translation of Gag and Gag-Pro-Pol precursor 
proteins; whether the same viral transcript can serve both functions is unclear, although 
a report has proposed that a single pool serves interchangeably for both functions 
(Butsch and Boris-Lawrie, 2000).  Transcripts are also spliced into subgenomic mRNAs 
for the translation of other viral proteins, which for simple retroviruses is a single 
spliced mRNA encoding the Env protein, however, for complex retroviruses involves 
several alternatively spliced mRNAs for the translation of accessory and regulatory 
proteins (Goff, 2001).   
  
In the case of HIV-1 infection, short fully spliced mRNAs encoding the regulatory 
proteins Tat and Rev are produced immediately after infection.  Unusually for a 
transcription factor, Tat binds to an RNA hairpin structure called TAR in the R region 
that recruits cellular factors and enhances transcription elongation through the 5’ LTR 
and into the viral genome.  (Kao et al., 1987; Dingwall et al., 1990).  The cellular 
positive transcription elongation factor (P-TEFb) complex consists of the protein 
Cyclin-T1 reported to bind to cyclin-dependent kinase 9 (CDK9), Tat and TAR, and is 
an important cofactor for Tat-mediated transactivation of viral RNA transcription 
(Mancebo et al., 1997; Bieniasz et al., 1998; Wei et al., 1998).  Binding of Tat to the 
Cyclin-T1 component of P-TEFb induces conformational changes in the complex that 
result in CDK9-mediated phosphorylation of both positive and negative regulators of 
elongation.  These include factors such as the negative elongation factor (NELF), the 
DRB sensitivity-inducing factor (DSIF) and importantly the C-terminal domain of RNA 
42
 
pol II, facilitating the maintenance of Tat-mediated transcription elongation (Kim et al., 
2002; Fujinaga et al., 2004; Yamada et al., 2006).  Recent studies have also provided 
evidence for the recruitment of additional transcription and elongation factors by Tat, 
such as AF4/FMR2 family, member 4 (AFF4), eleven nineteen leukemia (ENL), ALL1-
fused gene from chromosome 9 protein (AF9) and elongation factor, RNA polymerase 
II, 2 (ELL2) (He et al., 2010).   
 
1.5.7 RNA processing and nuclear export  
Viral transcripts are exported from the nucleus following transcription for subsequent 
assembly steps and the translation of viral proteins.  Interestingly, intron-containing 
viral mRNAs are exported into the cytoplasm, despite the fact that cellular mRNAs are 
prevented from export until they are fully spliced.  Retroviruses evade splicing in a 
number of ways, a general mechanism for which may be the inefficient recognition of 
viral splice sites by the cellular spliceosome (Katz and Skalka, 1990).  Simple 
retroviruses such as M-PMV produce unspliced mRNAs that serve as the viral genome 
and encode gag, pro and pol.  Alternatively, the Env protein is translated from a fully 
spliced transcript.  Cis-acting elements termed the constitutive transport elements 
(CTEs) located at the 3’ end of M-PMV unspliced and fully spliced mRNAs mediate 
nuclear export by interacting directly with the cellular NXT/NXF1 nuclear export 
pathway (Bray et al., 1994; Wiegand et al., 2002).   
 
Complex retroviruses encode genes for regulatory and accessory proteins in addition to 
gag, pro, pol and env.  The HIV-1 RNA contains four splice donors and eight splice 
acceptor sites resulting in the production of a multitude of partially spliced and fully 
spliced mRNAs (Figure 1.6).  A 9kb unspliced primary transcript can be incorporated 
into virions as the viral genome, and also serves as the template for translation of 
structural and enzymatic Gag and Gag-Pro-Pol proteins.  A bicistronic partially spliced 
4kb mRNA encodes for both the Env protein and the accessory protein Vpu, and 
individual 4kb transcripts encode for the accessory proteins Vif and Vpr.  Fully spliced 
1.8kb mRNAs encode the regulatory proteins Tat, Rev and the accessory protein Nef.  
Due to the position of the 5’ splice donor all transcripts contain the highly structured 5’ 
untranslated region (UTR).  Intron-containing HIV-1 transcripts are exported from the 
nucleus by the regulatory protein Rev, which binds to an RNA structure in the env gene 
called the RRE (Sodroski et al., 1986; Malim et al., 1989; Malim and Cullen, 1991).  
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Fully spliced transcripts lack the RRE and are, therefore, exported from the nucleus by 
the cellular NXT/NXF1 pathway.  Consequently, during early HIV-1 infection and the 
presence of low levels of Rev, fully spliced viral mRNA species predominate in the 
cytoplasm.  However, later in infection when the levels of Rev are higher, both 
unspliced and partially spliced mRNAs are exported into the cytoplasm (Karn and 
Stoltzfus, 2011).  Rev contains a nuclear export signal (NES) via which it mediates the 
export of intron-containing mRNAs by interacting with the cellular karyopherin 
chromosome region maintenance 1 (CRM1).  CRM1 exports Rev-RRE complexes into 
the cytoplasm by associating with Ran GTPase, following which Rev is imported back 
into the nucleus (Fischer et al., 1995; Fornerod et al., 1997; Neville et al., 1997).  The 
significance of CRM1 as an important Rev cofactor is supported by studies showing 
that the block to HIV-1 particle production in murine and rat cells can be rescued with 
























     
 
Figure 1.6.  Splicing patterns of the HIV-1 genome. 
 
The HIV-1 genome contains four splice donor (D1, D2, D3, D4; depicted in red) and eight splice acceptor 
sites (A1, A2, A3, A4 (a, b, c), A5, A8; depicted in black).  Unspliced 9kb transcripts encode Gag and the 
Gag-Pro-Pol polyprotein.  Incompletely spliced 4kb mRNAs encode Env, Vpu, Vif and Vpr proteins.  
Completely spliced 1.8kb transcripts encode the Tat, Rev and Nef proteins.  Adapted from (Karn and 



















1.5.8 Translation and viral proteins 
Retroviral transcripts contain a long and highly structured 5’UTR making them 
inefficient substrates for cap-dependent translation initiation (Parkin et al., 1988); 
nevertheless viral proteins are translated.  Several cellular factors have been implicated 
in aiding cap-dependent translation initiation (Hartman et al., 2006; Woolaway et al., 
2007; He et al., 2009; Bolinger et al., 2010; Swanson et al., 2010).  Furthermore, the use 
of a cap-independent internal ribosome entry sequence (IRES) has also been proposed, 
and IRES sequences have been identified in HIV-1 although this remains controversial 
(Buck et al., 2001; Brasey et al., 2003). 
 
All simple and complex retroviruses express the gag, pro and pol genes from unspliced 
mRNAs, coding for the structural and enzymatic proteins of the virus.  Gag translation 
is initiated at an AUG codon at the 5’ end of the gag gene till a stop codon at the 3’ end 
of the open reading frame (ORF) that terminates translation.  Some retroviruses, such as 
MLV, encode an additional longer Gag protein that is glycosylated, the translation of 
which initiates at a CUG codon upstream of the canonical AUG initiator codon.  For the 
majority of retroviruses, a myristic acid important for membrane targeting is added to 
the major Gag product at the first glycine residue (Henderson et al., 1983).  Gag is not 
only the core structural protein of virions, but is essential for packaging of the viral 
RNA as well as plasma membrane targeting for incorporation of the Env glycoprotein 
during virion budding (Goff, 2001). 
 
The expression of pro and pol varies between viruses according to their genome 
organisation.  In the case of gammaretroviruses, gag, pro and pol are in the same 
reading frame, however, there is a UAG stop codon between gag and pro-pol 
(Yoshinaka et al., 1985).  Mostly, translation terminates at this stop codon, producing 
Gag only, however, a small percentage of the time the ribosome reads through the stop 
codon by inserting an amino acid such as glutamine into the chain, resulting in the 
production a Gag-Pro-Pol polyprotein.  The presence of a downstream pseudoknot has 
been implicated in the mechanism of read-through (Wills et al., 1991).  Lentiviruses 
have gag and pro-pol in separate reading frames requiring a single frameshift for 
translation of the Gag-Pro-Pol polyprotein.  Similar to gammaretroviruses, translation 
results in the production of Gag predominantly, however, on occasion the ribosome 
slips by one nucleotide (-1) at the end of the gag ORF and continues translation 
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bypassing the stop codon in the previous reading frame (Jacks et al., 1988; Wilson et al., 
1988; Parkin et al., 1992).  For the betaretroviruses, gag, pro and pol are all in different 
ORFs and, therefore, two successive frameshifts are required for translation of the Gag-
Pro-Pol precursor protein (Jacks et al., 1987).  Pol is processed by the PR enzyme to 
produce the RT and IN enzymes that mediate defining steps of the retroviral life cycle 
(sections 1.5.3 and 1.5.5).  The coordinated synthesis of Gag and Gag-Pro-Pol ensures 
that the correct balance of structural and enzymatic proteins is achieved in the mature 
virion (Jacks et al., 1988). 
 
In the case of simple retroviruses the Env protein is translated from a fully spliced 
mRNA exported into the cytoplasm by the cellular NXT/NXF1 nuclear export 
machinery.  On the other hand, HIV-1 Env is translated from a partially spliced 
bicistronic mRNA that also encodes Vpu by a process termed leaky scanning.  The 
presence of a weak Kozak consensus around the vpu AUG initiator codon allows the 
ribosome to scan past it and initiate translation from the downstream env AUG codon 
(Schwartz et al., 1990; Schwartz et al., 1992).   
 
1.5.8.1 Primate lentivirus regulatory and accessory proteins 
In addition to the structural and enzymatic viral proteins, primate lentiviruses also 
encode regulatory proteins such as Tat and Rev, and accessory proteins such as Vif, 
Vpr, Vpx, Vpu and Nef.  These proteins are translated from either partially spliced 
transcripts (Vif, Vpu, Vpr, Vpx) or fully spliced mRNAs (Tat, Rev and Nef).   
 
The regulatory proteins Tat and Rev are dedicated to regulation of the viral life cycle, 
namely transcription of the viral RNA and nuclear export, respectively (sections 1.5.6 
and 1.5.7).  The accessory proteins have evolved to accomplish a range of functions 
such as evasion of the host immune response and counteraction of cellular restriction 
factors to enable effective replication and spread of the virus.  Vif, Vpu and Vpx are 
prime examples of viral factors that antagonise antiviral host proteins, the functions of 
which will be discussed in greater detail in later sections in context with the restriction 
factors (section 1.8.2). 
 
Nef is small viral accessory protein that is produced early during infection, similarly to 
Tat and Rev. SIVs use Nef instead of Vpu to counteract tetherin, however in addition to 
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this Nef is a multifunctional protein with roles in trafficking of host factors and escape 
from immune recognition.  Nef expression downregulates CD4 from the surface of 
infected cells via clathrin coated pits and endosomal pathways leading to the eventual 
degradation of CD4 in lysosomes (Chaudhuri et al., 2007).  Similarly, the HIV-
1/SIVcpz Vpu accessory protein also reduces the expression of CD4 on the surface of 
infected cells by interacting with CD4 in the endoplasmic reticulum (ER) and triggering 
its proteasomal degradation (Margottin et al., 1998).  Targeting of CD4 in this manner 
reduces the chances of superinfection, facilitates efficient virus release and in the case 
of Vpu-mediated degradation, prevents the formation of Env-CD4 complexes in the ER 
enhancing the incorporation of Env into assembling virions [reviewed in (Kirchhoff, 
2010)].  Nef also reduces the surface expression of major histocompatibility complex 
(MHC) class I molecules on infected cells by, firstly, redirecting them from the trans-
Golgi network to endosomal pathways instead of the cell surface and, secondly, 
downregulating MHC class I from the surface of the cell directly (Lubben et al., 2007).  
This serves to hamper the virus-specific CD8+ CTL response (Swigut et al., 2004).  
Interestingly, Nef selectively targets only human leukocyte antigen (HLA) A and B to 
avoid recognition and attack by natural killer (NK) cells (Cohen et al., 1999).  Nef also 
affects antigen presentation by MHC class II (Stumptner-Cuvelette et al., 2001) and, 
more recently, has been reported to induce apoptosis in bystander CD4+ T cells 
(Lenassi et al., 2010).  Furthermore, a crucial role for Nef has also emerged in the 
modulation of host cytoskeletal-dynamics and consequently immune activation in vivo.  
Nef partially associates with the cytoskeleton and localises to immunological synapses 
where it potentiates TCR signalling (Fackler et al., 1999; Fenard et al., 2005; Thoulouze 
et al., 2006). 
 
Vpr is a 96 amino acid protein that is packaged into budding viral particles.  Aside from 
the capacity of Vpr from certain SIV isolates to counteract the recently identified 
cellular restriction factor, sterile α motif (SAM) and HD domain containing protein 
(SAMHD1), Vpr expression is also able to arrest cells in the G2 phase of the cell cycle 
(Jowett et al., 1995; Goh et al., 1998).  Reports have attributed this to the association of 
Vpr with the cullin4-RING ubiquitin ligase (CRL4)-DNA damage-binding protein 1 
(DDB1) complex via an interaction with the DDB1-CUL4 associated factor 1 (DCAF1), 
which may target a cellular factor/s important for cell cycle progression to the 
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proteasome for degradation (Hrecka et al., 2007; Schrofelbauer et al., 2007).  Vpr has 
also been implicated in nuclear import (section 1.5.4).  
 
1.5.9 Assembly 
Translation of the viral structural proteins initiates the assembly of progeny virions.  
The Gag protein consists of the N-terminal MA domain which functions in plasma 
membrane targeting and Env incorporation.  The myristic acid, a basic patch in MA, as 
well as the phosphatidyl inositol (4,5) biphosphate (PI(4,5)P2) lipid in the plasma 
membrane are required for Gag membrane targeting (Ono et al., 2004).  The central CA 
region and NC domains mediate the protein-protein interactions for assembly of the 
immature virion, and NC also packages the viral genome amongst other functions.  For 
HIV-1, the C-terminal p6 region contains the late assembly domains for viral release.  
HIV-1 also encodes the spacer p2 and p1 peptides that assist the conformational 
changes in Gag during processing and maturation (Sundquist and Krausslich, 2011).  
The assembly process is directed primarily by the Gag precursor and minimal regions of 
Gag alone can assemble immature virions (Accola et al., 2000).  Experiments with HIV-
1 have shown that the MA domain is dispensable for assembly provided that the 
myristyl switch is intact (Reil et al., 1998).  Furthermore, swapping the NC domain with 
a leucine zipper dimerisation or tetramerisation motif allows efficient assembly, 
suggesting that the protein-protein interaction function of NC, but not RNA packaging, 
is necessary for assembly (Accola et al., 2000; Johnson et al., 2002).  On the other hand, 
mutations in the C-terminal domain of CA and p1 are detrimental for assembly (von 
Schwedler et al., 2003).   
 
In the case of gammaretroviruses and lentiviruses, the myristyl switch at the N-terminus 
of MA targets the Gag precursor to the inner face of the plasma membrane for 
assembly.  In contrast, betaretroviruses such as M-PMV assemble in the cytoplasm and 
are subsequently transported to the plasma membrane for Env incorporation and 
budding.  Interestingly, the substitution of a single amino acid in the MA domain of the 
M-PMV Gag precursor can shift the site of virion assembly to the plasma membrane 
(Rhee and Hunter, 1990).  The presence of a dominant cytoplasmic targeting-retention 




The Gag-Pro-Pol polyprotein, Env and, in the case of HIV-1, the accessory protein Vpr 
are incorporated into assembling virions by interacting with Gag.  The Env precursor, 
gp160, is synthesised and inserted into the ER cotranslationally for glycosylation.  
Heavily glycosylated gp160 is assembled into trimers and transported to the Golgi 
where it is cleaved by the cellular protease furin into the gp120 and gp41 subunits, 
following which the trimers are delivered to the plasma membrane and expressed on the 
cell surface.  Env is incorporated into virions at the site of assembly during viral 
budding through non-specific interactions between the cytoplasmic tail of gp41 and the 
MA region of Gag (Freed and Martin, 1996), which may require the cellular factor tail-
interacting protein, 47 kD (Tip47) (Bauby et al., 2010).  The HIV-1 accessory proteins 
Nef and Vif are also incorporated into assembling virions non-selectively.  Cellular 
proteins have also been detected in HIV-1 particles, such as MHC class II molecules, 
antiviral APOBEC3 proteins as well as the putative RNA helicase moloney leukemia 
virus 10 (MOV10) (Chertova et al., 2006) (section 1.13).     
  
1.5.9.1 RNA packaging 
The dimeric unspliced viral genome is incorporated into virions through interactions 
between the Psi at the 5’ end of the genome and the NC domain of Gag (Berkowitz et 
al., 1993).  The Cis-His boxes and basic residues in NC are important for this 
interaction (Housset et al., 1993).  The viral Psi is composed of a number of important 
stem loop structures that contribute to the overall efficiency of packaging (Fisher and 
Goff, 1998), and replacing one of these stem loops with a heterologous NC-binding 
sequence maintains efficient genome packaging demonstrating that binding to NC is the 
main function of these cis-acting elements (Clever et al., 2000).  The current model for 
HIV-1 genome packaging suggests that Gag binds to the dimeric genome in the 
cytoplasm and subsequently travels to the plasma membrane for assembly (Jouvenet et 
al., 2009; Kutluay and Bieniasz, 2010).  The unspliced primary transcript is also a 
template for the translation of Gag and Gag-Pro-Pol precursor proteins.  HIV-2 was 
previously reported to package its genome co-translationally (Kaye and Lever, 1999), 
although the efficient production of HIV-2 vectors has rendered these findings 
somewhat controversial.  On the other hand, MLV uses two separate pools for 
translation and assembly (Levin and Rosenak, 1976).  In the case of HIV-1, studies have 
attempted to understand whether translation and assembly are mutually exclusive events 
(Butsch and Boris-Lawrie, 2000) although this is still not completely clear.  Retroviral 
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particles also package tRNAs for the initiation of reverse transcription.  The Gag-Pro-
Pol precursor and genomic RNA selectively incorporate tRNAs, which are then 
annealed to the PBS for initiation of reverse transcription (Kleiman et al., 2010).    
 
1.5.10 Budding 
The viral lipid bilayer is derived from the cell plasma membrane during budding.  
Assembly is thought to occur at sites in the plasma membrane termed lipid rafts, 
supported by the enrichment of raft lipids in the viral membrane as well as PI(4,5)P2 
(Brugger et al., 2006; Chan et al., 2008).  HIV-1 budding is also polarised in that virions 
accumulate at sites in close connection with uninfected cells for cell-to-cell transmission 
across a virological synapse [reviewed in (Mothes et al., 2010)]. 
 
Viral release is catalysed by the host endosomal sorting complexes required for 
transport (ESCRT) machinery, which bind to the ‘late domain’ motifs in Gag.  The 
location and number of these motifs can vary depending on the virus.  HIV-1 harbours 
two such motifs in the C-terminal p6 domain and the main PTAP motif recruits the 
tumour susceptibility gene 101 (TSG101) subunit of the ESCRT-I complex  (Garrus et 
al., 2001; Martin-Serrano et al., 2001), whereas the second YPXL motif binds to the 
ESCRT-III factor ALIX (Strack et al., 2003).  The p6 domain also interacts with 
members of the neural precursor cell expressed, developmentally down-regulated 4 
(NEDD4) ubiquitin ligase family, an interaction also observed between the PPXY late 
domain motifs in retroviruses such as MLV (Weiss et al., 2010).  Both TSG101 and 
ALIX interactions ultimately orchestrate the recruitment of ESCRT-III and the vacuolar 
protein sorting 4 (VPS4) ATPase complexes, which perform the membrane fission step 
[reviewed in (Weiss and Gottlinger, 2011)].  The ESCRT-III charged multivesicular 
body proteins (CHMPs) CHMP2 and CHMP4 are necessary for HIV-1 budding, 
however, CHMP1 and CHMP3 have also been reported to play a role in this process 
(Morita et al., 2011).  CHMP4 filaments together with CHMP2 have been observed to 
form ‘spirals’ at the neck of the budding virus, which together with VPS4 mediate 
fission [reviewed in (Guizetti and Gerlich, 2012)].  Furthermore, the ATPase activity of 
VPS4 is required for disassembly and release of the ESCRT-III complex (Lata et al., 






Immature non-infectious viral particles bud from the plasma membrane and are 
processed by the viral PR enzyme for the production of mature infectious virions.  PR 
exists as a Gag-Pro-Pol fusion polyprotein in the immature particle, and is responsible 
for an intramolecular cleavage event to release itself from the precursor protein (Tang et 
al., 2008).  PR then processes the Gag and Gag-Pro-Pol proteins to the smaller structural 
and enzymatic components MA, NC, CA, p6 in the case of HIV-1, PR, RT and IN 
(section 1.4).  The morphology of the virion changes drastically during maturation from 
a spherical shape and electron-lucent centre to a more condensed shape with a 
characteristic core that is detached from the Env lipid bilayer (Goff, 2001).  Maturation 
of the virus activates gp41 for fusion, assembles capsid into the characteristic core and 
stabilises the genomic RNA.  Viruses lacking PR or the use of PR inhibitors produce 
progeny that are blocked at a step following entry, however, prior to reverse 
transcription (Kohl et al., 1988).   
 
1.6 Endogenous retroviruses (ERVs) 
Integration of the provirus into the host genome is essential for productive infection, 
providing a permanent template for the generation of viral transcripts.  Integration into 
the germline permits vertical transmission of the virus, an event that has transpired on 
multiple occasions over millions of years in a range of species including humans, 
leading to the generation of endogenous retroviruses (ERVs).  Approximately 8% of the 
human genome is derived from endogenous retroviral sequences.   
 
The first ERVs discovered were ASLV in chickens, and MLV and MMTV in mice by a 
series of immunological, virological and Mendelian inheritance studies, followed 
closely by the discovery of the RT enzyme [reviewed in (Weiss, 2006)].  The life cycle 
and genetic organisation of ERVs closely resembles that of exogenous retroviruses with 
gag, pro, pol and env sequences flanked by LTRs; however most ERVs are defective 
due to the acquisition of inactivating point mutations or larger deletions during 
endogenisation.  For this reason human ERVs (HERVs) are non-infectious, although 
evidence supports the possible existence of some active HERV-K elements (Turner et 
al., 2001).  Several full-length active ERVs have, however, been identified in mice.  The 
intracisternal A-type particle (IAP) family related to betaretroviruses are extremely 
active elements, present at approximately a thousand copies per cell (Kuff and Lueders, 
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1988) (Figure 1.7A).  IAP elements have a strictly intracellular life cycle due to the 
absence of a complete env gene and the presence of a sequence in MA that targets 
immature particles to the ER for budding (Ribet et al., 2008).  Interestingly, ERVs 
related to complex retroviruses, such as the lentiviruses, are rare in comparison to those 
derived from simple gammaretroviruses and betaretroviruses; although such 
endogenous sequences have recently been identified in rabbits, lemurs and sloths 
(Katzourakis et al., 2007; Gilbert et al., 2009; Katzourakis et al., 2009). 
 
As expected, ERV colonisation of the host germ line is associated with a range of 
potential mutagenic effects.  ERV insertions can affect the expression of nearby genes 
by modulating the transcription, splicing and stability of cellular transcripts [reviewed 
in (Stoye, 2012)].  However, aside from endogenous MMTV and MLV induced 
tumours in inbred mice, it has been difficult to correlate HERV activation as the cause 
or result of human diseases such as cancer, autoimmune disorders and 
neuropathological conditions [reviewed in (Ruprecht et al., 2008; Dreyfus, 2011; 
Leboyer et al., 2011)].  On the contrary, the odd beneficial outcome of ERV insertions 
is exemplified by the host syncytin genes that play a vital role in mammalian placenta 
formation, which have been derived from the capture of env genes from ERVs (Mi et 
al., 2000; Dupressoir et al., 2009).  The replication of exogenous and endogenous 
retroelements is controlled by cellular epigenetic mechanisms and restriction factors, 
which will be discussed in greater detail in later sections (section 1.8). 
 
1.7 Retrotransposons 
Retrotransposons are non-LTR endogenous retroelements that make up approximately 
35% of the human genome.  Human retrotransposons can be divided into the long 
interspersed nucleotide element-1 (LINE-1) family, short interspersed nucleotide 
elements (SINEs) Alu and SVA, and processed pseudogenes (Table 1.3).  These 
elements reverse transcribe via an RNA intermediate, however, the life cycle and 
genetic organisation of retrotransposons varies from that of retroviruses.  Due to the 
focus of this thesis on human LINE-1 and Alu retrotransposons, these will be discussed 






Table 1.3.  Human retrotransposons. 




Processed pseudogene ∼1% 
 
1.7.1 LINE-1 and Alu 
The LINE-1 family of retrotransposons are the only autonomously acting non-LTR 
elements in humans.  Although the majority of LINE-1 members are inactive due to 
truncations and mutations, approximately 80-100 full-length retrotransposition-
competent LINE-1s are active in an individual (Ostertag and Kazazian, 2001; Brouha et 
al., 2003; Martin et al., 2005).  Members of this retrotransposon family are 
approximately 6kb in length with a 5’ UTR and a 3’ UTR flanking two ORFs separated 
by a small spacer (Figure 1.7B).  An internal RNA pol II promoter is located in the 5’ 
UTR and the 3’ UTR contains the polyadenylation signal (Swergold, 1990).  Read-
through of the polyadenylation signal generates chimeric LINE-1 transcripts containing 
the 3’ flanking host sequences (Moran et al., 1999; Goodier et al., 2000).  The 5’ UTR 
also contains an antisense promoter (ASP) that has been implicated in the post-
transcriptional control of LINE-1 retrotransposition (Yang and Kazazian, 2006).  ORF1 
encodes a 40kda protein termed ORF1p that consists of an N-terminal coiled-coil 
domain required for trimerisation, a central RNA recognition motif (RRM) and a basic 
C-terminal domain, the latter two of which are necessary for nucleic acid binding.  
ORF1p also possesses nucleic acid chaperone activity important for nuclear import and 
subsequent reverse transcription and integration steps (Khazina and Weichenrieder, 
2009; Khazina et al., 2011)[reviewed in (Martin, 2010)].  ORF2 encodes the 150kda 
protein called ORF2p with endonuclease (EN) and RT enzymatic activities.  Reports 
have also shown the cysteine-rich domain at the C-terminal end to be important for 
retrotransposition (Mathias et al., 1991; Feng et al., 1996).  ORF1p and ORF2p are 
translated from a bicistronic transcript, and uniquely, ORF2p is translated by an 
unconventional termination and reinitiation mechanism and not IRES-mediated 
translation (Alisch et al., 2006; Dmitriev et al., 2007).  Both ORF1p and ORF2p 
demonstrate cis-preference by preferentially binding to their encoding mRNA in the 
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cytoplasm leading to the formation of a ribonucleoprotein (RNP) complex that serves as 
the equivalent of a retroviral RTC/PIC (Hohjoh and Singer, 1996; Kulpa and Moran, 
2006; Doucet et al., 2010).  
 
Alu is a human non-LTR nonautonomous retrotransposon that does not encode any 
proteins and is, therefore, dependent on LINE-1 ORF2p to facilitate its 
retrotransposition in trans (Dewannieux et al., 2003) (Figure 1.7B).  Full-length active 
Alu elements are approximately 300bp in length with a polyA tail and contain two 
monomeric sequences derived from the 7SL RNA, which is the signal recognition 
particle (SRP) RNA, separated by an adenosine-rich sequence.  The internal RNA pol 
III promoter is located in the left monomer [reviewed in (Beck et al., 2011)].  The left 
monomer also consists of a binding site for SRP 9/14, an interaction that is thought to 
associate Alu elements with ribosomes and nascent LINE-1 ORF2p.   
 
Unlike retroviruses, retrotransposons couple reverse transcription and integration by a 
mechanism called target-site primed reverse transcription (TPRT) that takes place in the 
nucleus (Figure 1.8).  As retrotransposition can occur in non-dividing cells, the RNP 
complex is actively imported into the nucleus (Kubo et al., 2006).  Within the nucleus, 
ORF2p-EN nicks a single strand of the host DNA to expose a free 3’ OH that serves as 
a primer for ORF2p-RT to initiate reverse transcription of the first cDNA strand using 
the mRNA as a template.  Cleavage of the second host DNA strand permits generation 
of the second cDNA strand using the first cDNA strand as a template.  The integrated 
LINE-1 or Alu copies are flanked by characteristic target site duplications (Cost et al., 
2002; Christensen and Eickbush, 2005).  Significantly, an ORF2p-EN independent 
mechanism of LINE-1 retrotransposition has also been proposed (Morrish et al., 2002; 









              
   
Figure 1.7.  IAP, LINE-1 and Alu genome organisation. 
 
(A) IAP genome organisation.  The LTR-containing IAP endogenous retrovirus (ERV) encodes only 
gag, pro and pol.  (B) LINE-1 and Alu genome organisation.  LINE-1 is a non-LTR retrotransposon 
consisting of a 5’ untranslated region (UTR), two open-reading frames (ORFs) and a 3’ UTR.  ORF1 
encodes a protein with a coiled-coil domain (CC), an RNA-recognition motif (RRM) a basic carboxy-
terminal domain (CTD).  ORF2 encodes a protein with endonuclease (EN) and reverse transcriptase (RT) 
enzymatic activities, as well as a cysteine-rich carboxy-terminal region (C).  The arrows in the 5’ UTR 
depict the sense and antisense LINE-1 promoters.  Alu is a non-LTR retrotransposon that is transcribed 
from a pol III promoter and is composed of two monomeric sequences derived from the 7SL RNA (L-
















          
 
Figure 1.8.  Target-primed reverse transcription. 
 
The LINE-1 ORF2p-EN activity nicks a single strand of the host DNA (1) exposing a free 3’ OH (2) that 
serves as a primer for initiation of reverse transcription by LINE-1 ORF2p-RT enzymatic activity and 
synthesis of the first cDNA strand (3).  LINE-1 ORF2p-EN activity nicks the other single strand of the 
host DNA (4) priming synthesis of the second cDNA strand using the first cDNA strand as a template (5).  
Complete extension and ligation of the first and second strands (6) generates an integrated copy of the 
retrotransposon cDNA flanked by characteristic target-site duplications (7).  DNA is illustrated in purple 
and RNA in green.  The red and orange boxes represent sites of complementarity.  Adapted from (Holmes 









1.7.2 Disease associations 
Retrotransposition events can be mutagenic in a number of ways.  Insertions can 
directly disrupt exons, or alternatively, integrations into introns can result in aberrant 
splicing of transcripts.  LINE-1 retrotranspositions have also been associated with large 
genomic deletions and inversions [reviewed in (Kazazian and Goodier, 2002)].  
Although infrequent in vivo, read-through of polyadenylation signals encourages the 
retrotransposition of cellular mRNAs, termed processed pseudogenes.  Remarkably, 
such a retrotransposition event mediated the insertion of the CypA cDNA into the 
TRIM5 locus in owl monkeys, resulting in the production of a novel HIV-1 restriction 
factor in this species (Sayah et al., 2004).  Such an event has also transpired 
independently in rhesus macaques, although the antiviral specificity of TRIMCyp in this 
species varies (Wilson et al., 2008).  Furthermore, the LINE-1 ORF2p-EN activity has 
been proposed to cause genomic instability by mediating double-strand breaks 
[reviewed in (Beck et al., 2011)].  Such events can occur in both the germ line, although 
less likely due to strong negative selection pressures, as well as somatic cells.  To date, 
at least 96 retrotransposition insertions have resulted in single gene diseases such as 
haemophilia, cystic fibrosis, breast cancer and colon cancer [reviewed in (Hancks and 
Kazazian, 2012)].  Somatic LINE-1 insertions have also been detected in lung, prostate 
and ovarian cancers (Iskow et al., 2010; Lee et al., 2012).  Interestingly, LINE-1 copy 
numbers are elevated in the human brain in comparison with the heart and liver (Coufal 
et al., 2009) and, remarkably, over 20,000 novel LINE-1 and Alu insertions have been 
identified in the human hippocampus and caudate nucleus (Baillie et al., 2011), 
collectively suggesting that somatic retrotransposition events may underlie non-
hereditary normal and abnormal neurobiological processes. 
 
1.8 Regulation of exogenous and endogenous retroelements 
Hosts have developed multiple transcriptional and post-transcriptional mechanisms to 
protect themselves from the pathogenic and mutagenic effects of exogenous and 
endogenous retroelements.  This section will review the most prominent of these innate 
lines of defence.   
 
1.8.1 Epigenetic regulation  
One of the crucial ways to control the replication of retroviruses and retrotransposons is 
to inhibit their transcription through extensive DNA methylation at promoter sequences.  
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This process is orchestrated by a family of DNA methyltransferase enzymes that target 
a methyl group to the cytosine residue of a CpG dinucleotide.  ERVs and 
retrotransposons in mice germ cells are targeted by DNA methylation through the 
nucleotide complementarity of small RNAs such as piwi-interacting RNAs (piRNAs).  
PIWI proteins, which are members of the Argonaute (AGO) family, drive these 
processes and male mice that are homozygous null for these factors display a loss of 
DNA methylation at retroelement promoters in germ cells and an increase in the 
abundance of ERV and retrotransposon transcripts (Aravin et al., 2007; Kuramochi-
Miyagawa et al., 2008).  Studies have also shown microRNAs (miRNAs) to control the 
methylation of gene promoters in mice, suggesting that other small RNA pathways may 
also facilitate such processes (Benetti et al., 2008; Sinkkonen et al., 2008).  
Alternatively, it has been known for some time that Moloney-MLV (M-MLV) 
replication is inhibited in embryonic carcinoma and embryonic stem cells.  Recent 
studies have attributed this to a PBS-mediated silencing complex containing the integral 
transcriptional silencing factor TRIM28 (Wolf and Goff, 2007; Wolf et al., 2008; Wolf 
et al., 2008; Wolf and Goff, 2009).  Interestingly, LINE-1 and Alu insertions have been 
implicated in several human cancers and their increased activity has been correlated 
with hypomethylation of retrotransposon promoters supporting the presence of this 
epigenetic regulatory pathway in humans [reviewed in (Belancio et al., 2010)].  LINE-1 
expression and retrotransposition are also enhanced in the absence of the methyl-CpG-
binding protein 2 (MeCP2), a factor necessary for global DNA methylation (Muotri et 
al., 2010).  Furthermore, piRNA clusters have been identified in humans as well (Girard 
et al., 2006) and, more recently, a report has identified naturally occurring endogenous 
short-interfering RNAs (endo-siRNAs) that silence human LINE-1 expression through 
DNA methylation of the promoter (Chen et al., 2012). 
 
1.8.2 Cellular restriction factors  
Mammalian cells express a range of proteins that restrict the replication of exogenous 
and endogenous retroelements at various stages of the life cycle.  Retroviruses, such as 
HIV-1, have also evolved a number of diverse accessory proteins to counteract these 






1.8.2.1 Fv4  
The Fv4 gene, identified in Japanese wild mice, confers resistance to infection by 
Friend virus (Suzuki, 1975).  This gene encodes a defective provirus lacking all of gag 
and most of pol, although retaining a complete env sequence with several mutations 
(Ikeda et al., 1985).  The mutated Env protein interacts with the E-MLV CAT-1 
receptor, therefore, downregulating it from the surface and blocking infection by viruses 
utilising the same receptor for entry (Kai et al., 1986; Ikeda and Sugimura, 1989). 
 
1.8.2.2 Fv1 
The Fv1 locus also controls the susceptibility of certain mouse strains to Friend MLV 
infection (Pincus et al., 1971; Pincus et al., 1975).  Two alleles of Fv1 confer resistance 
to particular MLVs, namely the Fv1b allele that blocks infection by N-tropic viruses and 
the Fv1n allele that restricts infection by B-tropic viruses; heterozygous mice can inhibit 
both N and B-tropic viruses.  The Fv1 gene encodes a Gag-like protein related to the 
murine ERV-L family, and characterisation of the block revealed that restricted viruses 
can enter the cell and reverse transcribe, however, the PIC is trapped in the cytoplasm 
and does not enter the nucleus (Pryciak and Varmus, 1992).  The CA protein and more 
specifically residue 110 determines sensitivity to Fv1, (Kozak and Chakraborti, 1996), 
however, the exact mechanism of action remains to be elucidated (Best et al., 1996; 
Benit et al., 1997). 
 
1.8.2.3 TRIM5α and TRIMCyp 
The identification of Fv1 led to the realisation that many mammalian cell lines, 
including human, could also restrict N-tropic MLVs.  Similar to Fv1, susceptibility of 
the virus to restriction was dependent on amino acid 110 of the CA protein, although the 
block to infection occurred prior to reverse transcription (Towers et al., 2000).  
Furthermore, nonhuman primate cell lines restricted HIV and SIV with similar 
characteristics (Cowan et al., 2002; Munk et al., 2002; Hatziioannou et al., 2003).  A 
screen for HIV-1 restriction factors by introducing a cDNA expression library from 
non-permissive rhesus macaque cells into permissive human cells resulted in the 
identification of a novel restriction factor TRIM5α (Hatziioannou et al., 2004; 




TRIM5α is a member of the ‘tripartite motif’-containing family of proteins, which 
consist of an N-terminal RING and B-box type 2 domain, a central coiled-coil domain 
for dimerisation, and in the case of TRIM5α a C-terminal domain called the B30.2 or 
PRYSPRY domain (Malim and Bieniasz, 2012).  Evolutionary and mutagenesis studies 
have deduced that the SPRY domain is responsible for the recognition of specific 
retroviral CA proteins (Sawyer et al., 2005; Stremlau et al., 2005; Yap et al., 2005).  
The restrictive activity of TRIM5α is fairly broad and dependent on the species of 
origin, for example, human TRIM5α can restrict N-MLV and equine infectious anaemia 
virus (EIAV), but not HIV-1, however, TRIM5α from Old World monkeys can restrict 
HIV-1 (Hatziioannou et al., 2004; Keckesova et al., 2004; Stremlau et al., 2004).  This 
capacity of TRIM5α proteins to ‘tolerate’ viruses that naturally infect the host in 
comparison to the restriction of viruses from other species is a potential mechanism for 
the prevention of cross-species transmission events.   
 
Lentiviral CA proteins also bind to the host protein CypA, and this interaction has been 
shown to increase the sensitivity of HIV-1 to TRIM5α-mediated restriction in Old 
World monkeys, but not in human cells (Berthoux et al., 2005; Keckesova et al., 2006).  
Alternatively, CypA has a stimulatory effect on HIV-1 infectivity in human cells 
possibly by acting as a cofactor, or alternatively, counteracting an unidentified antiviral 
factor (Sokolskaja et al., 2006).  Remarkably, in owl monkeys and rhesus macaques, 
retrotransposition events have transduced the CypA cDNA into the TRIM5α locus 
generating a chimeric gene encoding the TRIMCypA fusion protein in which CypA has 
replaced the PRYSPRY domain for capsid binding (Sayah et al., 2004).  Although the 
mechanism by which TRIM5α and TRIMCypA restrict retroviruses is not completely 
understood, studies suggest that accelerated disruption of the viral core may be an 
important factor (Stremlau et al., 2006; Wilson et al., 2008). 
 
1.8.2.4 ZAP 
The zinc-finger antiviral protein (ZAP) was identified in a rat cDNA library screen as an 
MLV restriction factor able to block the accumulation of viral RNAs in the cytoplasm, 
although transcribed viral transcripts could be readily detected in the nucleus (Gao et 
al., 2002).  Transfer of a small sequence from the 3’ end of the viral RNA to 
heterologous cellular mRNAs confers susceptibility to ZAP-mediated downregulation.  
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Studies have shown that ZAP binds to viral RNAs via its zinc-finger clusters targeting 
them for degradation via the RNA exosome (Guo et al., 2004; Guo et al., 2007).   
 
1.8.2.5 Tetherin  
A common experimental approach for the identification of cellular restriction factors is 
the fusion of cells permissive and non-permissive to viral infection or steps in the viral 
life cycle, to form heterokaryons that express factors from both cell types.  A dominant 
restrictive phenotype suggests the presence of an intrinsic restriction factor in the non-
permissive cell type and, alternatively, a susceptible phenotype supports the presence of 
a cofactor in permissive cells that is absent in non-permissive cells.  The HIV-1 
accessory protein Vpu was shown to be required for HIV-1 infection in heterokaryon 
experiments that revealed a dominant block to HIV-1 release in a type I interferon α 
(IFNα)-sensitive manner (Varthakavi et al., 2003; Neil et al., 2007).  HIV-1 particles 
remained trapped or tethered to the surface of infected cells in the absence of Vpu, 
following which they were internalised into endosomes (Neil et al., 2006).  
Subsequently, the IFNα-inducible restriction factor tetherin was identified by 
microarray studies (Neil et al., 2008; Van Damme et al., 2008).   
 
Tetherin is a type II transmembrane protein that functions as a dimer.  It contains an N-
terminal cytoplasmic and transmembrane domain, an extracellular coiled-coil domain 
necessary for dimerisation, and a C-terminal glycophosphatidylinositol (GPI) lipid 
anchor that is inserted back into the plasma membrane.  The configuration of tetherin 
rather than its primary sequence is important for antiviral activity, which also explains 
its capacity to restrict a diverse range of enveloped viruses (Perez-Caballero et al., 
2009).  However, the N-terminal transmembrane domain and GPI anchor are essential 
for its tethering ability, one pair of which inserts itself into the viral lipid envelope and 
the other pair remains attached to the plasma membrane (Malim and Bieniasz, 2012).   
 
Considering the broad antiviral activity of tetherin, HIVs and SIVs have evolved 
independent mechanisms to antagonise it.  HIV-1 Vpu is a small 14kda protein with a 
transmembrane domain and short cytoplasmic tail.  Vpu counteracts tetherin by binding 
to it and inducing its cell surface downregulation and ultimate degradation (Van 
Damme et al., 2008; Mitchell et al., 2009; Dube et al., 2010).  The Vpu transmembrane 
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domain and cytoplasmic tail determinants necessary for the antagonism of tetherin have 
been mapped (Vigan and Neil, 2010; Kueck and Neil, 2012).  The majority of SIVs do 
not encode Vpu and have instead resorted to using Nef for the counteraction of tetherin, 
which is thought to occur via the AP-2 clathrin adaptor complex (Zhang et al., 2009; 
Zhang et al., 2011).  Additionally, primate lentiviruses such as HIV-2 utilise the Env 
protein for tetherin antagonism (Le Tortorec and Neil, 2009).  Interestingly, human 
tetherin lacks a five-residue Nef-sensitivity motif in its cytoplasmic domain likely 
resulting in the exchange of tetherin counteraction activity to Vpu and Env, 
respectively, following the zoonotic transfer of SIVcpz and SIVsmm into humans 
(Sauter et al., 2009; Lim et al., 2010).  The inability of HIV-1 groups O and P to adapt 
to human tetherin like group M viruses may account for their limited contribution to the 
global HIV-1 pandemic (Sauter et al., 2011; Yang et al., 2011).   
 
1.8.2.6 SAMHD1  
HIV-1, however, not HIV-2/SIVsmm infection is inherently blocked in DCs and is 
inefficient in macrophages, an effect that was shown to be bypassed by providing the 
HIV-2/SIVsmm specific accessory protein Vpx in trans (Goujon et al., 2008; Sharova et 
al., 2008).  Recently, biochemical screens identified the 626 amino acid IFN-inducible 
protein SAMHD1 as the myeloid cell restriction factor counteracted by Vpx (Hrecka et 
al., 2011; Laguette et al., 2011).  Vpx binds and targets SAMHD1 for proteasomal 
degradation via the CRL4-DCAF1 E3 ubiquitin ligase complex (Hrecka et al., 2011; 
Ahn et al., 2012).  Vpx arose as a duplication of the Vpr gene, and is found in only two 
of eight major primate lentivirus lineages; however, Vpr is present in all lineages.  
Interestingly, some Vpr proteins can also counteract SAMHD1, and evolutionary 
studies provide evidence for the neofunctionalisation of Vpr to degrade SAMHD1 prior 
to the existence of Vpx (Lim et al., 2012).   
 
Aicardi-Goutières syndrome (AGS) is an autoimmune disease that affects individuals 
harbouring mutations in SAMHD1, characterised by the mimicking of congenital 
infections, an increase in IFNα production and symptoms reminiscent of systemic lupus 
erythematosus (SLE).  This supports a role for SAMHD1 in the negative regulation of 
IFNα production and immune modulation (Rice et al., 2009).  Mutations in the 3’ 
exonuclease three prime repair exonuclease 1 (TREX1) and the RNase H2 endonuclease 
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complex also contribute to AGS pathogenesis (Crow et al., 2006; Crow et al., 2006).  
Considering the functions of these factors in nucleic acid metabolism, it is not unlikely 
that SAMHD1 may also operate in a similar pathway.  Consistently, studies have shown 
SAMHD1 to be a dGTP-regulated dNTP triphosphohydrolase, implying that SAMHD1 
may restrict viruses by depleting the intracellular pool of nucleotides, therefore, 
impeding viral cDNA synthesis (Goldstone et al., 2011; Powell et al., 2011).  
Interestingly, the fact that HIV-1 has not acquired a factor to counteract SAMHD1, 
similar to HIV-2/SIVsmm, suggests that the counteraction of SAMHD1 is dispensable 
for HIV-1 replication.  Furthermore, recognising the role of SAMHD1 in immune 
regulation, not counteracting SAMHD1 may even be beneficial for the virus.   
 
1.8.2.7 TREX1 
Sensing of foreign nucleic acids by toll-like receptors (TLRs) and cytosolic sensors 
elicits a potent type I IFN response, a principal that underlies antiviral immune 
responses [reviewed in (Stetson and Medzhitov, 2006)], but can also result in 
autoimmune diseases such as AGS (Crow et al., 2006).  As discussed, mutations in 
TREX1 are associated with AGS and, furthermore, studies in TREX1-deficient mice 
exhibit a potent decrease in survival due to inflammatory myocarditis (Morita et al., 
2004).  TREX1 has been reported to metabolise reverse transcribed DNA derived from 
multiple endogenous retroelements and inhibit the retrotransposition of LINE-1 and IAP 
when overexpressed (Stetson et al., 2008).  More recently, a human endogenous 
retrovirus has been suggested to trigger Chilblain lupus, an autoimmune disease linked 
with TREX1 deficiency (Perl et al., 2010).  Furthermore, treating TREX1 knockout 
myocarditis mice with RT inhibitors resolves disease (Beck-Engeser et al., 2011).  
These studies strongly implicate TREX1 in the control of endogenous retroelement 
replication and their potential contribution to autoimmunity (Stetson et al., 2008).  
Highlighting the complexity of host-pathogen relationships, the nucleic acid 
metabolising function of TREX1 is necessary for the efficient spread and replication of 
HIV-1 since TREX1 digests excess reverse-transcribed HIV-1 DNA preventing the 
induction of a type I IFN response (Yan et al., 2010).  Furthermore, the SET complex, 
which includes TREX1, supports HIV-1 infection by preventing autointegration and, 





1.8.2.8 APOBEC3 proteins and HIV-1 
Vif is a 23kda accessory protein encoded by all primate lentiviruses.  Vif was shown to 
be required for HIV-1 replication in primary cells and also some immortalised cell lines 
such as HUT78 and CEM, yet was dispensable for others such as SupT1 and CEM-SS 
(Gabuzda et al., 1992; von Schwedler et al., 1993).  Heterokaryon experiments revealed 
a dominant restrictive phenotype that could be counteracted by Vif (Simon et al., 1998), 
following which cDNA subtraction experiments searching for factors expressed in non-
permissive cells but not permissive cells identified APOBEC3G (A3G), a member of 
the apolipoprotein B mRNA editing enzyme polypeptide like 3 (APOBEC3) family of 
proteins, as the restriction factor able to inhibit vif-deficient virus (Sheehy et al., 2002).   
 
The APOBEC family is composed of eleven members in humans each of which contain 
one or two copies of a cytidine deaminase (CDA) domain that edits cytidine residues to 
uridine residues in an RNA or DNA substrate.  A3G consists of two CDA domains, the 
C-terminal deaminase domain of which mediates deamination.  The N-terminal 
deaminase domain is not catalytically active although it is necessary for A3G packaging 
into nascent virions and Vif recognition (Navarro et al., 2005; Newman et al., 2005; 
Huthoff and Malim, 2007).   In the absence of Vif, A3G is incorporated into virions 
through interactions between the N-terminal CDA domain and the NC region of Gag 
bridged by interactions between A3G and RNA (Luo et al., 2004; Wang et al., 2007; 
Bogerd and Cullen, 2008).  Oligomerisation of A3G has been reported to be important 
for packaging and antiviral function as well (Huthoff et al., 2009).  Following infection 
of target cells, A3G associates with the RTC and preferentially deaminates the third 
cytosine residue in 5’-CCCA sequences that register as guanosine-to-adenosine (G-to-
A) hypermutations in the plus strand DNA, leaving the genome compromised and the 
virus non-infectious (Harris et al., 2003; Mangeat et al., 2003; Bishop et al., 2004).   
 
Studies have also revealed an editing-independent mechanism of A3G antiviral activity, 
whereby deaminase-deficient mutant A3G proteins can still inhibit HIV-1 infection 
(Newman et al., 2005).  Wild-type A3G reduces the accumulation of viral cDNA, 
originally believed to be a consequence of degradation of uridine-containing DNA by 
host DNA repair enzymes, although this theory has been disproved (Langlois and 
Neuberger, 2008).  Instead A3G may physically block RT translocation along the viral 
RNA template (Iwatani et al., 2007; Bishop et al., 2008).   
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Vif binds to A3G and targets it to the cellular cullin5-elonginBC-core-binding factor β 
(CBFβ) ubiquitin ligase complex for polyubiquitination and proteasomal degradation, 
preventing its packaging into assembling virions (Sheehy et al., 2003; Yu et al., 2003; 
Jager et al., 2011; Zhang et al., 2011).  Recognition of A3G by the N-terminal region of 
Vif determines the species-specific regulation of A3G by HIV and SIV Vif, a process 
with implications in the zoonotic transfer of SIVs into humans (Gaddis et al., 2004; 
Schrofelbauer et al., 2006; Russell and Pathak, 2007).   
 
APOBEC3F (A3F) is also a double CDA domain containing APOBEC3 protein that 
inhibits HIV-1 infection and is antagonised by Vif similar to A3G, although the 
antiviral activity of A3F is less potent than that observed for A3G (Bishop et al., 2004; 
Liddament et al., 2004; Wiegand et al., 2004; Holmes et al., 2007).  The preferred target 
site for A3F deamination is a 5’-TC instead of a 5’-CC.  The antiviral activity of 
remaining APOBEC3 proteins has also been investigated although the relevant 
contribution of these factors in vivo is questionable.  APOBEC3A (A3A) consists of a 
single CDA domain and has been implicated as the factor partially responsible for the 
resistance of immature monocytes to HIV-1 infection (Peng et al., 2007).  A3A also 
deaminates incoming foreign double-stranded DNA in producer cells resulting in its 
degradation (Stenglein et al., 2010).  Overexpression of APOBEC3B (A3B), a double 
CDA domain containing protein, and APOBEC3D/E (A3D/E), a single CDA domain 
containing protein, in single-cycle infectivity assays inhibits HIV-1 infection; however, 
this effect is only modest for A3D/E, and A3B is expressed at extremely low levels in 
CD4+ T cells probing its impact in natural infection (Bishop et al., 2004; Doehle et al., 
2005; Dang et al., 2006; Bogerd et al., 2007).  Alternatively, the single CDA domain 
containing APOBEC3C (A3C) protein is expressed in CD4+ T cells and has been 
reported to introduce low-level G-to-A mutations in some HIV-1 strains (Bourara et al., 
2007).  APOBEC3H (A3H) consists of a single CDA domain and up until recently only 
A3H haplotype II was shown to suppress HIV-1 infection as only this allele encoded a 
stable protein (OhAinle et al., 2008; Harari et al., 2009); however recently, additional 
A3H haplotypes were identified that also express stable proteins and inhibit HIV-1 
infection (Wang et al., 2011).  Studies suggest that similar to A3G and A3F, A3D/E is 
also sensitive to degradation by Vif, whereas A3H is only partially sensitive and A3B is 
resistant to Vif activity.  Taking into consideration sensitivity to Vif, relative expression 
66
 
levels required for restriction and side-by-side comparisons of all APOBEC3 proteins, 
evidence suggests that in addition to A3G and A3F only A3H and A3D/E significantly 
inhibit HIV-1 replication (Hultquist et al., 2011).  G-to-A hypermutations are readily 
detected in HIV-1 infected patients suggesting that the counteraction of APOBEC3 
proteins by Vif in vivo may be variable and incomplete.  Current studies are focusing on 
the importance of this balance in determining the course of HIV-1 infection and 
progression to AIDS [reviewed in (Malim, 2009)]. 
 
1.8.2.9 APOBEC3 proteins and other retroviruses  
The antiviral activity of APOBEC3 proteins extends beyond primate lentiviruses.  MLV 
is restricted by human A3G and A3B, but not by the only murine APOBEC3 (mA3) 
protein.  This effect that may be attributed to inefficient packaging of mA3 into MLV 
particles, cleavage of mA3 by the viral protease and/or resistance of MLV to mA3 
deaminase activity by an unknown mechanism (Bishop et al., 2004; Doehle et al., 2005; 
Abudu et al., 2006; Rulli et al., 2008).  Similarly, M-PMV can be inhibited by mA3, 
which is incorporated efficiently into nascent virions, however, is resistant to the host 
rhesus macaque A3G (rA3G) by selectively excluding it from particles (Doehle et al., 
2006).  The exact mechanism/s by which Vif-lacking simple retroviruses overcome 
restriction by APOBEC3 proteins requires further investigation.  Interestingly, the 
complex retrovirus HTLV-1 is relatively resistant to A3G by preventing its 
incorporation into virions through the activity of an acidic patch at the C-terminus of the 
NC domain (Derse et al., 2007). 
 
ERVs are active and mobile in the mouse genome, and have also been identified as 
targets for APOBEC3 deaminase-dependent activity; although A3A has been shown to 
restrict IAP replication by a packaging and editing-independent mechanism (Esnault et 
al., 2005; Bogerd et al., 2006; Esnault et al., 2006; Esnault et al., 2008).  Interestingly, 
genetic studies have also discovered evidence for human A3G activity against HERVs 
(Armitage et al., 2008; Lee et al., 2008). 
 
1.8.2.10 APOBEC3 proteins and retrotransposons 
APOBEC3 proteins play a significant role in the innate restriction of retrotransposons as 
well.  All human APOBEC3 proteins have been reported to variably inhibit LINE-1 
retrotransposition, with A3A and A3B exhibiting the most potent activity (Bogerd et al., 
67
 
2006; Muckenfuss et al., 2006; Kinomoto et al., 2007; Niewiadomska et al., 2007).  
Furthermore, silencing of endogenous A3B in cell lines and human embryonic stem 
cells enhances LINE-1 retrotransposition (Wissing et al., 2011).  A3A, A3B, A3C and 
A3G also restrict Alu retrotransposition in an ORF1p-independent manner (Bogerd et 
al., 2006; Hulme et al., 2007).  Reports have demonstrated that APOBEC3 proteins 
suppress LINE-1 and Alu retrotransposition by an editing-independent mechanism, and 
also observed a decrease in the accumulation of LINE-1 cDNA (Stenglein and Harris, 
2006; Hulme et al., 2007). 
 
1.9 APOBEC3 proteins and ribonucleoprotein (RNP) complexes  
Targeting and editing of viral DNA is an established activity of APOBEC3 proteins.  
Furthermore, a cellular function of APOBEC3 proteins is likely the regulation of 
endogenous retroelements.  However, whether these proteins can target cellular 
sequences and, if so, the mechanism by which host chromosomal DNA is protected 
from deleterious mutations is still unclear.  A3G associates with high-molecular-mass 
(HMM) RNP complexes in activated CD4+ T cells where its enzymatic activity is 
inhibited and, alternatively, is found within low-molecular-mass (LMM) RNP 
complexes in resting CD4+ T cells where it is enzymatically active (Chiu et al., 2005).  
Therefore, localisation of APOBEC3 proteins in the cytoplasm and sequestration into 
RNP complexes may be one such means for regulation of these proteins.  Mass 
spectrometry approaches have identified a panel of A3G and A3F-interacting RNA-
binding proteins (RBPs), which also includes MOV10 (Gallois-Montbrun et al., 2007; 
Gallois-Montbrun et al., 2008).  These associate with A3G in, predominantly, an RNA-
dependent manner, although their interaction with A3F is less sensitive to RNase 
digestion (Kozak et al., 2006; Gallois-Montbrun et al., 2007; Gallois-Montbrun et al., 
2008).  Several of these RBPs are mRNA processing body (P body) and stress granule 
(SG) factors, which are nonmembraned cytoplasmic RNP microdomains involved in the 
storage or degradation of translationally silenced mRNAs (section 1.10 and 1.11).  
Furthermore, A3G and A3F co-localise with these factors in P bodies and SGs 
(Wichroski et al., 2006; Gallois-Montbrun et al., 2007; Gallois-Montbrun et al., 2008) 
and A3G-RNA complexes have also been reported to shuttle between polysomes and 
SGs (Kozak et al., 2006).  Localisation of APOBEC3 proteins to P bodies correlates 
with their incorporation into virions and antiviral activity, which may implicate these 
cytoplasmic foci in the regulation of APOBEC3 function; however, depletion of P 
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bodies through knockdown of P body factors DEAD (Asp-Glu-Ala-Asp) box helicase 6 
(DDX6) and Lsm1 was shown to have no effect on the packaging of APOBEC3 
proteins into virions or their ability to restrict HIV-1 infection (Phalora et al., 2012).  
Therefore, the functional relevance of the localisation of A3F and A3G to P bodies and 
SGs, if any, remains to be characterised and may be relevant for an alternative cellular 
function.  Interestingly, A3G sequesters Alu RNA in HMM A3G RNP complexes 
preventing its association with the L1-ORF2p machinery, which may be a potential 
mechanism for A3G-mediated restriction of Alu retrotransposition (Chiu et al., 2006).   
 
1.10 Cytoplasmic mRNA processing bodies (P bodies) 
Gene expression is regulated by a balance between mRNA translation and decay.  
Degradation of the mRNA is mediated by deadenylation and removal of the 5’ cap by 
the decapping enzymes DCP1a/DCP2, following which exoribonuclease 1 (XRN1) 
digests the mRNA in a 5’ to 3’ direction.  For this to occur the nontranslating mRNA 
containing RNP complex (mRNP) must interact with the deadenylation/decapping 
machinery to form an mRNP/deadenylation/decapping complex that localises to 
cytoplasmic foci called P bodies [reviewed in (Parker and Sheth, 2007).  Alternatively, 
translating mRNPs associated with polysomes are cytoplasmically diffuse.  Therefore, P 
bodies are composed of aggregates of translationally repressed mRNPs in conjunction 
with the decay machinery, including the decapping enzymes DCP1a/DCP2, activator of 
decapping DDX6, the Lsm1-7 complex, the XRN1 exonuclease and the 
CCR4/POP2/NOT deadenylase complex (Ingelfinger et al., 2002; van Dijk et al., 2002; 
Cougot et al., 2004).  In addition, factors associated with small RNA-mediated post-
transcriptional RNA silencing pathways, such as the AGO proteins, GW182, MOV10, 
as well as the nonsense-mediated decay (NMD) factor Upf1 and antiviral proteins A3F 
and A3G also localise to P bodies (Eystathioy et al.; Lykke-Andersen, 2002; Liu et al., 
2005; Meister et al., 2005; Wichroski et al., 2006)  
 
P bodies are disrupted with RNase treatment signifying the important role of mRNAs in 
P body assembly (Teixeira et al., 2005).  Blocking mRNA turnover by inhibiting 
translation initiation increases the size and number of P bodies and, in contrast, 
inhibiting translation elongation whereby nontranslating mRNAs are trapped with 
ribosomes decreases both the size and number of P bodies (Teixeira et al., 2005).  
Protein components likely contribute to P body assembly as well.  In mammalian cells 
69
 
knockdown of GW182, DDX6, Lsm1, Lsm4 and Ge1 drastically depletes P bodies (Yu 
et al., 2005).  Some of these factors consist of a glutamine/asparagine (Q/N) rich prion-
like domain allowing self-aggregation of proteins implicating these domains in P body 
formation (Reijns et al., 2008).  Alternatively, individual P body components that 
function in translation repression pathways such as the AGO proteins, GW182, Upf1 
and DDX6 (Pillai et al., 2004; Coller and Parker, 2005; Isken et al., 2008; Zipprich et 
al., 2009) may contribute to P body assembly indirectly by increasing the pool of 
translationally repressed mRNPs for aggregation.   
 
The fate of nontranslating mRNAs in P bodies is thought to be dual, whereby they may 
be degraded or stored and returned to translation.  Besides the localisation of mRNA 
decay machinery to P bodies, inhibiting mRNA turnover by blocking deadenylation 
dramatically decreases the size of P bodies, however, they increase in size if mRNA 
turnover is blocked at the stage of decapping (Sheth and Parker, 2003).  Yeast studies 
have identified a reciprocal shuttling of mRNAs between P bodies and polysomes 
dependent on the translation state, (Brengues et al., 2005; Bhattacharyya et al., 2006), 
however, this has been proposed to be a selective process targeting only a limited 
population of mRNAs, and not a widespread phenomenon (Arribere et al., 2011).   
 
1.10.1 P bodies and retroelements 
The association of P bodies with retroelement life cycles is not surprising given the role 
of these cytoplasmic foci in RNA metabolism.  The yeast retrotransposons Ty1 and Ty3 
are members of the copia-like and gypsy-like family of endogenous retroelements.  
Genetic screens identified the Lsm1-7 complex and Dhh1 (yeast ortholog of DDX6) as 
being required for efficient Ty1 and Ty3 retrotransposition.  Ty3 transcripts, proteins 
and virus-like particles (VLPs) have been shown to localise to P bodies, and the 
disruption of essential P body components was reported to alter the subcellular 
distribution of these components (Beliakova-Bethell et al., 2006).  Mutations in the Ty3 
Gag NC domain resulted in the mislocalisation of Gag and defective VLP assembly 
suggesting that P bodies may function in Ty3 assembly and/or maturation (Larsen et al., 
2008).   
 
Studies also propose a link between P bodies and retroviral replication although these 
are more controversial, and conclude both positive and negative regulatory roles for P 
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bodies.  The highly conserved RNA helicase DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3, X-linked (DDX3), the yeast ortholog of which accumulates in P-bodies, 
has been reported to be required for the nuclear export of unspliced HIV-1 transcripts 
via the CRM1/Rev/RRE nuclear export pathway (Yedavalli et al., 2004).  Knockdown 
of DDX3 completely abrogated the export of intron-containing HIV-1 mRNA and 
effectively inhibited HIV-1 replication without affecting cell viability (Yedavalli et al., 
2004; Ishaq et al., 2008).  This has subsequently led to the discovery of small molecule 
inhibitors of DDX3 as a potential novel anti-HIV therapy (Garbelli et al., 2011; Radi et 
al., 2012).  However, human DDX3 cannot be detected in P bodies suggesting that the 
stimulatory role of this protein in the HIV-1 life cycle is independent of P bodies.  Reed 
et al recently proposed a function for DDX6 in HIV-1 Gag assembly independent of 
viral RNA packaging (Reed et al., 2012) and, similarly, DDX6 has been reported to be 
necessary for efficient packaging of the foamy virus genome (Yu et al., 2011).  In 
contrast, the intrinsic antiviral factors A3F and A3G localise to P-bodies (Wichroski et 
al., 2006; Gallois-Montbrun et al., 2007; Gallois-Montbrun et al., 2008), although 
Phalora et al verified no functional relevance for this localisation in terms of APOBEC3 
protein-mediated restriction of HIV-1 (Phalora et al., 2012).  A study has also reported 
silencing of core P-body components DDX6, GW182, Lsm1 and XRN1 to enhance 
HIV-1 infection and, furthermore, knockdown of DDX6 in peripheral blood 
mononuclear cells (PBMCs) derived from HIV-1 infected patients on HAART to 
reactivate the virus (Chable-Bessia et al., 2009).  However, Phalora et al recently 
confirmed no effect of P body depletion through knockdown of DDX6 and Lsm1 on 
HIV-1 replication (Phalora et al., 2012).  Interestingly, Lu et al observed an increase in 
IAP expression, retrotransposition, Gag protein abundance and accumulation of reverse 
transcript products following depletion of P bodies by knockdown of DDX6 or the 
eukaryotic initiation factor E transporter (eIF4E-T)(Lu et al., 2011).  
   
1.10.2 P bodies and other RNA viruses  
A role for P bodies in the replication of other positive-strand RNA viruses has also been 
reported.  The brome mosaic virus (BMV) depends on DDX6, the Lsm1-7 complex and 
DDX3 for translation of viral transcripts and also for genome replication, which likely 
occurs in P bodies (Noueiry et al., 2003; Mas et al., 2006).  Several reports have also 
highlighted a positive association between hepatitis C virus (HCV) and P bodies.  The 
HCV core protein interacts with DDX3 and silencing of DDX3 decreases HCV 
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replication (Ariumi et al., 2007).  Again, as human DDX3 does not localise to P bodies 
the role of this protein in HCV infection is likely independent of P bodies.  
Nevertheless, HCV infection also hijacks the P body components DDX6, Lsm1, XRN1 
and AGO2, but not DCP2, and redistributes these to viral production factories around 
lipid droplets for HCV replication (Ariumi et al., 2011).  Interestingly, although P body 
factors are essential for HCV replication, disruption of P bodies through the knockdown 
of a non-essential P body factor has no effect on replication; this suggests that 
individual P body components and not the microdomains themselves are required for 
HCV infection (Perez-Vilaro et al., 2012).  On the contrary, poliovirus infection induces 
the rapid degradation of P body components XRN1, DCP1a and the deadenylase 
subunit Pan3, ultimately resulting in the disruption of P bodies (Dougherty et al., 2011). 
   
1.11 Stress granules (SGs) 
SGs are cytoplasmic aggregates of stalled 48S translation initiation complexes that store 
translationally repressed mRNAs and form under conditions of cellular stress.  SGs are 
defined by their inclusion of 40S ribosomal subunits and eukaryotic translation 
initiation factor (eIF) 2, eIF3, eIF4A, eIF4B, eIF4E, eIF4G and eIF5 (Kedersha et al., 
2002), as well as RBPs such as the T-cell restricted intracellular antigen 1 (TIA-1), TIA-
1-related protein (TIAR), RasGAP SH3-domain binding protein 1 (G3BP1), histone 
deacetylase (HDAC) and Staufen1 [reviewed in (White and Lloyd, 2012)].  P body 
components such as the AGO proteins, MOV10, A3F and A3G can also redistribute to 
SGs during conditions of cellular stress, such as heat shock.  SGs are thought to 
represent an intermediate phase between actively translating polysomes and mRNA 
degrading P bodies, whereby mRNAs stored in SGs can be released for translation or 
alternatively targeted to P bodies for decay (Kedersha et al., 2000; Kedersha et al., 
2005), although the role of SGs and their association to polysomes and P bodies is still 
controversial (Mollet et al., 2008).  Furthermore, SGs and P bodies have also been 
observed to physically associate, which may facilitate potential exchanging of mRNAs 
(Kedersha et al., 2005). 
 
SGs can assemble in a number of ways, although a key mechanism involves 
phosphorylation of eIF2α by the eIF2 kinases protein kinase R (PKR), protein kinase 
RNA-like endoplasmic reticulum kinase (PERK), general control nonrepressed 2 
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(GCN2) or heme-regulated inhibitor kinase (HRI).  These are activated by various 
forms of cellular stress such as viral infection, oxidative stress and nutrient starvation.  
Phosphorylation of eIF2α reduces formation of the eIF2-GTP-tRNAMet ternary complex 
that is essential for the loading of tRNAMet onto the 40S ribosomal subunit for 
translation initiation.  Instead, TIA-1 and TIAR are assembled forming noncanonical 
pre-initiation complexes (Kedersha et al., 1999).  Subsequently, SGs can form through 
self-aggregation and post-translational modification of SG components.  TIA-1 and 
TIAR consist of three RRMs followed by a glutamine rich prion-like domain at the C-
terminal end.  Self-oligomerisation of TIA-1 or TIAR may play a significant role in 
early SG assembly (Gilks et al., 2004).  Furthermore, G3BP1 can also self-aggregate in 
a phosphorylation dependent manner (Tourriere et al., 2003).  Post-translational 
modification of proteins, such as O-linked-N-acetylglucosamine (O-Glc-Nac) 
modification of ribosomal proteins also contributes to SG formation (Ohn et al., 2008).   
 
1.11.1 SGs and retroelements  
Akin to P bodies, SGs have been proposed to play both inhibitory and stimulatory roles 
in the replication of several RNA viruses and retrotransposons.  As stated previously, 
the antiviral proteins A3F and A3G are relocalised from P bodies to SGs during 
conditions of cellular stress (Gallois-Montbrun et al., 2007; Gallois-Montbrun et al., 
2008).  The nuclear RBP src-associated in mitosis, 68 kDa (Sam68) is recruited to SGs 
through interactions with TIA-1 (Henao-Mejia and He, 2009).  The induction of SGs 
through Sam68 cytoplasmic mutants suppresses the expression of HIV-1 Nef, a 
phenomenon that correlates with the enrichment of Nef transcripts in SGs and a 
reduction in the downregulation of cell surface MHC class I and CD4 molecules 
(Henao-Mejia et al., 2009).  Similarly, the HTLV-1 regulatory protein Tax has been 
reported to interact with the essential SG component HDAC6 to inhibit the formation of 
SGs (Kwon et al., 2007; Legros et al., 2011).  In contrast, the SG component Staufen1 
preferentially forms novel RNP granules instead of SGs during HIV-1 infection to 
which HIV-1 Gag and viral RNA localise, and depletion of Staufen1 results in defective 
assembly of viral particles and genome packaging (Abrahamyan et al., 2010).  Likewise, 
SGs have also been implicated in the replication of retrotransposons.  LINE-1 ORF1p 
has been observed to form SGs and interact as well as co-localise with SG components 
such as the Y-box-binding protein 1 (YB-1), heterogeneous nuclear ribonucleoprotein 
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A1 (hnRNPA1) and AGO2 (Goodier et al., 2007).  Moreover, the formation of LINE-1 
RNP complexes consisting of the LINE-1 RNA, ORF1p and ORF2p is essential for 
retrotransposition and, interestingly, these have been observed to localise to cytoplasmic 
microdomains associated with SGs (Doucet et al., 2010).  
 
1.11.2 SGs and other RNA viruses  
Poliovirus induces the formation of SGs during early infection in favour of translation 
of viral proteins, however, these are dispersed in later stages of infection through the 
cleavage of G3BP1 by the viral 3C proteinase (White et al., 2007).  It was initially 
thought that TIA-1 SGs were resistant to disassembly by poliovirus infection, however, 
later studies revealed these to be devoid of essential SG-defining components, such as 
translation initiation factors (White and Lloyd, 2011).  Similarly, HCV infection also 
induces SGs, but inhibits their formation as infection proceeds.  HCV recruits specific 
components of SGs to viral replication factories and these co-localise with the HCV 
core protein and likely interact with the viral RNA to mediate efficient replication 
(Ariumi et al., 2011; Yi et al., 2011). 
 
1.12 miRNA and siRNA-mediated post-transcriptional RNA silencing pathways 
Small RNAs that associate with the RNA-induced silencing complex (RISC) are 
approximately 20-30 nucleotides in length and consist of 5’ phosphate and 3’ OH 
groups.  Most small RNAs are generated through the action of RNase III enzymes, 
specifically DICER, although piRNAs are derived from alternative DICER-independent 
mechanisms.  Following biogenesis small RNAs are sorted and associate with specific 
AGO proteins and it is this significant process that determines their biological function  
[reviewed in (Czech and Hannon, 2011)].  AGO proteins are central components of the 
RISC and in humans consist of eight proteins that can be divided into two subfamilies: 
the PIWI subfamily: HIWI (human PIWI), HILI (HIWI-like), PIWIL3 (PIWI-like 3), 
and HIWI2, and the AGO subfamily: AGO1, AGO2, AGO3 and AGO4 (Sasaki et al., 
2003).  In mammals, expression of the PIWI subfamily is restricted to germ cells where 
they bind to piRNAs and mediate sequence-specific transcriptional gene silencing 
(TGS) through DNA methylation.  Alternatively, the AGO protein subfamily associates 
predominantly with RNase III digested small RNAs, namely miRNAs and short-
interfering RNAs (siRNAs) that are generated as RNA duplexes.  During RISC 
assembly only the miRNA or siRNA guide strand is retained, whereas the passenger 
74
 
strand is ejected (Matranga et al., 2005).  The guide strand directs the RISC complex to 



















      
 
 
Figure 1.9.  miRNA and siRNA-mediated RNA silencing pathways. 
 
miRNAs are genome-encoded small RNAs that are processed in the nucleus from capped and 
polyadenylated primary miRNAs (pri-miRNAs) into precursor miRNAs (pre-miRNAs) by the 
microprocessor complex and exported into the cytoplasm by Exportin 5.  Further processing of the pre-
miRNA by the DICER-1 complex in the cytoplasm generates a miRNA: miRNA duplex.  Similarly, the 
DICER-1 complex cleaves long double-stranded RNA precursors into siRNA: siRNA duplexes as well.  
The passenger strand is ejected from the duplex and the guide strand is loaded onto an Argonaute (AGO)-
RNA-induced silencing complex (RISC).  Imperfect complementarity between the guide strand and target 
mRNA results in translation repression  (left box) and perfect complementarity results in cleavage of the 
target mRNA (right box).  Only the AGO2 protein possesses slicer activity and, therefore, mediates 





1.12.1 miRNA biogenesis 
miRNAs are ubiquitously encoded in the human genome and are transcribed by RNA 
pol II generating a primary miRNA (pri-miRNA) with a stem-loop structure that 
contains the mature miRNA (Lee et al., 2004).  Analogous to protein-coding transcripts, 
the pri-miRNA is also 5’ capped and polyadenylated (Lee et al., 2004).  The double-
stranded RBP Pasha/DiGeorge syndrome critical region gene 8 (DGCR8) and the 
RNase III enzyme Drosha form a complex called the Microprocessor that processes the 
pri-miRNA into an approximately 60-70 nucleotide precursor miRNA (pre-miRNA) 
(Denli et al., 2004; Gregory et al., 2004).  RNase III-mediated digestion results in a 
characteristic 2 nucleotide single-stranded 3’ overhang, which is recognised by Exportin 
5 that orchestrates the Ran-GTP-dependent nuclear export of the pre-miRNA (Lund et 
al., 2004).  Together with its double-stranded RBP partner TAR RNA-binding protein 2 
(TARBP2), DICER-1 mediates the cleavage of the pre-miRNA into an approximately 
22-23 nucleotide miRNA: miRNA duplex (Bernstein et al., 2001; Chendrimada et al., 
2005; Haase et al., 2005).   
 
1.12.2 siRNA biogenesis 
These small RNAs were initially identified in plants (Hamilton and Baulcombe, 1999), 
and were shown to be derived from double-stranded RNAs generated either as 
intermediates of viral replication or through the activity of an RNA-dependent RNA 
polymerase (RdRP) (Fire et al., 1998).  Studies in Drosophila melanogaster have shown 
that the introduction of long double-stranded RNAs results in DICER-2-mediated 
processing into siRNAs that are approximately 21 nucleotides in length (Lee et al., 
2004).  Drosophila melanogaster also encode endo-siRNAs that are expressed from 
endogenous loci and are likely involved in retrotransposon silencing.  Endo-siRNAs can 
originate from RNA transcripts with hairpin structures, transposon clusters and also 
through the annealing of sense and antisense transposon transcripts (Czech et al., 2008; 
Ghildiyal et al., 2008; Okamura et al., 2008).  Interestingly, an RdRP has also been in 
identified in Drosophila melanogaster (Lipardi and Paterson, 2009).  Furthermore, 
endo-siRNAs have been identified in mouse oocytes and embryonic stem cells (Tam et 
al., 2008; Watanabe et al., 2008).  As with exogenous siRNAs, the production of endo-
siRNAs is dependent on DICER activity.  In contrast, endo-siRNAs in plants and 
Caenorhabditis elegans are generated by a RdRP that copies single-stranded RNAs into 
long double stranded RNAs that may be processed by DICER activity. 
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1.12.3 Argonaute (AGO) proteins  
The AGO protein family is well conserved in various species with one member in 
Schizosaccharomyces pombe, five in Drosophila melanogaster, eight in humans, ten in 
Arabidopsis thaliana, and twenty-seven in Caenorhabditis elegans [reviewed in (Ender 
and Meister, 2010)].  In humans, the AGO subfamily is ubiquitously expressed in 
somatic cells, whereas the PIWI subfamily is restricted to the germ line.  In terms of 
functional domains, the AGO proteins are characterised by a PIWI-Argonaute-Zwille 
(PAZ) domain that binds to single-stranded RNA dinucleotide overhangs akin to those 
generated by DICER processing, and a PIWI domain similar to RNaseH, containing the 
catalytic activity (Cerutti et al., 2000).  Both siRNAs and miRNAs bind to members of 
the AGO subfamily of proteins, whereas piRNAs associate with the PIWI proteins.  
These small RNAs guide AGO-containing RISCs to target mRNAs for translation 
silencing.  Of the four human AGO proteins, only AGO2 mediates the endonucleolytic 
cleavage of perfectly complementary target mRNAs (Liu et al., 2004; Meister et al., 
2004).  In addition all AGO proteins can also silence target mRNAs with incomplete 
complementarity through translation repression and the recruitment of mRNA 
decapping and deadenylation machinery, likely through GW182 (Pillai et al., 2004; Sen 
and Blau, 2005; Behm-Ansmant et al., 2006).  However, the exact mechanisms 
underlying miRNA-mediated translation repression are still unclear.   
 
1.12.4 RISC assembly and silencing 
Mammals harbour a single DICER enzyme that sorts miRNAs and siRNAs between 
four AGO subfamily proteins.  Studies in Drosophila melanogaster, in which two 
DICER enzymes preferentially load miRNAs into AGO1 complexes for translation 
repression, and siRNAs into AGO2 complexes for slicing, show that the characteristic 
of the RNA duplex precursor may be important for the loading bias.  Precursor siRNA 
duplexes are highly or even perfectly complementary and, on the other hand, miRNA 
duplexes demonstrate imperfect base pairing, mismatches and bulges.  Secondly, 
terminal nucleotides also contribute to the sorting decision, whereby AGO1 prefers a 
terminal U and AGO2 favours a 5’ C (Czech et al., 2009).  Interestingly, the human 
AGO clade of proteins seem to portray no preference for duplex structure or terminal 
nucleotide, implying a more relaxed system of sorting (Liu et al., 2004; Meister et al., 




Loading of the RISC with miRNAs and siRNAs is an ATP-dependent process that 
requires assistance from a number of proteins (Yoda et al., 2010).  AGO proteins accept 
RNA duplexes following which the passenger strand is discarded during RISC 
maturation.  Both mammalian and Drosophila melanogaster AGO2 proteins can cleave 
the passenger strand in AGO2 complexes leading to maturation of the AGO2-RISC 
(Matranga et al., 2005).  This process is less well understood for AGO1, AGO3 and 
AGO4 complexes, although the mechanism has been proposed to be cleavage-
independent (Kawamata et al., 2009).  The guide strand directs the mature RISC to a 
target mRNA based on the complementarity of the seed region (2nd to 8th nucleotide) 
with the 3’ UTR of the target resulting in miRNA and siRNA-mediated translation 
repression or mRNA cleavage; although additional extensive base-pairing outside the 
seed region is also necessary for target mRNA cleavage. 
 
1.12.5 miRNA and siRNA-mediated regulation of retroelements 
RNA silencing is a key regulatory mechanism in eukaryotic cells with roles in various 
cellular processes, such as cellular development, differentiation, cell death as well as 
protection against genetic parasites.  As exogenous and endogenous retroelements 
depend on the host cell for efficient replication, their interaction with components of the 
RNA silencing pathway is not unanticipated.  HIV-1 infection has been reported to 
induce the accumulation of virus-specific small RNAs and, particularly, an 18 
nucleotide molecule antisense to the HIV-1 PBS, which is generated in a DICER-1-
dependent manner and shown to associate with AGO2 (Yeung et al., 2009).  Antiviral 
RNA interference (RNAi) has been a controversial concept in mammals, particularly 
owing to the lack of an RdRP for the production of RNA duplexes; however, the recent 
discovery of an RdRP in humans formed by an interaction between the human 
telomerase RT catalytic subunit (TERT) and the RNA component of mitochondrial 
RNA processing endoribonuclease (RMRP) (Maida et al., 2009), justifies careful 
examination of this regulatory pathway as a potential antiviral mechanism.   
 
Cellular miRNAs have also been implicated in the negative regulation of HIV-1 
replication and in the induction of latency.  In resting CD4+ T cells, miR-28, miR-125b, 
miR-150, miR-223 and miR-382 have been reported to target sequences located at the 
3’ end of viral transcripts resulting in the suppression of their expression (Huang et al., 
2007).  In contrast, the abundance of these miRNAs is reduced in activated CD4+ T 
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cells, which is thought to permit HIV-1 replication (Huang et al., 2007).  Similarly, 
miR-28, miR-150, miR-223, and miR-382 have been proposed to contribute to the 
resistance of peripheral blood monocytes to HIV-1 infection, whereby the suppression 
or induction of these miRNAs in monocytes has been suggested to facilitate or inhibit 
infectivity, respectively (Wang et al., 2009).  Likewise, the miR-29a was reported to 
target a sequence within the HIV-1 nef gene, restricting Nef expression and HIV-1 
replication, and these interactions were suggested to increase the association of HIV-1 
genomic RNA with RISC and P bodies (Ahluwalia et al., 2008; Nathans et al., 2009).  
Furthermore, depletion of DICER-1 has been suggested to enhance both HIV-1 virus 
production and infectivity (Nathans et al., 2009).  Virus encoded suppressors of RNA 
silencing (SRS) imply that viral replication may be restricted by miRNAs or siRNAs.  
Taking this into account, the HIV-1 Tat protein has been proposed to possess SRS 
activity through mutagenesis and heterogeneous chimera studies with SRS factors from 
plant viruses (Bennasser et al., 2005; Schnettler et al., 2009).   
 
Analogous to the negative regulation of HIV-1 by cellular miRNAs, the LINE-1 
retrotransposon contains a sense and antisense promoter in the 5’ UTR, and 
bidirectional transcription from these promoters has been reported to generate LINE-1 
encoded endo-siRNAs that can restrict LINE-1 retrotransposition by RNAi (Yang and 
Kazazian, 2006).  Consistently, a higher abundance of LINE-1 and IAP transcripts are 
detected in Dicer-1 knockout mouse embryonic stem cells (Kanellopoulou et al., 2005).  
Naturally occurring endo-siRNAs have also been reported to negatively regulate human 
LINE-1 expression, although the resultant mechanism for suppression is DNA 
methylation of the LINE-1 promoter (Chen et al., 2012). 
 
1.12.6 miRNA and siRNA-mediated regulation of other RNA viruses 
Although cellular miRNAs have been implicated in the inhibition of HIV-1 replication, 
not all cellular miRNAs negatively regulate RNA viruses.  The miR-122, which is 
expressed at high levels in human liver cells, is required for HCV replication, and 
directly binds to two target sites in the 5’ noncoding region of the viral genome 
regulating gene expression (Jopling et al., 2005; Jopling et al., 2008).  Inhibitors of 
miR-122 are currently being investigated as potential therapies for treating HCV 
infection. (Lanford et al., 2010)[reviewed in (Jopling, 2010)].  On the contrary, 
induction of an IFNβ response during HCV replication was reported to upregulate the 
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anti-HCV cellular miRNAs miR-1, miR-30, miR-128, miR-196, miR-296, miR-351, 
miR-431 and miR-448 and, in sync with previous reports, was suggested to 
downregulate expression of the HCV cofactor miR-122 (Pedersen et al., 2007).   
  
1.13 Moloney leukemia virus 10 (MOV10) 
Gallois-Montbrun et al identified the putative RNA helicase MOV10 as a A3F and 
A3G-interacting RBP (Gallois-Montbrun et al., 2007; Gallois-Montbrun et al., 2008) 
(section 1.9).  RNA helicases use ATP to remodel RNA or RNP complexes and can be 
classified into superfamilies (SFs) based on sequence similarity, structure and other 
mechanistic features.  The helicase core can contain up to 13 sequence motifs that carry 
out ATP binding and hydrolysis, nucleic acid binding and the coordination of these 
functions.  Domains involved in binding and hydrolysis of ATP, such as the Walker A 
and Walker B motifs, are fairly conserved between SFs.  MOV10 is a SF1 Upf1-like 
DEAG-box putative RNA helicase, whereby the ‘DEAG-box’ denotes the sequence of 
its Walker B motif [reviewed in (Fairman-Williams et al., 2010)] (Figure 1.10).  The C-
terminal domain of MOV10 consists of the putative RNA helicase motifs, however, the 
N-terminal domain contains no known protein sequences. 
 
MOV10, also known as GB110 (GTP-binding 110kda protein) in the mouse, was 
originally identified through an MLV proviral integration into the GB110 locus in the 
Mov-10 mouse strain (Mooslehner et al., 1991).  Functional studies showed that mouse 
embryonic stems cells lacking functional GB110 proliferated and differentiated 
analogous to wild-type cells (Hamann et al., 1993).  Human MOV10 is ubiquitously 
expressed in a range of adult tissues such as the heart, brain, lungs, liver, testes and 
ovaries with lower transcript levels detected in the smooth muscle, and highest 
transcript abundance in the adult CNS (Nagase et al., 2000).  Interestingly, cancer cells 
express higher levels of both MOV10 mRNA and protein in comparison with healthy 







        
 
 
Figure 1.10.  MOV10 domains and putative helicase motifs. 
 
The amino (N)-terminal (residues 1-495) of MOV10 contains no known protein motifs and the carboxy 
(C)-terminal (residues 496-1003) contains potentially thirteen putative RNA helicase motifs.  Five of 
these motifs have roles in ATP-binding and hydrolysis (illustrated in red), six function in nucleic acid 
binding (illustrated in green) and two coordinate ATP and nucleic-acid binding.  The Walker A and 
Walker B putative helicase motifs, which are highly conserved domains required for ATP-binding and 



















1.13.1 Cellular associations of MOV10 
MOV10 interacts with the antiviral factors A3F and A3G in an RNA-dependent manner 
and also co-localises with these proteins in cytoplasmic mRNA P bodies and SGs 
(Gallois-Montbrun et al., 2007; Gallois-Montbrun et al., 2008).  The RNA-dependent 
interaction between MOV10 and A3G has been proposed to be bridged by the 7SL 
RNA (Liu et al., 2012); however, a recent ‘interactome capture’ study that determined 
the RNAs bound by a panel of RBPs demonstrated that MOV10 broadly associates with 
a range of RNAs as opposed to interacting with a distinct subset (Castello et al., 2012), 
implying that multiple RNAs may be responsible for this interaction.   
 
Proteomics analyses and co-immunoprecipitation experiments have identified MOV10 
as interacting with the AGO proteins, AGO1 and AGO2 (Meister et al., 2005; 
Chendrimada et al., 2007).  These are essential constituents of the RISC, which is an 
RNP complex that directs small RNA-mediated post-transcriptional RNA silencing.  
MOV10 also associates with mature AGO complexes loaded with miRNAs (Meister et 
al., 2005).  AGO1 and AGO2 co-localise with MOV10 in P bodies and, interestingly, 
AGO proteins also interact with A3G and A3F although in an RNA-independent 
manner unlike MOV10 (Meister et al., 2005; Gallois-Montbrun et al., 2007; Gallois-
Montbrun et al., 2008).  Considering the association with AGO proteins and the RISC, 
MOV10 has been reported to be necessary for miRNA-guided cleavage of a reporter 
mRNA in cultured cells (Meister et al., 2005).  In contrast, Qi et al could not detect an 
interaction between MOV10 and the AGO1 or AGO2 proteins, although they identified 
MOV10 as an abundant protein in AGO3 and AGO4 purifications by mass 
spectrometry (Qi et al., 2008).  DICER-1 is an RNase III enzyme essential for the 
biogenesis of miRNAs and siRNAs (section 1.12), however, two groups reported 
conflicting data regarding the association of MOV10 with this enzyme reflecting a 
possible weak or transient association (Meister et al., 2005; Chendrimada et al., 2007) 
 
Huang et al proposed the cellular function of members of the APOBEC3 family, 
including A3G, to be the derepression of miRNA-mediated translation repression 
(Huang et al., 2007) and, interestingly a recent study suggested that A3G mediates this 
activity by interfering with the AGO2-MOV10 interaction, and consequently preventing 
maturation of the RISC (Liu et al., 2012).  However, Phalora et al recently ruled out a 
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role for APOBEC3 proteins in the specific regulation of miRNA function (Phalora et 
al., 2012). 
 
The broad RNA-binding capacity of MOV10 (Castello et al., 2012) likely explains the 
detection of MOV10 in a number of screens searching for RBP interaction partners.  
MOV10 copurifies with the mouse Y RNA-binding Ro protein in complex with the 
zipcode-binding protein (ZBP1) and YB-1 (Sim et al., 2012).  Ro has been implicated in 
cell survival following stress and the quality control of non-coding RNAs, both of 
which are modulated by Y RNAs (Sim and Wolin, 2011).  ZBP1 functions in RNA 
metabolism pathways with roles in mRNA localization, stability and translation as well 
as implications in stress responses (Huttelmaier et al., 2005; Stohr et al., 2006), and 
similarly YB-1 is a translation repressor with functions in cancer biology as well as 
cellular stress (Evdokimova et al., 2006; Yang and Bloch, 2007).  Interestingly, YB-1 
also interacts with A3G and A3F in a partially RNase-sensitive manner (Gallois-
Montbrun et al., 2007; Gallois-Montbrun et al., 2008).  MOV10 was also identified in 
Staufen2 complexes, with Upf1 and RNA helicase A (RHA) (Miki et al., 2011).  
Staufen2 is an RBP that regulates mRNA transport and translation in neurons (Duchaine 
et al., 2002) and its paralog Staufen1 localises to SGs where it has been suggested to 
function in recovery from cellular stress (Thomas et al., 2009).  Staufen1 has also been 
suggested to play a role in Upf1-mediated mRNA decay (Kim et al., 2005).  
Furthermore, RHA has been implicated in the translation of specific mRNAs, including 
HIV-1 transcripts and has also been identified as a RISC component (Hartman et al., 
2006; Robb and Rana, 2007).  The functional relevance of these interactions remains to 
be determined.   
 
Consistent with a potential role in post-transcriptional translation regulation, studies 
using rat hippocampal neurons have implicated MOV10 in a local translation control 
mechanism contributing to synaptic plasticity, whereby proteasomal degradation of 
MOV10 at synapses allows the association of specific mRNAs with polysomes for 
protein synthesis (Banerjee et al., 2009).  Similarly, MOV10 is also degraded by the 
proteasome at synapses in the rat amygdala relieving translational silencing and 
permitting long-term memory formation and retrieval (Jarome et al., 2011).  Besides 
post-transcriptional control of translation, Messaoudi-Aubert et al identified human 
MOV10 as interacting with the Polycomb-repressive complex 1 (PRC1), which consists 
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of the Polycomb group (PcG) proteins that function in noncoding RNA-mediated 
transcriptional repression.  Silencing of endogenous MOV10 was reported to upregulate 
the INK4a tumour suppressor gene accompanied by a reduction in histone methylation 
at this target locus (Messaoudi-Aubert et al., 2010). 
 
1.13.2 MOV10 homologs  
Post-transcriptional gene silencing (PTGS), later termed RNAi, is a mechanism by 
which eukaryotes such as higher plants, Caenorhabditis elegans and Drosophila 
melanogaster repress viruses and transposons at the RNA level (Ratcliff et al., 1997; 
Jensen et al., 1999; Ketting et al., 1999).  The RNAi process is initiated with a long 
double-stranded RNA product derived from the genetic element by a number of 
mechanisms, including the activity of an RdRP in plants (Fire et al., 1998) (section 
1.12.2).  The precursor double-stranded RNA is cleaved into small 21-23 nucleotide 
RNAs, which are loaded onto a RISC that mediates cleavage of a complementary RNA 
species (Hamilton and Baulcombe, 1999; Hammond et al., 2000; Zamore et al., 2000) 
(section 1.12).  In Arabidopsis thaliana, the silencing defective protein 1 (SDE1) is an 
RdRP and one of four silencing defective locuses.  The silencing defective protein 3 
(SDE3) is a MOV10 ortholog and, similar to SDE1, has been shown to be required for 
PTGS of the cucumber mosaic virus and a green fluorescent protein (GFP) transgene 
(Dalmay et al., 2001).  More recently, Garcia et al revealed SDE3 RNA-helicase 
activity and its AGO binding ability to be important for this antiviral action, as well as 
for transposon silencing via a pathway correlative with DNA methylation (Garcia et al., 
2012).   
 
In Drosophila melanogaster, RNAi against retrotransposons is accomplished by the 
PIWI subfamily of the AGO proteins, which includes the PIWI, Aubergine (Aub) and 
AGO3 proteins.  These proteins interact with and are guided by small RNAs called 
piRNAs that are derived in a DICER-independent manner mainly from piRNA clusters, 
composed of a dense population of truncated and immobilised sense and antisense 
orientation transposons (Brennecke et al., 2007).  Aub and AGO3 bound piRNAs 
overlap at the 5’ends by exactly 10 nucleotides, leading to the proposal of a model 
whereby Aub and AGO3 generate piRNAs by a slicer activity-dependent amplification 
loop termed the ping-pong cycle (Gunawardane et al., 2007).  Alternatively, the PIWI 
protein is a recipient of mainly cluster-derived piRNAs.  A report has determined that 
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all three members of the PIWI subfamily function in the germline, however, the PIWI 
protein alone also plays a role in somatic cells, whereby it interacts with piRNAs 
derived from the flamenco cluster to restrict particular families of retrotransposons 
(Malone et al., 2009).  Interestingly the MOV10 ortholog, Armitage, in Drosophila 
melanogaster is necessary for PIWI protein function, and knockdown of Armitage was 
shown to de-silence a retrotransposon reporter construct regulated by the flamenco 
cluster (Malone et al., 2009; Olivieri et al., 2010).  The PIWI protein co-
immunoprecipitates with Armitage, and silencing of endogenous Armitage decreases 
the levels and nuclear localisation of PIWI in both the germ line and somatic cells 
(Olivieri et al., 2010).  Furthermore, evidence suggests that Armitage functions in 
assembly and maturation of the RISC, whereby mutations in Armitage inhibit RNAi 
(Tomari et al., 2004).  Armitage likely plays a role in loading and assemby of the PIWI 
complex allowing its translocation into the nucleus, a process thought to be necessary 
for PIWI protein function (Saito et al., 2010). 
 
The mouse PIWI proteins MIWI (mouse PIWI), MILI (Miwi-like) and MIWI2 are 
expressed specifically in the mouse germ line.  Similar to the PIWI proteins in 
Drosophila melanogaster these proteins associate with piRNAs, however, in mice 
piRNAs are derived from discrete transposons as opposed to clusters, and there is also 
evidence for a MILI-dependent amplification loop (Aravin et al., 2007).  PIWI proteins 
in mammals control retrotransposons by TGS established by the methylation of these 
endogenous retroelements (Kuramochi-Miyagawa et al., 2008).  MOV10-like 1 
(MOV10L1) is a germ cell-specific mammalian paralog of MOV10 that interacts with 
MIWI, MILI and MIWI2 (Frost et al., 2010; Zheng et al., 2010).  Depletion of 
MOV10L1 decreases the abundance of MIWI and MILI proteins ultimately resulting in 
DNA demethylation and, therefore, derepression of LINE-1 and IAP endogenous 
retroelements (Frost et al., 2010; Zheng et al., 2010).  MOV10L1 mutant male mice are 
sterile due to the apoptosis of spermatocytes, which correlates with an upregulation in 
retrotransposon transcripts and proteins (Frost et al., 2010).  Interestingly, the 
expression of MOV10L1 has been reported to be impaired in Cryptorchid boys at high 
risk of azoospermia conferring clinical relevance to MOV10L1 in male infertility 





1.13.3 MOV10 and RNA viruses 
MOV10 has been implicated in the regulation of several RNA viruses suggesting that 
the capacity of MOV10 to regulate genetic elements has been evolutionarily conserved.  
Hepatitis delta virus (HDV) is a small RNA virus that encodes only the hepatitis delta 
antigen (HDAg) and, therefore, relies heavily on host factors for RNA-directed 
transcription of its genome.  MOV10 has been identified as an HDAg-interacting 
protein that also associates with a species of HDV-derived small 5’ capped RNAs 
implicated in viral transcription initiation (Haussecker et al., 2008).  Furthermore, 
knockdown of endogenous MOV10 was shown to have no effect on HDAg translation, 
however, HDV replication was inhibited suggesting that MOV10 may play a role in 
HDV RNA-directed transcription (Haussecker et al., 2008).  In contrast, MOV10 
overexpression inhibits HCV infection and, similarly, silencing of endogenous MOV10 
enhances the replication of vesicular stomatitis virus (VSV), the mechanisms for which 
remain to be established (Li et al., 2011; Schoggins et al., 2011).  A number of groups 
have now also reported that MOV10 overexpression potently inhibits HIV-1, SIV and 
MLV infectivity amongst other retroviruses, although the target/s and molecular 
mechanism/s for this inhibition still require further investigation.  Furthermore, the 
effect of silencing endogenous MOV10 on HIV-1 infectivity remains unclear, and has 
not yet been tested for other retroviruses (Burdick et al., 2010; Furtak et al., 2010; Wang 
et al., 2010).  The findings of these studies will be discussed in greater detail in later 

















The identification of host cell factors that can negatively (restriction factors) or 
positively (cofactors) regulate retroelements is imperative to understand the capacity of 
the host to protect its genome from the potentially detrimental effects of retroviruses 
and retrotransposons.  Several genome-wide screens have now identified thousands of 
cellular factors and multiple pathways that can stimulate or suppress HIV-1 infection, 
however, only thirty-four of these genes have been identified in two or more studies 
and, furthermore, a number of known and confirmed cellular factors are absent from 
these screens (Brass et al., 2008; Konig et al., 2008; Zhou et al., 2008; Liu et al., 2011).  
Therefore, the search for host restriction factors and cofactors that can modulate HIV-1 
infection is very much an active area of research.  Furthermore, with their associations 
in cancer biology as well as non-hereditary neurological diversity and disease, the 
discovery of factors that can suppress retrotransposons is similarly crucial. 
 
MOV10 is a putative RNA helicase that controls the replication of several RNA viruses 
and whose homologs function in the restriction of viruses and endogenous 
retroelements.  MOV10 interacts with members of the APOBEC3 family that restrict 
the replication of both retroviruses and retrotransposons, as well as the AGO proteins, 
which are core constituents of the RISC.  Furthermore, MOV10 co-localises with A3F, 
A3G and the AGO proteins in P bodies and SGs, which are cytoplasmic sites involved 
in mRNA storage and decay.  P bodies, SGs and miRNA or siRNA-mediated post-
transcriptional RNA silencing pathways have been implicated in the regulation of 
retroelements as well as other positive-strand RNA viruses.  Considering these 
associations of MOV10, this thesis will broadly aim to investigate the role of MOV10 in 
the replication of exogenous retroviruses from the lentivirus (HIV-1, HIV-2 and 
SIVmac), gammaretrovirus (MLV) and betaretrovirus (M-PMV) subfamilies.  The 
effect of MOV10 on the retrotransposition of the mouse LTR-containing ERV IAP, and 
the human non-LTR LINE-1 and Alu retrotransposons will also be determined.  
Furthermore, mechanistic and structure-function studies will begin to dissect the targets 
and functions of MOV10 in the retroelement life cycle, as well as aim to better 
understand the cellular function of MOV10 and its relationship with the APOBEC3 
proteins.  Overall this thesis will analyse the potential of MOV10 as a novel restriction 








































MATERIALS AND METHODS 
 
2.1 Plasmids 
The pCMV4-MOV10-HA plasmid was constructed by cloning a HindIII-XbaI digested 
MOV10 PCR product into the pCMV4 expression plasmid containing three 3’ HA 
epitope tags.  The pT7-MOV10 plasmid was constructed by cloning an XbaI-BamHI 
digested MOV10 PCR product into the pCGTHCFFLT7 (pT7) expression vector that 
contains two 5’ T7-epitope tags (Caceres et al., 1998).  The pcDNA3.1-myc-TIA-1 
plasmid was generated by cloning an EcoRI-XhoI digested TIA-1 PCR product into the 
pcDNA3.1(+) plasmid that contains three 5’ myc epitope tags.  The N-terminal MOV10 
mutant plasmid pT7-MOV10-N was constructed by cloning an XbaI-BamHI digested 
N-terminal MOV10 PCR fragment (residues 1-495) into the pT7 expression vector.  
Similarly, the C-terminal MOV10 mutant plasmid pT7-MOV10-C was constructed by 
cloning an XbaI-BamHI digested C-terminal MOV10 PCR product (residues 496-1003) 
into the pT7 plasmid.  To construct the MOV10 putative helicase mutant plasmids pT7-
MOV10-K530A, pT7-MOV10-DE645AA and pT7-MOV10-G648A, full-length 
MOV10 PCR products containing the relevant mutations were generated by overlapping 
polymerase chain reaction (PCR) and NheI-XmaI digested products were cloned into a 
similarly digested pT7-MOV10 backbone.  The shRNA-resistant pT7-MOV10-R 
plasmid was generated by producing a full-length MOV10 PCR product containing six 
silent mutations in the MOV10-specific shRNA target sequence (nucleotides 342 to 
363) by overlapping PCR and cloning the XbaI-XmaI digested product into a similarly 
digested pT7-MOV10 plasmid. 
 
The pcDNA3.1-myc-MOV10 and pcDNA3.1-myc-GFP control plasmids were 
generated by Dr. Sarah Gallois-Montbrun, the pCMV4-GFP-HA control plasmid was 
generated by Dr. Prabhjeet Phalora, and Dr. Chad Swanson cloned the pT7-GFP and 
pT7-Luc control plasmids.  Additionally, The subgenomic GPV-RRE construct was 
generated by Dr. Nathan Sherer by insertion of a SacI-EcoRI digested fragment of the 
pHIV-1NL4-3 plasmid into the pcDNA3.1(+) plasmid consisting of the RRE and CMV 
promoter-5’LTR fusion (Cullen, 1986).  The ∆MA+M-src and ∆NC+Zt GPV-RRE 
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mutant constructs were also generated by Dr. Nathan Sherer by cloning SacI-AgeI 
digested fragments from pHIV-1NL4-3 (∆MA+M-src) and pHIV-1NL4-3 (∆NC+Zt), which 
were kind gifts from Dr. David Ott, into a similarly digested GPV-RRE construct, and 
the codon-optimised GPV-RRE construct was also cloned by Dr. Nathan Sherer.  The 
pRev plasmid was generated by Dr. Chad. Swanson by cloning the Rev cDNA into the 
pcDNA3.1(+) plasmid.   
  
The pcDNA3.1-myc-AGO2 plasmid was a kind gift from Dr. Gregory Hannon.  The 
pHIV-1NL4-3 proviral plasmid was a kind gift from Dr. Malcolm Martin (Adachi et al., 
1986).  Plasmids for SIVmac vector production, pSIV3+ and pSIV-RMES4, were kind 
gifts from Dr. François-Loïc Cosset (Negre et al., 2000), and plasmids for HIV-1 vector 
production, p8.91 and pCSGW, were kind gifts from Dr. Didier Trono and Dr. Robin 
Ali, respectively (Zufferey et al., 1997; Bainbridge et al., 2001).  Plasmids for MLV 
virus production, pMLV and pMLV-Tat, were kind gifts from Dr. Stephen Goff and Dr. 
Juan Martin-Serrano, respectively (Martin-Serrano et al., 2003; Yueh and Goff, 2003).  
The plasmid for M-PMV virion production, pMT∆E, was a kind gift from Dr. Brian 
Cullen (Doehle et al., 2006).  The pVSV-G plasmid has been described previously 
(Fouchier et al., 1998).  The full-length pSIVmac239 and pHIV-2ROD proviral plasmids 
were kind gifts from Dr. Stuart Neil.  For endogenous retroelement experiments, the 
pGL3-IAP92L23neoTNF, pAlu-neoTet and pORF2p plasmids were kind gifts from Dr. 
Thierry Heidmann (Dewannieux et al., 2003; Dewannieux et al., 2004), and the 
pJM101/L1.3 plasmid was a kind gift from Dr. John Moran (Moran et al., 1999).  For 
Luc assays, the firefly Luc reporter constructs were kind gifts from Dr. Joan Steitz 
(Lytle et al., 2007), and the renilla Luc reporter constructs were kind gifts from Dr. 
Gyorgy Hutvagner (Johnston et al., 2010).  The pHIV-1IIIB/∆Vif, pCMV4-A3A-HA, 
pCMV4-A3B-HA and pCMV4-A3G-HA plasmids have been described previously 
(Bishop et al., 2004).   
 
Expression plasmids were verified by restriction enzyme mapping and/or sequencing 
where appropriate.  The primers used for cloning are listed in table 2.1.   





Table 2.1.  Primers for cloning. 
Plasmid Primer 
name 
Restriction site Sequence 
pCMV4-MOV10-HA 
 
















































oSA18 BamHI (Rev) AAAGGATCCTCAGA
GCTCATTCCTCCA 
 


















oSA85 XmaI (Rev) GGGCCTTGGCCCGG
GTCACAGCTAC 
 








pT7-MOV10-DE645AA oSA84 NheI (Fwd) CCACAAGTCACTGC
TAGCCAAGATC 
 
pT7-MOV10-DE645AA oSA85 XmaI (Rev) GGGCCTTGGCCCGG
GTCACAGCTAC 
 
















oSA85 XmaI (Rev) GGGCCTTGGCCCGG
GTCACAGCTAC 
 



















2.2 Reagents for RNAi 
GIPZ lentiviral vectors encoding the non-silencing control and MOV10-specific 
shRNAs were purchased from Open Biosystems (V2LHS_201304).  The non-silencing 
control and DICER-1 specific siRNAs were obtained from Ambion Life Technologies 
(s23756) and the efficiency of DICER-1 KD was measured by qPCR (section 2.12) with 
a TaqMan gene expression assay (Hs00229023_m1, Ambion Life Technologies).  The 
shRNA and siRNA sense sequences are listed in table 2.2.   
 













2.3.1 Polymerase chain reaction (PCR) 
Reactions were carried out in a total volume of 20.5 µl.  The mixtures contained 0.5 µl 
of plasmid DNA as the template (100 ng/µl), 0.7 µl of the forward and reverse primer 
each (10 pmol/µl) (MWG Eurofins), 4 µl of F-518 5X Phusion HF buffer (provides 
approximately 1.5mM MgCl2 in final reaction mixture) (Finnzymes, New England 
Biolabs (NEB)), 0.4 µl dNTP mix (10 mM each of dATP, dCTP, dGTP and dTTP), 0.2 
µl of F-530L Phusion high-fidelity DNA polymerase (2 U/µl) (Finnzymes, NEB) and 
14 µl of ddH2O.  PCR reactions were performed using the MJ Research PTC-200 Peltier 
Thermal Cycler with standard PCR conditions outlined in table 2.3.  The PCR product 
(2 µl) was analysed by agarose gel electrophoresis (section 2.3.3) and purified using the 









Table 2.3.  Standard PCR reaction conditions. 
 
Temperature Time Step 
1 98° C 30 seconds Initial denaturation 
 
2 98° C 
 
30 seconds Denaturation 
3 55° C 
 
60 seconds Annealing 
4 72° C 
 
15 – 60 seconds* Extension 
5 Go to step 2, repeat 30 times 
 
6 72° C 
 
10 minutes Final extension 




* Generally 15-30 seconds/kb, not exceeding 1 minute/kb.   
 
2.3.2 Site-directed mutagenesis (overlapping PCR) 
The first round of PCR included two PCR reactions, the end products of which 
consisted of the desired mutation/s:  (1) Using an outer forward primer with an internal 
reverse primer containing the mutation (2) Using an internal forward primer containing 
the mutation with an outer reverse primer.  The sequences of the forward and reverse 
internal primers should overlap.  The PCR products from these reactions were separated 
on an agarose gel (section 2.3.3) and purified using the QIAquick gel extraction kit 
(QIAgen) (section 2.3.7).  The PCR products were combined to form the template for 
the second round of PCR using the outer forward and reverse primers.  The PCR 
reaction was performed as presented in table 2.3.  The final PCR product was analysed 
by agarose gel electrophoresis (section 2.3.3) and purified using the QIAquick PCR 
purification kit (QIAgen) (section 2.3.4).   
 
2.3.3 Agarose gel electrophoresis 
1% agarose gels were prepared by adding 1 g of powdered agarose (Invitrogen) to 100 
ml of TBE buffer (0.09 M Tris, 0.09 M borate, 2 mM EDTA, pH 8.4 (1X solution)) 
(Fisher Scientific) and bringing to a boil to dissolve the agarose powder.  Following 
cooling of the solution, ethidium bromide was added (final concentration 0.5 µg/ml) and 
the mixture was poured into an electrophoresis tank to set.  DNA samples were prepared 
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by mixing with 6X loading dye (2.5 % Ficoll 400, 11 mM EDTA, 3.3 mM Tris-HCl, 
0.017 % SDS and 0.015 % Bromophenol Blue, pH 8.0) (NEB).  Samples were loaded 
onto the set gel and run in 1X TBE buffer.  The λ DNA-HindIII digest (band sizes 
23130, 9146, 6557, 4361, 2322 and 2027bps) and ΦX174 DNA-HaeIII digest (band 
sizes 1353, 1078, 872, 603, 310, 281, 271, 234, 194, 118 and 72bps) DNA ladders were 
also run as markers to determine the DNA size.  The gels were run at 100 volts for 
approximately 1hr.  DNA bands were visualized on an ultraviolet (UV) trans-
illuminator with a CCD camera and gel quantification software (Bio-Rad).   
 
2.3.4 PCR product purification  
Following analysis of the PCR product by agarose gel electrophoresis, the product was 
purified using the QIAquick PCR purification kit (QIAgen).  For this, 100 µl of Buffer 
PB (contains guanidine hydrochloride) was added to approximately 18.5 µl of the 
remaining PCR reaction mixture and thoroughly mixed.  The mixture was applied to a 
QIAquick spin column and centrifuged at 14000 rpm for 1 minute.  The flow-through 
was discarded.  To wash, 750 µl of Buffer PE (contains ethanol) was added to the 
column and centrifuged as described.  The flow-through was again discarded and the 
column was centrifuged for a further 1 minute to remove any residual ethanol from 
Buffer PE.  DNA was eluted in a sterile eppendorf tube by adding 50 µl of Buffer EB 
(10 mM Tris-Cl, pH 8.5) to the column, leaving the column to stand for approximately 
1 minute and then spinning as described.  
 
2.3.5 DNA digestion by restriction endonucleases 
Reactions were carried out in a total volume of 40 µl, which included 30 µl of the 
purified PCR product (or 2 µl of plasmid DNA (1 µg/µl) plus 28 µl of ddH20), 1 µl of 
each restriction enzyme (NEB), 4 µl of the appropriate 10X buffer (listed in NEB 
catalogue) and 4 µl of bovine serum albumin (final concentration 100 µg/ml) (NEB).  
Digests were performed at 37° C for approximately 2-3hrs, unless the manufacturers 
instructions specified otherwise.   
 
2.3.6 Dephosphorylation of digested DNA 
Digested plasmid DNA was treated with 1 µl of calf intestinal alkaline phosphatase 
(CIP) (NEB) at 37° C for 1hr to prevent religation of compatible ends. 
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2.3.7 Gel extraction and purification 
The digested DNA fragments were extracted and purified using the QIAquick gel 
extraction kit (QIAgen).  For this the digested DNA reaction mixtures were separated 
on an agarose gel and visualised as described (section 2.3.3).  Correct size DNA 
fragments were excised from the gel using a clean razor blade and transferred into 
sterile eppendorf tubes.  To dissolve the gel slice, 300 µl of Buffer QG (contains 
guanidine thiocyanate) was added to the tubes and these were then incubated at 50° C 
for approximately 10 minutes, with some vortexing.  100 µl of isopropanol was added to 
the dissolved mixture and 700 µl of this was applied to a QIAquick spin column.  The 
columns were centrifuged at 14000 rpm for 1 minute and the flow-through was 
discarded, and this step was repeated for any remaining dissolved gel mixture.  500 µl 
of Buffer QG was added to the columns and centrifuged as described, following which 
the columns were washed with 750 µl of Buffer PE and centrifuged as described.  The 
flow-through was discarded and the columns were centrifuged for a further 1 minute to 
remove any residual ethanol from Buffer PE.  The DNA was eluted into sterile 
eppendorf tubes by adding 50 µl of Buffer EB to the columns and leaving these to stand 
for approximately 1 minute prior to centrifugation as described.  The yield of the 
digested plasmid and insert DNA was determined by running 5 µl of the elutions on an 
agarose gel (section 2.3.3).   
 
2.3.8 DNA ligation 
Reactions were carried out in a total volume of 10 µl, which generally included 7 µl of 
the digested insert, 1 µl of the digested plasmid, 1 µl of T4 DNA ligase buffer 
(50 mM Tris-HCl, 10 mM MgCl2, 1 mM ATP, 10 mM Dithiothreitol, pH 7.5 (1X)) 
(NEB) and 1 µl of T4 DNA ligase (NEB).  The ligation reaction was performed at room 
temperature for approximately 4hrs to overnight, and used to transform competent 
bacteria (section 2.4.3).   
 
2.4 Bacteria  
2.4.1 Bacterial strains and maintenance 
Top10 Escherichia coli (E.coli) competent cells (Invitrogen) were used for the majority 
of transformations, except for the transformation of proviral DNA and lentiviral vectors 
for which Stable 2 (Stbl2) E.coli competent cells (Invitrogen) were used instead.  
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Bacterial cells were grown in Luria-Bertani (LB) Broth (1 LB tablet per 50 ml ddH20; 
each tablet contains 10 g/L enzymatic digest of casein, 5 g/L yeast extract (low sodium), 
5 g/L sodium chloride, 2 g/L inert agents, and 22 g/L total solids) (Sigma-Aldrich) or 
LB-Agar (37 g per 1 L of ddH20) set in 10 cm sterile dishes (Sterilin) for solid phase 
growth cultures.  Media was supplemented with the antibiotic Ampicillin (Calbiochem) 
to a final concentration of 100 µg/ml.   
 
2.4.2 Production of competent bacteria  
Top10 competent cells were inoculated into 10 ml of LB media overnight at 30°C with 
shaking at approximately 200 rpm.  The next day 50 ml of LB was inoculated with 1.25 
ml of the overnight bacterial culture and grown at 37°C with shaking as described until 
the optical density at 550 nm (OD550) reached between 0.45-0.55.  The cells were 
harvested by centrifugation at 3500 rpm for 10 minutes at 4°C.  The buffers for 
subsequent steps were pre-chilled on ice and filter sterilised.  The bacterial cell pellet 
was resuspended in 20 ml of TfB1 buffer (30 mM KAc, 100 mM RbCl, 10 mM CaCl2, 
50 mM MnCl2, 15% glycerol and ddH20 to a final volume of 100 ml) and chilled on ice 
for 5 minutes.  The cells were centrifuged as described again and resuspended in 2 ml of 
TfB2 buffer (10 mM PIPES, 75 mM CaCl2, 10 mM RbCl, 15% glycerol and ddH2O to 
a final volume of 100 ml).  The cell suspension was incubated on ice for 10 minutes and 
aliquoted into sterile eppendorf tubes, following which the competent bacterial cells 
were stored at -80°C.   
 
2.4.3 Transformation of competent bacteria 
Aliquots of competent bacterial cells were thawed on ice for approximately 10 minutes, 
and 30 µl of cells were incubated with 3 µl of the DNA ligation reaction or 1 µl of a 
plasmid stock (0.1 µg/µl) for 30 minutes on ice.  Top10 bacterial cells were heat 
shocked at 42°C for 45 seconds and then recovered on ice for 2 minutes, following 
which 1 ml of sterile LB media was added to the cells and they were cultured at 37°C 
for 1hr.  Stbl2 cells were transformed similarly, however, cells were heat shocked at 
42°C for 30 seconds and cultured at 30°C for 90 minutes.  For DNA ligation 
transformation reactions, bacterial cell cultures were centrifuged at 3500 rpm for 5 
minutes and the pellets were resuspended in 100 µl of LB media before being plated 
onto LB-Agar plates containing Ampicillin.  For plasmid stock transformations, 100 µl 
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of the bacterial culture was plated directly.  Plates streaked with Top10 and Stbl2 
bacterial cells were incubated overnight at 37°C or 30°C, respectively.   
 
2.5 Plasmid DNA extraction and purification from bacterial cultures 
2.5.1 Miniprep  
A single colony was selected from a transformed plate of bacteria and inoculated in 2 
ml of sterile LB media containing Ampicillin.  These were incubated overnight at 37°C 
or 30°C as described with shaking and the next day 1 ml of the cultures was removed 
into sterile eppendorf tubes and centrifuged at 6000 g for 10 minutes to pellet the cells.  
The supernatant was aspirated and the pellets were resuspended in 100 µl Buffer P1 (50 
mM Tris-HCL pH 8.0, 10 mM EDTA) containing RNase A (0.1 mg/ml final 
concentration) and then lysed in 100 µl Buffer P2 (200 mM NaOH and 1% SDS) by 
inverting the tubes 5X and incubating at room temperature for 5 minutes.  Following 
this the lysed mixture was neutralized by adding 100 µl of Buffer P3 (3 M KOAc, pH 
5.5) and again inverting the tubes 5X.  The tubes were incubated on ice for 10 minutes 
and then centrifuged at 14000 rpm for 20 minutes.  250 µl of the supernatant was 
transferred into fresh sterile eppendorf tubes and 175 µl of isopropanol was added to 
precipitate the DNA.  These were centrifuged as described and the supernatant was 
discarded.  The clear DNA pellet was washed in 70% ethanol and centrifuged at 14000 
rpm for 10 minutes.  The supernatant was discarded and the DNA pellet was air dried to 
remove any traces of ethanol and then resuspended in 50 µl ddH20.   
 
2.5.2 Midiprep/Maxiprep  
The midiprep/maxiprep was performed by alkaline lysis using the Machery-Nagel 
Nucleobond Xtra Midi/Maxi plasmid DNA purification kit (Machery-Nagel).  A single 
colony was selected from a transformed plate of bacteria and inoculated in 50 ml/200 ml 
of sterile LB media containing Ampicillin.  Bacterial cultures were incubated overnight 
at 37°C or 30°C as described with shaking.  The next day, cultures were pelleted by 
centrifugation at 6000 g for 15 minutes and resuspended in 8 ml/12 ml of Buffer RES 
containing RNase A (0.06 mg/ml final concentration).  The cells were lysed by adding 8 
ml/12 ml of Buffer LYS, inverting 5X and incubating at room temperature for 5 
minutes, following which 8 ml/12 ml of Buffer NEU was added and the lysate mixture 
was neutralised by gently inverting 15X.  The precipitate was added to Nucleobond 
Xtra Columns that had been equilibrated with 12 ml/25 ml of Buffer EQU, and allowed 
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to empty by gravity flow.  The columns were washed with 5 ml/15 ml of Buffer EQU, 
following which the column filter was discarded and the column was washed with 8 
ml/25 ml of Buffer WASH.  DNA was eluted into 50 ml falcon tubes by adding 5 ml/15 
ml of Buffer ELU to the columns and allowing these to elute by gravity flow.  The 
collected DNA was precipitated by adding 3.5 ml/10.5 ml of room temperature 
isopropanol and vortexing thoroughly prior to centrifugation at 15000 g for 30 minutes 
at 4°C.  The supernatant was discarded and the clear DNA pellets were gently re-
suspended in 70% ethanol and transferred to sterile eppendorf tubes.  These were 
centrifuged at 14000 rpm for 10 minutes and the supernatant was discarded, following 
which the DNA pellet was air dried and resuspended in 50 µl/100 µl of Buffer TE. 
 
The DNA concentration was determined using the Nanodrop ND-1000 
Spectrophotometer (Labtech International) at OD260 (an OD of 1 at 260 nm 
corresponds to 50 µg/ml of double-stranded DNA).  Plasmid stocks were diluted to a 
standard 1 µg/µl concentration when possible.   
 
2.6 Cell culture  
2.6.1 Cell lines and maintenance 
The human cell lines used in this study are listed in table 2.4.  The adherent 293T, HeLa 
and TZM-bl cell lines were cultured in Dulbecco’s modified Eagle medium (DMEM, 
Invitrogen), supplemented with 10% foetal calf serum (FCS) GIBCO), heat-inactivated 
for 30 minutes at 56°C, and 1% penicillin-streptomycin (Invitrogen).  Cells were 
cultured in 10 cm tissue culture dishes and passaged every 2 days by washing in 1X 
phosphate buffer saline (PBS) (Invitrogen) and detaching cells from the plate by adding 
3 ml of the Trypsin replacement, TrypLE Express (1X), Phenol Red reagent 
(Invitrogen).  Cells were incubated at 37°C for approximately 10 minutes and, 
depending on the confluency required for experiments, were split into new plates 
containing fresh DMEM media pre-warmed to 37°C.  Suspension HUT78, CEM and 
Jurkat T cell lines were cultured in Roosevelt Park Memorial Institute medium (RPMI) 
(Invitrogen), supplemented with 10% FCS and 1% penicillin-streptomycin as described.  
Cells were cultured in tissue culture flasks and passaged every 2 days by splitting cells 





Table 2.4.  Human cell lines. 
Cell line Origin Type 
293T Embryonic kidney fibroblasts expressing the 
SV40 large T antigen 
 
Adherent 
HeLa/HeLa-HA* Cervical adenocarcinoma epithelial cells 
 
Adherent 
TZM-bl HeLa cells expressing CD4, CXCR4, CCR5 and 
the HIV-1 Tat inducible lacZ gene 
 
Adherent 
HUT78 T cell leukemia cells Suspension 
 
CEM/CEM-SS** T cell leukemia cells 
 
Suspension 




* HeLa-HA cells are a clonal derivative of HeLa cells that support retrotransposition 
** CEM-SS cells are a clonal derivative of CEM cells 
 
2.6.2 Primary cells, maintenance and IFNα treatment 
Primary CD4+ T cells were cultured in RPMI supplemented with 10% FCS and 1% 
penicillin-streptomycin as described, as well as IL-2 (100 U/ml) (BD Pharmingen) and 
PHA (1 µg/ml) (Oxoid) or soluble anti-CD3 (1 µg/ml) (BD Pharmingen) and anti-CD28 
(1 µg/ml) (BD Pharmingen).  MDDCs and MDMs were cultured by Dr. Fransje Koning 
in RPMI supplemented with 10% FCS and 1% penicillin-streptomycin as described.  To 
obtain MDDCs, CD14+ monocytes were treated with GM-CSF (10 ng/ml) (Miltenyi 
Biotec) and IL-4 (100 ng/ml) (R&D Systems) for 5 days, and for MDMs CD14+ 
monocytes were allowed to adhere to the plate for 3hrs in RPMI medium supplemented 
only with 1% penicillin-streptomycin, following which 10% FCS and GM-CSF (100 
ng/ml) was added.  For IFNα experiments, CD4+ T cells, MDDCs and MDMs pre-
treated as described were cultured in the presence of IFNα (1000 U/ml) (PBL 
InterferonSource) for the indicated length of time.   
 
All cell lines and primary cells were maintained at 37°C with 5% CO2 and all tissue 






2.6.3 Primary cell isolations  
For primary CD4+ T cell isolations, Dr. Anna Le Tortorec isolated PBMCs from the 
blood of healthy donors using Lymphoprep (Axis-Shield), and also removed the CD14+ 
monocytes.  Remaining cells were provided and the CD4+ T cells were isolated using a 
CD4+ T cell isolation kit (Miltenyi Biotec), which isolates CD4+ T cells by depleting 
non-target cells.  Briefly, the number of cells was determined using a haemocytometer 
and these were pelleted by centrifugation at 300 g for 10 minutes.  The supernatant was 
discarded and the cell pellet was resuspended in 40 µl of MACS buffer (1X PBS, 0.5% 
BSA and 2 mM EDTA, pH 7.2) per 107 of total cells.  10 µl of the CD4+ T cell biotin-
antibody cocktail was added per 107 of total cells and incubated at 4°C for 10 minutes.  
30 µl of MACS buffer per 107 of total cells was added, following which 20 µl of the 
anti-biotin microbeads was added per 107 of total cells and incubated at 4°C for 15 
minutes.  Cells were washed in 1-2 ml of MACS buffer per 107 of total cells and 
centrifuged as described.  The supernatant was discarded and the cell pellet was 
resuspended in 500 µl of MACS buffer per 108 of total cells.  CD4+ T cells were 
isolated by magnetic separation using an LS column.  For this, the LS column was 
rinsed with 3 ml of MACS buffer and allowed to empty by gravity flow.  The cell 
suspension was applied to the column, and the flow-through containing unlabelled 
enriched CD4+ T cells was collected.  The column was again washed 3X with 3 ml of 
MACS buffer, and the flow-through was collected.  The CD4+ T cells were counted and 
10 x 106 cells were transferred to each flask for experiments.  2 x 106 cells were 
harvested for analysis on indicated days.  CD14+ monocytes were isolated by Dr. 
Fransje Koning by positive selection using CD14 MicroBeads (Miltenyi Biotec) and the 
experiments were also performed by Dr. Fransje Koning.  Cell lysates were provided for 
analysis as described. 
 
2.6.4 Freezing and thawing cell lines  
Semi-confluent plates or flasks of cells were pelleted at 1200 rpm for 5 minutes.  Cell 
pellets were resuspended in freezing medium (10% Dimethyl sulfoxide (DMSO) 
(Sigma-Aldrich) diluted in FCS) and aliquoted into cryovials on ice.  Cells were 
immediately stored at -80°C or transferred to liquid nitrogen the next day for long-term 
storage.  Cells were thawed by incubating frozen vials at 37°C for approximately 1 
minute and immediately transferring cells to 5 ml of pre-warmed medium.  Cells were 
washed by centrifuging at 1200 rpm for 5 minutes, resuspended in fresh media and 
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2.7.1 Plasmid transfections  
HeLa or 293T cells (2 x 105 or 1 x 105 cells (latter for immunofluorescence)) were 
plated 24hrs prior to plasmid transfection.  Alternatively, 70% confluent 10 cm tissue 
culture plates of 293T cells were transfected for some experiments.  For transfection of 
293T cells, a polyethyleneimine (PEI, Polysciences) mastermix was prepared (16 µl 
PE1 (1 mg/ml) and 180 µl of serum-free DMEM for transfection of a single well in a 6-
well dish, or 50 µl of PEI and 550 µl of serum-free DMEM for transfection of a 10 cm 
tissue culture dish) and incubated for 5 minutes at room temperature.  DNA amounts as 
stated in the figure legends were incubated with 196 µl or 600 µl, respectively, of the 
PEI mastermix for 20 minutes at room temperature and the transfection mixture was 
then added to 293T cells drop-by-drop.  For transfection of HeLa cells, a Fugene 6 
(Roche) mastermix was prepared (3 µl FuGENE to 1 µg DNA ratio diluted in Optimem 
(Invitrogen) to a total volume of 100 µl for transfection of a single well in a 6-well dish) 
and incubated for 5 minutes at room temperature.  DNA amounts as stated in the figure 
legends were incubated with 100 µl of the Fugene 6 mastermix and the transfection 
mixture was then added to HeLa cells drop-by-drop as described.  Fresh media was 
replaced approximately 6hrs post-transfection. 
 
2.7.2 siRNA transfections  
For siRNA transfections (50 µM or 75 µM diluted in RNase free ddH2O (Ambion Life 
Technologies)), HeLa cells were seeded (1 x 105) 2hrs before and allowed to adhere to 
the plate.  A Dharmafect1 (Dharmacon) master mix was prepared (1 µl Dharmafect1 
and 49 µl Optimem for transfection of a single well in a 24-well dish) and incubated for 
5 minutes at room temperature.  Separately, an siRNA mixture was prepared (0.66 µl 
siRNA and 49 µl Optimem) and 50 µl of the Dharmafect1 mastermix was added to each 
siRNA mixture, following which these were incubated for 20 minutes at room 
temperature.  Cell culture media was replaced with 400 µl of fresh media and 100 µl of 
the transfection mixture.  On Day 2 transfected cells were replaced with fresh media, 
and on Day 3 cells were split 1:4 into new 24-well plates, allowed to adhere to the plate 
and transfected again with siRNAs as described for the first day.  Approximately 12-
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15hrs post-transfection cells were transfected with plasmid DNA using the Fugene 6 
transfection reagent as described (section 2.7.1), and approximately 24hrs later cells 
were harvested for analysis as required. 
 
2.8 Transductions for generation of stable cell lines 
Lentiviral vectors for the production of HeLa, 293T and HUT78 non-silencing control 
and MOV10 KD stable cell lines were produced by transfecting 293T cells in 10 cm 
tissue culture dishes as described (section 2.7.1) with p8.91 (8 µg), the GIPZ lentiviral 
vector expressing either the non-silencing control shRNA or MOV10-specific shRNA 
(8 µg) and pVSV-G (2 µg).  Fresh media was replaced the following day, and 
approximately 48hrs post-transfection lentiviral vectors were harvested and filtered 
through a 0.45 µM filter (Millipore).  Cells to be transduced were plated 24hrs prior to 
transduction (2 x 105 cells).  For transduction of the cells, 1 ml of the cell culture 
medium was replaced with 1 ml of vector-containing supernatant.  Fresh media was 
replaced approximately 24hrs post-transduction.  The following day, cell supernatant 
was replaced with media containing puromycin dihydrochloride (1 µg/ml) (Sigma-
Aldrich).  Cells were maintained under selection and analysed when untransduced 
control cells died (approximately 3 days from selection).  The GIPZ lentiviral vectors 
also express GFP allowing the transduction efficiency to be determined by checking the 
percentage of GFP+ cells.   
 
2.9 Infectivity assays 
2.9.1 HIV-1 (subgenomic and provirus) 
HeLa and 293T parental cells or non-silencing control and MOV10 KD cells (2 x 105 
cells) were co-transfected with plasmids as stated in the figure legends using the 
protocol described (section 2.7.1).  Approximately 48hrs post-transfection, virus-
containing supernatant was harvested and filtered through a 0.45 µM filter, and cells 
were washed in 1X PBS and lysed in 500 µl of radioimmunoprecipitation assay (RIPA) 
buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton 
X-100, 1% sodium deoxycholate) for analysis by immunoblotting. 800 µl of the filtered 
viral supernatant was purified through 200 µl of a 20% sucrose cushion (diluted in 1X 
PBS) by centrifugation at 14000 rpm for 2hrs at 4°C and prepared for analysis by 
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immunoblotting where described.  100 µl of the filtered viral supernatant was diluted in 
400 µl of 0.5% Triton X-100 for analysis by p24Gag ELISA (Perkin-Elmer) 
 
2.9.1.1 p24Gag ELISA  
For 293T experiments, the 1:5 diluted viral supernatant was diluted further to 1:250 and 
for HeLa experiments these were diluted further to 1:10.  A 96-well plate pre-coated 
with a monoclonal antibody against HIV-1 p24Gag (in 0.01% Proclin-300 preservative) 
was washed 6X in ELISA wash buffer (0.05% Tween-20 in PBS with 0.1% 2-
chloroacetamide as a preservative) using a plate washer (BioTek Elx50).  200 µl of each 
p24Gag standard (10000, 2000, 500, 150, 60 and 25 pg/ml), prepared using a p24Gag 
positive control (200 ng/ml p24Gag in PBS, plus BSA, Triton-X 100 and 0.1% sodium 
azide as a preservative) diluted in the lysis buffer (0.5% Triton X-100 in PBS plus inert 
blue dye and 0.002% sodium azide as a preservative), was added to the plate.  A lysis 
buffer only negative control and an empty well was also included (A1).  200 µl of the 
samples were then added to wells and the plate was incubated at 37°C for 1hr.  The 
plate was washed 6X in ELISA wash buffer prior to adding 100 µl of the detector 
antibody (biotinylated rabbit polyclonal anti-p24Gag antibody in PBS containing animal 
sera, casein and human serum non-reactive for Hepatitis B surface antigen and antibodies to 
HIV-1, HIV-2, and HCV, plus 0.2% Proclin-300 and 0.1% sodium azide as a preservative) 
to all wells except the empty A1 well.  The plate was incubated at 37°C for 30 minutes, 
following which the plate was washed 6X in ELISA wash buffer.  The streptavidin-
HRP concentrate (in citrate buffer with BSA, detergent and 0.5% 2-chloroacetamide as 
a preservative) was diluted 1:100 into the streptavidin-HRP diluent  (PBS with BSA, 
0.05% Tween-20 and 0.5% 2-chloroacetamide as a preservative), and 100 µl of this 
mixture was added to each well except A1.  The plate was incubated at 37°C for 30 
minutes and then washed 6X in ELISA wash buffer.  An ortho phenylenediamine-HCL 
(OPD) tablet was dissolved in 11 ml of substrate diluent (citrate buffer containing 0.03% 
hydrogen peroxide and 0.002% sodium stannate as a stabiliser) and 100 µl of this solution 
was added to each well including A1.  The plate was incubated at room temperature for 
10-15 minutes in the dark, following which the reaction was stopped by adding 100 µl 
of the STOP solution (4N sulfuric acid).  The plate was read using a Benchmark Plus 
microplate spectrophotometer (Bio-Rad) at dual (subtractive) wavelengths of 405 nm 
and 630 nm. Values were analysed using the Microplate Manager 5.2.1 software (Bio-
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Rad) to determine the p24Gag concentration (pg/ml).  All the reagents described were 
provided in the p24Gag ELISA kit.    
 
2.9.1.2 TZM-bl assay 
TZM-bl cells (1 x 105) were plated 24hrs prior to infection.  These cells express the lacZ 
gene from under the HIV-1 Tat protein inducible HIV-1 LTR.  Equal amounts of virus 
normalised by the p24Gag concentration (1-5 ng) was used to infect the TZM-bl cells.  
Approximately, 30hrs post-infection cells were lysed in 100 µl Tropix Lysis solution 
(100 mM potassium phosphate pH 7.8, 0.2% Triton X-100) (Applied Biosystems) for 
approximately 5 minutes at room temperature, and the plates were then frozen overnight 
at -80°C.  Plates were thawed and lysed cells were harvested.  20 µl of the lysates were 
added to a 96-well white polystyrene plate.  The β-galactosidase substrate was prepared 
by diluting the Tropix Galacton-Star substrate 1:50 in the reaction buffer diluent (100 
mM sodium phosphate pH 7.5, 1 mM MgCl2, 5% Sapphire-II enhancer) (Applied 
Biosystems) and adding 100 µl of this solution to each well containing the cell lysates.  
β-galactosidase activity was measured using a luminescence counter (Perkin-Elmer) and 
Wallac 1420 Workstation software.  
 
2.9.2 HIV-1 infection of producer cells 
VSV-G pseudotyped HIV-1NL4-3 strain virus was produced by transfecting a 10 cm 
tissue culture plate of 293T cells with plasmids as stated in the figure legends using the 
protocol described (section 2.7.1).  The virus concentration was determined by p24Gag 
ELISA (section 2.9.1.1).  The MOI of the virus stock was determined with a p24Gag 
intracellular FACS stain (Dako).  Briefly HeLa or 293T cells were infected with a range 
of viral concentrations in a total volume of 1 ml for approximately 4hrs, following 
which the cells were washed 3X in 1X PBS and replaced with 2 mls of fresh media.  
Approximately, 48hrs post-infection the supernatant was removed and 1 ml of the 
TrypLE Express reagent was added to detach the cells from the plate.  Cells were 
transferred to an eppendorf tube and washed in FACS buffer (1X PBS plus 5% FCS by 
centrifuging at 8000 rpm for 5 minutes.  The supernatant was discarded and the cell 
pellets were resuspended in 100 µl of Buffer A and incubated at room temperature for 
10-15 minutes.  This step inactivates the virus.  Cells were washed in 1.5 ml FACS 
buffer by centrifuging as described.  The supernatant was discarded and the cells pellets 
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were resuspended in 100 µl of Buffer B and 2 µl of the KC57-RD1 p24Gag monoclonal 
antibody (Beckman Coulter).  These were incubated for 20 minutes at room temperature 
in the dark and then washed 4X in FACS buffer by centrifuging as described.  The cell 
pellets were resuspended in 200 µl of FACS buffer and analysed using a FACS Canto II 
Flow Cytometry System (BD Biosciences).  Mock-infected cells were also stained and 
included in the analysis as a negative control.  HeLa or 293T non-silencing control and 
MOV10 KD cells (2 x 105) were infected with 25 ng (MOI 0.3) of the VSV-G 
pseudotyped HIV-1NL4-3 strain virus in a total volume of 1 ml for approximately 4hrs as 
described for the p24Gag intracellular FACS stain.  Approximately 48hrs post-infection, 
the virus-containing supernatant was harvested and filtered, and the cells were lysed as 
described (section 2.9.1).  The virus concentration was determined by p24Gag ELISA 
(section 2.9.1.1) and the virion infectivity was measured by TZM-bl assay (section 
2.9.1.2).   
 
2.9.3 HIV-1 spreading replication 
HUT78 non-silencing control and MOV10 KD cells were generated as described 
(section 2.8).  Cells (1 x 106 cells) were pelleted by centrifuging at 300 g for 5 minutes 
and resuspended in 1 ml of medium containing 100 ng of wild-type HIV-1NL4-3 strain 
virus produced in 293T cells.  These were incubated at 37°C for 2hrs, following which 
the cells were washed in 5 ml of 1X PBS by centrifuging as described.  The cells pellets 
were resuspended in 10 ml of medium and transferred to flasks for culturing.  Cells 
were passaged every 2 days by replacing 5 ml of the culture with fresh media, and the 5 
ml cell suspension removed was pelleted by centrifugation as described.  100 µl of the 
virus-containing supernatant was diluted in 400 µl of 0.5% Triton X-100 for analysis by 
p24Gag ELISA (section 2.9.1.1).  The cells were resuspended in RIPA buffer for analysis 
by immunoblotting.   
 
2.9.4 SIVmac and HIV-1 vectors  
293T parental or non-silencing control and MOV10 KD cells (2 x 105 cells) were 
transfected with plasmids as stated in the figure legends using the protocol described 
(section 2.7.1).  Approximately 48hrs post-transfection, vector-containing supernatant 
was harvested and filtered through a 0.45 µM filter.  293T cells (1 x 105 cells) were 
plated 24hrs prior to transduction with 500 µl of the vector-containing supernatant.  
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Approximately 24hrs post-transduction, the cell supernatant was removed and cells 
were washed in 1X PBS, following which the TrypLE Express reagent was added to 
detach cells from the plate.  Cells were fixed in 4% PFA (Electron Microscopy 
Sciences) (diluted in 1X PBS) for 10 minutes at room-temperature.  Cells were washed 
3X in 1X PBS by centrifuging at 1200 rpm for 5 minutes.  Cell pellets were 
resuspended in 200 µl of 1X PBS and analysed using a FACS Canto II Flow Cytometry 
System (BD Biosciences) to determine the percentage of GFP+ cells.   
 
2.9.5 SIVmac and HIV-2 provirus 
293T cells (2 x 105) were transfected with plasmids as stated in the figure legends using 
the protocol described (section 2.7.1).  Approximately 48hrs post-transfection, virus-
containing supernatant was harvested and filtered through a 0.45 µM filter.  800 µl of 
the filtered viral supernatant was purified through a 20% sucrose cushion by 
centrifugation at 14000 rpm for 2hrs at 4°C and prepared for analysis by 
immunoblotting.  Cells were lysed in RIPA buffer and analysed by immunoblotting.  
For HIV-2, TZM-bl cells (1 x 105 cells) were plated and infected with 500 µl of the 
virus-containing supernatant 24hrs later.  Approximately 24hrs post-infection, cells 
were lysed and analysed by TZM-bl assay (section 2.9.1.2) to quantify the production of 
infectious virus. 
 
2.9.6 MLV and M-PMV 
293T parental or non-silencing control and MOV10 KD cells were transfected with 
plasmids as stated in the figure legends using the protocol described (section 2.7.1).  
Approximately 48hrs post-transfection, virus-containing supernatant was harvested and 
filtered through a 0.45 µM filter.  For M-PMV, 800 µl of the filtered viral supernatant 
was purified through a 20% sucrose cushion by centrifugation at 14000 rpm for 2hrs at 
4°C and prepared for analysis by immunoblotting.  Cells were also lysed in RIPA buffer 
and analysed by immunoblotting.  TZM-bl cells (1 x 105 cells) were plated and infected 
with 500 µl of the MLV or M-PMV-containing supernatant 24hrs later.  Approximately 
24hrs post-infection, cells were lysed and analysed by TZM-bl assay (section 2.9.1.2) to 





2.10 Quantification of HIV-1 viral RNA packaging 
HeLa or 293T cells were transfected in 10 cm tissue culture dishes with plasmids as 
stated in the figure legends using the protocol described (section 2.7.1).  Approximately 
48hrs post-transfection, virions were harvested and filtered through a 0.45 µM filter.  
100 µl of the virus-containing supernatant was diluted in 400 µl of 0.5% Triton X-100 
for analysis by p24Gag ELISA (section 2.9.1.1).  The remaining filtered viral supernatant 
was treated with RQ1 DNase (20 U/ml) (Promega) and magnesium chloride (10 mM 
final concentration) for 2-3hrs at 37°C.  Equal amounts of virus normalised by the 
p24Gag concentration was purified through a 20% sucrose cushion by ultracentrifugation 
at 28000 rpm for 1hr and 15 minutes at 4°C.  RNA was extracted from the viral pellet 
using the QIAgen RNeasy Mini kit (QIAgen).  Briefly, the supernatant was carefully 
removed and the viral pellet was lysed in 350 µl of Buffer RLT (contains guanidine 
thiocyanate).  The lysate was homogenised by transferring it to a QIA shredder spin 
column and centrifuging at 14000 rpm for 2 minutes.  The flow-through was collected 
in a 2 ml collection tube.  350 µl of 70% ethanol was added to the homogenised lysate 
and mixed thoroughly by pipetting.  Approximtely 700 µl of the sample was transferred 
to an RNeasy spin column and centrifuged at 10000 rpm for 15 seconds.  The flow-
through was discarded.  For on-column DNase digestion, 350 µl of Buffer RW1 
(contains guanidine thiocyanate and ethanol) was added to wash the column by 
centrifugation at 10000 rpm for 15 seconds and the flow-through was discarded.  100 µl 
of RQ1 DNase was added to the column and incubated at room temperature for 30 
minutes.  The column was washed again with 350 µl of Buffer RW1 and centrifugation 
as described.  The flow-through was discarded.  Following this the column was washed 
with 500 µl of Buffer RPE (contains ethanol) and centrifuged as described.  The flow-
though was discarded and the same step was repeated, however, this time with 
centrifugation at 10000 rpm for 2 minutes to remove any traces of ethanol.  RNA was 
eluted by adding 30 µl of RNase-free water to the column and centrifuging at 10000 
rpm for 1 minute.  The RNA concentration was determined using the Nanodrop ND-
1000 Spectrophotometer at OD260 (an OD of 1 at 260 nm corresponds to 40 µg/ml of 
RNA).   
 
For the reverse-transcription (RT)-PCR reaction, equal amounts of RNA (within the 
range 0.002-0.2 µg/ µl) diluted in RNase-free water to a total volume of 25 µl was 
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added to 25 µl of the 2X RT mastermix, prepared using the High Capacity cDNA 
reverse transcription kit (Applied Biosystems).  The RT mastermix was made up of 5 µl 
of 10X random primers, 5 µl of 10X RT buffer, 2 µl of 25X dNTP (100mM), 2.5 µl of 
the MultiScribe RT enzyme (50 U/ µl) and 10.5 µl of RNase-free water.  Duplicate 
samples minus the RT enzyme were included to ensure efficient removal of DNA 
contamination by RQ1 DNase digestion.  The RT reaction was performed using the 
2720 Thermal Cycler (Applied Biosystems) according to conditions outlined in table 
2.5.  The level of HIV-1 viral RNA packaged into virions was determined by qPCR 
(section 2.12) using a primer-probe set that recognises sequences within the Gag p6 
region (oNS172f, oNS173r and oNS174p FAMTAMRA).  The primer-probe sequences 
are listed in table 2.7.    
 
Table 2.5.  RT-PCR reaction conditions. 
 Temperature Time 
1 25° C 
 
10 minutes 
2 37° C 
 
120 minutes 
3 85° C 
 
5 minutes 





2.11 Quantification of HIV-1 reverse transcripts 
293T cells were transfected in 10 cm tissue culture dishes with plasmids as stated in the 
figure legends using the protocol described (section 2.7.1).  Approximately 48hrs post-
transfection, virions were harvested and filtered through a 0.45 µM filter.  100 µl of the 
virus-containing supernatant was diluted in 400 µl of 0.5% Triton X-100 for analysis by 
p24Gag ELISA (section 2.9.1.1).  HUT78 cells (1 x 106 cells) were spin-infected with 20 
ng of wild-type HIV-1NL4-3 strain virus at 2000 g for 2hrs at 4°C.  The supernatant was 
aspirated and cells were washed 3X in cold 1X PBS by centrifuging at 2000 g for 10 
minutes.  The cells pellets were resuspended in media and cultured.  Cells were 
harvested at the indicated time-points and pelleted by centrifugation at 2000 g for 10 
minutes.  DNA was extracted from the cell pellet using the QIAgen DNeasy kit 
(QIAgen).  Briefly, the pelleted cells were lysed in 200 µl 1X PBS, 20 µl Proteinase K 
and 200 µl of Buffer AL (contains guanidine hydrochloride) at 70°C for 10 minutes.  
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200 µl of 96-100% ethanol was added to the samples and mixed thoroughly by 
vortexing.  The mixture was added to a DNeasy Mini spin column and centrifuged at 
8000 rpm for 1 minute.  The flow-through was discarded.  500 µl of Buffer AW1 
(contains guanidine hydrochloride and ethanol) was added to the column and 
centrifuged as described.  The flow-through was discarded.  500 µl of Buffer AW2 
(contains ethanol) was then added to the column and centrifuged at 14000 rpm for 3 
minutes.  DNA was eluted by adding 200 µl of Buffer AE to the column and spinning at 
8000 rpm for 1 minute.  The DNA concentration was determined using the Nanodrop 
ND-1000 Spectrophotometer at OD260.  To digest input plasmid DNA, equal amounts 
of extracted DNA (diluted in nuclease-free water to a total volume of 20.5 µl) was 
incubated with 2 µl of DpnI enzyme and 2.5 µl of the appropriate buffer at 37°C for 
2hrs.  Minus strand strong stop DNA levels were quantified by qPCR (section 2.12) 
using a primer-probe set that recognises sequences between R and the U5-PBS junction 
(oHC64, oHC65 and oHC66 FAMTAMRA).  The primer-probe sequences are listed in 
table 2.7.  
 
2.12 Quantitative PCR (qPCR) 
The qPCR reactions were performed in triplicate.  The mastermix was prepared with 5 
µl TaqMan Universal PCR mastermix (Applied Biosystems), 1 µl each of the forward 
and reverse primer (9 pmol/µl) and 1 µl of the probe (2.5 pmol/µl).  8 µl of the qPCR 
mastermix was added to 2 µl of either diluted or neat sample cDNA or a serial dilution 
of the pHIV-1NL4-3 plasmid standard (nuclease-free water only, 2, 5, 10, 50, 100, 103, 
104, 105, 106, 107, 108 and 109 molecules per 2 µl diluted in salmon sperm DNA (20 
ng/ml)) in a 384-well clear optical reaction plate (Applied Biosystems).  For TaqMan 
gene expression assays, the mastermix was prepared with 10 µl of the TaqMan 
Universal PCR mastermix, 1 µl of the TaqMan assay, 4 µl of the cDNA and 5 µl of 
nuclease-free water.  For relative quantification, samples were normalised to GAPDH 
mRNA levels.  The qPCR reaction was performed using the ABI Prism 7900HT 
Sequence Detection System (Applied Biosystems) according to PCR conditions 
outlined in table 2.6, and analysed using the SDS2.3 software (Applied Biosystems).  






Table 2.6.  qPCR reaction conditions. 
 Temperature Time 
1 50° C 2 minutes 
 
2 95° C 
 
10 minutes 
3 95° C 
 
15 seconds 
4 60° C 
 
1 minute 




Table 2.7.  qPCR primer-probe set sequences. 











oHC66 FAMTAMRA ACACAACAGACGGGCACACACTA 
 
 
2.13 Immunoblotting  
2.13.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Cells lysed in RIPA buffer were diluted 1:2 in 2X dissociation buffer (125mM Tris-HCl 
pH 6.8, 20% glycerol, 4% SDS, 0.2% Bromophenol blue and ddH20.  10% β-
mercaptoethanol was added just prior to use).  Denaturing gels were cast using a large 
vertical electrophoresis system (CBS Scientific) (Either 7% (proteins > 80 kda) or 10% 
(proteins < 80 kda) acrylamide bis/solution 37.5:1 (Bio-Rad), 375 mM Tris-HCL pH 
8.8, 0.1% SDS, 0.1% ammonium persulphate, 0.0004% N, N, N’, N’-
tetramethylethylenediamine (TEMED) in ddH20).  The gels were leveled and prevented 
from drying by layering 0.1% SDS on top of the running gel and this was removed prior 
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to adding the stacking gel (4.5% acrylamide bis/solution, 125 mM Tris-HCL pH 6.8, 
0.1% SDS, 0.1% ammonium persulphate, 0.001% TEMED and ddH20).  Samples were 
boiled for 10 minutes prior to loading.  A protein ladder was also loaded as a marker for 
protein size (Benchmark Prestained protein ladder) (NEB).   
 
2.13.2 Immunoblot analysis 
Proteins were transferred onto 0.45 µm nitrocellulose membranes (Anachem) at 60 volts 
for approximately 4hrs in a large electrophoretic blotting system (CBS Scientific) 
containing transfer buffer (27.6 mM Tris Base, 0.2 M glycine, 20% methanol diluted in 
ddH20, pH > 8.8).  Membranes were blocked in 1% milk solution (1% milk powder in 
1X PBS and 0.1% Tween-20 (Fisher Scientific)) at room temperature for 1hr, following 
which membranes were incubated with the primary antibody in milk solution for 
approximately 1-2hrs at room temperature.  The membranes were washed 3X in wash 
buffer (1X PBS and 0.1% Tween-20) and incubated with 800λ Infrared IRDye 
conjugated secondary antibodies in milk solution for 1hr at room temperature in the 
dark.  Subsequently, the membranes were washed again as described and imaged using 
a Li-cor Odyssey infrared scanner (Li-cor Biosciences).  Primary and secondary 
antibodies used are listed in table 2.8 and 2.9 (IB).   
 
2.14 Immunofluorescence 
HeLa cells (1 x 105) cells were plated onto coverslips and transfected with plasmids as 
stated in the figure legends using the protocol described (section 2.7.1).  Where 
described, HeLa non-silencing control and MOV10 KD cells (1 x 105) were also plated, 
however, these cells were not transfected with any plasmids.  Approximately 24hrs later 
cells were washed 3X in 1X PBS and fixed with 4% PFA for 10 minutes at room 
temperature.  Cells were washed again as described and permeabilised with 0.2% Triton 
X-100 for 15 minutes at room temperature.  Subsequently, cells were blocked and 
quenched in NGB buffer (50 mM NH4Cl, 2% goat serum, 2% BSA and 0.05% sodium 
azide in PBS) for 1hr at room temperature, following which the primary antibody was 
diluted in NGB buffer and added to the cells for 1-2hrs at room temperature.  Coverslips 
were washed as described before incubation with the appropriate Alexa Fluor 
conjugated secondary antibody diluted in the NGB buffer for 1hr at room temperature in 
the dark.  The secondary antibody was removed and cells were incubated for an 
additional 1 minute with the DAPI stain (30 nm final concentration) (Molecular 
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Probes).  Coverslips were washed as described and mounted onto glass slides (Fisher 
Scientific) using 10 µl of Mowiol mounting media (Calbiochem).  The slides were dried 
overnight in the dark and images were collected using a TCS SP2 AOBS confocal laser-
scanning microscope (DM IRE2: Leica), with a 63X oil objective lens and processed 
with the LSC software (version 2.02, Leica) and Adobe Photoshop (CS5.1).  Primary 
and secondary antibodies used are listed in table 2.8 and 2.9 (IF).   
 
Table 2.8.  Primary antibodies for immunoblotting and immunofluorescence. 
Antibody Species Dilution Source 




Rabbit 1/1000 (IB) (Newman et al., 2005) 
Anti-TRIM22 
 
Rabbit 1/250 (IB) Sigma-Aldrich 
Anti-Hsp90 Rabbit 1/3000 (IB) Santa Cruz 
 
Anti-DDX6 Rabbit  1/500 (IF) Cambridge Biosciences 
 
Anti-Ge1 Mouse  1/500 (IF) Santa Cruz 
 
Anti-T7 Mouse 1/10000 (IB, IF) Novagen 
 
Anti-myc (9E10) Mouse 1/1000 (IB, IF) (Evan et al., 1985) 
 
Anti-HIV-1 p24Gag (24.2) Mouse 1/1000 (IB) 
 
(Fouchier et al., 1997) 
 
Anti-HIV-1 p24Gag (183) 
(HIV-2, SIVmac) 
 
Mouse 1/100 (IB) Kind gift from Dr. Stuart 
Neil 
 
Anti-HIV-1 p24Gag (UP598) 
 
Rabbit  1/500 (IF) (Simon et al., 1997) 
Anti-HIV-1 p17Gag (UP595) Rabbit 1/500 (IF) (Swanson et al., 2004) 
 
Anti-M-PMV p27Gag  
(78 S-136) 




* IB = immunoblotting  






Table 2.9.  Secondary antibodies for immunoblotting and immunofluorescence. 
Antibody Conjugation  Dilution Source 
800nmλ Goat α-mouse IRDye 
 
1/10000 (IB) Li-cor Biosciences 
800nmλ Goat α-rabbit 
 
IRDye 1/10000 (IB) Li-cor Biosciences 
800nmλ Donkey α-goat IRDye 
 
1/10000 (IB) Li-cor Biosciences 
488nmλ Goat α-mouse  Alexa Fluor 488 1/500 (IF) Molecular Probes 
 
594nmλ Goat α-rabbit Alexa Fluor 594 1/500 (IF) Molecular Probes 
 
 
* IB = immunoblotting  
* IF = immunofluorescence 
 
2.15 Retrotransposition assay 
Parental HeLa-HA or non-silencing control and MOV10 KD HeLa-HA cells (2 x 105 
cells) were transfected with plasmids as stated in the figure legends using the protocol 
described (section 2.7.1).  The next day 1 ml of the TrypLE Express reagent was added 
to detach the cells from the plate, and cells were transferred into 10 cm tissue culture 
dishes.  The following day the cell culture was selected with G418 (1 mg/ml final 
concentration) (Sigma-Aldrich).  Approximately 5 days later fresh media containing 
G418 was replaced.  Approximately 12-15 days later, when the control untransfected 
cells had died, cells were washed 3X in 1X PBS and fixed in 4% PFA for 10 minutes at 
room temperature.  Cells were washed again as described, following which the cells 
were stained in 0.4% Giemsa stain (dissolved in 70% ethanol) (Sigma-Aldrich) for 40 
minutes at room temperature.  The cells were washed 3X in ddH20 and G418-resistant 
cell colonies were counted.   
 
2.16 Luciferase assays 
Parental HeLa-HA or non-silencing control and MOV10 KD HeLa-HA cells (1 x 105 
cells) were transfected with plasmids as stated in the figure legends using the protocol 
described (section 2.7.1).  Luc assays were performed using the Dual Luciferase 
Reporter kit (Promega).  For this, approximately 24hrs post-transfection, cells were 
washed in 1X PBS before being lysed in 100 µl of 1X Passive Lysis Buffer (diluted in 
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ddH20) at room temperature for 15 minutes with gentle shaking.  The Luciferase Assay 
Reagent II (LAR II) was prepared by dissolving the Luciferase Assay substrate in the 
Luciferase Assay Buffer II provided.  100 µl of LAR II was added to 20 µl of the cell 
lysate in a white polystyrene 96-well plate and mixed well.  Firefly activity was 
measured immediately using a luminescence counter and the Wallac 1420 Workstation 
software.  Following these readings, 100 µl of the Stop & Glo reagent, prepared by 
diluting the Stop & Glo substrate 1:50 into the Stop & Glo Buffer provided, was added 
to the wells to quench firefly Luc activity and measure Renilla Luc activity.  Readings 



















































MOV10 overexpression restricts the replication of 
retroviruses and retrotransposons 
 
3.1 Introduction 
Human MOV10 regulates the replication of several RNA viruses (Haussecker et al., 
2008; Li et al., 2011; Schoggins et al., 2011).  This function appears to be evolutionarily 
conserved as MOV10 homologs are necessary for the inhibition of viruses and 
endogenous retroelements (Dalmay et al., 2001; Frost et al., 2010; Olivieri et al., 2010; 
Zheng et al., 2010) (chapter 1 section 1.13.2).  Furthermore, MOV10 interacts with 
members of the APOBEC3 family that inhibit the replication of both retroviruses and 
retrotransposons (Gallois-Montbrun et al., 2007; Gallois-Montbrun et al., 2008) (chapter 
1 sections 1.8.2.8 to 1.8.2.10), and also associates with miRNA and siRNA-mediated 
post-transcriptional RNA silencing pathways, which too have been implicated in the 
regulation of retroelements (Meister et al., 2005) (chapter 1 section 1.12.5).  MOV10 
and members of the APOBEC3 and AGO family co-localise in P bodies and redistribute 
to SGs under conditions of stress (Meister et al., 2005; Gallois-Montbrun et al., 2007; 
Gallois-Montbrun et al., 2008).  Reports have identified P bodies and SGs, as well as 
individual components of these RNP microdomains, as playing both restrictive and 
stimulatory roles in the life cycle of exogenous and endogenous retroelements (Chable-
Bessia et al., 2009; Henao-Mejia et al., 2009; Doucet et al., 2010) (chapter 1 sections 
1.10.1 and 1.11.1).  Considering these associations, the potential capacity of MOV10 to 
regulate retroelements was established by undertaking side-by-side comparisons of the 
effect of MOV10 ectopic overexpression on the replication of a panel of retroviruses 






3.2 HIV-1 subgenomic and full-length provirus assays 
MOV10 was identified as an A3F and A3G interacting RBP (Gallois-Montbrun et al., 
2007; Gallois-Montbrun et al., 2008), both of which are intrinsic HIV-1 restriction 
factors (Bishop et al., 2004; Liddament et al., 2004; Wiegand et al., 2004) (chapter 1 
section 1.8.2.8).  Therefore, the effect of MOV10 overexpression on the production and 
infectivity of HIV-1 particles was determined initially using a subgenomic system as 
well as full-length HIV-1.  The subgenomic construct (GPV-RRE) was generated from 
the HIV-1NL4-3 provirus and encodes gag, pro, pol, vif and part of vpr, as well as the 
RRE directing nuclear export via the CRM1/Rev pathway (Figure 3.1A).  GPV-RRE 
contains only part of the 5’ U3 (sequence 3’ to TATA box) and complete R and U5 
sequences fused to the herpesvirus cytomegalovirus (CMV) promoter, and has a 
polyadenylation signal derived from the bovine growth hormone (BGH).  Additionally, 
the GPV-RRE construct maintains the 5’ splice donor and two 3’ splice acceptor sites.   
 
For the subgenomic and provirus assays, HeLa or 293T cells were transfected with 
either GPV-RRE and a plasmid expressing Rev (pRev), or a plasmid expressing the 
full-length HIV-1NL4-3 provirus (pHIV-1NL4-3) (Adachi et al., 1986) (Figure 3.1B).  For 
MOV10 overexpression experiments, cells were co-transfected with GPV-RRE or 
pHIV-1NL4-3 together with a plasmid expressing MOV10 (pMOV10) or either a GFP or 
firefly luciferase (Luc) control plasmid (pGFP/pLuc).  VLP or virion production was 
quantified by p24Gag enzyme-linked immunosorbent assay (ELISA) (p24Gag corresponds 
to CA).  For full-length proviral experiments, equal amounts of virus normalised by the 
p24Gag concentration was added to a TZM-bl reporter cell line expressing a HIV-1 Tat 
inducible β-galactosidase (β-gal) reporter gene, to establish the effect of MOV10 












                
 
Figure 3.1.  HIV-1 subgenomic and full-length provirus assays.  
 
(A) Subgenomic GPV-RRE construct.  The GPV-RRE construct was derived from the HIV-1NL4-3 
provirus and encodes gag, pro, pol, vif and part of vpr.  The RRE, 5’ splice donor site and two 3’ splice 
acceptor sites are also retained.  Transcription is driven from a cytomegalovirus (CMV) promoter that is 
fused to part of the 5’ U3, and complete R and U5 sequences and the 3’ UTR is replaced with a 
polyadenylation signal from the bovine growth hormone (BGH).  (B) GPV-RRE and proviral assays.  
HeLa or 293T cells were co-transfected with either pHIV-1NL4-3 (proviral assays) or GPV-RRE and a 
plasmid expressing the HIV-1 Rev protein (pRev) together with equal concentrations of a plasmid 
expressing the cDNA of a protein of interest, for example, MOV10.  Approximately 48hrs post-
transfection virions or virus-like particles (VLPs) in the supernatant were harvested and quantified by 
p24Gag ELISA.  For proviral assays, equal amounts of virus normalised by the p24Gag concentration was 
added to a TZM-bl reporter cell line expressing a HIV-1 Tat protein inducible β-galactosidase (β-gal) 













3.3 Effect of MOV10 overexpression on HIV-1 virus production and infectivity 
3.3.1 Expression of N-terminally and C-terminally-tagged MOV10 proteins 
The MOV10 cDNA was cloned into three plasmids with either an N-terminal or C-
terminal tag to test the effect of these differential tags on MOV10 protein expression.  
The plasmids pcDNA3.1-myc-MOV10 (myc-MOV10), pCMV4-MOV10-HA 
(MOV10-HA) and pT7-MOV10 (T7-MOV10) were transfected into 293T cells, 
following which cells were harvested and MOV10 expression was analysed by 
immunoblotting with an anti-MOV10 antibody.  MOV10 was expressed efficiently 
from all three plasmids although MOV10 protein abundance varied with MOV10-HA 
being expressed at the highest levels  (Figure 3.2A).  
 
3.3.2 Overexpression of MOV10 inhibits HIV-1 VLP production 
To determine the effect of MOV10 overexpression on VLP production, either myc-
MOV10, MOV10-HA, T7-MOV10 or the pGFP control in the relevant plasmid 
backbone was transfected into 293T cells together with GPV-RRE and pRev.  VLP 
production was quantified by p24Gag ELISA and results showed a potent decrease in 
VLP production, whereby this was reduced by over 90% with myc-MOV10 and 
MOV10-HA overexpression, and completely in the case of T7-MOV10 overexpression 
compared to the pGFP control (Figure 3.2B).  The capacity of MOV10-HA to inhibit 
VLP production was reduced relative to T7-MOV10 despite higher levels of expression 
(Figure 3.2A), and this may be attributed to the C-terminal HA-tag affecting MOV10 
protein function.     
 
3.3.3 MOV10 overexpression inhibits HIV-1 virus production and the infectivity of 
virions produced  
The N-terminally and C-terminally-tagged MOV10 plasmids or relevant pGFP controls 
were also transfected into 293T cells together with pHIV-1NL4-3 to determine the effect 
of MOV10 overexpression on HIV-1 virus production and infectivity and, secondly, to 
ensure that the differential tags did not affect MOV10 protein function in the context of 
the full-length provirus.  Virus production was quantified by p24Gag ELISA and 
consistent with the subgenomic constructs MOV10 overexpression decreased HIV-1 
virus production by approximately 80%, 70% and 95% with myc-MOV10, MOV10-HA 
and T7-MOV10 overexpression, respectively, in comparison with the pGFP control 
(Figure 3.2C, left panel).  Interestingly, the potency of inhibition was moderately 
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reduced in comparison with the subgenomic system, as ectopically overexpressed 
MOV10 inhibited VLP production more effectively than wild-type virus.  Equal 
amounts of virus normalised by the p24Gag concentration was added to TZM-bl cells to 
measure the effect of MOV10 overexpression on the infectivity of virions produced.  A 
dramatic decrease in virion infectivity was observed, whereby this was completely 
abolished with myc-MOV10 and T7-MOV10 overexpression and reduced by 
approximately 90% with MOV10-HA overexpression relative to the pGFP control 
(Figure 3.2C, right panel).  Again, despite higher MOV10-HA expression levels (Figure 
3.2A), its ability to inhibit HIV-1 virus production and infectivity was reduced in 
comparison with myc-MOV10 and T7-MOV10, and for this reason the pCMV4-
MOV10-HA plasmid was not used for any further experiments.  Therefore, 

























           
 
Figure 3.2.  MOV10 overexpression inhibits HIV-1 virus production and the 
infectivity of virions produced. 
 
(A) Expression of N-terminally and C-terminally tagged MOV10 proteins.  The MOV10 cDNA was 
cloned into three expression plasmids with N-terminal and C-terminal tags to generate pcDNA3.1-myc-
MOV10, pCMV4-MOV10-HA and pT7-MOV10.  293T cells were transfected with each of these 
plasmids and harvested approximately 24hrs post-transfection.  Cells were lysed and analysed by 
immunoblotting with anti-MOV10 and anti-Hsp90 antibodies.  (B) Overexpression of MOV10 inhibits 
HIV-1 VLP production.  293T cells were co-transfected with GPV-RRE (0.5 µg), pRev (0.25 µg) and 
MOV10 expressing plasmids described in panel (A) (1.5 µg) or pcDNA3.1-myc-GFP, pCMV4-GFP-HA 
and pT7-GFP (1.5 µg) as a control.  VLPs were quantified by p24Gag ELISA as described in Figure 3.1B.  
(C) MOV10 overexpression inhibits HIV-1 virus production and the infectivity of virions produced.  
293T cells were co-transfected with pHIV-1NL4-3 (0.5 µg) and MOV10 expressing plasmids described in 
panel (A) (1.5 µg) or plasmids expressing GFP controls as described in panel (B).  Virus production was 
quantified by p24Gag ELISA and infectivity was measured by TZM-bl assay as described in Figure 3.1B.  









3.4 MOV10 overexpression decreases HIV-1 virus production and the infectivity of 
virions produced in a dose-dependent manner 
To test that MOV10-mediated inhibition of HIV-1 virus production and infectivity was 
not simply attributed to the ectopic overexpression of very high levels of MOV10, and 
also to test the potency of MOV10, pT7-MOV10 (pMOV10) was titrated into HeLa or 
293T cells together with pHIV-1NL4-3.  The pT7-Luc (pLuc) control was also co-
transfected with pMOV10 to ensure equivalent amounts of DNA in all transfections.  
Virus production was quantified by p24Gag ELISA and results showed that MOV10 
overexpression decreased HIV-1 virion production in a concentration-dependent 
manner, whereby at the lowest pMOV10 concentration of 0.1 µg virus production was 
decreased by approximately 30% in HeLa and 293T cells, and at the highest pMOV10 
amount of 1.5 µg this was reduced by approximately 70% and 80% in HeLa and 293T 
cells, respectively, compared to the pLuc control (Figure 3.3A).  Cell lysates were also 
analysed by quantitative immunoblotting with an anti-p24Gag antibody, which detects 
precursor and processed Gag bands, to determine whether MOV10 overexpression 
affected Gag abundance or processing.  Total cellular Gag levels were measured by 
quantifying all the Gag bands and at the maximum pMOV10 concentration Gag 
abundance was decreased by approximately 40% and 50% in HeLa and 293T cells, 
respectively, relative to the pLuc control (Figure 3.3A, compare lanes 1 and 7).  
Furthermore, Gag processing (total processed Gag bands divided by total Gag bands) 
was also reduced by approximately 10% and 40% in HeLa and 293T cells, respectively, 
in comparison to the pLuc control (Figure 3.3A, compare lanes 1 and 7).   
 
Equal amounts of virus normalised by the p24Gag concentration was added to TZM-bl 
cells to determine the effect of MOV10 titration on virion infectivity.  Results showed a 
dose-dependent decrease in HIV-1 virion infectivity with increasing concentrations of 
pMOV10, whereby at the lowest pMOV10 concentration of 0.1 µg the infectivity of 
virions produced was reduced by approximately 30% and 70% for HeLa and 293T cells, 
respectively, and at the highest pMOV10 concentration of 1.5 µg infectivity was 
decreased by approximately 90% for HeLa cells, and completely in the case of 293T 
cells compared to the pLuc control (Figure 3.3B).  These data demonstrate that MOV10 
overexpression decreases HIV-1 virus production and the infectivity of virions 
produced in a dose-dependent manner, and also reduces Gag expression and processing. 
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Figure 3.3.  MOV10 overexpression decreases HIV-1 virus production and the 
infectivity of virions produced in a dose-dependent manner. 
 
(A) MOV10 overexpression decreases HIV-1 virus production in a dose-dependent manner.  HeLa 
or 293T cells were co-transfected with pHIV-1NL4-3 (0.5 µg) and pT7-MOV10 (pMOV10) at the indicated 
increasing concentrations or pT7-luciferase (Luc) as a control (pLuc).  Virions were quantified by p24Gag 
ELISA as described in Figure 3.1B.  Cells were lysed and analysed by immunoblotting with anti-T7, anti-
p24Gag and anti-Hsp90 antibodies.  (B) Overexpression of MOV10 decreases the infectivity of HIV-1 
virions produced in a concentration-dependent manner.  The infectivity of equal amounts of virus 
normalised by the p24Gag concentration from experiments depicted in panel (A) was measured by TZM-bl 
assay as described in Figure 3.1B.  Results are normalised to the pLuc control, which is set at 100%.  










3.5 Overexpression of P body and SG factors AGO2 and TIA-1 does not affect 
HIV-1 virus production or infectivity 
The subcellular localisation of MOV10 is cytoplasmically diffuse and punctate with 
MOV10 detected in cytoplasmic P bodies and SGs (Gallois-Montbrun et al., 2007; 
Gallois-Montbrun et al., 2008).  AGO2 interacts with MOV10 and is also localised to P 
bodies, and similarly redistributes to SGs during cellular stress (Meister et al., 2005).  
TIA-1 is localised only to SGs and is essential for SG assembly (Kedersha et al., 1999; 
Gilks et al., 2004).  A number of proteins that localise to P bodies and SGs have been 
implicated in the regulation of retroelements, including HIV-1 (chapter 1 sections 
1.10.1 and 1.11.1).  To determine whether the capacity to regulate HIV-1 replication is 
an inherent property of P body and SG proteins such as MOV10, the effect of AGO2 
and TIA-1 overexpression on HIV-1 virus production and infectivity was determined.  
 
293T cells were co-transfected with either pcDNA3.1-myc-MOV10 (pMOV10), 
pcDNA3.1-myc-AGO2 (pAGO2), pcDNA3.1-myc-TIA-1 (pTIA-1) or the pcDNA3.1-
myc-GFP (pGFP), and cell lysates were analysed by immunoblotting with an anti-myc 
antibody to determine the relative expression levels of these proteins (Figure 3.4A).  
Subsequently, 293T cells were co-transfected with pHIV-1NL4-3 and either pMOV10, 
pAGO2, pTIA-1 or the pGFP control as described above.  The effect on virion 
production was measured by p24Gag ELISA and results showed that unlike MOV10 
overexpression, ectopic overexpression of AGO2 or TIA-1 did not decrease HIV-1 
virion production (Figures 3.4B and C).  In fact, TIA-1 overexpression moderately 
enhanced virus production (Figure 3.4C).  The effect of these proteins on the infectivity 
of virions produced was also determined by TZM-bl assay and, similarly, both AGO2 
and TIA-1 overexpression had no effect on HIV-1 infectivity either (Figures 3.4B and 
C).  Therefore, although MOV10 overexpression inhibits HIV-1 virus production and 









                       
  
Figure 3.4.  Overexpression of P body and SG factors AGO2 and TIA-1 does not 
affect HIV-1 virus production or infectivity. 
 
(A) AGO2 and TIA-1 expression levels.  293T cells were co-transfected with either pcDNA3.1-myc-
MOV10 (pMOV10), pcDNA3.1-myc-AGO2 (pAGO2), pcDNA3.1-myc-TIA-1 (pTIA-1) or the 
pcDNA3.1-myc-GFP (pGFP) control (1.5 µg).  Cell lysates were analysed by immunoblotting with anti-
myc and anti-Hsp90 antibodies.  (B) AGO2 overexpression has no effect on HIV-1 virus production 
or infectivity.  293T cells were co-transfected with pHIV-1NL4-3 (0.5 µg) and either pMOV10, pAGO2 or 
the pGFP control (1.5 µg).  Virus production was quantified by p24Gag ELISA and infectivity was 
measured by TZM-bl assay as described in Figure 3.1B.  (C) Overexpression of TIA-1 does not effect 
HIV-1 virus production or infectivity.  293T cells were co-transfected with pHIV-1NL4-3 (0.5 µg) and 
either pMOV10, pTIA-1 or the pGFP control (1.5 µg).  Virus production was quantified by p24Gag ELISA 
and infectivity was measured by TZM-bl assay as described in Figure 3.1B.  Results are normalised to the 











3.6 Effect of MOV10 overexpression on other primate lentiviruses  
3.6.1 SIVmac and HIV-1 vector system assay 
As MOV10 overexpression potently inhibits HIV-1, the analysis of its antiviral activity 
was extended to the primate lentivirus SIVmac, which is a pathogenic SIV that arose as 
a result of infection of rhesus macaque monkeys with SIVsmm in US primate centres 
(Apetrei et al., 2005).  Vector systems were adopted for these experiments; the SIVmac 
packaging plasmid (pSIV3+) encodes gag, pro, pol and all the regulatory and accessory 
proteins except nef, and also lacks env (Negre et al., 2000) (Figure 3.5A, top panel).  
The cis-acting element RRE is retained, however, the Psi is removed, and complete 5’ R 
and U5 sequences are fused to the CMV promoter for transcription.  A polyadenylation 
signal derived from the simian vacuolating virus 40 (SV40) replaces the 3’ LTR.  The 
SIVmac genome plasmid (pSIV-RMES4) is devoid of all viral proteins and expresses 
GFP from a CMV promoter (Negre et al., 2000) (Figure 3.5A, lower panel).  The Psi, 
cPPT, RRE, and 3’ LTR are intact, and the 5’ R and U5 sequences are fused to a CMV 
promoter.  A HIV-1 vector system was also tested as a control to ensure that results 
observed with the full-length provirus were reproducible with vectors.  The HIV-1 
packaging plasmid (p8.91) is similar to pSIV3+, however, it lacks all the accessory 
proteins and contains a polyadenylation signal derived from the insulin gene (Zufferey 
et al., 1997) (Figure 3.5B, top panel).  The HIV-1 genome plasmid (pCSGW) is also 
similar to pSIV-RMES4, however GFP is expressed from a spleen focus-forming virus 
(SFFV) promoter, which is placed just upstream of a woodchuck hepatitis virus post-
transcriptional regulatory element (WPRE) for enhanced expression (Bainbridge et al., 
2001) (Figure 3.5B, lower panel).  Also the 5’ LTR is intact, however, this plasmid is a 
self-inactivating vector (SIN) and, therefore, the 3’ LTR lacks the U3 region. 
 
To produce SIVmac and HIV-1 vectors, 293T cells were co-transfected with either 
pSIV3+ and pSIV-RMES4 or p8.91 and pCSGW, respectively, together with a plasmid 
expressing the VSV glycoprotein (pVSV-G)(Fouchier et al., 1998) (Figure 3.5C).  For 
MOV10 overexpression experiments, plasmids for SIVmac or HIV-1 vector production 
were co-transfected into 293T cells together with pT7-MOV10 (pMOV10) or pT7-Luc 
(pLuc) as a control.  VSV-G pseudotyped particles incorporating a GFP-expressing 
genome were harvested and equal amounts of vector-containing supernatant was added 
to 293T cells.  The effect of MOV10 overexpression on the production of infectious 
retrovirus particles was determined by measuring the percentage of GFP+ cells.         
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Figure 3.5.  SIVmac and HIV-1 vector system assay. 
 
(A) SIVmac vector system constructs.  The SIVmac packaging plasmid, pSIV3+, encodes gag, pro, pol, 
all regulatory and accessory proteins and contains the RRE, however, lacks the Psi, env and nef.  The U3 
sequence is also deleted from the 5’ LTR and replaced with the CMV promoter.  The 3’ LTR is entirely 
replaced with a polyadenylation signal from the simian vacuolating virus 40 (SV40).  The SIVmac 
genome plasmid, pSIV-RMES4, is devoid of all viral proteins, and contains the Psi, cPPT and RRE.  A 
CMV promoter drives expression of GFP.  A CMV promoter also replaces the 5’ LTR U3 sequence, 
however, the 3’ LTR is intact.  (B) HIV-1 vector system constructs.  The HIV-1 packaging plasmid, 
p8.91, encodes gag, pro, pol, tat, rev and consists of the RRE, however, lacks all accessory proteins, env 
and the Psi.  The U3 sequence in the 5’ LTR is replaced with the CMV promoter, and the complete 3’ 
LTR is replaced with a polyadenylation signal derived from the insulin gene (INS).  The HIV-1 genome 
plasmid, pCSGW, lacks all viral proteins, and contains the Psi, RRE and cPPT.  A spleen focus-forming 
virus (SFFV) promoter drives GFP expression, which is just upstream of a woodchuck hepatitis virus 
post-transcriptional regulatory element (WPRE).  The 5’ LTR is intact, however, this is a self-inactivating 
(SIN) vector and, therefore, lacks the U3 sequence in the 3’ LTR.  (C) Vector system assay.  293T cells 
were co-transfected with pSIV3+, pSIV-RMES4 and pVSV-G to produce SIVmac vectors, or p8.91, 
pCSGW and pVSV-G to produce HIV-1 vectors, together with pT7-MOV10 (pMOV10) or the pT7-Luc 
(pLuc) control.  Vectors were harvested approximately 48hrs post-transfection and equal volumes of 
vector-containing supernatant was added to 293T cells.  The effect on production of infectious vector 
particles was determined by quantifying the percentage of GFP+ 293T cells by fluorescence activated cell 
sorting  (FACS).   
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3.6.2 MOV10 overexpression inhibits the production of infectious SIVmac and HIV-2 
particles 
The effect of MOV10 overexpression on the production of infectious SIVmac and HIV-
1 vectors was tested as described, and similar to the observations for wild-type HIV-1, 
the production of both SIVmac and HIV-1 infectious particles was dramatically reduced 
by over 90% compared to the pLuc control (Figure 3.6A).  The vector system assay 
does not differentiate between an inhibition in SIVmac vector production or infectivity, 
as determined for the wild-type HIV-1 experiments.  Therefore, to assess whether 
MOV10 overexpression could decrease SIVmac particle production, 293T cells were 
co-transfected with a plasmid expressing a full-length SIVmac239 provirus 
(pSIVmac239) and pMOV10 at increasing concentrations or the pLuc control.  HIV-2 
was also included in the analysis for which 293T cells were co-transfected with a 
plasmid expressing the full-length HIV-2ROD provirus (pHIV-2ROD) together with 
pMOV10 or the pLuc control.  Cell lysates and sucrose-cushion purified virions were 
analysed by immunoblotting using an anti-HIV-1 p24Gag antibody that recognises 
epitopes within SIVmac p27Gag and HIV-2 p26Gag (corresponds to CA in these viruses).  
Similar to wild-type HIV-1, MOV10 overexpression decreased SIVmac and HIV-2 
virion production in a dose-dependent manner (Figure 3.6B).  In the case of HIV-2, Gag 
expression was also notably reduced (Figure 3.6B, compare lanes 6 and 9), however, 
this could not be clearly determined for SIVmac due to variations in loading as 
determined by the Hsp90 loading control (Figure 3.6B, lanes 4 and 5).   
 
The effect of MOV10 overexpression on the production of infectious HIV-2 virions was 
determined by adding equal volumes of virus-containing supernatant to TZM-bl cells, 
as the HIV-2 Tat protein also transactivates transcription from the HIV-1 LTR.  Results 
showed a pMOV10 concentration-dependent decrease in the production of infectious 
HIV-2 virions, whereby at the highest pMOV10 concentration of 1 µg virions were no 
longer infectious (Figure 3.6C).  The decrease in HIV-2 infectivity was more dramatic 
than that for HIV-1 at similar concentrations of pMOV10, however, this is likely 
attributed to the fact that HIV-2 virions were not normalised prior to their addition to 
TZM-bl cells.  Nevertheless, factoring in the small decrease in HIV-2 virus production 
as determined by immunoblotting (Figure 3.6B), it seems likely that MOV10 
overexpression inhibits the infectivity of HIV-2 virions as well. 
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Figure 3.6.  MOV10 overexpression inhibits the production of infectious SIVmac 
and HIV-2 particles. 
 
(A) MOV10 overexpression inhibits the production of infectious SIVmac and HIV-1 vectors.  293T 
cells were co-transfected with p8.91 (1 µg), pCSGW (1 µg) and pVSV-G (0.5 µg) for HIV-1 vector 
production or pSIV3+ (1 µg), pSIV-RMES4 (1 µg) and pVSV-G (1 µg) for SIVmac vector production, 
together with pMOV10 or pLuc (0.5 µg).  The effect on production of infectious vectors was determined 
by FACS as described in Figure 3.5C.  (B) MOV10 overexpression decreases SIVmac and HIV-2 
virion production.  293T cells were co-transfected with a full-length SIVmac provirus, pSIVmac239 (0.5 
µg) or a full-length HIV-2ROD provirus, pHIV-2ROD (0.5 µg), together with pMOV10 at the indicated 
increasing concentrations or the pLuc control.  Cell lysates and virions purified through a 20% sucrose 
cushion were analysed by immunoblotting with anti-HIV-1 p24Gag and anti-Hsp90 antibodies.  (C) 
Overexpression of MOV10 inhibits the production of infectious HIV-2 virions.  The effect on 
production of infectious virions was determined by TZM-bl assay by adding equal volumes of HIV-2 
virus-containing supernatant from the experiment in panel (B) to TZM-bl reporter cells.  Results for panel 
(A) and (C) are normalised to the pLuc control, which is set at 100%.  For panel (A) a single control bar 
set at 100% is graphed for simplicity and these values are the mean ± SD of 3 independent experiments.                              
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3.7 Effect of MOV10 overexpression on retroviruses from other genera  
3.7.1 MOV10 overexpression abolishes the production of infectious MLV virions 
As MOV10 overexpression potently inhibits members of the primate lentivirus family 
the capacity of this protein to restrict retroviruses from within other genera was 
investigated.  MLV is a gammaretrovirus, which belongs to the group of simple 
retroviruses that encode only gag, pro, pol and env.  The effect of MOV10 ectopic 
overexpression on the production of infectious MLV particles was determined by co-
transfecting 293T cells with a plasmid expressing the full-length MLV provirus 
(pMLV) (Yueh and Goff, 2003) and a surrogate genome expressing the HIV-1 Tat 
protein (pMLV-Tat) (Martin-Serrano et al., 2003), together with pVSV-G and either 
pT7-MOV10 (pMOV10) or the pT7-Luc (pLuc) control (Figure 3.7A).  VSV-G 
pseudotyped MLV virions were harvested and equal amounts of virus-containing 
supernatant was added to TZM-bl reporter cells.  Remarkably, MOV10 overexpression 
abolished the production of infectious MLV virions completely (Figure 3.7B).  Again, 
as MLV virions were not normalised prior to their infection of TZM-bl cells, the effect 
of MOV10 overexpression on MLV virion production and infectivity could not be 
differentiated.  Therefore, ectopic overexpression of MOV10 not only restricts primate 



















                
 
Figure 3.7.  MOV10 overexpression abolishes the production of infectious MLV 
virions. 
 
(A) MLV assay.  293T cells were co-transfected with a plasmid expressing the full-length MLV provirus, 
pMLV, a surrogate MLV plasmid expressing the HIV-1 Tat protein, pMLV-Tat, and pVSV-G together 
with pT7-MOV10 (pMOV10) or the pT7-Luc (pLuc) control.  Approximately 48hrs post-transfection, 
MLV virions were harvested and equal volumes of virus-containing supernatant was added to TZM-bl 
cells to determine the effect on production of infectious virions.  (B) MOV10 overexpression abolishes 
the production of infectious MLV virions.  293T cells were co-transfected with pMLV (0.2 µg), 
pMLV-Tat (0.2 µg), pVSV-G (0.1 µg) and either pMOV10 or the pLuc control (0.5 µg).  The effect on 
production of infectious virions was determined as described in panel (A).  Results are normalised to the 














3.7.2 Production of infectious M-PMV virions is restricted by MOV10 overexpression  
M-PMV belongs to the betaretrovirus genera of the retrovirus family and is also a 
simple retrovirus that encodes only gag, pro, pol and env.  To determine the effect of 
MOV10 overexpression on the production of infectious M-PMV, a plasmid expressing 
the full-length M-PMV provirus in which env is replaced with HIV-1 tat (pMT∆E) 
(Doehle et al., 2006) was co-transfected into 293T cells together with pVSV-G and 
either pT7-MOV10 (pMOV10) or the pT7-Luc (pLuc) control (Figures 3.8A and B).  
VSV-G pseudotyped M-PMV virions expressing HIV-1 Tat were harvested and equal 
amounts of virus-containing supernatant was added to TZM-bl cells to establish the 
effect of MOV10 overexpression on production of infectious particles (Figure 3.8B).  
Similar to previous results with HIV-1, HIV-2, SIVmac and MLV, the production of 
infectious M-PMV virions was dramatically reduced by over 95% relative to the pLuc 
control (Figure 3.8C).  Cell lysates and sucrose-cushion purified virions were also 
analysed by immunoblotting using an antibody that recognises an epitope within M-
PMV p27Gag (corresponds to CA), which detects both precursor and processed Gag 
bands.  As for HIV-1, HIV-2 and SIVmac, MOV10 overexpression decreased the 
production of M-PMV virions and markedly reduced cellular Gag expression in a 
pMOV10 concentration-dependent manner (Figure 3.8D, compare lanes 1 and 3).  
Together, these data support a potential antiviral role for MOV10 in the replication of 















               
Figure 3.8.  Production of infectious M-PMV virions is restricted by MOV10 
overexpression.  
 
(A) M-PMV proviral construct (pMT∆E).  pMT∆E expresses a full-length M-PMV provirus in which 
env is replaced with HIV-1 tat.  (B) M-PMV assay.  293T cells were co-transfected with pMT∆E and 
pVSV-G together with pT7-MOV10 (pMOV10) or the pT7-Luc (pLuc) control.  Approximately 48hrs 
post-transfection, M-PMV virions were harvested and the effect on production of infectious virions was 
determined by TZM-bl assay by adding equal volumes of virus-containing supernatant to the TZM-bl 
reporter cell line.  (C) Production of infectious M-PMV virions is restricted by MOV10 
overexpression.  293T cells were co-transfected with pMT∆E (1 µg) and pVSV-G (0.5 µg) together with 
pMOV10 or the pLuc control (0.5 µg).  The effect on production of infectious virions was determined as 
described in panel (B).  (D) MOV10 overexpression decreases M-PMV virion production.  Cell 
lysates and M-PMV virions purified through a 20% sucrose cushion from the experiments in panel (C) 
were analysed by immunoblotting with anti-M-PMV p27Gag and anti-Hsp90 antibodies (* refers to non-
specific bands).  Results for panel (C) are normalised to the pLuc control, which is set at 100% and these 
values are the mean ± SD of 3 independent experiments.  The data in panel (D) is representative of 2 
independent experiments.   
135
 
3.8 Effect of MOV10 overexpression on endogenous retroelements  
3.8.1 Retrotransposition assay 
MOV10 overexpression restricts retroviruses from the lentivirus, gammaretrovirus and 
betaretrovirus subfamilies and, therefore, displays broad antiretroviral activity.  The 
genome organisation of ERVs is similar to that of exogenous retroviruses, although 
these have an intracellular life cycle partially owing to the lack of a functional env gene, 
and have also entered the germ line allowing them to be vertically transmitted (chapter 1 
section 1.6).  On the other hand, retrotransposons are endogenous retroelements with 
distinct genome organisation from retroviruses and furthermore, retrotransposons 
couple the process of reverse transcription and integration through a mechanism called 
TPRT that takes place in the nucleus (chapter 1 section 1.7.1).  Considering the broad 
antiretroviral effect of MOV10 overexpression, as well as the essential roles of MOV10 
homologs in the suppression of endogenous retroelements (Frost et al., 2010; Olivieri et 
al., 2010; Zheng et al., 2010) (chapter 1 section 1.13.2), the capacity of MOV10 to 
regulate ERVs and retrotransposons was investigated.  The effect of MOV10 ectopic 
overexpression on the replication of the highly active mouse LTR-containing ERV IAP, 
and the human non-LTR autonomous LINE-1 and non-autonomous Alu 
retrotransposons was determined.  
 
Established cell-culture based retrotransposition assays were adopted to test this (Boeke 
et al., 1985; Moran et al., 1996; Esnault et al., 2002).  Plasmids expressing IAP (pGL3-
IAP92L23neoTNF) (Dewannieux et al., 2004), LINE-1 (pJM101/L1.3) (Moran et al., 
1999) and Alu (pAlu-neoTet) (Dewannieux et al., 2003), all of which contain an 
antisense neomycin resistance gene cassette (neo) at the 3’ end driven by its own 
promoter and disrupted by an intron, were used to test this (Figure 3.9).  Expression of 
neo occurs only after a complete retrotransposition cycle: specifically, transcription of 
the retroelement RNA, splicing of the intron in the neo cassette, translation of proteins, 
reverse transcription and integration of the retroelement cDNA into the host 






                       
 
Figure 3.9.  Retrotransposition assay. 
 
The IAP, LINE-1 and Alu cDNA contains an antisense neomycin resistance gene cassette (neo) at the 3’ 
end disrupted by an intron and driven by its own promoter.  Neo expression occurs only after transcription 
of the RNA, splicing out of the intron, reverse transcription and integration of the cDNA into the host cell 
genome.  The retrotransposition frequency was determined by G418 selection of the cultures and counting 

















3.8.2 MOV10 overexpression suppresses the retrotransposition of LTR and non-LTR 
endogenous retroelements 
HeLa cells were co-transfected with pGL3-IAP92L23neoTNF (pIAP), pJM101/L1.3 
(pLINE-1) or pAlu-neoTet (pAlu) together with either pT7-MOV10 (pMOV10) or the 
pT7-Luc (pLuc) control.  For Alu retrotransposition assays cells were also co-
transfected with a plasmid expressing LINE-1 ORF2p (pORF2p) as Alu elements do not 
encode any proteins and depend on LINE-1 proteins for their retrotransposition.  
MOV10 overexpression drastically reduced the number of G418-resistant cell colonies 
for all endogenous retroelements tested, with almost no colonies detectable for Alu and 
IAP, and over a 95% decrease in colonies for LINE-1 relative to the pLuc control 
(Figure 3.10A).  Therefore, ectopic overexpression of MOV10 potently restricts the 
retrotransposition of the mouse ERV IAP and human retrotransposons LINE-1 and Alu. 
 
To ensure that overexpression of MOV10 had no direct effect on neo expression or 
selection, HeLa cells were co-transfected with a pcDNA3.1 plasmid containing a neo 
cassette (pcDNA3.1-neo) together with pT7-MOV10 (pMOV10) or the pT7-Luc (pLuc) 
control.  A similar number of colonies were counted with MOV10 overexpression as the 
pLuc control suggesting that MOV10 does not directly hinder neo expression or 
selection, and specifically suppresses the propagation of LTR and non-LTR endogenous 
retroelements (Figure 3.10B).  Therefore, MOV10 overexpression restricts the 












                   
 
Figure 3.10.  MOV10 overexpression suppresses the retrotransposition of LTR and 
non-LTR endogenous retroelements.  
 
(A) MOV10 overexpression suppresses the retrotransposition of LTR and non-LTR endogenous 
retroelements.  HeLa cells were co-transfected with plasmids expressing the IAP (pGL3-
IAP92L23neoTNF) (1.5 µg), LINE-1 (pJM101/L1.3) (1.5 µg) or Alu (pAlu-neoTet) (1 µg) cDNAs 
containing the neo cassette as described in Figure 3.9, together with pT7-MOV10 (pMOV10) or the pT7-
Luc (pLuc) control (1 µg).  For Alu retrotransposition assays, HeLa cells were also co-transfected with a 
plasmid expressing LINE-1 ORF2p (pORF2p) (0.5 µg).  The retrotransposition frequency was determined 
by G418 selection of the cultures as described in Figure 3.9.  (B) MOV10 overexpression has no direct 
effect on neo expression or selection.  HeLa cells were co-transfected with a pcDNA3.1 plasmid 
containing a neo cassette (pcDNA3.1-neo) (0.3 µg) together with pMOV10 or the pLuc control (1 µg).  
The retrotransposition frequency was determined by G418 selection of the cultures as described in Figure 
3.9.  Results are normalised to the pLuc control, which is set at 100%.  For panel (A) a single control bar 







The interactions and associations of MOV10 with antiviral proteins and pathways 
implicated in the regulation of retroviruses and retrotransposons (Meister et al., 2005; 
Gallois-Montbrun et al., 2007; Gallois-Montbrun et al., 2008) (chapter 1 sections 
1.10.1, 1.11.1 and 1.12.5), as well as the essential role of MOV10 homologs Armitage 
and MOV10L1 in the suppression of ERVs and retrotransposons (Frost et al., 2010; 
Olivieri et al., 2010; Zheng et al., 2010) (chapter 1 section 1.13.2) makes MOV10 a 
credible candidate in the search for novel anti-retroelement host factors.  The results 
presented in this chapter reveal that MOV10 overexpression potently inhibits the 
production and infectivity of a diverse panel of exogenous retroviruses, as well as a 
highly active mouse ERV, and also effectively suppresses the retrotransposition of 
human non-LTR retrotransposons.  These data support a potential inhibitory role for 
MOV10 in the retroelement life cycle. 
 
Ectopically overexpressed MOV10 decreases the production of HIV-1, HIV-2, SIVmac 
and M-PMV virions in a dose-dependent manner (Figures 3.3A, 3.6B and 3.8D).  The 
overall decrease in cellular Gag abundance may account for this observation and, 
furthermore, as virion assembly is a cooperative process a reduction in intracellular Gag 
expression may impact plasma membrane targeting and, therefore, Gag processing  
(Hatziioannou et al., 2005).  This seems to be true for HIV-1 virion production in 293T 
cells whereby at the maximum concentration of pMOV10 both cellular Gag levels and 
processing are reduced (Figure 3.3A, right panel).  However, for HIV-1 virion 
production in HeLa cells although the percentage decrease in cellular Gag expression is 
equivalent to that observed in 293T cells, the effect on Gag processing is minimal 
(Figure 3.3A, left panel), implying that plasma membrane targeting is mostly normal.  
Alternatively, Gag targeting to the plasma membrane may not be impacted at all and for 
virus produced in 293T cells, MOV10 overexpression may directly affect processing 
and, therefore, virion maturation.  These differential observations may underlie the more 
potent inhibition of HIV-1 virus production in 293T cells compared to HeLa cells at 
higher concentrations of MOV10 (Figure 3.3A).  Furthermore, this disparity between 
cell types may be attributed to higher MOV10 expression levels in 293T cells owing to 
the presence of the SV40 large T antigen, which induces DNA replication from the 
SV40 origin of replication in a plasmid.  HIV-2 and M-PMV cellular Gag abundance is 
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also notably decreased suggesting that this common mode of action similarly impacts 
multiple retroviruses (Figures 3.6B and 3.8D). 
 
Three groups have now assessed the role of MOV10 in HIV-1 replication (Burdick et 
al., 2010; Furtak et al., 2010; Wang et al., 2010).  Furtak et al and Burdick et al 
similarly reported a dose-dependent decrease in HIV-1 virion production with MOV10 
overexpression (Burdick et al., 2010; Furtak et al., 2010) and, furthermore, the latter 
group also detected a MOV10 concentration-dependent decrease in Gag expression and 
efficiency of Gag processing (Burdick et al., 2010).  In contrast, Wang et al observed no 
effect of MOV10 overexpression on HIV-1 Gag processing (Wang et al., 2010), a 
difference that may be at least partially explained by lower MOV10 expression levels in 
producer cells.  It would be important to determine whether the reduction in cellular 
Gag abundance is an outcome of decreased Gag translation or increased Gag turnover, 
or possibly an alternative mechanism. 
 
Interestingly, MOV10 overexpression inhibits the production of VLPs more effectively 
than wild-type virions.  VLPs are produced from the GPV-RRE subgenomic construct, 
which encodes only complete gag, pro, pol and vif genes (Figure 3.1A).  Therefore, 
more effective inhibition of VLPs may be attributed to the lack of a viral accessory 
factor that can directly or indirectly counteract MOV10 during wild-type infection.  
Transfection of a plasmid expressing the HIV-1 regulatory protein Tat in trans does not 
antagonise MOV10-mediated inhibition of VLP production, excluding Tat as the 
missing factor responsible (data not shown).  Although the percentage difference by 
which MOV10 overexpression inhibits VLPs and wild-type virions is a moderate 5-15% 
(Figures 3.2B and C), in the context of endogenous levels of MOV10 and physiological 
infection the presence of a viral accessory protein able to counteract MOV10 could 
make the difference between inefficient and efficient viral spread and replication.  
 
Overexpression of MOV10 in producer cells also drastically decreases the infectivity of 
HIV-1 virions produced, the inhibition of which is more potent than that observed for 
virion production (Figure 3.3B).  Additionally, MOV10 overexpression also restricts the 
production of infectious SIVmac, HIV-2, MLV and M-PMV particles (Figures 3.6A 
and C, 3.7B and 3.8C).  The production of HIV-2 infectious particles is abolished at the 
maximum pMOV10 concentration, however, the effect on virion production is only 
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moderate (Figures 3.6B and C).  Therefore, defective HIV-2 virion production does not 
completely account for the potent decrease in virion infectivity.  Alternatively, M-PMV 
cellular Gag expression and virion production are greatly reduced in comparison with 
HIV-1 and HIV-2 at similar concentrations of pMOV10 (Figure 3.8D).  For this reason 
it is difficult to differentiate the effect of MOV10 overexpression on M-PMV virion 
production or infectivity.  These results agree with those reported by other groups, 
whereby overexpression of human MOV10 inhibited HIV-1, SIVmac, African green 
monkey derived SIV (SIVagm), feline immunodeficiency virus (FIV), EIAV and MLV 
(Burdick et al., 2010; Furtak et al., 2010; Wang et al., 2010).  Moreover, Furtak et al 
and Burdick et al also observed a stronger inhibition of HIV-1 virion infectivity 
compared to virion production (Burdick et al., 2010; Furtak et al., 2010).  In contrast, 
overexpression of MOV10 in target cells has no effect on HIV-1 infectivity (Burdick et 
al., 2010; Wang et al., 2010). 
  
MOV10 is a P body component that shifts to SGs under conditions of cellular stress 
(Gallois-Montbrun et al., 2007).  The role of P body and SG factors in the life cycle of 
retroviruses, and especially HIV-1, has been controversial whereby both inhibitory and 
stimulatory functions have been proposed (chapter 1 sections 1.10.1 and 1.11.1).  Reed 
et al proposed a role for the P body protein DDX6 in HIV-1 Gag assembly (Reed et al., 
2012).  In contrast, Chable-Bessia et al reported the silencing of P body components 
DDX6, GW182, Lsm1 and XRN1 to facilitate HIV-1 infection (Chable-Bessia et al., 
2009).  Furthermore, the intrinsic HIV-1 restriction factors A3F and A3G co-localise 
with MOV10 in P bodies and SGs (Gallois-Montbrun et al., 2007; Gallois-Montbrun et 
al., 2008).  However, Phalora et al recently confirmed no effect of P body depletion 
through knockdown of DDX6 and Lsm1 on HIV-1 replication, incorporation of 
APOBEC3 proteins into virions or APOBEC3-mediated restriction of HIV-1 infection 
(Phalora et al., 2012).  Consistent with these latter findings, the results presented in this 
chapter demonstrate that the capacity to regulate HIV-1 is not inherent to all P body and 
SG proteins.  Overexpression of the P body and SG component AGO2, which interacts 
with MOV10 and members of the APOBEC3 family (Meister et al., 2005; Gallois-
Montbrun et al., 2007; Gallois-Montbrun et al., 2008), has no effect on HIV-1 virus 
production or the infectivity of virions produced (Figure 3.4B).  Likewise, 
overexpression of the essential SG protein TIA-1, at a concentration that was observed 
to induce SGs (data not shown), did not decrease HIV-1 virus production or infectivity 
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either, and actually increased virion production moderately (Figure 3.4C).  Similarly, 
Wang et al showed the overexpression of P body components AGO1, AGO2 and DDX3 
to have no effect on HIV-1 infectivity, and Burdick et al reported comparable results for 
DCP1a and DCP2 overexpression (Burdick et al., 2010; Wang et al., 2010).  Therefore, 
individual proteins, and likely their cellular functions, as opposed to the association of 
these factors with P bodies determines their capacity to regulate HIV-1 replication, and 
similar detailed analyses will be required to understand the relationship between SGs 
and HIV-1 infection. 
 
The MOV10 ortholog Armitage in Drosophila melanogaster and mammalian paralog 
MOV10L1 are both essential for piRNA-guided suppression of endogenous 
retroelements (Olivieri et al., 2010) Frost, 2010 #77}(Zheng et al., 2010) (chapter 1 
section 1.13.2).  Armitage is necessary for PIWI protein function, which mediates 
PTGS of endogenous retroelements in both the germ line and somatic cells (Olivieri et 
al., 2010).  Alternatively, MOV10L1 is required for the function of mouse PIWI 
proteins, which mediate TGS of ERVs and retrotransposons, such as IAP and LINE-1, 
in the germ line of male mice through DNA methylation (Frost et al., 2010; Zheng et 
al., 2010).  Interestingly, ectopic overexpression of human MOV10 suppresses the 
retrotransposition of genetically diverse IAP, LINE-1 and Alu endogenous 
retroelements implying that the capacity of MOV10 to restrict ERVs and 
retrotransposons is evolutionarily conserved (Figure 3.10A).  A recent study similarly 
showed MOV10 overexpression to inhibit IAP retrotransposition (Lu et al., 2012).    
 
Interestingly, human LINE-1 derived endo-siRNAs have been reported to restrict LINE-
1 retrotransposition by an RNAi mechanism (Yang and Kazazian, 2006) and, more 
recently, natural occurring endo-siRNAs have been proposed to transcriptionally silence 
LINE-1 expression through DNA methylation of the promoter (Chen et al., 2012).  
Furthermore, knockdown of DICER-1 enhances LINE-1 retrotransposition (Yang and 
Kazazian, 2006).  The role of P bodies and SGs in the replication of ERVs and 
retrotransposition remains to be established, although individual P body and SG factors 
have been implicated in the regulation of endogenous retroelements.  The APOBEC3 
family of proteins restrict the retrotransposition of LINE-1 and Alu retrotransposons 
(chapter 1 section 1.8.2.10), and knockdown of P body proteins DDX6 and eIF4E-T 
enhances IAP retrotransposition (Lu et al., 2011).  Furthermore, LINE-1 ORF1p has 
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been reported to co-localise with other SG factors in SGs (Goodier et al., 2007).  The 
mechanism by which MOV10 overexpression suppresses IAP, LINE-1 and Alu 
retrotransposition is not yet clear, and may be dependent on its known cellular 
associations with small RNA-mediated post-transcriptional RNA silencing pathways, P 
bodies and SGs and/or the APOBEC3 proteins.  However, Lu et al recently 
demonstrated P bodies to be dispensable for the restriction of IAP replication by 





































































MOV10 overexpression restricts the replication of 
retroelements: mechanism and structure-function analysis 
 
4.1 Introduction 
The results presented in chapter 3 demonstrate that MOV10 overexpression restricts the 
replication of a diverse panel of retroviruses and retrotransposons.  For exogenous 
retroviruses this inhibitory activity has dual aspects, whereby ectopic overexpression of 
MOV10 decreases cellular Gag expression and virion production, and also potently 
reduces the infectivity of virions produced. In this chapter, the localisation of MOV10 
and HIV-1 Gag as well as analysis of domains within HIV-1 Gag that may be necessary 
for MOV10-mediated reduction in virion production were explored to begin to dissect 
the mechanism by which MOV10 affects the production of retroviral particles.  The 
mechanism by which MOV10 overexpression decreases the infectivity of retroviral 
particles produced is unclear.  As MOV10 is a putative RNA helicase, the effect of 
MOV10 ectopic overexpression on the incorporation of HIV-1 viral RNA into nascent 
virions was determined.  Furthermore, the interaction of MOV10 with antiviral proteins 
A3F and A3G (Gallois-Montbrun et al., 2007; Gallois-Montbrun et al., 2008) questions 
whether MOV10 may function by impacting the process of reverse transcription.  
Lastly, the dependence of MOV10 anti-retroelement activity on its putative RNA 









4.2 Ectopically overexpressed MOV10 and HIV-1 Gag co-localise in SG-like 
cytoplasmic domains 
MOV10 overexpression decreases the production of HIV-1 virions, which may be 
caused by the reduction in cellular Gag abundance.  The subcellular localisation of 
ectopically overexpressed MOV10 and HIV-1 Gag was determined to loosely assess 
whether MOV10 may mediate this effect through an association with Gag.  HeLa cells 
were co-transfected with GPV-RRE and pRev, together with pcDNA3.1-myc-MOV10 
(pMOV10).  Cells were fixed in 4% paraformaldehyde (PFA) and analysed by 
immunofluorescence using anti-myc, anti-p17Gag (p17Gag corresponds to MA) and anti-
p24Gag antibodies.  Cells were also stained with 4',6-diamidino-2-phenylindole (DAPI) 
which is a fluorescent dye that binds to DNA highlighting the cell nucleus.  
Remarkably, MOV10 and HIV-1 Gag strongly co-localised in cytoplasmic aggregates 
closely resembling SGs (Figure 4.1), implying that MOV10 may decrease HIV-1 virion 























                
 
 
Figure 4.1.  Ectopically overexpressed MOV10 and HIV-1 Gag co-localise in SG-
like cytoplasmic domains. 
 
HeLa cells were plated onto coverslips and co-transfected with GPV-RRE (1 µg) and pRev (0.25 µg), 
together with pcDNA3.1-myc-MOV10 (pMOV10) (0.5 µg).  Approximately 24hrs post-transfection cells 
were fixed in 4% paraformaldehyde (PFA) and stained with anti-myc, anti-p17Gag and anti-p24Gag primary 
antibodies and appropriate Alexa Fluor conjugated secondary antibodies, as well as the 4',6-diamidino-2-
phenylindole (DAPI) fluorescent dye to stain the nucleus.  Coverslips were mounted onto slides and 


































4.3 Gag determinants and MOV10 antiviral activity 
4.3.1 GPV-RRE constructs 
Co-localisation of ectopically overexpressed MOV10 and HIV-1 Gag indicates that 
MOV10 may directly or indirectly interact with Gag and/or interfere with Gag functions 
to mediate the decrease in cellular Gag expression and, therefore, potentially virion 
production.  GPV-RRE NC (∆NC+Zt) and MA (∆MA+M-src) domain mutants were 
tested to determine whether MOV10 overexpression requires these Gag domains for the 
reduction in virion production (Figure 4.2A).  ∆MA+M-src lacks the MA domain, 
however, contains a heterologous myristylation sequence derived from the c-src gene 
for efficient plasma membrane targeting.  Similarly, ∆NC+Zt is deleted of the NC 
region and this is replaced with a leucine zipper tetramerisation motif (Z) that allows 
Gag-Gag interactions for assembly, however, is devoid of RNA packaging.   
 
Alternatively, as MOV10 is a putative RNA helicase, it may interact with HIV-1 viral 
RNA and affect cellular Gag expression in this manner.  To investigate whether 
sequence-specific determinants and cis-acting elements within the HIV-1 genome are 
necessary for the reduction in virion production by MOV10 overexpression, a codon-
optimised GPV-RRE construct was tested, in which the A-biased codon-usage of HIV-1 
is swapped to allow optimal expression in mammalian cells.   
 
4.3.2 NC, MA and sequence-specific elements of HIV-1 genomic RNA are 
dispensable for the decrease in VLP production by MOV10 overexpression  
HeLa cells were co-transfected with either GPV-RRE, ∆NC+Zt, ∆MA+M-src or codon-
optimised GPV-RRE, together with pRev and pcDNA3.1-myc-MOV10 (pMOV10) or 
the pcDNA3.1-myc-GFP (pGFP) control.  Cell lysates and sucrose-cushion purified 
VLPs were analysed by immunoblotting with anti-p24Gag, anti-myc and anti-Hsp90 
antibodies.  As cell cultures were treated with the protease inhibitor saquinavir only a 
single p55Gag band was detected by immunoblotting.  MOV10 overexpression 
consistently decreased the cellular Gag abundance and production of HIV-1 VLPs with 
the codon-optimised GPV-RRE (Figure 4.2B, lanes 3 and 4), ∆NC+Zt (Figure 4.2B, 
lanes 5 and 6) and ∆MA+M-src (Figure 4.2B, lanes 7 and 8) constructs.  Therefore, 
ectopically overexpressed MOV10 does not depend on NC or interfere with the RNA 
packaging function of NC for inhibition of VLP production.  Similarly, the MA domain 
149
 
of Gag and sequence-specific elements within the viral RNA are also dispensable for 
the mechanism by which MOV10 overexpression decreases HIV-1 Gag expression and 











































                          
 
 
Figure 4.2.  NC, MA and sequence-specific elements of HIV-1 genomic RNA are 
dispensable for the decrease in VLP production by MOV10 overexpression. 
 
(A) GPV-RRE constructs.  The GPV-RRE derived ∆MA+M-src construct lacks the MA domain, 
however, consists of a heterologous myristylation sequence derived from the c-src gene.  The GPV-RRE 
based ∆NC+Zt construct lacks the NC region and this is replaced with a leucine zipper tetramerisation 
motif (Z).  (B) NC, MA and sequence-specific elements of HIV-1 genomic RNA are dispensable for 
the decrease in VLP production by MOV10 overexpression.  293T cells were co-transfected with 
either GPV-RRE, ∆MA+M-src, ∆NC+Zt or a codon-optimised GPV-RRE construct (0.5 µg) together with 
pRev (0.25 µg) and pcDNA3.1-myc-MOV10 (pMOV10) or the pcDNA3.1-myc-GFP (pGFP) control (1.5 
µg).  Cell cultures were treated with the protease inhibitor saquinavir.  Cell lysates were analysed by 
immunoblotting with anti-myc, anti-p24Gag and anti-Hsp90 antibodies, and VLPs purified through a 20% 
sucrose cushion were also analysed by immunoblotting with an anti-p24Gag antibody.  Data are 




4.4 MOV10 overexpression decreases HIV-1 genomic RNA packaging into virions 
MOV10 is a putative RNA helicase, the cellular function of which is still unclear.  
Interestingly, MOV10 has been identified in several screens searching for interaction 
partners of various RBPs (Miki et al., 2011; Sim et al., 2012) and, moreover, a recent 
study has demonstrated the RNA-binding activity of MOV10 to be fairly broad and 
non-specific (Castello et al., 2012).  Taking this into account, an interaction between 
MOV10 and HIV-1 viral RNA would not be surprising.  As defective genome 
incorporation into nascent virions would compromise virion infectivity, the effect of 
MOV10 overexpression on HIV-1 viral RNA packaging was investigated as a potential 
mechanism by which ectopically overexpressed MOV10 may impact virion infectivity.  
 
HeLa or 293T cells were co-transfected with pHIV-1NL4-3 and either pT7-MOV10 
(pMOV10) or the pT7-GFP (pGFP) control.  Equal amounts of virus normalised by the 
p24Gag concentration was sucrose-cushion purified, following which the RNA was 
extracted and cDNA was synthesised.  The level of viral RNA packaged into virions 
was determined by quantitative polymerase chain reaction (qPCR) using a primer-probe 
set that recognises sequences in the HIV-1NL4-3 p6 domain.  Ectopic overexpression of 
MOV10 decreased the level of HIV-1 genomic RNA detected in virions, which was 
reduced by approximately 40% and 60% for virions produced in HeLa and 293T cells, 
respectively, relative to the pGFP control (Figure 4.3).  Harvested virion preparations 
and extracted RNA were treated with DNase to remove any residual transfected pHIV-
1NL4-3 cDNA from the analysis.  The efficiency of this treatment was verified by 
including duplicate samples minus the RT enzyme during the cDNA synthesis reaction 
and, subsequently, quantifying the level of viral cDNA in these samples by qPCR 
(Figure 4.3, denoted with an asterisk).  Therefore, ectopically overexpressed MOV10 
may interact with HIV-1 viral RNA directly or indirectly resulting in a decrease in HIV-








                                  
 
Figure 4.3.  MOV10 overexpression decreases HIV-1 genomic RNA packaging into 
virions. 
 
HeLa and 293T cells were co-transfected in 10cm tissue culture dishes with pHIV-1NL4-3 and pT7-
MOV10 (pMOV10) or pT7-GFP (pGFP) at a DNA (µg) ratio of 3:1, respectively.  Approximately 48hrs 
post-transfection virus-containing supernatant was harvested and treated with DNase and magnesium 
chloride for 2-3hrs.  Virions were quantified by p24Gag ELISA as described in chapter 3 Figure 3.1B.  
Equal amounts of virus normalised by the p24Gag concentration was purified through a 20% sucrose 
cushion and the pelleted virions were lysed.  RNA was extracted and treated with DNase for a further 
30mins to digest any remaining input proviral plasmid DNA, and cDNA was synthesised from equal 
concentrations of the RNA by reverse-transcription polymerase chain reaction (RT-PCR).  The viral RNA 
copy number in virions was measured by quantitative PCR (qPCR) using a primer-probe set that 
recognises sequences in the HIV-1NL4-3 p6 domain.  Duplicate samples minus the RT enzyme were also 
included as controls to ensure that the majority of transfected proviral plasmid DNA was digested (*).  






4.5 Ectopic overexpression of MOV10 produces HIV-1 virions defective in reverse 
transcription in target cells 
The antiviral proteins A3F and A3G are packaged into assembling HIV-1 virions and 
impair reverse transcription in target cells by introducing C-to-U deamination events in 
the minus strand DNA that register as G-to-A hypermutations in the plus strand DNA, 
compromising the viral genome and HIV-1 infectivity (chapter 1 section 1.8.2.8).  
These proteins also inhibit the accumulation of viral cDNA by an editing-independent 
mechanism.  Similarly, MOV10 is packaged into HIV-1 particles (Chertova et al., 
2006), the incorporation of which has been reported to require an RNA-dependent 
interaction with the NC region of Gag (Burdick et al., 2010; Wang et al., 2010; Abudu 
et al., 2012).  Considering the interaction of MOV10 with A3F or A3G, the effect of 
MOV10 overexpression on the efficiency of reverse transcription in target cells was 
determined.   
 
Virus was produced by co-transfecting 293T cells with pHIV-1NL4-3 and either pT7-
MOV10 (pMOV10) or the pT7-Luc (pLuc) control.  Equal amounts of virus normalised 
by the p24Gag concentration was used to infect the HUT78 T cell line in a time-course, 
whereby cells were harvested at 0hrs, 8hrs, 24hrs and 48hrs post-infection.  DNA was 
extracted from the cell lysates and the level of minus strand strong stop DNA was 
measured by qPCR using a primer-probe set that recognises sequences between R and 
the U5-PBS junction (Figure 4.4).  MOV10 overexpression decreased the accumulation 
of minus strand strong stop DNA by approximately 20-fold at 8hrs and 24hrs, and by 
over 500-fold at 48hrs compared to the pLuc control (Figure 4.4).  The significant 
increase in accumulation of reverse transcripts at 48hrs for the pLuc control is likely 
indicative of further rounds of spreading infection, which appear to be blocked with 
MOV10 overexpression (Figure 4.4).  Furthermore, minus strand transfer and plus 
strand transfer DNA could not be detected with primer-probe sets recognising 
sequences in U3 and the U5-PBS junction or R and sequences just downstream of the 
PBS, respectively (data not shown).  Therefore, MOV10 overexpression impairs the 






                        
 
Figure 4.4.  Ectopic overexpression of MOV10 produces HIV-1 virions defective in 
reverse transcription in target cells. 
 
293T cells were co-transfected in 10cm tissue culture dishes with pHIV-1NL4-3 and pT7-MOV10 
(pMOV10) or the pT7-Luc (pLuc) control at a DNA (µg) ratio of 3:1, respectively.  Approximately 48hrs 
post-transfection virus was harvested and quantified by p24Gag ELISA as described in chapter 3 Figure 
3.1B.  Equal amounts of virus (20 ngs) normalised by the p24Gag concentration was used to spin-infect the 
HUT78 T cell line for 2hrs.  Cells were harvested and lysed at 0hrs, 8hrs, 24hrs and 48hrs post spin-
infection and DNA was extracted.  Minus strand strong stop DNA copy numbers were measured by qPCR 
using a primer-probe set that recognises sequences between R and the U5-PBS junction (illustrated by 















4.6 N-terminal and C-terminal MOV10 mutants 
4.6.1 Overexpression of the N-terminal domain of MOV10 maintains the antiviral 
activity of full-length MOV10 
MOV10 is a 1003 amino acid putative RNA helicase, the N-terminal 495 residues of 
which consist of no known protein motifs, and the C-terminal 508 amino acids of which 
contain the putative RNA helicase motifs (chapter 1 section 1.13).  The results 
presented in this chapter so far demonstrate that ectopically overexpressed MOV10 
inhibits the infectivity of HIV-1 virions by decreasing viral RNA packaging into virions 
and impairing reverse transcription, although additional as yet unidentified mechanisms 
may also contribute.  These findings associate MOV10 with RNA stages of the HIV-1 
life cycle, suggesting that the putative RNA helicase activity of MOV10 may be 
important for its antiretroviral function. 
 
To test this, MOV10 N-terminal and C-terminal domain fragments were cloned into the 
pT7 plasmid generating pT7-MOV10-N (pMOV10-N) and pT7-MOV10-C (pMOV10-
C).  HeLa or 293T cells were co-transfected with pHIV-1NL4-3 and either full-length 
pT7-MOV10 (pMOV10), pMOV10-N, pMOV10-C or the pT7-Luc control (pLuc).  The 
effect on virus production was quantified by p24Gag ELISA and results showed that 
overexpression of the N-terminal domain decreased HIV-1 virus production by over 
80% for HeLa and 293T cells compared to the pLuc control (Figure 4.5).  This 
percentage decrease in virion production was more potent than that observed with full-
length MOV10 for HeLa cells, however, this is likely due to higher expression levels of 
the N-terminal protein relative to full-length MOV10 (Figure 4.5, lane 3).  In contrast, 
the C-terminal protein is a loss of function mutant as overexpression of this domain did 
not decrease HIV-1 virus production, and even moderately enhanced it (Figure 4.5).  To 
measure the effect on virion infectivity, equal amounts of virus normalised by the 
p24Gag concentration was added to TZM-bl cells.  Similarly to the virus production 
results, overexpression of both full-length MOV10 and the N-terminal protein almost 
abolished HIV-1 infectivity, however, overexpression of the C-terminal protein had no 
effect on infectivity (Figure 4.5).  Therefore, ectopic overexpression of the N-terminal 
domain of MOV10, and not the C-terminal putative helicase domain, maintains the anti-
HIV-1 activity of full-length MOV10.  
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Figure 4.5.  Overexpression of the N-terminal domain of MOV10 maintains the 
antiviral activity of full-length MOV10. 
 
HeLa or 293T cells were co-transfected with pHIV-1NL4-3 (0.5 µg) and either full-length pT7-MOV10 
(pMOV10), pT7-MOV10-N (pMOV10-N), pT7-MOV10-C (pMOV10-C) or the pT7-Luc control (pLuc) 
(1.5 µg).  Virus production was quantified by p24Gag ELISA (black bars) and virion infectivity was 
measured by TZM-bl assay (grey bars) as described in chapter 3 Figure 3.1B.  Cell lysates were analysed 
by immunoblotting with anti-T7, anti-p24Gag and anti-Hsp90 antibodies.  Results are normalised to the 






4.6.2 Ectopic overexpression of full-length MOV10 is essential for suppression of 
LINE-1 retrotransposition 
MOV10 overexpression also potently suppresses the replication of endogenous 
retroelements (chapter 3 section 3.8); therefore, to determine the importance of MOV10 
putative RNA helicase activity for this function, the effect of ectopically overexpressing 
the N-terminal and C-terminal MOV10 proteins on LINE-1 retrotransposition was 
investigated.  HeLa cells were co-transfected with pJM101/L1.3 (pLINE-1) and either 
pT7-MOV10 (pMOV10), pMOV10-N, pMOV10-C or the pT7-Luc control (pLuc).  
Following G418 selection of cultures, enumeration of cell colonies revealed over an 
80% and 40% decrease in LINE-1 retrotransposition with overexpression of the N-
terminal and C-terminal proteins, respectively, relative to the pLuc control (Figure 4.6).  
On the other hand, overexpression of full-length MOV10 almost completely suppressed 
LINE-1 retrotransposition (Figure 4.6).  These results indicate that overexpression of 
both the N-terminal and C-terminal domains of MOV10 is necessary for efficient 























                       
 
Figure 4.6.  Ectopic overexpression of full-length MOV10 is essential for 
suppression of LINE-1 retrotransposition. 
 
HeLa cells were co-transfected with pJM101/L1.3 (pLINE-1) (1.5 µg) containing the neo cassette as 
described in chapter 3 Figure 3.9, and either full-length pT7-MOV10 (pMOV10), pT7-MOV10-N 
(pMOV10-N), pT7-MOV10-C (pMOV10-C) or the pT7-Luc control (pLuc) (1 µg).  The 
retrotransposition frequency was determined by G418 selection of the cultures as described in chapter 3 
Figure 3.9.   Results are normalised to the pLuc control, which is set at 100%.  Values are the mean ± SD 





























4.6.3 Subcellular localisation of N-terminal and C-terminal MOV10 proteins varies 
from that of full-length MOV10 
The MOV10 N-terminal and C-terminal proteins consist of sizeable deletions that may 
have affected the subcellular distribution and, therefore, function of these mutants in 
comparison with full-length MOV10.  Therefore, to assess the localisation of MOV10 
and MOV10 mutants, HeLa cells were transfected with pT7-MOV10 (pMOV10), 
pMOV10-N or pMOV10-C following which cells were fixed and analysed by 
immunofluorescence using an anti-T7 antibody.  Cells were also stained with an 
antibody against the P body marker DDX6.  The distribution of full-length MOV10 was 
cytoplasmically diffuse and punctate with MOV10 strongly co-localising with DDX6 in 
P bodies (Figure 4.7A).  In contrast, the N-terminal protein did not localise to P bodies 
and, moreover, disrupted P bodies as well (Figure 4.7B, top panel).  This differential 
localisation may be attributed to higher expression levels of the N-terminal protein in 
comparison with full-length MOV10 as determined by immunoblotting (Figure 4.5).  
Similarly, the C-terminal protein did not localise to P bodies either, although this mutant 
had no effect on P bodies unlike that observed for the N-terminal protein (Figure 4.7B, 
lower panel).  Additionally, the C-terminal protein also localised to the nucleus.  These 
results demonstrate that the expression levels and subcellular localisation of truncated 
N-terminal and C-terminal MOV10 proteins varies greatly from that of full-length 
MOV10, questioning the reliability of these mutant proteins in assessing wild-type 


















      
 
 
Figure 4.7.  Subcellular localisation of N-terminal and C-terminal MOV10 proteins 
varies from that of full-length MOV10. 
 
(A) Full-length MOV10 is cytoplasmically diffuse and in P bodies.  HeLa cells were plated onto 
coverslips and co-transfected with full-length pT7-MOV10 (pMOV10) (1.5 µg).  Approximately 24hrs 
post-transfection cells were fixed in 4% PFA and stained with an anti-T7 primary antibody and 
appropriate Alexa Fluor conjugated secondary antibody, as well as DAPI.  Coverslips were mounted onto 
slides and analysed by immunofluorescence.  (B) Subcellular distribution of N-terminal and C-
terminal MOV10 mutants varies from that of full-length MOV10.  HeLa cells were plated onto 
coverslips and co-transfected with pT7-MOV10-N (pMOV10-N) or pT7-MOV10-C (pMOV10-C) (1.5 
µg).  Coverslips were analysed by immunofluorescence as described in panel (A).  Data are representative 









4.7 Full-length MOV10 putative helicase mutants 
4.7.1 MOV10 putative helicase mutants  
Judging from the experiments with N-terminal and C-terminal MOV10 proteins the 
putative RNA helicase activity of MOV10 appears to be dispensable for MOV10 
antiviral function and, furthermore, both the N-terminal and C-terminal proteins seem to 
be required for suppression of LINE-1 retrotransposition to levels observed with full-
length MOV10.  However, the expression levels and subcellular localisation of these 
truncated MOV10 mutants varied greatly from that of full-length MOV10 making the 
interpretation of these data somewhat difficult.  Consequently, full-length MOV10 
putative helicase mutants were generated to assess the contribution of MOV10 putative 
RNA helicase activity for the inhibition of HIV-1 and LINE-1 replication.  Fairman-
Williams et al aligned SF1 helicases from Escherichia coli, yeast and humans [reviewed 
in (Fairman-Williams et al., 2010)], and analysis of these alignments revealed highly 
conserved residues in the Walker A and Walker B putative helicase motifs of MOV10.  
Subsequently three MOV10 Walker A and Walker B putative helicase mutants were 
generated by alanine substitution of (1) the conserved lysine residue at position 530 
(K530A), (2) the conserved aspartic acid and glutamic acid residues at positions 645 
and 646 (DE645AA) and (3) the less well conserved glycine amino acid at position 648 
(G648A) (Figure 4.8).  Upf1 is a SF1 helicase, and the latter mutation was based on the 
published Upf1 Walker B ATPase mutant (DESTQ to DEAAQ) (Franks et al., 2010).  
The putative helicase mutants were cloned into the pT7 plasmid generating pT7-
MOV10-K530A (pMOV10-K530A), pT7-MOV10-DE645AA (pMOV10-DE645AA) 














                
 
 
Figure 4.8.  MOV10 putative helicase mutants. 
 
Three MOV10 Walker A and Walker B putative helicase mutants were generated.  K530A is a Walker A 
mutant in which the lysine residue (K) is substituted with an alanine (A).  DE645AA is a Walker B 
mutant in which the aspartic acid and glutamic acid residues (DE) are replaced with alanines (AA).  


































4.7.2 Overexpression of K530A and DE645AA only partially maintains the antiviral 
activity of wild-type MOV10 
To assess whether MOV10 depends on its putative RNA helicase activity for inhibition 
of HIV-1, 293T cells were co-transfected with pHIV-1NL4-3 and either pT7-MOV10 
(pMOV10), pMOV10-K530A, pMOV10-DE645AA, pMOV10-G648A or the pT7-Luc 
(pLuc) control.  The virion concentration was determined by p24Gag ELISA and results 
showed an approximately 60% and 40% decrease in virion production with K530A and 
DE645AA overexpression, respectively, relative to the pLuc control (Figure 4.9).  In 
comparison, wild-type MOV10 overexpression decreased virion production by 
approximately 90% demonstrating that the K530A and DE645AA proteins are partial 
loss of function mutants (Figure 4.9).  In contrast, overexpression of the G648A mutant 
maintained the antiviral activity of wild-type MOV10 (Figure 4.9).  Variations in 
expression level did not account for these differential observations as all three MOV10 
mutants were expressed at similar levels as wild-type MOV10 (Figure 4.9, compare 
lane 2 with 3, 4 and 5).  The effect of overexpressing these MOV10 putative helicase 
mutants on the infectivity of HIV-1 virions was determined by TZM-bl assay.  Similar 
to the observations for virion production, ectopic overexpression of wild-type MOV10 
and G648A almost abolished infectivity completely, whereas overexpression of K530A 
and DE645AA reduced infectivity by approximately 80% and 40%, respectively, 
compared to the pLuc control (Figure 4.9).  Therefore, K530A and DE645AA are 
partial loss of function MOV10 mutants implying that MOV10 putative RNA helicase 











                                           
 
Figure 4.9.  Overexpression of K530A and DE645AA only partially maintains the 
antiviral activity of wild-type MOV10. 
 
293T cells were co-transfected with pHIV-1NL4-3 (0.5 µg) and either wild-type pT7-MOV10 (pMOV10), 
pT7-MOV10-K530A (pMOV10-K530A), pT7-MOV10-DE645AA (pMOV10-DE645AA), pT7-MOV10-
G648A (pMOV10-G648A) or the pT7-Luc control (pLuc) (1.5 µg).  Virus production was quantified by 
p24Gag ELISA (black bars) and virion infectivity was measured by TZM-bl assay (grey bars) as described 
in chapter 3 Figure 3.1B.  Cell lysates were analysed by immunoblotting with anti-T7, anti-p24Gag and 
anti-Hsp90 antibodies.  Results are normalised to the pLuc control, which is set at 100%.  Values are the 










4.7.3 Overexpression of K530A and DE645AA only partially maintains the capacity of 
wild-type MOV10 to suppress LINE-1 retrotransposition 
Similarly, the contribution of MOV10 putative RNA helicase activity for MOV10-
mediated suppression of endogenous retroelements was determined by testing the effect 
of ectopically overexpressing these MOV10 mutants on LINE-1 retrotransposition.  
HeLa cells were co-transfected with pJM101/L1.3 (pLINE-1) and either pT7-MOV10 
(pMOV10), pMOV10-K530A, pMOV10-DE645AA, pMOV10-G648A or the pT7-Luc 
control (pLuc).  Cell cultures were G418 selected and the colonies were counted and, 
similar to the observations for HIV-1, overexpression of wild-type MOV10 and G648A 
inhibited LINE-1 retrotransposition completely, however, ectopic overexpression of 
K530A and DE645AA reduced retrotransposition by approximately 60% and 30% 
respectively, compared to the pLuc control (Figure 4.10).  These results demonstrate 
that highly conserved residues within the MOV10 Walker A and Walker B putative 
RNA helicase motifs are necessary for efficient MOV10-mediated inhibition of both 
HIV-1 and LINE-1 replication, which implies that MOV10 putative RNA helicase 





















                    
 
Figure 4.10.  Overexpression of K530A and DE645AA only partially maintains the 
capacity of wild-type MOV10 to suppress LINE-1 retrotransposition. 
 
HeLa cells were co-transfected with pJM101/L1.3 (pLINE-1) (1.5 µg) consisting of the neo cassette as 
described in chapter 3 Figure 3.9, and either wild-type pT7-MOV10 (pMOV10), pT7-MOV10-K530A 
(pMOV10-K530A), pT7-MOV10-DE645AA (pMOV10-DE645AA), pT7-MOV10-G648A (pMOV10-
G648A) or the pT7-Luc control (pLuc) (1 µg).  The retrotransposition frequency was determined by G418 
selection of the cultures as described in chapter 3 Figure 3.9.   Results are normalised to the pLuc control, 



















4.7.4 Subcellular localisation of MOV10 putative helicase mutants 
The subcellular distribution of the MOV10 putative helicase mutants was determined by 
transfecting HeLa cells with pMOV10-K530A, pMOV10-DE645AA or pMOV10-
G648A, and cells were fixed and analysed by immunofluorescence using an anti-T7 
antibody.  Again, cells were also stained with an anti-DDX6 antibody, which serves as a 
marker for P bodies.  Interestingly, the K530A and DE645AA mutants showed a similar 
distribution to that observed for the N-terminal MOV10 protein, whereby both mutants 
were cytoplasmically diffuse and also disrupted P bodies (Figure 4.11, top and middle 
panel).  K530A and DE645AA mutants were expressed at similar levels to wild-type 
MOV10 as determined by immunoblotting (Figure 4.9), indicating that the varied 
distribution observed for the N-terminal MOV10 protein was unlikely due to its higher 
expression levels (Figure 4.7B).  In contrast, the subcellular localisation of the 
functional G648A mutant reflected that of wild-type MOV10, whereby G648A was 
cytoplasmically diffuse and co-localised with DDX6 in P bodies (Figure 4.11, lower 
panel and Figure 4.7A).  Therefore, substitution of just one or two conserved residues 
within the MOV10 Walker A or Walker B motif is sufficient to alter the subcellular 
distribution of MOV10 and impact on its anti-retroelement activity, implying that the 



















       
 
 
Figure 4.11.  Subcellular localisation of MOV10 putative helicase mutants. 
 
HeLa cells were plated onto coverslips and co-transfected with either pT7-MOV10-K530A (pMOV10-
K530A), pT7-MOV10-DE645AA (pMOV10-DE645AA) or pT7-MOV10-G648A (pMOV10-G648A) 
(1.5 µg).  Wild-type MOV10 subcellular localisation is described in (Figure 4.7A).  Approximately 24hrs 
post-transfection cells were fixed in 4% PFA and stained with an anti-T7 primary antibody and 
appropriate Alexa Fluor conjugated secondary antibody, as well as DAPI.  Coverslips were mounted onto 




















4.8 Discussion  
The capacity of MOV10 overexpression to restrict the replication of a broad panel of 
genetically diverse exogenous and endogenous retroelements ranging from HIV-1 to 
LINE-1 provides clues for its mode of action, such that MOV10 may target a factor or 
step common in the life cycle of these retroviruses and retrotransposons.  This chapter 
aimed to identify some of these targets and, secondly, focused on exploring the 
importance of MOV10 putative RNA helicase activity for its anti-retroelement function 
through structure-function analyses.  
 
MOV10 overexpression decreases the cellular Gag abundance of HIV-1, HIV-2 and M-
PMV (chapter 3 sections 3.4, 3.6 and 3.7) and this may contribute to the decrease in 
virus production.  Immunofluorescence studies revealed that ectopically overexpressed 
MOV10 and HIV-1 Gag co-localise in cytoplasmic aggregates that resemble SGs 
(Figure 4.1).  Although further studies with appropriate SG markers and controls will be 
necessary to confirm whether MOV10 and Gag indeed co-localise in SGs, this finding 
may be suggestive of a potential mechanism by which ectopically overexpressed 
MOV10 may decrease cellular Gag abundance through an association with Gag, or even 
sequestration of it, in cytoplasmic aggregations.  Interestingly, MOV10 was recently 
identified in a screen as a HIV-1 Gag interaction partner, although the nature of this 
interaction was not investigated further (Engeland et al., 2011).  In the event that an 
association between MOV10 and Gag is responsible for the decrease in HIV-1 virion 
production, the results presented in this chapter reveal that the NC and MA domains of 
Gag are dispensable for such an interaction as ectopically overexpressed MOV10 
effectively decreases the cellular Gag expression and production of HIV-1 VLPs 
lacking these domains (Figure 4.2B).  Furthermore, the NC domain is responsible for 
packaging of the viral RNA into virions, which confirms that MOV10 overexpression 
does not decrease HIV-1 VLP production by interfering with RNA packaging either 
(Figure 4.2B).   
 
As an alternative hypothesis, considering that MOV10 is a putative RNA helicase that 
has also been reported to function in miRNA-mediated post-transcriptional RNA 
silencing pathways (Meister et al., 2005), ectopically overexpressed MOV10 may 
interact with unspliced viral transcripts and inhibit Gag translation directly.  However, 
this potential interaction between MOV10 and viral RNA must be independent of the 
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viral RNA sequence and cis-acting elements as MOV10 overexpression effectively 
decreases the production of HIV-1 VLPs produced from a codon-optimised construct as 
well (Figure 4.2B).  This is not unlikely considering the broad RNA binding ability of 
MOV10 (Castello et al., 2012).   
 
Ectopic overexpression of MOV10 not only decreases the production of HIV-1 virions, 
but also potently reduces the infectivity of virions produced (chapter 3 section 3.4), and 
this is also true for HIV-2 (chapter 3 section 3.6).  MOV10 overexpression inhibits the 
production of infectious SIVmac, M-PMV and MLV particles as well, therefore, this 
finding may extend to these retroviruses; however, this could not be confirmed for all 
retroviruses tested, as the respective assays used did not differentiate between an effect 
on virus production or infectivity.  MOV10 overexpression decreases the level of HIV-1 
genomic RNA packaged into virions (Figure 4.3), and whether this affects viral RNA 
dimerisation remains to be established.  The association of MOV10 with RNA 
metabolism pathways may account for this effect although further studies will be 
required to verify this.  Compared to the control, HIV-1 genome incorporation is 
reduced by approximately 40% and 60% in virions produced from HeLa and 293T cells, 
respectively (Figure 4.3), however, at a similar concentration of pMOV10, infectivity of 
HIV-1 virions is reduced more potently.  These results suggest that either the effect on 
viral RNA packaging is amplified in terms of its impact on virus infectivity, or 
alternatively, ectopically overexpressed MOV10 inhibits the infectivity of HIV-1 
virions by more than one mechanism.   
 
Proteomics studies detected endogenous MOV10 in HIV-1 virions produced from 
infected monocyte-derived macrophages (MDMs) (Chertova et al., 2006).  More 
recently studies have identified this interaction to be dependent on the NC domain of 
Gag and residues within the N-terminal domain of MOV10, as well as putative helicase 
motifs in the MOV10 C-terminal domain (Wang et al., 2010; Abudu et al., 2012).  
Furthermore, MOV10 interacts with members of the APOBEC3 family that restrict 
HIV-1 infection by interfering with the process of reverse transcription.  Consistently, 
MOV10 overexpression produces virions that are defective in the accumulation of 
minus strand strong stop DNA (Figure 4.4) and also late reverse transcription products 
in target cells (data not shown).  Other groups have reported similar decreases in the 
synthesis of early and late reverse transcripts (Burdick et al., 2010; Furtak et al., 2010; 
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Wang et al., 2010), however, it is not yet clear whether this is a consequence of reduced 
genome packaging, or whether MOV10 may directly impede reverse transcription.  
Interestingly, ectopically overexpressed MOV10 also decreases the accumulation of 
IAP reverse transcription products and inhibits IAP retrotransposition, although has no 
effect on IAP RNA packaging into VLPs (Lu et al., 2012).  Therefore, reverse 
transcription may be a common target for MOV10-mediated restriction of diverse 
exogenous and endogenous retroelements. 
 
These results associate MOV10 with RNA stages of the HIV-1 life cycle and, therefore, 
MOV10 putative RNA helicase activity may be important for this function.  Early 
structure-function studies revealed that overexpression of the N-terminal domain of 
MOV10, which contains no known protein motifs, decreases the production and 
infectivity of HIV-1 virions as effectively as full-length MOV10 (Figure 4.5).  In sharp 
contrast, overexpression of the C-terminal putative RNA helicase domain of MOV10 
has no effect on HIV-1 virus production or infectivity, and in fact enhances virus 
production slightly (Figure 4.5).  These results suggest that the antiviral activity of 
MOV10 is localised to its N-terminal domain.  Furtak et al reported similar findings 
with the overexpression of N-terminal and C-terminal MOV10 proteins (Furtak et al., 
2010).  However, the reliability of these results is questionable as both the N-terminal 
and C-terminal proteins are expressed at higher levels relative to full-length MOV10 
making any direct extrapolations regarding MOV10 inhibitory function inaccurate 
(Figure 4.5).  Moreover, unlike full-length MOV10 the C-terminal protein also localises 
to the nucleus (Figure 4.7B, lower panel) suggesting that such large truncations can 
drastically alter the subcellular localisation of proteins and, therefore, their function as 
well.  In the case of LINE-1 replication, both the N-terminal and C-terminal proteins 
suppress LINE-1 retrotransposition, however, not as effectively as the full-length 
protein (Figure 4.6), suggesting that both domains may be important for restriction of 
LINE-1 mobilisation.  Alternatively, mislocalisation of the C-terminal protein to the 
nucleus may interfere with steps such as TPRT, producing a phenotype unrepresentative 
of full-length MOV10 activity.    
 
The MOV10 putative helicase mutants reflect a better system in comparison with the N-
terminal and C-terminal proteins for such structure-function analyses, and these proteins 
are expressed at levels similar to wild-type MOV10 as well (Figure 4.9).  Interestingly, 
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the K530A and DE645AA mutants are partial loss of function MOV10 mutants as 
overexpression of these proteins decreased HIV-1 virus production and infectivity less 
effectively than wild-type MOV10 (Figure 4.9).  In contrast, G648A is a functional 
MOV10 mutant with antiviral activity comparable to wild-type MOV10 (Figure 4.9).  
These results suggest that the conserved lysine residue in the Walker A motif and the 
aspartic acid and glutamic acid residues in the Walker B motif are necessary for 
MOV10-mediated inhibition of HIV-1 virus production and infectivity.  Similarly, these 
residues are also critical for the suppression of LINE-1 retrotransposition as ectopically 
overexpressed K530A and DE645AA mutants suppress LINE-1 retrotransposition less 
effectively than wild-type MOV10 (Figure 4.10).   
 
Intriguingly, Furtak et al substituted just the conserved glutamic acid residue in the 
Walker B motif with a glutamine (E646Q), and showed that ectopically overexpressed 
E646Q decreased the infectivity of HIV-1 virions akin to wild-type MOV10 (Furtak et 
al., 2010).  Therefore, it may be that the aspartic acid residue in the Walker B motif 
alone is essential for MOV10 antiviral activity.  Although the use of different 
substitutions i.e. glutamine instead of alanine complicates the direct comparison of these 
data.  Furthermore, as K530A and DE645AA are only partial loss of function MOV10 
mutants this implies that residues within other putative helicase motifs or even the N-
terminal domain of MOV10 may contribute to anti-retroelement activity.  Consistently, 
Wang et al tested several mutants generated by substituting alanines in place of key 
residues within seven putative helicase motifs, and reported that the ectopic 
overexpression of each mutant decreased HIV-1 infectivity less effectively than wild-
type MOV10 (Wang et al., 2010).  Furthermore, Abudu et al mapped the antiviral 
region of MOV10 to amino acids 99-949 indicating that residues spanning the majority 
of MOV10 may be necessary for its inhibitory activity (Abudu et al., 2012).  
 
Interestingly, the subcellular distribution of K530A, DE645AA and also the N-terminal 
MOV10 protein varies from that of wild-type MOV10, whereby these proteins do not 
localise to P bodies and, furthermore, appear to either prevent the formation of P bodies 
or disrupt them (Figures 4.7 and 4.11).  In contrast, the subcellular localisation of 
G648A reflects that of wild-type MOV10.  These results suggest that these conserved 
residues within the Walker A and Walker B motifs may be important for P body 
formation and/or stability.  Furthermore, the N-terminal domain of MOV10 may 
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function in mediating the localisation of MOV10 to P bodies, as the C-terminal protein 
alone does not localise to DDX6 P bodies (Figure 4.7B, lower panel), although further 
studies will be necessary to confirm this.  Secondly, as K530A and DE645AA are 
partial loss of function MOV10 mutants, it is tempting to speculate that P bodies or P 
body factors may be important for the anti-retroelement activity of MOV10, although 
Lu et al recently reported MOV10 overexpression to effectively suppress IAP 





















































Endogenous MOV10 suppresses endogenous retroelements, 
but not exogenous retroviruses 
 
5.1 Introduction 
Although MOV10 overexpression potently restricts retroviruses and retrotransposons, 
these data do not confirm a physiological role for endogenous MOV10 in the control of 
retroelements, and are simply indicative of potential MOV10 anti-retroelement activity.  
Therefore, the effect of silencing endogenous MOV10 by RNAi on the replication of 
exogenous and endogenous retroelements was investigated.  Additionally, the Type I 
IFN response is activated during viral infections and may also be triggered in response 
to intracellular genetic parasites in the absence of necessary host regulatory factors 
[reviewed in (Pitha, 2011)](Stetson et al., 2008).  This family of cytokines blocks both 
early and late stages of viral replication through the onset of an antiviral state mediated 
by the upregulation of antiviral IFN-stimulatory genes (ISGs) as well as the activation 
of myeloid and lymphoid cells important for combating infection [reviewed in (Stetson 
and Medzhitov, 2006; Pitha, 2011)](Goujon and Malim, 2010).  Members of the 
APOBEC3 family of proteins and tetherin are induced by IFNα treatment (Neil et al., 
2007; Koning et al., 2009); therefore, the effect of IFNα treatment on MOV10 protein 
expression was assessed to address whether MOV10 may also be stimulated by IFNα to 
levels sufficient for the natural restriction of retroelements.  The requirement of MOV10 
for miRNA or siRNA-mediated post-transcriptional RNA silencing pathways, formation 
of cytoplasmic P bodies and APOBEC3 protein function (Meister et al., 2005; Gallois-
Montbrun et al., 2007; Gallois-Montbrun et al., 2008) was also investigated through 
MOV10 knockdown studies as a way to better understand the cellular function of 






5.2 Effect of depleting endogenous MOV10 on HIV-1 replication  
5.2.1 Silencing endogenous MOV10 has no effect on HIV-1 virus production or the 
infectivity of virions produced 
MOV10 knockdown (KD) cell lines were produced by transducing HeLa or 293T cells 
with lentiviral vectors expressing either a non-silencing control short hairpin RNA 
(shRNA) or a MOV10-specific shRNA.  These vectors also encoded a puromycin 
resistance gene and, therefore, successfully transduced cells were selected with 
puromycin treatment.  HeLa or 293T non-silencing control and MOV10 KD cell lysates 
were analysed by immunoblotting with an anti-MOV10 antibody to determine the 
efficiency of MOV10 KD, and MOV10 could not be detected at the protein level even 
when the amount of lysate analysed was greatly increased (Figure 5.1A).  Furthermore, 
the growth rate of MOV10 KD cells was similar to that of the non-silencing control 
cells (data not shown).  MOV10 overexpression decreases the production of HIV-1 
virions and also inhibits the infectivity of virions produced.  To assess whether natural 
levels of MOV10 similarly restrict HIV-1 the effect of depleting endogenous MOV10 
on the production and infectivity of HIV-1 virions was investigated.  For this HeLa or 
293T non-silencing control and MOV10 KD cells were transfected with pHIV-1NL4-3 
and virion production and infectivity were determined by p24Gag ELISA and TZM-bl 
assay, respectively.  Silencing of endogenous MOV10 had no effect on the production 
(Figure 5.1A) or infectivity (Figure 5.1B) of HIV-1 virions suggesting that endogenous 
















                   
 
Figure 5.1.  Silencing endogenous MOV10 has no effect on HIV-1 virus production 
or the infectivity of virions produced. 
 
(A) Silencing endogenous MOV10 has no effect on HIV-1 virus production.  MOV10 knockdown 
(KD) cell lines were produced by transducing HeLa or 293T cells with lentiviral vectors expressing either 
a non-silencing control shRNA or a MOV10-specific shRNA.  Cell cultures were treated with puromycin 
to select for successfully transduced cells.  HeLa or 293T non-silencing control or MOV10 KD cells were 
transfected with pHIV-1NL4-3 (1 µg).  Virus production was quantified by p24Gag ELISA as described in 
chapter 3 Figure 3.1B.  Cell lysates were analysed by immunoblotting with anti-MOV10, anti-p24Gag and 
anti-Hsp90 antibodies.  (B) Endogenous MOV10 KD has no effect on the infectivity of HIV-1 virions 
produced.  The infectivity of equal amounts of virus normalised by the p24Gag concentration from the 
experiments in panel (A) was measured by TZM-bl assay as described in chapter 3 Figure 3.1B.  Results 
are normalised to the non-silencing control, which is set at 100%.  Values are the mean ± SD of 4 










5.2.2 Depletion of endogenous MOV10 has no effect on HIV-1 virus production or 
the infectivity of virions produced (infection assay) 
Production of HIV-1 virions through the transfection of cells with pHIV-1NL4-3 does not 
reflect physiological infection, and may saturate any potential subtle phenotypes 
attributed to the depletion of endogenous MOV10.  For this reason the effect of 
endogenous MOV10 depletion on HIV-1 virus production and infectivity was 
established with an alternative assay whereby producer cells were infected with virus as 
opposed to transfected with pHIV-1NL4-3, resembling natural infection more closely.  
For the infection assay, VSV-G pseudotyped HIV-1 virions were produced in 293T 
cells by co-transfecting cells with pHIV-1NL4-3 and pVSV-G (Figure 5.2).  Equal 
amounts of virus normalised by the p24Gag concentration (MOI 0.3) was used to infect 
HeLa or 293T non-silencing control and MOV10 KD cells, and the effect on virus 
production and infectivity was determined by p24Gag ELISA and TZM-bl assay as 
previously described.  However, similarly to the transfection assay, MOV10 knockdown 
had no significant effect on HIV-1 virion production (Figure 5.3A) or the infectivity of 
virus produced (Figure 5.3B).  These results verify that natural levels of MOV10 do not 
impact HIV-1 virus production or infectivity.    
 
5.2.3 Spreading HIV-1 replication is unaffected by silencing of endogenous MOV10 
MOV10 was also depleted in the HUT78 T cell line by transducing cells with lentiviral 
vectors expressing either the non-silencing control or MOV10-specific shRNA as 
described (section 5.2.1).  Again, analysis of HUT78 cell lysates by immunoblotting 
with an anti-MOV10 antibody revealed that the KD was efficient, whereby MOV10 
could not be detected at the protein level (Figure 5.4).  As these cells express CD4 and 
CXCR4, the effect of endogenous MOV10 depletion on multiple rounds of HIV-1 
replication was determined.  HUT78 non-silencing control and MOV10 KD cells were 
infected with equal amounts of wild-type HIV-1NL4-3 virus and the effect on spreading 
replication was assessed by determining the concentration of p24Gag in the culture 
supernatant at days 2, 4, 6 and 8 by p24Gag ELISA.  Similar to the observations with 
single-cycle infectivity assays, silencing of endogenous MOV10 had no effect on 
spreading HIV-1 replication (Figure 5.4).  Therefore, endogenous levels of MOV10 do 




             
 
 
Figure 5.2.  Infection assay. 
 
293T cells were co-transfected with pHIV-1NL4-3 and pVSV-G to produce VSV-G pseudotyped virus.  
Virions were quantified by p24Gag ELISA and an equal amount of virus (25 ngs, MOI 0.3) normalised by 
the p24Gag concentration was used to infect HeLa or 293T non-silencing control and MOV10 KD cells.  
Approximately 48hrs post-infection virus-containing supernatant was harvested.  Virus production was 
quantified by p24Gag ELISA and virion infectivity was measured by TZM-bl assay as described in chapter 
















                 
 
 
Figure 5.3.  Depletion of endogenous MOV10 has no effect on HIV-1 virus 
production or the infectivity of virions produced (infection assay). 
  
(A) Depletion of endogenous MOV10 has no effect on HIV-1 virus production (infection assay).  
HeLa or 293T non-silencing control and MOV10 KD cells were infected with VSV-G pseudotyped HIV-
1NL4-3 virus as described in Figure 5.2.  Virus production was quantified by p24Gag ELISA as described in 
Figure 5.2.  Cell lysates were analysed by immunoblotting with anti-MOV10, anti-p24Gag and anti-Hsp90 
antibodies.  (B) HIV-1 virion infectivity is unaffected by endogenous MOV10 silencing (infection 
assay).  The infectivity of equal amounts of virus normalised by the p24Gag concentration from the 
experiments in panel (A) was measured by TZM-bl assay as described in Figure 5.2.  Results are 
normalised to the non-silencing control, which is set at 100%.  Values are the mean ± SD of 7 
independent experiments.  The data were analysed with an unpaired one-tailed t test. (HeLa virus 
production p = 0.0611, 293T virus production p = 0.2007, HeLa infectivity p = 0.3080 and 293T 









               
 
 
Figure 5.4.  Spreading HIV-1 replication is unaffected by silencing of endogenous 
MOV10. 
 
HUT78 non-silencing control and MOV10 KD T cell lines were produced by transducing cells with 
lentiviral vectors expressing a non-silencing control shRNA or a MOV10-specific shRNA, respectively.  
Cell cultures were treated with puromycin to select for successfully transduced cells.  HUT78 non-
silencing control or MOV10 KD cells were infected with equal amounts of HIV-1NL4-3 virus (100 ngs) and 
passaged every 2 days.  Medium was harvested on days 2, 4, 6 and 8 and virus production was quantified 
as described in chapter 3 Figure 3.1B.  Cell lysates were analysed by immunoblotting with anti-MOV10 






















5.3 Depletion of endogenous MOV10 has no significant effect on the production of 
infectious SIVmac, MLV or M-PMV particles 
Ectopically overexpressed MOV10 drastically decreases the production of infectious 
SIVmac and M-PMV particles by over 90% relative to the control, and completely 
abolishes the production of MLV virions (chapter 3 sections 3.6 and 3.7).  Considering 
that MOV10 KD had no effect on HIV-1 replication, the impact of silencing 
endogenous MOV10 on the production of infectious SIVmac, MLV and M-PMV 
particles was also assessed.  SIVmac and HIV-1 vectors were produced as previously 
described (chapter 3 section 3.6) by co-transfecting 293T non-silencing control and 
MOV10 KD cells with either pSIV3+ and pSIV-RMES4 or p8.91 and pCSGW, 
respectively, together with pVSV-G.  The VSV-G pseudotyped vectors were harvested 
and equal amounts of vector-containing supernatant was added to 293T cells.  
Quantification of the percentage of GFP+ cells revealed that similar to wild-type HIV-1 
experiments, MOV10 KD had no significant effect on the production of SIVmac 
particles either (Figure 5.5).  MLV and M-PMV virions were also produced as 
previously described (chapter 3 section 3.7) by co-transfecting 293T non-silencing 
control and MOV10 KD cells with either pMLV, pMLV-Tat and pVSV-G or pMT∆E 
and pVSV-G, respectively, and equal amounts of virus-containing supernatant was 
added to TZM-bl cells.  Silencing of endogenous MOV10 had no effect on the 
production of infectious MLV and M-PMV virions either (Figure 5.5).  A role for 
undetectable levels of residual MOV10 in the KD cells cannot be ruled out, however, 
these results suggest that, similar to the observations for HIV-1, endogenous levels of 














           
 
 
Figure 5.5.  Depletion of endogenous MOV10 has no significant effect on the 
production of infectious SIVmac, MLV or M-PMV particles. 
 
293T non-silencing control and MOV10 KD cells were transfected with plasmids as described in chapter 
3 Figure 3.6A, 3.7B and 3.8C for the production of SIVmac, HIV-1, MLV and M-PMV particles.  The 
effect on production of infectious SIVmac and HIV-1 vectors was determined by FACS analysis as 
described in chapter 3 Figure 3.5C, and for MLV and M-PMV virions this was determined by TZM-bl 
assay as described in chapter 3 Figure 3.7A and 3.8B.  Results are normalised to the non-silencing 
control, which is set at 100%.  A single control bar set at 100% is graphed for simplicity.  Values are the 
mean ± SD of 3 independent experiments.  The data were analysed with an unpaired one-tailed t test.  





























5.4 Spreading HIV-1 replication has no effect on endogenous MOV10 protein 
abundance  
Although A3F and A3G are potent HIV-1 restriction factors their antiviral activity 
during physiological infection is hampered through targeting of these proteins for 
proteasomal degradation by the viral accessory protein Vif (Sheehy et al., 2003; 
Wiegand et al., 2004) (chapter 1 section 1.8.2.8).  Similarly, the broad antiviral factor 
tetherin is antagonised by the primate lentivirus Vpu, Nef and Env proteins resulting in 
its downregulation and degradation, permitting efficient release of viral particles from 
the surface of infected cells (Neil et al., 2007; Le Tortorec and Neil, 2009; Zhang et al., 
2009)(chapter 1 section 1.8.2.5).  More recently, the HIV-2/SIVsmm Vpx protein was 
also shown to counteract the myeloid cell restriction factor SAMHD1, similarly 
targeting it for proteasomal degradation and consequently permitting infection of 
otherwise poorly infected DCs and macrophages (Hrecka et al., 2011; Laguette et al., 
2011) (chapter 1 section 1.8.2.6).  Ectopically overexpressed MOV10 effectively 
inhibits the replication of exogenous retroviruses, however, these viruses are refractory 
to restriction by natural levels of MOV10; therefore, the possibility that viral proteins 
may antagonise endogenous MOV10 and, therefore, counteract its antiviral activity was 
investigated. 
 
To test this the HUT78 and CEM-SS T cell lines were infected with equal amounts of 
wild-type HIV-1NL4-3 virus in a spreading replication assay and cell lysates were 
analysed by immunoblotting with an anti-MOV10 antibody to detect endogenous 
MOV10 levels.  For HUT78 cell lysates, A3G levels were also detected with an anti-
A3G antibody as a control for degradation.  The results showed that endogenous 
MOV10 levels were unaffected by HIV-1 replication as similar levels of MOV10 were 
detected in both infected and mock-infected cells.  An exception to this was at day 6 and 
day 8 for HUT78 and CEM-SS cells, respectively, however this was a consequence of 
cell death as deduced by the Hsp90 levels (Figure 5.6, lane 6 left panel and lane 8 right 
panel).  Moreover, A3G was degraded as expected by day 4 (Figure 5.6, left panel).  







                       
 
 
Figure 5.6.  Spreading HIV-1 replication has no effect on endogenous MOV10 
protein abundance. 
 
HUT78 and CEM-SS T cell lines were mock-infected or infected with equal amounts (100 ngs) of HIV-
1NL4-3 virus in a spreading replication assay.  The cultures were passaged every 2 days and harvested at 
the indicated days.  Cell lysates were analysed by immunoblotting with anti-MOV10, anti-p24Gag and 
anti-Hsp90 antibodies.  For HUT78 cells, A3G protein levels were also detected by immunoblotting with 





























5.5 Effect of IFNα treatment on endogenous MOV10 protein levels and localisation 
5.5.1 IFNα treatment does not stimulate MOV10 protein expression or alter the 
subcellular localisation of endogenous MOV10 in cell lines 
The results presented so far demonstrate that although ectopically overexpressed 
MOV10 potently decreases the production of infectious retroviral particles, natural 
levels of MOV10 do not restrict the replication of these retroviruses.  Furthermore, 
MOV10 protein expression is not affected by HIV-1 replication indicating that unlike 
other antiretroviral factors MOV10 is not degraded by a viral protein, which would 
otherwise explain the lack of a phenotype in MOV10 KD studies.  An alternative theory 
is that during physiological infection MOV10 protein expression may be stimulated to 
levels sufficient for the restriction of retroviruses, mimicking the observations with 
MOV10 overexpression.  The family of Type I IFN cytokines are produced during early 
infection and are critical for the onset of an antiviral innate and adaptive immune 
response.  Interestingly, IFNα treatment induces expression of the antiviral APOBEC3 
proteins, tetherin and SAMHD1 and, therefore, the effect of IFNα treatment on MOV10 
protein expression was also determined. 
 
293T or the CEM, HUT78 and Jurkat T cell lines were cultured in the presence of IFNα 
for approximately 24hrs, following which cell lysates were analysed by immunoblotting 
with anti-MOV10 and anti-Hsp90 antibodies.  As a control for IFNα treatment, levels of 
the known ISG TRIM22 were also detected with an anti-TRIM22 antibody.  TRIM22 
could not be detected in 293T cells, however, IFNα treatment notably stimulated 
TRIM22 protein expression in CEM, HUT78 and Jurkat cells compared to the mock-
treated cells (Figure 5.7A).  In contrast, MOV10 protein expression remained 
unchanged in IFNα-treated and mock-treated cells for all cell lines tested (Figure 5.7A).  
The effect of IFNα treatment on MOV10 protein expression was also investigated in a 
time-course to determine the kinetics of this reaction and ensure that MOV10 protein 
expression was not stimulated earlier or later than 24hrs.  For this HeLa or 293T cells 
were cultured in the presence of IFNα for 12hrs, 24hrs, 36hrs and 48hrs, and cell lysates 
were analysed by immunoblotting with anti-MOV10 and anti-Hsp90 antibodies.  
MOV10 protein expression was not induced at any of these time points with IFNα 
treatment in HeLa or 293T cells relative to the mock-treated cells (Figure 5.7B).  
Therefore, MOV10 protein expression is not induced by IFNα in cell lines. 
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Alternatively, IFNα treatment may alter the subcellular localisation of MOV10 in a way 
that could potentially enhance its antiviral activity.  To test this HeLa cells were 
cultured in the presence of IFNα for 24hrs following which cells were fixed and 
analysed by immunofluorescence using an anti-MOV10 antibody.  However, the 
subcellular distribution of MOV10 in IFNα-treated and mock-treated cells was similar, 
whereby MOV10 was cytoplasmically diffuse and localised to P bodies (Figure 5.7C).  
Therefore, IFNα treatment has no effect on endogenous MOV10 subcellular distribution 

























                       
 
 
Figure 5.7.  IFNα treatment does not stimulate MOV10 protein expression or alter 
the subcellular localisation of endogenous MOV10 in cell lines. 
 
(A) IFNα treatment does not stimulate MOV10 protein expression in cell lines.  293T, CEM, HUT78 
and Jurkat cells were treated with IFNα for approximately 24hrs.  Cell lysates were analysed by 
immunoblotting with anti-MOV10, anti-TRIM22 and anti-Hsp90 antibodies.  (B) MOV10 protein 
abundance is not induced by IFNα treatment in a time-course.  HeLa and 293T cells were treated 
with IFNα for 12hrs, 24hrs, 36hrs and 48hrs.  Cell lysates were analysed by immunoblotting with anti-
MOV10 and anti-Hsp90 antibodies.  (C) IFNα treatment does not alter the subcellular localisation of 
endogenous MOV10 in cell lines.  HeLa cells were treated with IFNα for approximately 24hrs, fixed in 
4% PFA and stained with an anti-MOV10 primary antibody and appropriate Alexa Fluor conjugated 
secondary antibody.  Coverslips were mounted onto slides and analysed by immunofluorescence.  Scale 




5.5.2 MOV10 protein expression is not induced by IFNα treatment in primary cells 
IFNα treatment does not induce MOV10 protein expression in a panel of cell lines, 
however, the IFNα-responsiveness of cell lines may vary from that of primary cells.  
Therefore, the effect of IFNα treatment on MOV10 protein expression in primary CD4+ 
T cells, monocyte-derived DCs (MDDCs) and MDMs was assessed.  Naïve CD4+ T 
cells were isolated from 2 donors and ex vivo analysis of cell lysates by immunoblotting 
with anti-MOV10 and anti-Hsp90 antibodies revealed that MOV10 was expressed in 
these cells (Figure 5.8A, donor 2 lane 1).  The lack of detection in donor 1 and only 
faint MOV10 protein levels in donor 2 is likely attributed to low cell numbers as 
deduced by Hsp90 levels.  Activation of naïve CD4+ T cells with anti-CD3/CD28 or 
interleukin-2 (IL-2)/phytohaemagglutinin (PHA) stimulation resulted in the detection of 
higher MOV10 levels with the latter treatment after 5 days (Figure 5.8A, both donors 
lane 5) due to higher levels of cell proliferation with IL-2/PHA stimulation compared to 
anti CD3/CD28 stimulation as deduced from the Hsp90 levels (Figure 5.8A, both 
donors compare lanes 4 and 5).  IL-2/PHA pre-stimulated CD4+ T cells were cultured 
in the presence of IFNα for 24hrs or 48hrs and cell lysates were analysed by 
immunoblotting with anti-MOV10 and anti-Hsp90 antibodies.  Results showed that at 
both time-points MOV10 protein abundance remained unchanged relative to the mock-
treated cells (Figure 5.8B) confirming that MOV10 protein expression is not induced by 
IFNα treatment in primary CD4+ T cells. 
 
MDDCs and MDMs were cultured in the presence of granulocyte-macrophage colony-
stimulating factor (GM-CSF) and interleukin-4 (IL-4), or GM-CSF alone for 5 days, 
respectively, following which cells were treated with IFNα.  Cell lysates were analysed 
by immunoblotting with anti-MOV10 and anti-Hsp90 antibodies, as well as an antibody 
against A3G as a positive control for IFNα-mediated induction in MDDCs.  Similar to 
primary CD4+ T cells, IFNα treatment of MDDCs for 6hrs and 30hrs, and MDMs for 
30hrs had no effect on MOV10 protein expression compared to mock-treated cells 
(Figure 5.8C).  These results demonstrate that IFNα treatment does not stimulate 
MOV10 protein expression in a range of cell lines or primary cells, including CD4+ T 
cells and macrophages, which are the natural targets for HIV-1 infection.   
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Figure 5.8.  MOV10 protein expression is not induced by IFNα treatment in 
primary cells.  
 
(A) MOV10 is expressed in primary CD4+ T cells.  Naïve CD4+ T cells were isolated from peripheral 
blood mononuclear cells (PBMCs) from two donors.  Cell lysates were analysed ex vivo by 
immunoblotting with anti-MOV10 and anti-Hsp90 antibodies.  Cells were also plated and activated with 
anti-CD3/CD28 or interleukin-2 (IL-2)/phytohaemagglutinin (PHA) stimulation.  Cells were harvested at 
days 2 and 5 and lysates were analysed by immunoblotting with anti-MOV10 and anti-Hsp90 antibodies.  
293T non-silencing control and MOV10 KD cell lysates were included in the analysis as a marker for the 
MOV10 band.  (B) MOV10 protein expression is not induced by IFNα treatment in primary CD4+ 
T cells.  CD4+ T cells pre-stimulated with IL-2/PHA for 2 days were either mock-treated or cultured in 
the presence of IFNα for 24hrs or 48hrs.  Cell lysates were analysed by immunoblotting with anti-
MOV10 and anti-Hsp90 antibodies.  (C) MOV10 protein expression is not induced by IFNα 
treatment in monocyte-derived dendritic cells (MDDCs) and macrophages (MDMs).  Primary 
monocytes were differentiated into MDDCs and MDMs by treating cells with granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4), or GM-CSF alone for 5 days, respectively.  
Subsequently, cells were cultured in the absence or presence of IFNα for the indicated times.  Cell lysates 
were analysed by immunoblotting with anti-MOV10 and anti-Hsp90 antibodies, and also anti-A3G for 




5.6 Effect of depleting endogenous MOV10 on the replication of endogenous 
retroelements 
5.6.1 Silencing of endogenous MOV10 enhances the retrotransposition of LTR and 
non-LTR endogenous retroelements 
The results so far demonstrate that endogenous levels of MOV10 do not control the 
replication of exogenous retroviruses.  Ectopically overexpressed human MOV10 also 
potently suppresses the replication of the mouse ERV IAP and human retrotransposons 
LINE-1 and Alu (chapter 3 section 3.8).  To determine whether natural levels of 
MOV10 suppress the replication of these endogenous retroelements, the effect of 
endogenous MOV10 silencing on IAP, LINE-1 and Alu retrotransposition was 
determined.  HeLa non-silencing control and MOV10 KD cells were transfected as 
previously described (chapter 3 section 3.8) with pGL3-IAP92L23neoTNF (pIAP), 
pJM101/L1.3 (pLINE-1) or pAlu-neoTet (pAlu) and pORF2p, and cell cultures were 
G418 selected.  Interestingly, depletion of endogenous MOV10 significantly enhanced 
IAP, LINE-1 and Alu retrotransposition by 2-fold, 4-fold and 5-fold, respectively 
(Figure 5.9A).  Again to assess whether MOV10 KD affected the expression or 
selection of neo directly, or alternatively, increased the transfection efficiency of these 
cells, HeLa non-silencing control and MOV10 KD cells were transfected with 
pcDNA3.1-neo and the retrotransposition assay was performed as described.  A similar 
number of colonies were counted for the non-silencing control and MOV10 KD cells 
confirming that silencing of endogenous MOV10 has no effect on neo expression, 
selection or the transfection efficiency of cells (Figure 5.9B).  Therefore, natural levels 














                  
 
 
Figure 5.9.  Silencing of endogenous MOV10 enhances the retrotransposition of 
LTR and non-LTR endogenous retroelements. 
 
(A) Silencing of endogenous MOV10 enhances the retrotransposition of LTR and non-LTR 
endogenous retroelements.  HeLa non-silencing control or MOV10 KD cells were transfected with 
pGL3-IAP92L23neoTNF (pIAP), pJM101/L1.3 (pLINE-1) or pAlu-neoTet (pAlu) as described in chapter 3 
Figure 3.10A.  The retrotransposition frequency was determined by G418 selection of the cultures as 
described in chapter 3 Figure 3.9.  (B) Endogenous MOV10 KD has no direct effect on neo 
expression, selection or the transfection efficiency of cells.  HeLa non-silencing control and MOV10 
KD cells were transfected with pcDNA3.1-neo as described chapter 3 Figure 3.10B.  The 
retrotransposition frequency was determined by G418 selection of the cultures as described in chapter 3 
Figure 3.9.  Results are normalised to the non-silencing control, which is set at 100%.  For panel (A) a 
single control bar set at 100% is graphed for simplicity.  Values are the mean ± SD of 3 independent 
experiments.  The data were analysed with an unpaired one-tailed t test.  (LINE-1 **p ≤ 0.0056, Alu ***p 




5.6.2 Restoration of MOV10 expression in MOV10 KD cells rescues the control of 
LINE-1 retrotransposition 
To ensure that the enhanced retrotransposition of endogenous retroelements was 
attributed specifically to the depletion of endogenous MOV10 and not an unanticipated 
off-target effect, a silencing resistant version of MOV10 was generated by introducing 
silent mutations into the shRNA target sequence.  This was cloned into the pT7 plasmid 
generating pT7-MOV10-R (pMOV10-R).  To test the shRNA-resistance of pMOV10-R, 
HeLa MOV10 KD cells were transfected with increasing concentrations of either 
sensitive pMOV10 or resistant pMOV10-R, and cell lysates were analysed by 
immunoblotting with anti-MOV10, anti-T7 and anti-Hsp90 antibodies.  Results showed 
that the abundance of MOV10-R was elevated in comparison to wild-type MOV10 
(Figure 5.10A, compare lanes 5 and 6 with 11 and 12), verifying the resistance of this 
construct to the MOV10-specific shRNA expressed in MOV10 KD cells.  The effect of 
ectopically overexpressed MOV10-R on the production of infectious MLV and M-PMV 
virions was also examined to assess the antiviral function of MOV10-R relative to wild-
type MOV10.  Analysis of cell lysates by immunoblotting with anti-T7 and anti-Hsp90 
antibodies demonstrated MOV10-R and wild-type MOV10 expression levels to be 
similar (Figure 5.10B, lower panel) and, moreover, ectopically overexpressed MOV10-
R decreased the production of infectious MLV and M-PMV as effectively as wild-type 
MOV10 (Figure 5.10B).   
 
 Subsequently, the effect of restoring MOV10 expression in MOV10 KD cells on LINE-
1 retrotransposition was determined by transfecting HeLa non-silencing control or 
MOV10 KD cells with pJM101/L1.3 (pLINE-1), and transfecting MOV10 KD cells 
with increasing concentrations of pMOV10-R or the pT7-Luc (pLuc) control.  The non-
silencing control cells were also transfected with pLuc to ensure equivalent amounts of 
DNA in all transfections.  Results showed an expected increase in LINE-1 
retrotransposition with MOV10 KD relative to the non-silencing control cells (Figure 
5.10C, compare lanes 1 and 2).  Moreover, expression of pMOV10-R in MOV10 KD 
cells restored the control of LINE-1 retrotransposition (Figure 5.10C, lanes 3 and 4).  
These results confirm that depletion of specifically endogenous MOV10, and not an off-





          































Figure 5.10.  Restoration of MOV10 expression in MOV10 KD cells rescues the 
control of LINE-1 retrotransposition. 
 
(A) Testing the shRNA-resistance of pT7-MOV10-R.  HeLa MOV10 KD cells were transfected with 
increasing concentrations of pT7-MOV10 (pMOV10) or pT7-MOV10-R (pMOV10-R) as indicated.  Cell 
lysates were analysed by immunoblotting with anti-MOV10, anti-T7 and anti-Hsp90 antibodies.  (B) The 
antiviral activity of MOV10-R is similar to wild-type MOV10.  293T cells were co-transfected with 
plasmids for the production of MLV and M-PMV virions as described in chapter 3 Figure 3.7B and 3.8C 
together with wild-type pT7-MOV10 (pMOV10) or pT7-MOV10-R (pMOV10-R) (0.5 µg).  The effect 
on production of infectious virions was determined by TZM-bl assay as described in chapter 3 Figure 
3.7A and 3.7B.  Cell lysates were analysed by immunoblotting with anti-T7 and anti-Hsp90 antibodies.  
(C) Restoration of MOV10 expression in MOV10 KD cells rescues the control of LINE-1 
retrotransposition.  HeLa non-silencing control and MOV10 KD cells were transfected with 
pJM101/L1.3 (pLINE-1) as described in chapter 3 Figure 3.10A, and MOV10 KD cells were also 
transfected with pT7-MOV10-R (pMOV10-R) or the pT7-Luc (pLuc) control at the indicated 
concentrations.  Non-silencing control cells were transfected with pLuc to ensure equal amounts of DNA 
in all transfections.  Cells were harvested and lysed approximately 48hrs post-transfection and analysed 
by immunoblotting with anti-T7 and anti-Hsp90 antibodies.  The retrotransposition frequency was 
determined by G418 selection of the cultures as described in chapter 3 Figure 3.9.  Results for panels (B) 
and (C) are normalised to the relative controls, which are set at 100%.  For panel (C) values are the mean 



















5.7 Requirement for MOV10 in small RNA-mediated post-transcriptional RNA 
silencing pathways 
5.7.1 MOV10 is not necessary for miRNA-mediated translation repression  
To better understand the mechanism by which natural levels of MOV10 control the 
retrotransposition of endogenous retroelements, the cellular associations of MOV10 
were explored.  Meister et al identified an interaction between MOV10 and members of 
the AGO protein family, and also proposed a role for MOV10 in miRNA-mediated 
cleavage of a reporter mRNA (Meister et al., 2005).  To determine whether MOV10 is 
required for miRNA-mediated translation repression and, therefore, also establish 
whether this is a potential mechanism by which endogenous MOV10 suppresses 
retrotransposition, an established firefly Luc reporter assay was adopted (Lytle et al., 
2007).  The wild-type (WT) reporter construct expresses firefly Luc with a 3’ UTR 
containing four endogenous let-7 miRNA binding sites from a CMV promoter, and in 
the case of the mutant reporter construct these endogenous let-7 miRNA binding sites 
are mutated (Lytle et al., 2007) (Figure 5.11A).  Therefore, endogenous let-7 miRNA 
will bind and repress firefly Luc expression from the WT reporter construct, but not the 
mutant reporter construct.  HeLa non-silencing control and MOV10 KD cells were 
transfected with the WT or mutant reporter constructs, together with a plasmid 
expressing renilla Luc (pRenilla) as a control for transfection efficiency (Figure 5.11A).  
Cell lysates were analysed with a dual Luc reporter assay to measure relative firefly and 
renilla Luc activities, and firefly Luc activity was normalised to renilla Luc activity to 
normalise for small changes in transfection efficiency.  As expected, Luc activity was 
repressed by approximately 5-fold in the case of the WT reporter construct relative to 
the mutant construct for non-silencing control cells (Figure 5.11B).  Interestingly, this 
level of repression was maintained in the MOV10 KD cells indicating that MOV10 is 
not essential for endogenous let-7 miRNA-mediated repression of a reporter construct in 
HeLa cells (Figure 5.11B).   
 
DICER is an RNase III enzyme essential for miRNA and siRNA biogenesis (chapter 1 
section 1.12).  As a control for this assay, HeLa cells were transfected with non-
silencing control or DICER-1 specific siRNAs, which achieved an approximately 70% 
KD in DICER-1 transcript levels as determined by qPCR (Figure 5.11C, right panel).  
Non-silencing control and DICER-1 KD cells were co-transfected with the WT or 
mutant firefly Luc reporter constructs and pRenilla.  Relative firefly and renilla Luc 
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activities were determined and normalised as described, and as expected the results 
showed a decrease in Luc activity with the WT reporter construct relative to the mutant 
reporter construct for non-silencing cells.  Moreover, confirming the validity of this 
approach, the partial DICER-1 knockdown resulted in moderate derepression of Luc 
activity compared to that observed for the non-silencing control cells (Figure 5.11C, left 
panel).  Therefore, unlike DICER-1, MOV10 is not essential for miRNA-mediated 






























               
Figure 5.11.  MOV10 is not necessary for miRNA-mediated translation repression. 
 
(A) Firefly Luc reporter constructs.  The wild-type (WT) construct is driven by a CMV promoter and 
encodes firefly Luc with four endogenous let-7 miRNA binding sites.  The mutant construct is driven by a 
CMV promoter and encodes firefly Luc with mutated endogenous let-7 miRNA binding sites.  The renilla 
construct is expressed from a herpes simplex virus thymidine kinase  (HSV-TK) promoter.  (B) MOV10 
is not necessary for miRNA-mediated translation repression.  HeLa non-silencing control and 
MOV10 KD cells were co-transfected with the WT or mutant firefly Luc reporter constructs (0.1 µg) 
together with the renilla construct (0.1 µg).  Approximately 24hrs post-transfection cells were lysed and 
the relative firefly and renilla Luc activities were measured using a dual-Luc reporter assay system.  
Firefly Luc activity was normalised to renilla Luc activity.    (C) Knockdown of DICER-1 relieves 
miRNA-mediated translation repression.  HeLa cells were transfected with non-silencing control or 
DICER-1-specific siRNAs to produce HeLa non-silencing control and DICER-1 KD cells, respectively.  
RNA was extracted from these cells and cDNA was synthesised.  DICER-1 mRNA levels were measured 
by qPCR (right panel).  HeLa non-silencing control and DICER-1 KD cells were co-transfected with the 
WT or mutant firefly constructs (0.1 µg) together with the renilla construct (0.1 µg) and relative firefly 
and renilla Luc activities were measured as described in panel (B).  Results in panels (B) and (C) are 
normalised to the non-silencing control, which is set at 100%.  For panel (B) values are the mean ± SD of 
3 independent experiments.   
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5.7.2 MOV10 is not necessary for miRNA-mediated mRNA cleavage  
Although MOV10 associates with the AGO1 and AGO2 proteins, it is not essential for 
miRNA-mediated translation repression of a reporter construct in HeLa cells.  However, 
MOV10 has been reported to be necessary for miRNA-mediated mRNA cleavage 
(Meister et al., 2005).  Therefore, to confirm whether MOV10 is indeed essential for the 
miRNA-mediated RNA cleavage pathway and, therefore, also explore this is a potential 
mechanism by which endogenous MOV10 controls retrotransposition, an established 
renilla Luc reporter assay was used (Johnston et al., 2010).  A wild-type (WT) reporter 
construct expressing renilla Luc with three 100% complementary endogenous let-7 
miRNA binding sites from under a CMV promoter, and a mutant reporter construct 
encoding renilla Luc with mutated endogenous let-7 miRNA binding sites (Figure 
5.12A) were transfected into HeLa non-silencing control or MOV10 KD cells.  Both the 
WT and mutant constructs also expressed firefly Luc from a second downstream 
promoter as a control for transfection efficiency (Figure 5.12A).  For this assay, 
endogenous let-7 miRNA will cleave the WT reporter construct due to 100% 
complementary binding sites.  Relative renilla and firefly Luc activities were measured 
using a dual Luc reporter assay as described, and renilla Luc activity was normalised to 
firefly Luc activity to control for small changes in transfection efficiency.  As expected, 
Luc activity was decreased drastically by approximately 50-fold in the case of the WT 
reporter construct compared to the mutant reporter construct for non-silencing control 
cells (Figure 5.12B).  However, similar to the observation for translation repression, 
Luc activity was reduced to similar levels in MOV10 KD cells as well (Figure 5.12B).  
Therefore, MOV10 is not essential for miRNA-mediated cleavage of a reporter mRNA 









                  
 
  
Figure 5.12.  MOV10 is not necessary for miRNA-mediated mRNA cleavage. 
 
(A) Renilla Luc reporter constructs.  The wild-type (WT) construct is driven by a CMV promoter and 
encodes renilla Luc with three perfectly complementary endogenous let-7 miRNA binding sites.  The 
mutant construct also contains the CMV promoter, however, encodes renilla Luc with three mutated 
endogenous let-7 miRNA binding sites.  Both the WT and mutant constructs also encode firefly Luc, 
which is expressed from a second HSV-TK promoter.  (B) MOV10 is not necessary for miRNA-
mediated mRNA cleavage.  HeLa non-silencing control and MOV10 KD cells were transfected with 
either the WT or mutant renilla Luc reporter constructs (0.1 µg).  Cells were lysed approximately 24hrs 
post-transfection and relative renilla and firefly Luc activities were measured with a dual Luc reporter 
assay system.  Renilla Luc activity was normalised to firefly Luc activity.  Results are normalised to the 
















5.7.3 Endogenous MOV10 silencing has no effect on P bodies 
MOV10 interacts with AGO1 and AGO2 proteins, which are core constituents of the 
RISC, and also interacts with members of the APOBEC3 family of proteins (Meister et 
al., 2005; Gallois-Montbrun et al., 2007; Gallois-Montbrun et al., 2008).  Moreover, 
MOV10 co-localises with these factors in cytoplasmic mRNA P bodies (Gallois-
Montbrun et al., 2007; Gallois-Montbrun et al., 2008).  Interestingly, miRNA or siRNA-
mediated post-transcriptional RNA silencing pathways as well as the APOBEC3 
proteins have also been implicated in the negative regulation of endogenous 
retroelements (chapter 1 sections 1.8.2.9, 1.8.2.10 and 1.12.5).  Localisation to P bodies 
appears to be the common denominator between these various functions and pathways.  
To determine whether depletion of endogenous MOV10 facilitates retrotransposition 
due to alterations in P bodies, for example, their depletion, the effect of MOV10 
silencing on P bodies was investigated.  HeLa non-silencing control and MOV10 KD 
cells were fixed and analysed by immunofluorescence using antibodies against the P 
body markers DDX6 and GE1.  Results showed no effect of MOV10 KD on both 
DDX6 and GE1 P bodies compared to the non-silencing control cells (Figure 5.13).  
This result confirms that the increase in retrotransposition observed with endogenous 
MOV10 silencing is not attributed to an effect on P bodies, as P bodies remain 












             
 
 
Figure 5.13.  Endogenous MOV10 silencing has no effect on P bodies. 
 
HeLa non-silencing and MOV10 KD cells were fixed in 4% PFA and stained with anti-DDX6 and anti-
GE1 primary antibodies, followed by appropriate Alexa Fluor conjugated secondary antibodies and 
























5.8 MOV10 relationship with APOBEC3 proteins  
5.8.1 MOV10 is dispensable for suppression of LINE-1 retrotransposition by 
members of the APOBEC3 family 
Overexpression of all APOBEC3 proteins variably restricts the retrotransposition of 
LINE-1 and also Alu retrotransposons, with A3A and A3B being the most potent 
members (Bogerd et al., 2006) (chapter 1 section 1.8.2.10).  Moreover, silencing of 
endogenous A3B enhances LINE-1 replication in HeLa and embryonic stem cells 
(Wissing et al., 2011).  As endogenous levels of MOV10 suppress retrotransposition 
and MOV10 interacts with members of the APOBEC3 family (Gallois-Montbrun et al., 
2007; Gallois-Montbrun et al., 2008) the functional relevance of this association for 
APOBEC3 anti-retrotransposon activity was explored.  The effect of endogenous 
MOV10 depletion on APOBEC3-mediated restriction of LINE-1 retrotransposition was 
assessed by co-transfecting HeLa non-silencing control and MOV10 KD cells with 
pJM101/L1.3 (pLINE-1) and pCMV4-A3A-HA (pA3A), pCMV4-A3B-HA (pA3B), 
pCMV4-A3G-HA (pA3G) or the pCMV4-GFP-HA (pGFP) control (Bishop et al., 
2004).  The retrotransposition assay was performed as described and enumeration of 
colonies revealed that ectopically overexpressed A3A effectively inhibited LINE-1 
retrotransposition both in the presence and absence of MOV10 (Figure 5.14A).  
Additionally, overexpression of A3B and A3G suppressed LINE-1 retrotransposition by 
approximately 70% and 50%, respectively, in the non-silencing control cells relative to 
the pGFP control, and this level of inhibition was maintained in the MOV10 KD cells 
(Figure 5.14A).  Therefore, ectopically overexpressed A3A, A3B and A3G do not 
depend on MOV10 for restriction of LINE-1 retrotransposition.  On the other hand, as 
the majority of APOBEC3 transcripts, except A3B and A3C, cannot be detected in 
HeLa cells, endogenous MOV10 likely controls the retrotransposition of endogenous 
retroelements independently of APOBEC3 proteins as well. 
 
5.8.2 MOV10 is not required for A3G antiviral activity  
Similarly, the requirement of MOV10 for A3G antiviral activity against HIV-1 was also 
tested by co-transfecting HeLa non-silencing control and MOV10 KD cells with a 
plasmid expressing a vif-deficient HIV-1 IIIB provirus (pHIV-1IIIB/∆Vif) (Bishop et al., 
2004) and either pA3G or the pGFP control.  The infectivity of HIV-1 virions was 
reduced by approximately 200-fold with A3G overexpression and, similarly to LINE-1 
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retrotransposition, this potent reduction was sustained in the MOV10 KD cells, 


































                       
 
Figure 5.14.  MOV10 is dispensable for the restriction of LINE-1 and HIV-1 
replication by APOBEC3 proteins. 
 
(A) MOV10 is dispensable for suppression of LINE-1 retrotransposition by members of the 
APOBEC3 family.  HeLa non-silencing control and MOV10 KD cells were co-transfected with 
pJM101/L1.3 (pLINE-1) as described in chapter 3 Figure 3.10A together with either pCMV4-A3A-HA 
(pA3A), pCMV4-A3B-HA (pA3B), pCMV4-A3G-HA (pA3G) or the pCMV4-GFP-HA (pGFP) control 
(1 µg).  The retrotransposition frequency was determined by G418 selection of the cultures as described 
in chapter 3 Figure 3.9.  (B) MOV10 is not required for A3G antiviral activity.  HeLa non-silencing 
control and MOV10 KD cells were co-transfected with pHIV-1IIIB/∆Vif (0.5 µg) and either pA3G or the 
pGFP control (0.5 µg).  Equal amounts of virus normalised by the p24Gag concentration was added to 
TZM-bl cells to measure the effect on virion infectivity as described in chapter 3 Figure 3.1B.  For panel 
(A) results are normalised to the non-silencing control, which is set at 100%.  Values are the mean ± SD 
















5.9 Discussion  
Although MOV10 overexpression restricts the replication of a diverse panel of 
retroviruses and retrotransposons, this chapter investigates this anti-retroelement 
activity in the context of natural levels of MOV10.  Several groups have now tested the 
effect of depleting endogenous MOV10 on the production and infectivity of HIV-1 
virions, and contrasting conclusions have been reported whereby Furtak et al detected 
an approximately 2-fold decrease in virion infectivity, Wang et al observed an 
approximately 2.5-fold increase in infectivity and Burdick et al reported no difference in 
infectivity, although a 2-fold decrease in virus production was detected (Burdick et al., 
2010; Furtak et al., 2010; Wang et al., 2010).  Furthermore, Wang et al also reported an 
increase in HIV-1 spreading replication with silencing of endogenous MOV10 (Wang et 
al., 2010).  Here this analysis was extended beyond HIV-1 to include SIVmac, MLV 
and M-PMV, and results from multiple experiments demonstrate no statistically 
significant effect of silencing endogenous MOV10 on the production, infectivity or 
replication of HIV-1 (Figures 5.1, 5.3 and 5.4), as well as the production of infectious 
SIVmac, MLV or M-PMV particles (Figure 5.5).  A second unrelated MOV10-specific 
shRNA produced comparable results (data not shown), although further experiments 
were not performed with this construct due to the MOV10 KD being less stable in cell 
lines produced with this shRNA vector.  
 
Several cellular restriction factors are antagonised by the primate lentivirus Vif, Vpu, 
Vpx, Nef and Env proteins, targeting them for degradation and hence resulting in the 
counteraction of their antiviral activity (chapter 1 sections 1.8.2.5, 1.8.2.6 and 1.8.2.8).  
However, MOV10 expression was unaffected by spreading HIV-1 replication 
confirming that endogenous MOV10 is not degraded by HIV-1 encoded proteins 
(Figure 5.6).  However, this does not rule out a mechanism by which exogenous 
retroviruses may counteract MOV10 in a degradation-independent manner.  Conversely, 
Wang et al showed HIV-1 replication to decrease the abundance of endogenous MOV10 
protein in cell lines and also PBMCs, and this reduction was observed as early as 36hrs 
post-infection, although MOV10 protein stability and transcript levels were unaffected 
(Wang et al., 2010).  Alternatively, the type I IFN response is activated early during 
infection and induces the expression of antiviral proteins as well as MOV10 at the 
mRNA level; therefore, it was hypothesised that during physiological infection 
endogenous MOV10 protein expression may be induced to levels sufficient for the 
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restriction of exogenous retroviruses.  However, results confirmed no effect of IFNα 
treatment on MOV10 protein expression in cell lines or HIV-1 primary cell targets 
(Figures 5.7 and 5.8).  Therefore, natural levels of MOV10 do not control the 
replication of exogenous retroviruses.   
 
It may be argued that residual levels of MOV10 may account for the lack of an effect of 
endogenous MOV10 KD on exogenous retroviruses, however, notably, silencing of 
endogenous MOV10 significantly enhances the retrotransposition of LTR and non-LTR 
endogenous retroelements (Figure 5.9).  Furthermore, expression of a silencing resistant 
version of MOV10 in MOV10 KD cells restores control of LINE-1 retrotransposition, 
confirming the specificity of this observation (Figure 5.10).  Lu et al also recently 
described ectopically overexpressed MOV10 to suppress IAP retrotransposition in a 
dose-dependent manner, however; in contrast, they reported a 2-fold decrease in IAP 
retrotransposition with MOV10 KD (Lu et al., 2012).   
 
To further delve into the molecular mechanism/s by which endogenous MOV10 may 
control retrotransposition, the cellular associations of MOV10 were considered (chapter 
1 section 1.13.1).  MOV10 interacts with members of the AGO protein family, which 
are core components of the RISC involved in miRNA and siRNA-mediated post-
transcriptional RNA silencing pathways, and has also been reported to be necessary for 
miRNA-mediated cleavage of a target reporter mRNA (Meister et al., 2005).  
Interestingly, LINE-1 encoded endo-siRNAs have been reported to suppress LINE-1 
retrotransposition by an RNAi mechanism (Yang and Kazazian, 2006).  However, the 
results presented here confirm that MOV10 is dispensable for endogenous let-7 
miRNA-mediated translation repression and slicer activity, at least in HeLa cells 
(Figures 5.11 and 5.12).  It may be that MOV10 interacts with only specific miRNAs, 
not including let-7; however, the abundance and highly conserved nature of the let-7 
miRNA family as well as their multifunctional role in development, cell cycling, 
proliferation, apoptosis as well as terminal differentiation, makes this seem less likely.  
 
MOV10 interacts and co-localises with post-transcriptional RNA silencing machinery 
and the APOBEC3 proteins in cytoplasmic P bodies (Meister et al., 2005; Gallois-
Montbrun et al., 2007; Gallois-Montbrun et al., 2008).  Several reports have implicated 
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APOBEC3 proteins and post-transcriptional RNA silencing pathways in the negative 
regulation of endogenous retroelements (chapter 1 sections 1.8.2.9, 1.8.2.10 and 1.12.5) 
and, furthermore, studies have proposed both stimulatory and inhibitory roles for other 
factors that localise to P bodies in the life cycle of ERVs and retrotransposons as well 
(chapter 1 section 1.10.1).  Lu et al reported silencing of the P body components DDX6 
and eIF4E-T to enhance IAP expression, retrotransposition, protein levels and also the 
accumulation of reverse transcripts (Lu et al., 2011).  On the other hand, yeast Ty1 and 
Ty3 retrotransposons depend on P bodies and localising factors for VLP assembly and 
retrotransposition (Beliakova-Bethell et al., 2006; Larsen et al., 2008).  Interestingly, 
structure-function studies in chapter 4 revealed that MOV10 mutants demonstrating 
partial loss of anti-LINE-1 function did not localise to P bodies and even disrupted P 
bodies (chapter 4 sections 4.6 and 4.7) implying that P bodies may be important for 
MOV10-mediated suppression of LINE-1 retrotransposition.  Considering this it was 
hypothesised that depletion of endogenous MOV10 may enhance retrotransposition by 
modulating the size or number of P bodies, however, MOV10 KD had no effect on P 
bodies disproving this hypothesis (Figure 5.13).  Consistently, Lu et al reported MOV10 
overexpression to have no effect on the size or number of P bodies as well and, 
secondly, also proposed that ectopically overexpressed MOV10 was able to effectively 
suppress IAP retrotransposition in the absence of P bodies (Lu et al., 2012).  These 
results confirm that MOV10 is not an essential P body component and that variations in 
retrotransposition with MOV10 overexpression or KD are not a consequence of visible 
modulations in P bodies.  Furthermore, the report from Lu et al implies that P bodies 
may be dispensable for MOV10-mediated control of retrotransposition, however, it will 
be important to test whether endogenous levels of MOV10 effectively control 
retrotransposition in the absence of P bodies, as these cytoplasmic foci may essentially 
function as sites where high levels of endogenous MOV10 may aggregate permitting an 
amplified response against endogenous retroelements. 
 
Finally, particular interest has been paid to the interaction of MOV10 with antiviral A3F 
and A3G proteins as Gallois-Montbrun et al initially performed these studies to identify 
cellular factors that could potentially regulate the editing activity of these enzymes, 
which presumably left astray would prove detrimental to the host (Gallois-Montbrun et 
al., 2007; Gallois-Montbrun et al., 2008).  However, the interaction between MOV10 
and APOBEC3 proteins appears not to hold any functional relevance for APOBEC3 
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anti-retroelement activity as ectopically overexpressed A3A, A3B and A3G suppress 
LINE-1 retrotransposition as effectively in the presence or absence of endogenous 
MOV10 (Figure 5.14A).  Similarly, ectopically overexpressed A3G inhibits HIV-1 
infectivity effectively in MOV10 KD cells (Figure 5.14B).  Burdick et al similarly 
reported the HIV-1 inhibitory activities of A3G and MOV10 to be additive (Burdick et 
al., 2010).  Therefore, MOV10 does not regulate at least the anti-retroelement function 















































































DISCUSSION AND FUTURE WORK 
 
6.1 Background, findings and outstanding questions 
Exogenous and endogenous retroelements are defined by their obligate requirement to 
reverse transcribe their RNA genome into a DNA copy that is permanently integrated 
into the host chromosomal DNA, permitting both persistence and transduction into the 
germ line for vertical transmission.  Retroviruses are the causative agents for numerous 
oncogenic diseases and pathogenic immunodeficiencies, a prime example of which is 
HIV-1 that is responsible for the global AIDS pandemic.  Furthermore, human LINE-1 
and Alu somatic retrotransposon insertional events have been associated with several 
cancers and also implicated in non-hereditary neurobiological disease and diversity 
[reviewed in (Hancks and Kazazian, 2012)](Coufal et al., 2009; Baillie et al., 2011).  
Epigenetic regulatory mechanisms and cellular restriction factors such as the APOBEC3 
proteins, tetherin, SAMHD1 and potentially TREX1 provide an innate line of defence 
against the varied cytopathic and mutagenic effects of such genetic parasites (chapter 1 
section 1.8).  Identification of the full panel of these cellular factors is essential to better 
understand host-pathogen relationships and, moreover, inform novel therapies.  
 
The findings presented in this thesis focus on the human putative RNA helicase MOV10 
and its potential capacity to be a novel cofactor or restriction factor of retroviruses and 
retrotransposons.  The basis of this study originated from the knowledge of multiple 
reports, primarily including the cellular associations of MOV10 with APOBEC3 
proteins, post-transcriptional RNA silencing pathways as well as P bodies and SGs 
(Meister et al., 2005; Gallois-Montbrun et al., 2007; Gallois-Montbrun et al., 2008) 
(chapter 1 section 1.13.1).  This was further instigated by studies highlighting the 
crucial role of MOV10 homologs in the suppression of ERVs and retrotransposons in 
Drosophila melanogaster and mice (Frost et al., 2010; Olivieri et al., 2010; Zheng et al., 
2010) (chapter 1 section 1.13.2).  Demonstrating evolutionary conservation, the results 
presented in this thesis illustrate that human MOV10 may represent a novel restriction 
factor of highly active LINE-1 and Alu retrotransposons (chapter 3 section 3.8 and 
chapter 5 section 5.6).  In contrast experiments with exogenous retroviruses revealed 
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that although ectopically overexpressed MOV10 holds the potential to restrict the 
replication of viruses belonging to distinct retrovirus genera, natural levels of MOV10 
are unable to do so (chapter 3 sections 3.4, 3.6, 3.7 and chapter 5 sections 5.2 and 5.3).  
Overexpression studies reveal that the inhibitory effect of MOV10 may target multiple 
stages in the life cycle of retroelements, including reverse transcription (chapter 4 
section 4.5), however the molecular mechanism by which MOV10 mediates these 
effects remains unclear.  Nevertheless, MOV10 is dispensable for APOBEC3 protein-
mediated restriction of LINE-1 and HIV-1 replication, miRNA-mediated post-
transcriptional RNA silencing pathways and also the assembly of P bodies, suggesting 
that the molecular mechanism by which MOV10 targets retroelements is likely isolated 
from these known cellular interactions and associations (chapter 5 sections 5.7 and 5.8).  
Furthermore, highly conserved residues within the MOV10 Walker A and Walker B 
putative helicase motifs play a necessary, although not sufficient, role in MOV10 anti-
retroelement activity (chapter 4 section 4.7).   
 
Taking these results into account, the predominate focus of future work should involve 
further dissection of remaining MOV10 cellular associations and, subsequently, the 
identification of a cellular function for MOV10 that may ultimately assist in 
enlightening the molecular mechanism by which this protein restricts such divergent 
retroelements.  Secondly, overexpression experiments with HIV-1 that have since been 
confirmed by Lu et al for IAP (Lu et al., 2012) strongly insinuate that MOV10 may 
target the process of reverse transcription.  Therefore, it would be important to, firstly, 
confirm these findings with endogenous levels of MOV10 and, secondly, identify the 
mechanism by which MOV10 impairs reverse transcription.  Finally, continual detailed 
structure-function studies would be required to discover residues within MOV10 
sufficient for its restrictive properties, also addressing the question of the contribution of 
MOV10 putative RNA helicase activity.  The findings presented in this thesis and future 
work will be discussed in this chapter in greater detail.   
 
6.2 Ectopically overexpressed MOV10 and retroelements 
Overexpression studies are one mechanism by which insights into the potential role of 
an endogenous protein may be discovered.  The results in chapter 3 reveal that MOV10 
overexpression decreases the cellular Gag expression of exogenous retroviruses, which 
may contribute to the reduction in virion production (chapter 3 sections 3.4, 3.6 and 
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3.7).  Pulse-chase analysis will determine whether this reduction in cellular Gag 
abundance is owed to decreased Gag protein stability or possibly less Gag translation.  
For the latter, it would also be important to measure viral RNA levels to differentiate 
between transcriptional or post-transcriptional effects of MOV10 overexpression on 
Gag translation.  MOV10 associates with the AGO proteins, which are central 
components of the RISC that performs miRNA or siRNA–mediated post-transcriptional 
RNA silencing.  MOV10 depletion studies have suggested that MOV10 may be 
important for AGO2-mediated slicer activity (Meister et al., 2005).  Furthermore, two 
studies have identified MOV10 as a key regulator of protein translation in rat synapses 
implicating MOV10 in synaptic plasticity and long-term memory formation (Banerjee 
et al., 2009; Jarome et al., 2011).  Therefore, considering these reports and the 
colocalisation of ectopically overexpressed MOV10 and HIV-1 Gag in cytoplasmic 
aggregations closely resembling SGs (chapter 4 section 4.2), it may be that MOV10 
controls retroviral Gag translation by sequestering viral RNA in cytoplasmic 
microdomains and mediating degradation of these transcripts through post-
transcriptional RNA silencing pathways.  It would be interesting to determine the nature 
of these cytoplasmic granules and, secondly, determine whether viral RNA colocalises 
with MOV10 and Gag in these SG-like aggregates.  Interestingly, both Gag and 
genomic RNA can be detected in SGs under certain experimental conditions 
(unpublished data, Dr. Nathan Sherer).   
 
Conversely, the results presented in chapter 5 demonstrate that MOV10 is dispensable 
for miRNA-mediated translation repression and cleavage of a reporter mRNA in HeLa 
cells, arguing against the involvement of such a pathway in the potential regulation of 
Gag translation (chapter 5 section 5.7).  Consistently, ectopically overexpressed 
MOV10 decreases cellular Gag expression and HIV-1 VLP production from a codon-
optimised construct (chapter 4 section 4.3) implying that the MOV10 mechanism of 
action is independent of sequence-specific determinants within viral transcripts.  
Therefore, the broad RNA binding capacity of MOV10 may be important for the 
mechanism by which MOV10 decreases the cellular Gag abundance and production of 
retroviral particles (Castello et al., 2012).  Moreover, MOV10 interacts with a panel of 
other RBPs with potential roles in translation regulation, as well as the Y RNA-binding 
Ro protein, which associates with non-coding RNAs, and the RNA helicase Upf1, 
which mediates mRNA decay (Miki et al., 2011; Sim et al., 2012).  These cellular 
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associations may be significant for the mechanism by which MOV10 decreases cellular 
Gag expression and virion production and, therefore, future experiments should focus 
on elucidating the functional relevance of these interactions. 
 
Additionally, at higher MOV10 expression levels Gag processing is also impacted 
(chapter 3 section 3.4).  This may be attributed to reduced intracellular Gag abundance 
and, therefore, less Gag plasma membrane targeting for assembly.  Alternatively, higher 
concentrations of MOV10 in the cell may be directly detrimental for virion maturation.  
Supporting the latter claim, electron microscopy (EM) studies from the group of Dr. 
Vineet KewalRamani detected immature HIV-1 particles budding through the cell 
plasma membrane with MOV10 overexpression (Retroviruses Meeting, 2010, Cold 
Spring Harbor Laboratory).  It is not understood how ectopically overexpressed 
MOV10 may directly impair Gag processing, however, this effect seems to be 
dependent on an increase in MOV10 protein levels above a certain threshold, such as 
that observed for wild-type HIV-1 experiments in 293T cells (chapter 3 section 3.4).   
 
MOV10 overexpression also produces significantly less infectious HIV-1 virus, and 
similarly reduces the production of infectious HIV-2, SIVmac, MLV and M-PMV 
particles (chapter 3 sections 3.4, 3.6 and 3.7).  Furthermore, ectopically overexpressed 
MOV10 also potently suppresses the retrotransposition of the mouse LTR-containing 
ERV IAP, and human non-LTR LINE-1 and Alu retrotransposons.  As MOV10 
overexpression decreases the cellular Gag abundance of exogenous retroviruses, it 
would be interesting to assess whether ectopically overexpressed MOV10 has similar 
effects on IAP Gag expression and the abundance of LINE-1 proteins as well.  Lu et al, 
however, recently demonstrated MOV10 overexpression to have no effect on IAP Gag 
levels (Lu et al., 2012). 
 
Interestingly, the highly conserved lysine, aspartic acid and glutamic acid residues in 
the Walker A and Walker B putative helicase motifs of MOV10 are necessary for its 
inhibitory activity against both HIV-1 and LINE-1, and the less well conserved glycine 
amino acid in the Walker B motif is dispensable for MOV10 anti-retroelement activity 
(chapter 4 section 4.7).  However, K530A and DE645AA are only partial loss of 
function MOV10 mutants suggesting that other residues essential for MOV10 anti-
retroelement activity remain to be identified.  On the other hand, as either Walker A or 
215
 
Walker B putative helicase sequences remain intact in the DE645AA or K530A 
mutants, respectively, it may be that each motif alone is able to accomplish sufficient 
ATP binding and hydrolysis so that MOV10 is still able to somewhat restrict 
retroelements.  For this reason a single MOV10 putative helicase mutant was also 
generated in which all three conserved lysine, aspartic acid and glutamic acid residues 
were substituted with alanine.  Although the molecular weight and also expression of 
this protein was marginally lower than that for wild-type MOV10, this double Walker A 
and Walker B helicase mutant displayed a complete loss of antiviral function, implying 
that these conserved residues alone may be sufficient for MOV10 anti-retroelement 
activity (data not shown).  MOV10 also contains three other putative helicase motifs 
involved in ATP binding and hydrolysis activity, and it would be worth similarly 
substituting conserved residues within these motifs to determine their relative 
contribution to MOV10 inhibitory activity.   
 
Abudu et al identified MOV10 residues 99-949 as the minimal antiviral region 
implicating residues within the N-terminal and C-terminal putative helicase motif as 
being necessary for the restriction of HIV-1 by MOV10 (Abudu et al., 2012); however, 
these experiments were conducted through MOV10 N-terminal and C-terminal 
truncations and considering the sensitivity of MOV10 to such deletions, as reflected by 
alterations in MOV10 protein expression and subcellular localisation relative to the wild 
type protein (chapter 4 section 4.6), this method of identifying residues critical for 
MOV10 anti-retroelement activity seems questionable.  Interestingly, murine MOV10 
and human MOV10 are over 90% identical at the protein level, however, murine 
MOV10 is marginally less active against HIV-1, and inhibits MLV with considerably 
less efficiency than human MOV10 (Wang et al., 2010).  Such comparative analysis of 
MOV10 from various species may assist in narrowing down residues important for 
human MOV10 inhibitory activity.  Importantly, the helicase status of MOV10 has not 
yet been confirmed; therefore, prior to attributing its function to putative RNA helicase 
activity, it would be necessary to test MOV10 in a helicase assay.  A thin-layer 
chromatography-based ATP hydrolysis assay using purified protein and radioactively 
labelled ATP is a semi-quantitative method that could be performed to determine 





6.3 Endogenous MOV10 and retroelements 
Although ectopically overexpressed MOV10 restricts a diverse panel of exogenous and 
endogenous retroelements, the physiological relevance of these findings for exogenous 
retroviruses remains uncertain as depletion of endogenous MOV10 by RNAi has no 
obvious effect on the production, infectivity or replication of HIV-1, or the production 
of infectious SIVmac, MLV or M-PMV particles (chapter 5 sections 5.2 and 5.3).  Yu et 
al similarly reported silencing of endogenous MOV10 to have no effect on foamy virus 
replication, which belongs to the distantly related spumavirus subfamily of retroviruses 
(Yu et al., 2011).  For these experiments MOV10 is undetectable at the protein level by 
immunoblotting and it may be argued that residual levels of undetectable MOV10 may 
remain functional; however, IAP, LINE-1 and Alu retrotransposition is significantly 
enhanced with a similar level of depletion of endogenous MOV10.   
 
Exogenous retroviruses, such as the primate lentiviruses, encode several examples of 
proteins able to degrade host cell restriction factors such as the APOBEC3 proteins, 
tetherin and SAMHD1 (chapter 1 section 1.8.2).  However, spreading HIV-1 replication 
has no effect on the abundance of endogenous MOV10 protein confirming that a viral 
protein does not similarly degrade MOV10 to counteract its antiviral activity (chapter 5 
section 5.4).  Whether a viral protein is able to antagonise MOV10 in a degradation-
independent manner remains to be established.  Interestingly, MOV10 overexpression 
decreases the production of HIV-1 VLPs with moderately higher efficacy relative to 
wild-type virions (chapter 3 section 3.3) and, furthermore, although not statistically 
significant, the production of infectious HIV-1 vectors appears to be slightly enhanced 
with MOV10 KD as well (chapter 5 section 5.3).  HIV-1 VLPs and vectors are 
produced from constructs lacking the majority of viral accessory proteins, therefore, it is 
tempting to speculate that a viral protein absent in the GPV-RRE (chapter 3 section 3.2) 
or p8.91 (chapter 3 section 3.6) constructs may be able to counteract endogenous 
MOV10 in the context of the wild-type virus.  Supporting this speculation, SIVmac 
vectors are produced with the pSIV3+ packaging plasmid, which encodes the majority 
of viral accessory and regulatory proteins (chapter 3 section 3.6), and in this instance 
unlike for HIV-1 vectors, there is no hint of an increase in production of infectious 
SIVmac particles with MOV10 KD (chapter 5 section 5.3).  Further experiments with 
lentiviral packaging plasmids harbouring varying deletions in viral accessory proteins 
will be required to ascertain the reality of this theory. 
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Alternatively, the antiviral effect of MOV10 overexpression may be recapitulated 
through stimulation of MOV10 protein expression, for example, by cytokines.  The type 
I IFN response is triggered early during infection and IFNα stimulates the expression of 
a number of known antiviral proteins.  MOV10 protein expression, however, is not 
induced by IFNα treatment in cell lines or primary CD4+ T cells and MDMs, the 
natural targets for primate lentiviral infection (chapter 5 section 5.5).  Furthermore, 
IFNα treatment does not alter the subcellular distribution of MOV10 either (chapter 5 
section 5.5).  IFNβ is also a member of the type I IFN family and the effect of this 
cytokine on MOV10 protein abundance remains to be determined.  Furthermore, HIV-1 
infection is associated with the elicitation of a cytokine storm whereby levels of 
proinflammatory cytokines such as tumour necrosis factor alpha (TNFα) and 
interleukin-15 (IL-15) are rapidly elevated, along with a slower increase in the levels of 
interleukin-6 (IL-6) and IFNγ (Stacey et al., 2009).  Further experiments should focus 
on assessing the effects of these cytokines on MOV10 protein expression.   
 
Therefore, endogenous retroelements are sensitive to suppression by natural levels of 
MOV10; however, the control of exogenous retroviruses may be dependent on a 
specific threshold of endogenous MOV10 that may be attained by cytokine stimulation 
during infection.  Furthermore, this requirement for higher levels of MOV10 may be 
attributed to a potential degradation-independent counteraction of MOV10 by a viral 
accessory protein.  Hence, MOV10 may be a component of a pathway or multiple 
pathways that exogenous retroviruses encounter during physiological infection and 
future experiments should aim to test these hypotheses.    
 
6.4 MOV10 targets in the retroelement life cycle 
Retroviruses package their dimeric genome through interactions between the NC 
domain of Gag and the Psi stem-loop structure, and this binding is thought to occur in 
the cytoplasm (chapter 1 section 1.5.9.1).  Ectopically overexpressed MOV10 decreases 
the packaging of HIV-1 genomic RNA into nascent virions, which likely contributes 
wholly or partially to the infectivity defect in target cells (chapter 4 section 4.4).  
Ectopically overexpressed MOV10 also decreases HIV-1 cellular Gag abundance and 
Gag processing (chapter 3 section 3.4).  As unspliced viral transcripts serve as both the 
viral genome and mRNA for translation of Gag and Gag-Pro-Pol precursor proteins, 
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transcriptional or post-transcriptional targeting of unspliced viral transcripts may 
decrease viral RNA abundance or availability, and also decrease the expression of viral 
structural (Gag) and enzymatic proteins (PR, RT and IN).  Therefore, a potential target 
for MOV10 in the HIV-1 life cycle may be unspliced viral transcripts and future studies 
should focus on testing this hypothesis.  Supporting this notion, Burdick et al revealed 
that HIV-1 viral RNA co-immunoprecipitates with ectopically overexpressed MOV10 
(Burdick et al., 2010).  Furthermore, Wang et al demonstrated MOV10 overexpression 
to have no effect on the abundance of unspliced 9kb viral transcripts or spliced mRNAs 
(Wang et al., 2010) providing precedence for a potential post-transcriptional mechanism 
for targeting of unspliced viral transcripts.  Considering the capacity of MOV10 to bind 
a broad range of RNAs (Castello et al., 2012) and the fact that MOV10 overexpression 
decreases the cellular Gag abundance of HIV-2 and M-PMV as well (chapter 3 sections 
3.6 and 3.7), targeting of unspliced viral transcripts may be a common mechanism by 
which MOV10 inhibits exogenous retroviruses.   
 
As an alternative more direct mechanism, MOV10 is packaged into budding HIV-1 
virions through an RNA-dependent interaction with the NC region of Gag (Chertova et 
al., 2006; Wang et al., 2010; Abudu et al., 2012) and, therefore, MOV10 overexpression 
may physically impede the association of viral RNA with NC for packaging.  The 
nature of the RNA species necessary for MOV10 packaging into virions is unclear 
although MOV10 is incorporated into virions in the absence of viral RNA, albeit with 
moderately less efficiency (Burdick et al., 2010).  On the contrary, overexpression of 
MOV10 has been reported to have no effect on IAP Gag levels or RNA incorporation 
into VLPs (Lu et al., 2012) implying that there may be some intrinsic differences 
between the regulation of exogenous retroviruses and ERVs, or alternatively IAP 
assembly at the ER as opposed to the plasma membrane may be accountable for these 
variable observations. 
 
HIV-1 virions produced from cells overexpressing MOV10 are also defective in the 
accumulation of reverse transcription products in target cells (chapter 4 section 4.5), 
which is not attributed to a defect in target cell attachment or entry (Furtak et al., 2010; 
Wang et al., 2010).  Although this may be an indirect effect of decreased genome 
incorporation into virions, the impact on viral cDNA synthesis is more potent that the 
reduction in viral RNA packaging suggesting that ectopically overexpressed MOV10 
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may directly impair reverse transcription as well.  Interestingly, in the event that 
MOV10 targets unspliced viral transcripts the abundance of the RT enzyme would also 
be reduced, which would account for the defect in reverse transcription.  Future 
experiments should aim to analyse the effect of MOV10 overexpression on the 
abundance of viral PR, RT and IN enzymes.   
 
Alternatively, as endogenous MOV10 is also packaged into HIV-1 virions (Chertova et 
al., 2006) it may directly interfere with the process of reverse transcription.  However, 
the functional relevance of MOV10 incorporation into virions in terms of its antiviral 
activity remains unclear.  Structure-function studies from the group of Dr. Vineet 
KewalRamani revealed that the antiviral N-terminal domain of MOV10 is not packaged 
into HIV-1 virions, and in contrast the C-terminal loss of function MOV10 putative 
helicase domain is efficiently incorporated into nascent particles (Retroviruses Meeting, 
2010, Cold Spring Harbor Laboratory).  Although these data negate a correlation 
between MOV10 packaging and antiviral activity, conclusions cannot be drawn from 
such experiments owing to the variable expression and subcellular localisation of these 
truncated MOV10 mutants compared to the full-length protein (chapter 4 section 4.6).  
Comparisons between the packaging efficiency and antiviral activity of MOV10 
putative helicase mutants K530A, DE645AA and G648A may provide a better system 
for addressing this question.   
 
Analogous to the observations with HIV-1, Lu et al reported MOV10 overexpression to 
decrease the accumulation of IAP reverse transcription products and, furthermore, 
MOV10 was also packaged into IAP VLPs (Lu et al., 2012).  LINE-1 and Alu 
retrotransposons couple reverse transcription and integration through a process called 
TPRT that takes place in the nucleus (chapter 1 section 1.7.1).  The effect of MOV10 on 
TPRT, if any, remains to be elucidated.  It is difficult to comprehend how MOV10 may 
directly interfere with TPRT considering that the subcellular localisation of MOV10 is 
cytoplasmic (chapter 4 section 4.6).  However, analysis of MOV10 steady-state 
distribution by immunofluorescence may overlook any potential shuttling of MOV10 
into the nucleus.  Additionally, despite the positive correlation between nuclear 
localisation of APOBEC3 proteins and suppression of LINE-1 retrotransposition, Pak et 
al recently demonstrated that targeting of otherwise nuclear A3B to the cytoplasm by 
mutating four residues at the N-terminus of the protein retained the capacity of A3B to 
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suppress LINE-1 replication (Pak et al., 2011).  Extrapolating from observations with 
HIV-1, it would be important to explore the effect of MOV10 overexpression on the 
abundance and localisation of LINE-1 RNA and proteins, as ectopically overexpressed 
MOV10 may suppress retrotransposition by similarly targeting retrotransposon 
transcripts and, therefore, impacting the expression of LINE-1 proteins and downstream 
processes such as TPRT in this manner.    
 
Therefore, studies with wild-type HIV-1 have established that MOV10 overexpression 
affects multiple stages of the HIV-1 life cycle including cellular Gag expression, Gag 
processing, viral RNA packaging and reverse transcription (chapter 3 section 3.4 and 
chapter 4 sections 4.4 and 4.5).  Although the cellular Gag abundance of HIV-2 and M-
PMV is also decreased (chapter 3, sections 3.6 and 3.7), a thorough investigation is 
necessary to determine whether these observations are true for all retroviruses and also 
retrotransposons tested.  Furthermore, it remains to be seen whether MOV10 possesses 
the capacity to target each of these various stages individually, or whether it mediates its 
inhibitory activity by targeting the genomic RNA of these retroelements resulting in the 
establishment of the multiple downstream defects.  The latter hypothesis is further 
supported by the ability of MOV10 to associate with a broad range of RNAs with 
limited specificity (Castello et al., 2012), as well as unspliced HIV-1 transcripts 
(Burdick et al., 2010).  Finally, these experiments are performed with ectopically 
overexpressed MOV10 and, therefore, eventually it would be important to assess the 
capacity of natural levels of MOV10 to target these stages of the retroelement life cycle.  
 
6.5 Importance of cellular associations for MOV10 mechanism of action 
The list of MOV10 cellular associations is extensive most likely reflecting the ability of 
MOV10 to associate with a broad range of RNAs (Castello et al., 2012).  Consistently, 
MOV10 interacts with several RBPs and localises to cytoplasmic P bodies and SGs, 
which are sites for mRNA storage and degradation (chapter 1 section 1.13.1).  The 
cellular function/s of human MOV10 remains unknown, however, studies in rat 
hippocampal and amygdala cells have revealed an essential role for MOV10 in 
translational control at synapses (Banerjee et al., 2009; Jarome et al., 2011).  The 
identification of functionally relevant MOV10 cellular associations is essential to 
discover the cellular function/s of human MOV10 and, moreover, establish the 
molecular mechanism by which MOV10 restricts retroelements.  
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Evidence from several studies now suggests that MOV10 likely exists in an RNP 
complex in association with antiviral APOBEC3 and AGO proteins, and these RNP 
complexes localise to P bodies and SGs (Meister et al., 2005; Gallois-Montbrun et al., 
2007; Gallois-Montbrun et al., 2008).  Consistent with its interaction with AGO 
proteins, MOV10 has been proposed to be necessary for miRNA-mediated cleavage of a 
reporter mRNA.  This suggests that a cellular function of MOV10 may be miRNA-
mediated post-transcriptional RNA silencing, which agrees with the reports confirming 
a role for MOV10 in translation regulation in the rat brain (Banerjee et al., 2009; Jarome 
et al., 2011).  However the results presented in chapter 5 demonstrate that MOV10 is 
dispensable for both endogenous let-7 miRNA-mediated translation repression and 
slicer activity in HeLa cells, at least in the context of reporter constructs (chapter 5 
section 5.7).  It would be important to repeat these experiments in other cell types to 
ensure that this effect is not HeLa cell-specific and, secondly, despite the 
multifunctional role of endogenous let-7 miRNAs and their high abundance, assays 
employing other endogenous miRNAs should also be tested.  Nevertheless, these data 
imply that MOV10 may not restrict the replication of retroelements through miRNA-
mediated translation repression or RNA cleavage pathways.  To verify this further, the 
inhibitory activity of MOV10 may be tested in DICER-1 depleted cells.  .  
 
A previous report has proposed that a cellular function of A3G may be the derepression 
of miRNA-mediated translation repression (Huang et al., 2007), and more recently this 
group has suggested that A3G mediates these effects by interfering with the interaction 
between MOV10 and AGO2, ultimately blocking maturation of the RISC (Liu et al., 
2012).  However, Phalora et al confirmed no effect of APOBEC3 proteins on miRNA 
function (Phalora et al., 2012) and, similarly, the findings presented here do not identify 
a role for MOV10 in miRNA-mediated translation repression either.  Based on these 
data and the independent anti-retroelement activities of MOV10 and APOBEC3 
proteins (chapter 5 section 5.8), the role of the MOV10, APOBEC3 and AGO protein 
RNP complex remains unclear, and does not seem to be functionally relevant at least in 
the context of MOV10 inhibitory activity. 
 
MOV10 localises in P bodies and redistributes to SGs under conditions of cellular stress 
(Gallois-Montbrun et al., 2007).  P bodies and localising factors have been implicated in 
the negative and positive regulation of exogenous and endogenous retroelements 
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(chapter 1 section 1.10.1).  However, Phalora et al recently confirmed no effect of 
depleting P bodies through knockdown of DDX6 and Lsm1 on HIV-1 replication 
(Phalora et al., 2012).  In contrast, Lu et al reported knockdown of DDX6 and eIF4E-T 
to enhance IAP retrotransposition (Lu et al., 2011), implying that although P bodies do 
not regulate HIV-1 replication, they may still play a role in the life cycle of endogenous 
retroelements.  MOV10 is not an essential P body factor as depletion (chapter 5 section 
5.7) or overexpression of MOV10 (Lu et al., 2012) has no affect on the size or number 
of P bodies.  Furthermore, ectopically overexpressed MOV10 inhibits IAP 
retrotransposition effectively in P body depleted cells (Lu et al., 2012) suggesting that P 
bodies may be dispensable for MOV10-mediated restriction of endogenous 
retroelements.  It would be important to determine whether P bodies are similarly 
dispensable for the suppression of retrotransposition by natural levels of MOV10 as 
these cytoplasmic foci may reflect sites for endogenous MOV10 aggregation, which 
may permit a more effective response again endogenous retroelements.  In contrast, this 
aggregation may not be necessary in the context of MOV10 overexpression due to the 
generally increased concentration of MOV10 in cells.   
 
Alternatively, considering that ectopically overexpressed MOV10 and HIV-1 Gag co-
localise in SG-like cytoplasmic aggregates (chapter 4 section 4.2), and HIV-1 Gag and 
viral RNA can be detected in SGs under certain experimental conditions as well 
(unpublished data, Dr. Nathan Sherer), the role of SGs in MOV10 anti-retroelement 
activity warrants further investigation.  HIV-1 Gag and genomic RNA also associate 
with Staufen1 RNP complexes that are distinct from P bodies and SGs (Abrahamyan et 
al., 2010), and considering the previously identified interaction of MOV10 with 
Staufen2 RNP complexes (Miki et al., 2011) it would be worth exploring whether 
MOV10 also associates with Staufen1 RNP complexes and the relevance, if any, of this 
potential interaction.  Nonetheless, MOV10 interacts with a magnitude of other RBPs 
such as ZBP1, YB-1, Upf1 and RHA, which have been implicated in cellular processes 
such as translation control, mRNA degradation and RISC loading (Miki et al., 2011; 
Sim et al., 2012).  It would be necessary to establish the functional relevance of these 
cellular associations as a way to potentially identify a cellular role for MOV10 and, 
moreover, isolate the mechanism by which MOV10 is able to restrict a broad panel of 




Furthermore, extrapolating from studies with MOV10 homologs may also provide an 
insight into the MOV10 mechanism of action.  MOV10L1 is the germline-restricted 
mammalian paralog of MOV10 that interacts with mammalian PIWI proteins and is 
essential for piRNA-guided suppression of ERVs and retrotransposons through DNA 
methylation.  Therefore, future research should be extended to similarly assess the 
capacity of MOV10 to control endogenous retroelements at the level of transcription 
through epigenetic regulatory mechanisms.  Interestingly, naturally occurring endo-
siRNAs have been proposed to regulate the expression of LINE-1 through DNA 
methylation of the LINE-1 promoter in human somatic cells and, moreover, breast 
cancer cells that are associated with increased LINE-1 expression display reduced levels 
of these endo-siRNAs (Chen et al., 2012).  Furthermore, supporting the association of 
MOV10 with epigenetic regulatory pathways, Messaoudi-Aubert et al revealed MOV10 
to interact with components of the Polycomb-repressive complex 1 in human cells, 
which together with the Polycomb-repressive complex 2 mediates transcriptional 
repression through the methylation and ubiquitination of nucleosomal histones 
(Messaoudi-Aubert et al., 2010).   
 
6.6 A physiological role for MOV10: A bigger picture 
The human germline and, as discovered more recently, somatic cells are prone to 
mutagenic effects attributed to retrotransposition events.  LINE-1 expression is 
detectable in a wide range of human tissues (Belancio et al., 2010), and to date 
approximately 96 single gene diseases have been caused by retrotransposon insertions a 
huge proportion of which are, unsurprisingly, cancers [reviewed in (Hancks and 
Kazazian, 2012)].  LINE-1 and Alu activity is elevated in several cancers and this 
phenomenon correlates with hypomethylation of retrotransposon promoters implying 
that a breakdown in epigenetic regulatory mechanisms that would normally suppress 
retrotransposition may facilitate oncogenic insertional mutations [reviewed in (Belancio 
et al., 2010)](Iskow et al., 2010).  Coufal et al revealed LINE-1 expression to be 
elevated in the human brain relative to other organs (Coufal et al., 2009) and, 
fascinatingly, Baillie et al identified over 20,000 novel LINE-1 and Alu insertions in the 
human hippocampus and caudate nucleus (Baillie et al., 2011) highlighting the human 
brain as a hotspot for somatic retrotransposition.  These reports stress the significance of 
retrotransposition as a potential non-hereditary mechanism contributing to neurological 
diversity and disease.  Nevertheless, Lee et al recently discovered somatic 
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retrotransposon insertions in epithelial tumours, although not in cancers of the brain 
(Lee et al., 2012).  These data may reflect the presence of regulatory pathways or 
cellular restriction factors in non-transformable cell types that may be missing or 
expressed at lower levels in cells susceptible to transformation.   
 
Interestingly, human MOV10 transcripts are expressed at the highest level in the adult 
CNS including the hippocampus and caudate nucleus (Nagase et al., 2000) and, 
furthermore, MOV10 protein abundance is also increased in cancer cells compared to 
normal healthy cells (Nakano et al., 2009).  Considering the elevated expression of 
retrotransposons in the human brain and various cancers, it would be interesting to 
determine whether the correlative MOV10 expression pattern holds any functional 
relevance.  The results presented in chapter 5 demonstrate that natural levels of MOV10 
suppress the retrotransposition of human LINE-1 and Alu retrotransposons (chapter 5 
section 5.6), therefore, it may be hypothesised that higher expression levels of MOV10 
in the human brain may control the mobilisation of retrotransposons during conditions 
of deregulation, such as neurogenesis, limiting the likelihood of a retrotransposon 
insertion with a mutagenic consequence.  Alternatively, lower expression levels of 
MOV10 in other tissues may not suffice in the suppression of retrotransposons 
increasing the probability of insertional mutagenesis.  Therefore, similar to MOV10L1 
in the germline, the role of MOV10 may be to suppress the retrotransposition of 
endogenous retroelements in somatic cells as a mechanism to protect cells exposed to 
high levels of retrotransposon deregulation from deleterious mutations.  
 
The retrotransposition assay may be employed for preliminary experiments to compare 
the effects of endogenous MOV10 depletion on LINE-1 and Alu replication in cells 
from the human brain versus those from tissues expressing lower levels of MOV10.  
Although a MOV10 knockout mouse has not yet been generated, such mice would be 
extremely valuable to feasibly test this hypothesis.  Interestingly, blood cells are also 
refractory to transformation by retrotransposon insertions (Lee et al., 2012) and, 
therefore, it would be worth comparing MOV10 expression levels in cells from the 
blood, brain and other tissues reported to express lower levels of MOV10 (Nagase et al., 






In view of MOV10 cellular associations and homolog functions, the aim of this thesis 
was to broadly ascertain the role of the human putative RNA helicase MOV10 in the 
replication of a panel of genetically diverse exogenous and endogenous retroelements, 
including members from the lentivirus, gammaretrovirus and betaretrovirus subfamilies, 
as well as an LTR-containing ERV and non-LTR retrotransposons.  In summary, the 
results presented in this thesis demonstrate that ectopically overexpressed MOV10 
possesses the capacity to potently restrict all retroviruses and retrotransposons tested.  
Importantly however, RNAi-mediated depletion of endogenous MOV10 has no effect 
on the replication of exogenous retroviruses, although specifically enhances the 
propagation of endogenous retroelements.  These results demonstrate that natural levels 
of MOV10 suppress the retrotransposition of LTR and non-LTR endogenous 
retroelements.  Although endogenous MOV10 protein levels are unaffected by retroviral 
replication excluding the possibility of a viral protein degrading MOV10 as a 
counteraction mechanism, the possibility of a degradation-independent mechanism of 
MOV10 antagonism remains to be investigated.  Furthermore, MOV10 protein 
expression is not induced by IFNα treatment ruling out a scenario in which MOV10 
levels may be sufficiently stimulated for the restriction of exogenous retroviruses 
mimicking the overexpression results.  However, a magnitude of other cytokines are 
triggered during natural infection and the effect of these on MOV10 protein abundance 
remains to be established.   
 
Ectopically overexpressed MOV10 targets both early and late stages of the HIV-1 life 
cycle resulting in a decrease in cellular Gag abundance, virion processing and 
maturation, genomic RNA packaging and accumulation of reverse transcription 
products.  Further studies should extend these findings to other retroviruses and 
retrotransposons and, moreover, investigate the ability of natural levels of MOV10 to 
target these multiple stages.  It is unclear if ectopically overexpressed MOV10 targets 
each of these various stages individually or whether these phenotypes are a consequence 
of MOV10 targeting retroelement transcripts either transcriptionally or post-
transcriptionally.  Structure-function studies have highlighted conserved residues within 
the MOV10 Walker A and Walker B putative ATP-binding and hydrolysis motifs as 
being necessary for MOV10 anti-retroelement activity; although these are not sufficient 
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for MOV10 inhibitory activity and other key residues will need to be identified through 
similar experiments.  Significantly, these results reveal a potential requirement for 
MOV10 putative RNA helicase activity for the restriction of retroelements.  The 
molecular mechanism by which MOV10 targets retroviruses and retrotransposons is 
still a mystery.  Focusing on the cellular associations of MOV10 it is now clear that the 
anti-retroelement activities of MOV10 and members of the APOBEC3 protein family 
are independent, and that MOV10 is not essential for miRNA-mediated post-
transcriptional translation repression or mRNA cleavage pathways in cultured cells.  It 
is important to continue dissecting the cellular associations of MOV10 as a way to 
potentially identify the cellular role of MOV10 and the mechanism for its inhibitory 
activity.   
 
In sum, MOV10 possesses the capacity to restrict the replication of a broad range of 
genetically distinct retroviruses and retrotransposons implying that MOV10 is a 
component of a cellular pathway or process that retroelements encounter; however, 
further investigation is necessary to provide a physiological understanding of the 
relationship between MOV10 and exogenous retroviruses.  Significantly, the specificity 
of natural levels of MOV10 in the suppression of endogenous retroelements highlights 
MOV10 as a potential novel restriction factor of retrotransposons in somatic cells.  This 
is valuable knowledge with possible therapeutic implications considering that human 
retrotransposon insertions are now known to be the causative agents of countless single 
gene diseases including several cancers, haemophilia and cystic fibrosis, and have also 
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Endogenous MOV10 inhibits the retrotransposition
of endogenous retroelements but not the
replication of exogenous retroviruses
Shetal Arjan-Odedra1, Chad M Swanson1, Nathan M Sherer1,3, Steven M Wolinsky2 and Michael H Malim1*
Abstract
Background: The identification of cellular factors that regulate the replication of exogenous viruses and
endogenous mobile elements provides fundamental understanding of host-pathogen relationships. MOV10 is a
superfamily 1 putative RNA helicase that controls the replication of several RNA viruses and whose homologs are
necessary for the repression of endogenous mobile elements. Here, we employ both ectopic expression and gene
knockdown approaches to analyse the role of human MOV10 in the replication of a panel of exogenous
retroviruses and endogenous retroelements.
Results: MOV10 overexpression substantially decreased the production of infectious retrovirus particles, as well the
propagation of LTR and non-LTR endogenous retroelements. Most significantly, RNAi-mediated silencing of
endogenous MOV10 enhanced the replication of both LTR and non-LTR endogenous retroelements, but not the
production of infectious retrovirus particles demonstrating that natural levels of MOV10 suppress retrotransposition,
but have no impact on infection by exogenous retroviruses. Furthermore, functional studies showed that MOV10 is
not necessary for miRNA or siRNA-mediated mRNA silencing.
Conclusions: We have identified novel specificity for human MOV10 in the control of retroelement replication and
hypothesise that MOV10 may be a component of a cellular pathway or process that selectively regulates the
replication of endogenous retroelements in somatic cells.
Keywords: MOV10, Retrovirus, Retrotransposon, APOBEC3
Background
Exogenous retroviruses and endogenous retroelements
replicate in the host by reverse transcribing their RNA
genomes into DNA copies that are permanently integrated
into the host genome, making them some of the most suc-
cessful parasites studied. Approximately 45% of the
human genome is derived from mobile elements, with ac-
tive long interspersed nucleotide element-1 (LINE-1), Alu
and SINE-R/VNTR/Alu (SVA) retrotransposition events
contributing to disease-producing insertional mutations
in humans [1-4]. Host cells have evolved multiple tran-
scriptional and post-transcriptional control mechanisms
to protect themselves and their genomes from the
pathogenic and mutagenic effects of such parasites.
Cellular restriction factors form an effective innate
defence against a range of exogenous retroviruses and
intracellular retroelements. The human APOBEC3 (apo-
lipoprotein B mRNA-editing enzyme catalytic polypep-
tide 1-like 3) family of cytidine deaminases are potent
intrinsic antiviral factors that restrict a broad range of
exogenous retroviruses [5-9] as well as the propagation
of numerous endogenous retroelements [6-10]. Similarly,
TRIM5α [11], tetherin [12] and SAMHD1 [13,14] are
restriction factors that can inhibit the replication of ex-
ogenous retroviruses at different steps in the retroviral
life cycle [15]. Intriguingly, the cytosolic exonuclease
TREX1 metabolises reverse-transcribed DNA derived
from endogenous retroelements and, presumably,
restricts their retrotransposition [16], yet is a co-factor
for human immunodeficiency virus type-1 (HIV-1)
* Correspondence: michael.malim@kcl.ac.uk
1Department of Infectious Diseases, King's College London School of
Medicine, 2nd Floor, Borough Wing, Guy's Hospital, London Bridge, London,
SE1 9RT, UK
Full list of author information is available at the end of the article
© 2012 Arjan-Odedra et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Arjan-Odedra et al. Retrovirology 2012, 9:53
http://www.retrovirology.com/content/9/1/53
infection [17] revealing the complexity of host-pathogen
interactions.
MOV10 (Moloney leukaemia virus 10) is a superfamily
1 (SF1) putative RNA helicase that acts as a co-factor or
inhibitory factor for a number of RNA viruses. MOV10 is
required for the replication of human hepatitis delta virus
(HDV) [18] but restricts hepatitis C virus (HCV) and ves-
icular stomatitis virus (VSV) replication [19,20]. The anti-
viral function of MOV10 is evolutionarily conserved as its
ortholog in Arabidopsis thaliana, SDE3 (silencing defect-
ive protein 3), regulates small-RNA mediated silencing of
specific exogenous viruses [21], whereas its ortholog in
Drosophila melanogaster, Armitage, and its mammalian
paralog, MOV10-like-1 (MOV10L1), are necessary for
piRNA-mediated repression of endogenous retroelements
[22-26]. MOV10 has also been reported to associate with
the RNA-induced silencing complex (RISC) that mediates
small RNA-mediated RNA silencing [27]. Recently, we
and others identified MOV10 as interacting with the anti-
viral APOBEC3 proteins, APOBEC3G (A3G) and APO-
BEC3F (A3F), in an RNA-dependent manner [28,29].
Taken together, these observations suggest that human
MOV10 may regulate a wide range of RNA viruses and
could also control the retrotransposition of endogenous
retroelements in mammals.
Supporting the hypothesis that MOV10 is an antiviral
factor, several groups have reported that MOV10 overex-
pression restricts the infectivity of HIV-1 and other retro-
viruses [30-33], although the proposed mechanisms of
action differ. Endogenous MOV10 is packaged into HIV-1
virions produced from infected monocyte-derived macro-
phages, and recently it was reported that MOV10 pack-
aging requires the nucleocapsid region of Gag [30,32-34].
Crucially, these reports varied substantially in their conclu-
sions regarding the effect of depleting endogenous MOV10
on HIV-1 replication in that they either observed a slight
decrease in infectivity [31], a modest increase in infectivity
[32], or a small decrease in virus production with no differ-
ence in infectivity [30]. These contrasting results have led
to confusion over whether MOV10 is a co-factor or an in-
hibitory factor for HIV-1 replication. Furthermore, the pos-
sible role of MOV10 in regulating the replication of
endogenous retroelements in mammalian cells awaits
examination.
To define MOV10′s capacity to regulate retroelements,
we undertook side-by-side comparisons of the effects of
MOV10 overexpression and depletion on the replication of
a number of exogenous retroviruses and the retrotranspo-
sition of endogenous retroelements. Our results indicate
that MOV10 overexpression restricts the production of
infectious virions for a broad range of exogenous retro-
viruses and also potently inhibits the mobilisation of
endogenous retroelements. Importantly, silencing of en-
dogenous MOV10 has no effect on the replication of
exogenous retroviruses though it significantly enhances the
transposition of human endogenous retrotransposons and
a mouse endogenous retrovirus. Furthermore, we report
that MOV10 is not necessary for miRNA or siRNA-
mediated RNA silencing in cultured cells.
Results
MOV10 overexpression restricts the production of
infectious retrovirus particles
To determine whether the overexpression of MOV10
affects HIV-1 virion production and infectivity, we co-
transfected HeLa or 293T cell lines with pHIV-1NL4-3
[35] and increasing amounts of pMOV10 or a plucifer-
ase (pLuc) control vector (pT7-MOV10 or pT7-Luc).
The virion concentration was determined by p24Gag
enzyme-linked immunosorbent assay (ELISA). We
observed a consistent dose-dependent decrease in the
production of virions from HeLa and 293T cells,
whereby at the maximum dose of pMOV10 virus pro-
duction was reduced by ~70% and ~80%, respectively
(Figure 1A). We then tested the infectivity of these
virions by adding equal amounts of virus normalised by
the p24Gag concentration to the TZM-bl reporter cell
line. Overexpression of MOV10 decreased the infectiv-
ity of HIV-1 virions substantially in a dose-dependent
manner, and at the maximum amount of pMOV10
infectivity was reduced by ~80% for HeLa cells and to
undetectable levels for 293T cells (Figure 1B). Cell
lysates were analysed by immunoblotting to determine
whether MOV10 overexpression affected Gag expres-
sion or processing. We quantified all the Gag bands to
measure total cellular Gag levels and also determined
the percentage of Gag processing (total processed Gag
bands divided by total Gag bands). Total cellular Gag
levels decreased by ~40% and ~50% in HeLa and 293T
cells, respectively, at the maximum pMOV10 amount
when compared with the pLuc control (Figure 1A, com-
pare lanes 1 and 7). Furthermore, Gag processing was
slightly reduced by ~10% and ~40% in HeLa and 293T
cells, respectively (Figure 1A, compare lanes 1 and 7).
Therefore, the overexpression of MOV10 decreased the
production and infectivity of HIV-1 virions in a dose-
dependent manner, and also caused a modest decrease
in Gag expression and processing.
We then determined whether MOV10 overexpression
also restricts the infectivity of a selection of divergent retro-
viruses including rhesus macaque-derived simian immuno-
deficiency virus (SIVmac, a lentivirus), murine leukaemia
virus (MLV, a gammaretrovirus) and Mason-Pfizer monkey
virus (M-PMV, a betaretrovirus). We produced SIVmac
vectors by transfecting 293T cells with an SIVmac Gag-Pol
packaging plasmid (pSIV3-RMES4) [36], a GFP-expressing
SIVmac vector (pSIV-RMES4) [36] and pVSV-G [37]. As a
control, we also tested analogous VSV-G pseudotyped
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HIV-1 vectors, produced using the HIV-1 Gag-Pol plasmid
p8.91 [38], the HIV-1 GFP-expressing vector pCSGW [39]
and pVSV-G. Plasmids for lentiviral vector production were
co-transfected with either pMOV10 or the pLuc control.
The effect on the production of infectious particles was





















































































































































































































Figure 1 MOV10 overexpression restricts the production of infectious retrovirus particles for a broad range of exogenous retroviruses.
(A) MOV10 overexpression decreases HIV-1 virus production. HeLa or 293T cells were co- transfected with pHIV-1NL4-3 and increasing amounts of
pT7-MOV10 as indicated or the pT7-Luc control. Virus concentration in the medium was determined by a p24Gag ELISA. Cell lysates were analysed
by quantitative immunoblotting with anti-T7, anti- p24Gag and anti-Hsp90 antibodies. (B) Overexpression of MOV10 inhibits the infectivity of HIV-1
virions. The TZM-bl reporter cell line expressing a HIV-1 Tat inducible β-gal reporter gene was infected with equal amounts of virus normalised by
the p24Gag concentration from each of the indicated samples. Cells were lysed and β-gal activity was measured to determine virus infectivity. (C)
MOV10 overexpression inhibits the production of infectious SIVmac, MLV and M-PMV particles. For HIV-1 and SIVmac lentiviral vector production,
293T cells were co-transfected with p8.91, pCSGW and pVSV-G, or pSIV3+, pSIV-RMES4 and pVSV-G, respectively, together with pT7-MOV10 or
pT7-Luc. 293T cells were infected with lentiviral particles and infectivity was determined by measuring the percentage of GFP-positive 293T cells
by FACS. For MLV and M-PMV virion production, 293T cells were co-transfected with pNCS/FLAG, pMSCV/Tat and pVSV-G, or pMTΔE and pVSV-G,
respectively, together with pT7-MOV10 or pT7-Luc. Infectivity was determined using TZM-bl cells. (D) Overexpression of MOV10 decreases the
production of M-PMV virions. Cell lysates and sucrose cushion purified M-PMV virions were analysed by immunoblotting with anti p27Gag and
anti-Hsp90 antibodies (* refers to non-specific bands). For (A), (B) and (C) results are normalised to the pLuc control, which is set at 100%. For (C)
a single control bar set at 100% is graphed for simplicity. Values are the mean ± SD of 3 independent experiments.
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percentage of GFP-positive cells. Similar to the wild-type
HIV-1 experiments (Figure 1B), overexpression of MOV10
reduced the production of infectious HIV-1 and SIVmac
particles by over 80% relative to the pLuc control
(Figure 1C).
To test MLV infectivity, we co-transfected 293T cells
with a full-length MLV proviral plasmid (pNCS/FLAG)
[40] together with a surrogate MLV genome expressing
HIV-1 Tat (pMSCV/Tat) [41] and pVSV-G. To analyse
M-PMV infectivity, 293T cells were co-transfected with
a M-PMV proviral plasmid in which env is replaced with
HIV-1 tat (pMTΔE) [42] together with pVSV-G. Plas-
mids for the production of both MLV and M-PMV vir-
ions were co-transfected together with either pMOV10
or the pLuc control. The effect on the production of in-
fectious MLV and M-PMV virions was determined by
infecting the TZM-bl reporter cells. Overexpression of
MOV10 decreased the production of MLV and M-PMV
infectious virions by over 80% with respect to the pLuc
control (Figure 1C). We also analysed sucrose cushion
purified M-PMV virions and cell lysates by immunoblot-
ting to determine the effect of MOV10 overexpression
on virus production. Similar to HIV-1 (Figure 1A), we
observed a decrease in M-PMV precursor p78Gag and
processed p27Gag levels in the cell lysate as well as a
decrease in virion production with increasing concentra-
tions of pMOV10 relative to the pLuc control
(Figure 1D, compare lane 1 with lanes 2 and 3). These
results show that MOV10 overexpression can restrict
the production and infectivity of retroviruses from mul-
tiple genera.
Overexpression of MOV10 inhibits the retrotransposition
of LTR and non-LTR endogenous retroelements
Similar to exogenous retroviruses, endogenous retroele-
ments replicate via an RNA intermediate that is reverse
transcribed and integrated into the host genome. Consid-
ering the association of MOV10 homologs with the sup-
pression of endogenous mobile elements [22-24], we next
assessed whether overexpression of MOV10 inhibits the
retrotransposition of some representative endogenous ret-
roelements. We tested the non-LTR autonomous human
LINE-1 and its dependent non-autonomous short inter-
spersed nucleotide element (SINE) Alu retrotransposons,
both of which reverse transcribe by target-site primed
reverse transcription (TPRT) in the nucleus [1]. We also
included the mouse intracisternal A-type particle (IAP),
which is related to the betaretrovirus family of exogenous
retroviruses, though it has a strictly intracellular life cycle
[43].
Established cell culture-based retrotransposition assays
were used to study these retroelements [44-46]. Briefly,
HeLa cells were transfected with expression plasmids for
human LINE-1 (pJM101/L1.3) [47], human Alu (pAlu-
neoTet) [48] or mouse IAP (pGL3-IAP92L23neoTNF) [49]
all of which contain an antisense neomycin resistance
gene cassette (neo) in the 3′UTR driven by its own pro-
moter and disrupted by an intron. Neo expression occurs
only after a full retrotransposition event: specifically, tran-
scription of the retroelement RNA, removal of the intron
by splicing, translation of the proteins, reverse transcrip-
tion and then integration of the cDNA into the host cell
genome, allowing for enumeration of retrotransposition
by counting G418-resistant colonies. The Alu element is
dependent on LINE-1 enzymes for replication; therefore,
to measure Alu element retrotransposition, the cells were
also co-transfected with a plasmid encoding the LINE-1
ORF2 protein (pCEP-ORF2) [48], which encodes the
LINE-1 endonuclease and reverse transcriptase enzymatic
activities. Either pMOV10 or the pLuc control was
co-transfected to determine the effect of MOV10 over-
expression on the replication of these endogenous retro-
elements. Similar to the observations made with exogenous
retroviruses (Figure 1), overexpression of MOV10
decreased human LINE-1, Alu and mouse IAP retro-
transposition by over 90% when compared with the
pLuc control (Figure 2A).
As a control, HeLa cells were also transfected with a
pcDNA3.1 vector that contains a neomycin resistance
expression cassette (pcDNA3.1-neo) to ensure that
MOV10 overexpression did not affect neo expression
or selection directly. The cultures were G418-selected
and the colonies were counted as described for the ret-
rotransposition assays, with similar numbers of col-
onies seen in the context of MOV10 overexpression as
for the pLuc control (Figure 2B). Therefore, MOV10
overexpression inhibits the propagation of multiple
endogenous retroelements.
Silencing endogenous MOV10 does not affect the
production of infectious retroviral particles
We next determined the effect of depleting endogenous
MOV10 on HIV-1 production and infectivity in the con-
text of one full cycle of viral replication. Stable HeLa and
293T non-silencing control and MOV10 knockdown (KD)
cell lines were produced by transducing HeLa or 293T cells
with lentiviral vectors expressing either a non-silencing
control shRNA or a MOV10-specific shRNA, which
reduced MOV10 protein steady-state abundance to un-
detectable levels when compared with the non-silencing
control cells (Figure 3A). The depletion of endogenous
MOV10 did not affect the growth rate of these cells (data
not shown). HeLa or 293T non-silencing control and
MOV10 KD cell lines were infected with equal amounts of
VSV-G pseudotyped HIV-1NL4-3 and virion production
and infectivity were determined. Depletion of endogenous
MOV10 showed no significant effect on the amount
(Figure 3A) or infectivity (Figure 3B) of virions produced
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in comparison to the non-silencing control in both HeLa
and 293T cells. Similar experiments were performed with
comparable results using a second, unrelated MOV10-
specific shRNA (data not shown). To determine whether
depletion of endogenous MOV10 affects multiple rounds
of HIV-1 replication, we infected stable non-silencing con-
trol or MOV10 KD Hut78 T cells with equal amounts of
HIV-1NL4-3 and determined the effect on virus production.
Consistent with the single-cycle infectivity assays, silencing
of MOV10 had no effect on spreading HIV-1 replication
(Figure 3C).
To determine whether endogenous MOV10 regulates
the production of infectious SIVmac, MLV or M-PMV,
virions were produced as described above in 293T non-
silencing control or MOV10 KD cells and the effect on
infectious particle production was determined. Deple-
tion of endogenous MOV10 had no significant effect
on the production of HIV-1, SIVmac, MLV or M-PMV
infectious particles (Figure 3D). Although we cannot
rule out the possibility that undetectable levels of re-
sidual MOV10 in our KD cultures are still functional,
these data strongly suggest that endogenous levels of
MOV10 do not control the replication of exogenous
retroviruses.
Depletion of endogenous MOV10 specifically enhances
the retrotransposition of endogenous retroelements
We next determined the effect of silencing endogenous
MOV10 on LINE-1, Alu and IAP replication in the
HeLa non-silencing control or MOV10 KD cells. In the
absence of detectable MOV10, statistically significant 4-
fold, 5-fold and 2-fold enhancements in retrotransposi-
tion frequencies were detected for LINE-1, Alu and IAP,
respectively (Figure 4A). We also transfected HeLa non-
silencing control or MOV10 KD cell lines with the
pcDNA3.1-neo control plasmid and obtained similar
number of colonies with the non- silencing control and
MOV10 KD cell lines verifying that silencing of en-
dogenous MOV10 does not effect neo expression and se-
lection directly, and also has no effect on transfection
efficiency (Figure 4B).
To confirm that the increase in endogenous retroelement
replication was due to the depletion of endogenous
MOV10 and not an unanticipated off-target effect, we con-
structed a silencing resistant MOV10 vector, pMOV10-R,
by introducing silent mutations that prevented recognition
by the shRNA. The antiviral activity of MOV10 was un-
affected by these mutations as overexpression of pMOV10-






























































Figure 2 Overexpression of MOV10 suppresses the retrotransposition of both LTR and non-LTR endogenous retroelements. (A) MOV10
overexpression restricts the replication of LINE-1, Alu and IAP. HeLa cells were co-transfected with pLINE-1 (pJM101/L1.3), pAlu (pAlu-neoTet plus
pCEP-ORF2), or pIAP (pGL3- IAP92L23neoTNF) together with pT7-MOV10 or pT7-Luc. Cells were selected with G418 for 12-14 days to measure
retrotransposition frequency and then fixed and stained with Giemsa. (B) MOV10 overexpression has no affect on neo expression or selection.
HeLa cells were co-transfected with a pcDNA3.1 control vector containing a neomycin resistance cassette (pcDNA3.1-neo) together with
pT7-MOV10 or pT7-Luc. The cells were G418 selected and the colonies were quantified as described in panel (A). Results are normalised to the
pLuc control, which is set at 100%. For (A) a single control bar set at 100% is graphed for simplicity. Values are the mean ± SD of 3 independent
experiments.


























































































































































































Figure 3 Silencing endogenous MOV10 has no significant effect on the production of infectious retrovirus particles for a panel of exogenous
retroviruses. (A) Depletion of endogenous MOV10 has no effect on HIV-1 virus production. Stable MOV10 KD cells were produced by transducing
HeLa or 293T cells with lentiviral vectors expressing either a non-silencing control shRNA or a MOV10-specific shRNA. HeLa or 293T non-silencing
control and MOV10 KD cells were infected with VSV-G pseudotyped HIV-1NL4-3. Virus concentration in the medium was determined as described in
Figure 1A. Cell lysates were analysed by immunoblotting with anti-p24Gag, anti-Hsp90 or anti-MOV10 antibodies, the latter of which was used to verify
the MOV10 KD. (HeLa virus production p = 0.0611, 293T virus production p = 0.2007). (B) Silencing of endogenous MOV10 has no effect on HIV-1
virion infectivity. Virion infectivity was determined as described in Figure 1B. (HeLa infectivity p = 0.3080, 293T infectivity p = 0.4812). (C) Depleting
endogenous MOV10 has no effect on spreading HIV-1 replication. Hut78 non-silencing control or MOV10 KD cells were infected with equal amounts
of HIV-1NL4-3 and passaged every 2 days. Medium was harvested on days 2, 4, 6 and 8 and virus production was determined as described in Figure 1A.
Cell lysates were analysed by immunoblotting with anti-MOV10 and anti-Hsp90 antibodies. (D) MOV10 silencing has no effect on the production of
infectious SIVmac, MLV and M-PMV particles. 293T non-silencing control or MOV10 KD stable cells were transfected as described in Figure 1C for the
production of HIV-1, SIVmac, MLV and M-PMV particles. Infectivity was determined as described in Figure 1C. (HIV-1 p = 0.1358, SIVmac p = 0.1040,
MLV p = 0.4907, M- PMV p = 0.4919). For (A), (B) and (D) results are normalised to the non-silencing control, which is set at 100%. For (D) a single
control bar set at 100% is graphed for simplicity. Values are the mean ± SD of 7 independent experiments for (A) and (B) or 3 independent
experiments for (D). The data were analysed with an unpaired one- tailed t test.
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virions to a similar magnitude as parental pMOV10 (data
not shown). The shRNA resistance of pMOV10-R was con-
firmed by titrating sensitive pMOV10 and resistant
pMOV10-R into the HeLa MOV10 KD cells, and analysing
cell lysates by immunoblotting (Additional file 1A). Results
showed that the levels of MOV10 encoded by pMOV10-R
were elevated in the KD cells relative to those seen with the
parental pMOV10 vector (Additional file 1A, compare
lanes 5 and 6 with 11 and 12). Next, we transfected
MOV10 KD cells with pMOV10-R to test the functional
consequence of restoring MOV10 expression, and found
that the suppression of LINE-1 retrotransposition was re-
established (Additional file 1B).
Thus, endogenous human MOV10 specifically represses
the propagation of intracellular retroelements.
MOV10 is not necessary for miRNA or siRNA-mediated
mRNA silencing
MOV10 interacts with the Argonaute proteins, which
are central effector components of the RISC, and has
been reported to be necessary for siRNA-mediated
mRNA silencing by an endogenous miRNA [27]. To
determine whether MOV10 is necessary for small RNA-
mediated RNA silencing, which is one possible mechan-
ism by which MOV10 may control the replication of
endogenous retroelements, we initially tested the re-
quirement of MOV10 for miRNA-mediated mRNA
repression. HeLa non-silencing control or MOV10 KD
cell lines were transfected with either a firefly (FF) luci-
ferase reporter construct containing four copies of the
endogenous let-7 miRNA binding site (FF4LCS; let-7
WT) or a negative control carrying mutations in the
target seed region of the let-7 binding sites (FFr4mLCS;
let-7 mutant), together with a control plasmid expressing
renilla luciferase (pRenilla) [50]. Cells were lysed and the
relative FF luciferase and renilla luciferase activities were
determined. FF luciferase activity was normalised to the
renilla luciferase activity to control for transfection
efficiency.
As expected, the let-7 WT luciferase activity was
repressed ~5-fold compared to the let-7 mutant luciferase
activity in the non-silencing control cells (Figure 5A). A
similar 5-fold repression in let-7 WT luciferase activity
relative to the let-7 mutant luciferase activity was observed
in the MOV10 KD cells suggesting that MOV10 is not
required for endogenous let-7 miRNA-mediated mRNA
repression in HeLa cells (Figure 5A). As a control for this
assay, we also knocked down DICER-1, which is an RNase
III enzyme essential for miRNA biogenesis, and co-


































































Figure 4 Depletion of endogenous MOV10 significantly enhances the retrotransposition of endogenous retroelements. (A) Silencing of
endogenous MOV10 significantly enhances the retrotransposition of LINE-1, Alu and IAP. As described in Figure 2A, HeLa non-silencing control or
MOV10 KD stable cell lines were transfected with retroelement expression plasmids and retrotransposition was quantified. (LINE-1 **p ≤ 0.0056,
Alu ***p ≤ 0.0005, IAP **p ≤ 0.0096). (B) MOV10 silencing does not effect neo expression or selection directly. As described in Figure 2B, HeLa
non-silencing control or MOV10 KD cells were transfected with the pcDNA3.1-neo control vector and colonies were quantified. Results are
normalised to the non-silencing control, which is set at 100%. For (A) a single control bar set at 100% is graphed for simplicity. Values are the
mean ± SD of 3 independent experiments. The data were analysed with an unpaired one-tailed t test.
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with the FF luciferase reporter constructs and pRenilla. As
expected, and confirming the validity of our approach, a
70% decrease in DICER-1 mRNA expression resulted in a
partial derepression of the let-7 miRNA activity (Additional
file 2).
To determine whether MOV10 is required for siRNA-
mediated mRNA silencing as previously reported [27],
HeLa non-silencing control or MOV10 KD cells were
transfected with renilla luciferase reporter constructs
containing three copies of perfectly complementary let-7
miRNA binding sites (psi-CHECK2-let-7X3; let-7 WT)
or mutated let-7 binding sites (psi-CHECK2-let-7X3m;
let-7 mutant) [51]. The perfect complementarity be-
tween endogenous let-7 miRNA and the reporter mRNA
promotes siRNA-mediated cleavage instead of miRNA-
mediated repression. Both let-7 WT and let-7 mutant
constructs also expressed FF luciferase from a second
promoter and the renilla luciferase activity was normal-
ised to FF luciferase activity to control for transfection
efficiency. In the non-silencing control cells, let-7 WT
luciferase activity was repressed by ~50-fold relative to
the let-7 mutant luciferase activity, and this level of
repression was maintained in the MOV10 KD cells
(Figure 5B). These results imply that, at least in HeLa
cells, MOV10 is not essential for miRNA or siRNA-
mediated mRNA silencing.
MOV10 is dispensable for the restriction of LINE-1 or HIV-1
replication by APOBEC3 proteins
Overexpression experiments have previously shown that
a number of APOBEC3 proteins such as APOBEC3A
(A3A), APOBEC3B (A3B) and A3G inhibit the retro-
transposition of endogenous retroelements [6-8,10] and
the depletion of endogenous A3B increases the replica-
tion of human LINE-1 in HeLa and human embryonic
stem cells [10]. Since MOV10 was identified as an
APOBEC3-interacting protein, we determined whether
A3A, A3B or A3G require MOV10 for the restriction of
LINE-1. HeLa non-silencing control or MOV10 KD cells
were co-transfected with either pA3A, pA3B, pA3G or a
pGFP control (pCMV4-HA tagged A3A, A3B, A3G or
GFP) [52] together with pLINE-1 as described. A3A
completely inhibited LINE-1 retrotransposition both in
the presence or absence of MOV10 (Additional file 3A).
A3B restricted LINE-1 replication in the non-silencing
control and MOV10 KD cells by 70% and 66%, respect-
ively, while A3G inhibited LINE-1 retrotransposition by
50% and 56%, respectively, relative to the non-silencing
control and MOV10 KD pGFP controls (Additional file
3A). Therefore, A3A, A3B and A3G do not require
MOV10 for the inhibition of LINE-1 mobilisation.
Similarly, we also tested whether MOV10 is required
for A3G antiviral activity by co-transfecting HeLa non-
silencing control and MOV10 KD cells with pA3G or a
pGFP control together with a plasmid expressing a vif-
deficient HIV-1 provirus (pHIV-1IIIB/Δvif ) [52]. Virion
infectivity was determined using the TZM-bl reporter
cell line and results showed that A3G still inhibited
HIV-1 infectivity in the absence of endogenous MOV10,
suggesting that MOV10 is not required for A3G antiviral
activity (Additional file 3B).
Discussion
Host cell restriction factors inhibit the replication of a

























































































Figure 5 MOV10 is not necessary for miRNA or siRNA-mediated
mRNA silencing. (A) MOV10 is not necessary for miRNA-mediated
mRNA repression. HeLa non-silencing control or MOV10 KD cells
were co-transfected with either FF4LCS (let-7 WT) or FFr4mLCS (let-7
mutant) together with pRenilla. Relative luciferase activities were
measured using a Dual-LuciferaseW Reporter Assay System and FF
luciferase activity was normalised to the renilla luciferase activity. (B)
MOV10 is not required for siRNA-mediated mRNA cleavage. HeLa
non-silencing control or MOV10 KD cells were transfected with
either psi-CHECK2-let-7X3 (let-7 WT) or psi-CHECK2-let-7X3m (let-7
mutant). Luciferase activities were measured as described in panel
(A) and renilla luciferase activity was normalised to FF luciferase
activity. Results are normalised to the non-silencing control, which is
set at 100%. Values are the mean ± SD of 3 independent
experiments.
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retroelements. Identifying the full complement of these
proteins is necessary to understand the capacity of the
host to regulate and control these genetic parasites.
MOV10 has been reported to modulate the replication
of a variety of RNA viruses including HCV, HDV and
VSV [18-20]. Here, we analysed whether MOV10 con-
trols the replication of exogenous retroviruses and
endogenous retroelements.
Our results show that MOV10 overexpression restricts
the production of infectious retrovirus particles (Figure 1).
This broadly agrees with previously published reports
[30-32], and extends the finding to the betaretrovirus M-
PMV (Figure 1C and D). Similar to Furtak et al., [31] we
observe a greater decrease in HIV-1 virion infectivity com-
pared to virion production, and this is more obvious in
293T cells (Figure 1A and B). We also observe a modest
decrease in cellular HIV-1 Gag abundance and processing
similar to that reported by Burdick et al. [30], as well as a
more noticeable decrease in cellular Gag abundance and
processing for M-PMV (Figure 1A and D). As virion
assembly is a cooperative process, decreases in total intra-
cellular Gag abundance may account for the reductions in
Gag processing [53]. MOV10 can also be packaged into
budding HIV-1 virions [30,32-34] and, interestingly, the
overexpression of MOV10 in HIV-1 producing cells
decreases the accumulation of early reverse transcription
products in target cells (data not shown) [31,32]. The
mechanism(s) underlying the defects in virion production
and reverse transcription are unclear, though the generality
of these observations across retroviral genera suggests a
common mode of action.
As described above, three groups have analysed the
role of endogenous MOV10 in HIV-1 replication, but
have reported variable results [30-32]. It was important
for us to test the effect of depleting endogenous
MOV10 on HIV-1 replication, and we extended this to
include a panel of exogenous retroviruses. Contrary to
the previous reports, we observe that depletion of
endogenous MOV10 has no affect on the production of
infectious retroviral particles or spreading HIV-1 repli-
cation (Figure 3). This result is similar to that reported
recently for foamy virus, a distantly related retrovirus
belonging to the spumaretrovirus subfamily, where
knockdown of MOV10 had no effect on viral replica-
tion [54]. In sum, while it appears that endogenous
levels of MOV10 do not restrict retroviral replication,
we speculate that the results of overexpression studies
implicate MOV10 as a component of a pathway or mul-
tiple pathways that exogenous retroviruses encounter.
MOV10 has also been reported to be a type I
interferon-stimulated gene [19], but whether interferon
or other cytokines can stimulate sufficient levels of
MOV10 protein to impact exogenous retrovirus infec-
tions is not yet known.
The MOV10 ortholog Armitage is required for the
repression of endogenous mobile elements in both germ
cells and somatic cells in Drosophila melanogaster
[22,25,26]. Similarly, the MOV10 paralog, MOV10L1,
has been shown to be necessary for the silencing of
endogenous retrotransposons in the germ line of male
mice [23,24]. Therefore, we analysed whether human
MOV10 could inhibit endogenous retroelements. Similar
to its effect on exogenous retroviruses, the overexpres-
sion of MOV10 potently inhibits the transposition of the
human endogenous retrotransposons LINE-1 and Alu as
well as the mouse endogenous retrovirus IAP (Figure 2A).
Unlike the exogenous retroviruses, however, the depletion
of endogenous MOV10 significantly enhances the replica-
tion of LINE-1, Alu and IAP (Figure 4A), which in the
case of LINE-1 can be reversed by restoration of MOV10
expression with an shRNA-resistant version of MOV10
(Additional file 1). The mechanism by which MOV10 con-
trols these LTR and non-LTR endogenous retroelements
is unknown, but previous studies have shown that Dicer1
knockout mouse embryonic stem cells have increased
levels of LINE-1 and IAP transcripts [55]. Furthermore,
Yang et al., [56] showed that human LINE-1 bidirectional
transcripts produced from the LINE-1 sense and antisense
promoters (ASP) are processed to yield LINE-1 specific
endogenous siRNAs that suppress LINE-1 retrotransposi-
tion by an RNAi mechanism.
Although it has been reported that MOV10 associates
with the RISC pathway and is necessary for siRNA-
mediated silencing of target mRNAs [27], our findings
to date using reporter constructs indicate that MOV10
is not absolutely required for miRNA or siRNA-
mediated mRNA silencing in cultured cells (Figure 5A
and B); therefore, whether this is a mechanism by which
MOV10 could regulate endogenous retroelements is
unclear. MOV10 also localises to mRNA processing
bodies (PBs) [27,29], which are cytoplasmic sites involved
in the storage and decay of translationally repressed RNA
species, and it has recently been reported that silencing of
the PB-associated proteins DDX6 and 4E-T increases IAP
transcript levels and promotes IAP retrotransposition
[57]. Taking this into consideration, we are currently in-
vestigating the pathway/mechanism by which MOV10
regulates retroelement mobility.
Human MOV10 is expressed in a wide range of adult
tissues including the heart, lungs, liver, testes and ovaries
with the highest transcript levels detected in the adult
brain including the hippocampus and caudate nucleus
[58]. Intriguingly, recent studies have shown that LINE-
1 transcripts are expressed in most human somatic
tissues as opposed to being confined to the germ line
[3]. Furthermore, active LINE-1, Alu and SVA element
retrotranspositions in the human hippocampus and
caudate nucleus have been reported to contribute to the
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genetic mosaicism of the human brain that may underlie
both normal and abnormal neurobiological processes
[2,4]. Based on our observations that endogenous MOV10
regulates LINE-1 and Alu replication (Figure 4A), it will
be interesting to determine whether human MOV10 may
be involved in the modulation of somatic retrotransposi-
tion and contribute to the control of retrotransposition-
mediated genetic variation.
Conclusion
MOV10 overexpression potently restricts the replication
of a broad range of exogenous and endogenous retroele-
ments. Silencing endogenous MOV10 has no effect on the
replication of exogenous retroviruses, but it significantly
enhances the retrotransposition of endogenous retroele-
ments. We hypothesise that MOV10 may contribute to
the regulation of endogenous retroelement mobilisation in
somatic cells.
Methods
Cell culture, MOV10 RNAi and plasmids
Human HeLa and 293T cells were cultured in Dulbecco's
modified Eagle's medium while Hut78 cells were cultured
in RPMI. Both types of media were supplemented with
10% fetal bovine serum plus penicillin-streptomycin and
L-glutamine. 293T cells were co-transfected with lentiviral
vectors expressing either a non-silencing control or
MOV10-specific shRNAmir in the miR-30 context con-
taining a puromycin resistance gene (GIPZ Lentiviral
shRNAmir, Open Biosystems V2LHS_201304), together
with the HIV-1 p8.91 packaging plasmid and pVSV-G (see
plasmids below). HeLa, 293T and Hut78 cells were trans-
duced with the recombinant lentiviral stocks and stably
transduced cells were selected with puromycin treatment.
The pT7-MOV10 and pT7-Luc plasmids were con-
structed by cloning XbaI-BamHI digested full-length
MOV10 and FF luciferase PCR products into the
pCGTHCFFLT7 expression vector that contains two
5′-T7-epitope tags [59]. The pMOV10-R plasmid was
constructed by introducing six silent mutations into the
MOV10-specific shRNA target sequence (nucleotides
342 to 363) by overlapping PCR (Primers: Forward
5′ TTTATGACAGGGCCGAATACCTCCACGGAAAA
CATGGTGTGG 3′, Reverse 5′ CCACACCATGTTT
TCCGTGGAGGTATTCGGCCCTGTCATAAA 3′) and
cloning the XbaI-XmaI digested PCR product into a
similarly digested pT7-MOV10 vector. The HIV-1NL4-3
strain provirus was used for this study [35]. Plasmids
for exogenous retrovirus and endogenous retroelement
experiments have been described previously: pVSV-G
[37]; HIV-1, p8.91 and pCSGW [38,39]; SIVmac,
pSIV3+ and pSIV-RMES4 [36]; MLV, pNCS/FLAG and
pMSCV/Tat [40,41] M-PMV, pMTΔE [42]; LINE-1,
pJM101/L1.3 [47]; Alu, pAlu-neoTet and pCEP-ORF2
[48]; IAP, pGL3- IAP92L23neoTNF [49]. Plasmids for
the luciferase assays were described previously:
FF4LCS, FFr4mLCS, pRenilla, psi-CHECK2-let-7X3
and psi-CHECK2-let-7X3m [50,51].
Virus production and infectivity assays
For wild-type HIV-1 virus production, parental HeLa or
293T cells (2 x 105 cells) were transfected with 0.5 μg of
a plasmid expressing the full-length HIV-1NL4-3 strain
provirus (pHIV-1NL4-3) using either FuGENE 6 (Roche)
according to manufacturer's instructions at a 3 μl
FuGENE to 1 μg DNA ratio for the HeLa cells, or 16 μl
(1 mg/ml) PEI (per well of a 6-well dish) for the 293T
cells. For MOV10 overexpression experiments, pHIV-
1NL4-3 was co-transfected with the indicated concentra-
tion of pT7-MOV10 and the appropriate concentration
of the pT7-Luc control plasmid to ensure equivalent
amounts of DNA in all transfections. For HIV-1 and
SIVmac lentiviral vector production, parental 293T cells
or 293T non-silencing control and MOV10 KD cells
were co-transfected as described with 1 μg p8.91, 1 μg
pCSGW and 0.5 μg pVSV-G, or 1 μg pSIV3+, 1 μg
pSIV-RMES4 and 0.5 μg pVSV-G, respectively. MLV and
M-PMV virions were produced by co-transfecting paren-
tal 293T cells or non-silencing control and MOV10 KD
cells as described with 0.2 μg pNCS/FLAG, 0.2 μg
pMSCV/Tat and 0.1 μg pVSV-G, or 1 μg pMTΔE and
0.5 μg pVSV-G, respectively. Plasmids for lentiviral
vector or MLV and M-PMV virion production were co-
transfected with 0.5 μg pT7-MOV10 or pT7-Luc for
MOV10 overexpression experiments. Cells were lysed
~40 h post-transfection and virus particles were fil-
tered through a 0.45 μM filter. The concentration of
HIV-1 p24Gag in the supernatant was quantified by a
p24Gag enzyme-linked immunosorbent assay (ELISA)
(Perkin-Elmer).
For HIV-1 infectivity, the TZM-bl reporter cell line
(1 x 105 cells) expressing a HIV-1 Tat inducible β-gal
reporter gene was challenged with equal amounts of
virus normalised by the p24Gag concentration. Cells were
lysed ~24 h post-infection and β-gal activity was deter-
mined using the Galacto-StarTM System (Applied Biosys-
tems) according to the manufacturer's instructions. For
HIV-1 and SIVmac lentiviral vector infectivity, 293T
cells (1 x 105 cells) were challenged with equal amounts
of vector- containing medium and infectivity was deter-
mined ~24 h post-infection by measuring the percentage
of GFP-positive 293T cells using a FACS Canto II Flow
Cytometry System (BD Biosciences). MLV and M-PMV
virion infectivity was determined by infecting TZM-bl
cells (1 x 105 cells) with equal amounts of virus-
containing medium and infectivity was determined as
described for the wild-type HIV-1 experiments.
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HIV-1 infection of producer cells and spreading infection
For endogenous MOV10 silencing experiments, HeLa or
293T non-silencing control and MOV10 KD cells (2 x
105 cells) were infected with equal amounts of VSV-G
pseudotyped wild type HIV-1NL4-3 virus normalised by
the p24Gag concentration (25 ngs) in a total of 1 ml
medium (6-well dish). The cells were washed 4 h later
and 2 mls of fresh medium was replaced. For spreading
replication, non-silencing control or MOV10 KD Hut78
cells (1 x 106 cells) were infected with equal amounts of
virus normalised by the p24Gag concentration (100 ngs)
and cells were passaged every 2 days. Medium was
harvested on days 2, 4, 6 and 8 and virus production
was measured by p24Gag ELISA.
Immunoblotting
Cells were lysed in radioimmunoprecipitation assay
(RIPA) buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl,
1 mM EDTA, 0.1% SDS, 1% Triton X-100, 1% sodium
deoxycholate) and filtered virions were pelleted through
a 20% sucrose cushion and lysed. Proteins were resolved
by SDS-PAGE and transferred to a nitrocellulose mem-
brane for immunoblotting. HIV-1 precursor p55Gag and
processed p24Gag were detected using a mouse anti-
p24Gag antibody [60]. M-PMV precursor p78Gag and
processed p27Gag were detected using goat anti-p27Gag
antisera (78 S-136, Microbiological Association). T7-
tagged MOV10 and Hsp90 were detected with mouse
anti-T7 (Novagen) and rabbit anti-Hsp90 (Santa Cruz
Biotechnology) antibodies, respectively. Endogenous
MOV10 was detected with a rabbit anti-MOV10 anti-
body (Proteintech). Secondary IRdye800 conjugated anti-
bodies (Li-Cor Biosciences) were used for quantitative
immunoblotting with the Odyssey infrared scanner
(Li-Cor Biosciences).
Retrotransposition assays
For LINE-1, Alu and IAP retrotransposition assays
parental HeLa cells or HeLa non-silencing control and
MOV10 KD cells (2 x 105 cells) were co-transfected as
described with either 1.5 μg pJM101/L1.3, 1 μg
pAlu-neoTet plus 0.5 μg pCEP-ORF2 or 1.5 μg
pGL3-IAP92L23neoTNF, respectively. Plasmids were
co-transfected with 1 μg pT7-MOV10 or pT7-Luc for
MOV10 overexpression experiments. Cells were G418
selected (1 mg/ml) 2 days post-transfection. At ~12-15
days post-transfection, the cells were fixed in 4% parafor-
maldehyde and colonies were stained with 0.4% Giemsa
(Sigma) for counting. For control pcDNA3.1-neo experi-
ments cells were transfected with 0.3 μg of a pcDNA3.1
empty vector containing a neomycin resistance cassette,
and the assay was performed similarly to the retrotranspo-
sition assays.
Luciferase assays
For the miRNA assays, HeLa non-silencing control or
MOV10 KD cells (1 x 105 cells) were co-transfected as
described with either 0.1 μg FF4LCS or FFr4mLCS
together with 0.1 μg pRenilla. For the siRNA assays, the
cells were transfected with 0.1 μg psi-CHECK2-let-7X3
or psi-CHECK2-let-7X3m. Cells were lysed ~24 h post-
transfection. Relative luciferase activities were measured
using a Dual-LuciferaseW Reporter Assay System (Pro-
mega) according to the manufacturer's instructions.
Additional files
Additional file 1: Restoration of MOV10 expression rescues the
control of LINE-1 retrotransposition. (A) HeLa MOV10 KD cells were
transfected with increasing concentrations of >pT7-MOV10 or
pT7-MOV10-R. Cells were analysed by immunoblotting with anti-MOV10,
anti-T7 and anti-Hsp90 antibodies. (B) HeLa non-silencing control or
MOV10 KD cells were co-transfected with pLINE-1 (pJM101/L1.3)
together with pT7-MOV10-R or pT7-Luc at the indicated concentrations,
following which the cultures were G418 selected and colonies were
counted to measure the retrotransposition frequency. Cell lysates were
analysed by immunoblotting with anti-MOV10, anti-T7 and anti-Hsp90
antibodies. For (B) results are normalised to the non-silencing control,
which is set at 100%. Values are the mean ± SD of 3 independent
experiments.
Additional file 2: Knockdown of DICER-1 relieves miRNA-mediated
mRNA repression. HeLa cells were transfected with non-silencing
control or DICER-1-specific siRNAs to produce non-silencing control or
DICER-1 KD cells, respectively. These cells were co-transfected with
either FF4LCS (let-7 WT) or FFr4mLCS (let-7 mutant) together with
pRenilla. The relative luciferase activities were measured using a
Dual-LuciferaseW Reporter Assay System. FF luciferase activity was
normalised to renilla luciferase activity.
Additional file 3: MOV10 is not required for restriction of LINE-1 or
HIV-1 infection by APOBEC3 proteins. (A) HeLa non-silencing control
or MOV10 KD cells were co-transfected with pLINE-1 (pJM101/L1.3) and
pCMV4-HA tagged A3A, A3B, A3G or a GFP control. Cells were G418
selected and colonies were quantified to determine the
retrotransposition frequency. (B) HeLa non-silencing control or MOV10
KD cells were co-transfected with pHIV-1IIIB/Δvif and either pA3G or
pGFP. Infectivity was determined by infecting TZM-bl cells with equal
amounts of virus normalised by the p24Gag concentration. For (A) results
are normalised to the non-silencing control, which is set at 100%. Values
are the mean ± SD of 3 independent experiments.
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